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Abstract
In this thesis, new tools have been developed for decoding structure-function relationships governing
complex biopolymers that have emerged as key players in biology, biotechnology, and medicine.
Specifically:
(1.) The first part of this thesis addresses the structure-function relationship of synthetic biodegradable
plastics that are at the forefront of nanotechnology for spatiotemporally-regulated targeting and
sustained release of drugs to treat Cancer and other chronic diseases. A Voxel-based 3-D platform for
accurately simulating all phases of polymeric nanoparticle erosion and drug release is introduced. Using
the developed Voxel platform, the release of anti-inflammatory and anti-cancer drugs such as
doxorubicin and dexamethasone from poly lactic-co-glycolic acid (PLGA) nanoparticles is precisely
predicted. The Voxel platform emerges as a powerful and versatile tool for deducing the dynamics in
interplay of polymer, drug, and water molecules, thus permitting the rational design of optimal
nanotechnology treatments for cancer.
(2.) The second part of this thesis is focused on development of tools to elucidate structure-function
relationships of complex polysaccharides (glycans) that specifically interact with proteins to modulate a
host of biological processes including growth, development, angiogenesis, cancer, anticoagulation,
microbial pathogenesis, and viral infections. First, towards the fine structure determination of complex
linear glycans (glycosaminoglycans or GAGs), enzymatic tools are developed for both depolymerizing
GAGs at specific linkages and for effectively modulating their functional groups. Specifically, the
development and integrated biochemical-structural characterization of the Chondroitinase ABC-II
enzyme that depolymerizes dermatan sulfate and chondroitin sulfate GAGs (CSGAGs), and the 6-0-
Sulfatase and N-Sulfamidase enzymes that de-sulfate functional groups on heparin and heparan sulfate
GAGs (HSGAGs) are described. Second, the interaction of branched glycans with proteins is analyzed
using the interplay of Influenza virus surface proteins (mainly Hemagglutinin and Neuraminidase) with
host cell surface sialylated glycan receptors as a model system. For this purpose, the novel triple
reassortant "Swine Flu" pandemic virus (or 2009 HINI virus) is studied. Finally, in order to overcome
the challenges facing protein structure prediction in the "Twilight Zone" of low homology that is
rampant in glycan-binding protein (lectin) families, a new tool is introduced for modeling the 3-D
structure of proteins directly from sequence. Specifically, it is identified that protein core atomic
interaction networks (PCAINs) are evolutionarily non-tinkered and fold-conserved, and this finding is
utilized towards assignment of folds, structures, and potential glycan substrates to lectin sequences. It is
further demonstrated that the developed tool is effective universally; thus emerging as a promising
platform for generic protein sequence-to-structure and function mapping in a broad spectrum of
biological applications.
Thesis Supervisor: Ram Sasisekharan, Professor of Biological Engineering and Director of Harvard-
MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge,
USA
Dedicatedto VS
for my conversations wit/i Science
Acknowledgments
To my advisor, Dr. Ram Sasisekharan: sincere thanks for encouraging me to think out-
of-the-box; for teaching me the value of focus and razor sharp vision while still permitting me to
explore the wide vistas of Science; for the timeless conversations on a broad spectrum of
scientific and technological topics; for the think-big and can-do attitudes that have been a
privilege to learn from; for supporting me through difficult times on personal fronts; and most of
all, for providing a rich and vibrant research environment with a fantastic set of individuals
where Science is Science in its all-encompassing, limitless, unbounded beauty.
To my committee member, Dr. Rahul Raman: thanks for providing me the handholding
that I needed to get started and going with this thesis research; for introducing me to
glycobiology and teaching me glycomics tools; for the limitless patience exuded in steering me
as I've erred and learnt; for finding time for our conversations despite the several other
responsibilities; for showing by example how electrical/computer engineers can apply and excel
in Biological Engineering; and for the constant words of wisdom on all aspects of graduate life
that have greatly helped me over the last five years.
To my committee member and chair, Dr. Alan Grodzinsky: it has been my fortune to
interact and learn from you right from my first two semesters at MIT when I was your student in
20.410 and 20.430. Your interdisciplinary lectures and discussions fusing electrical, mechanical,
chemical, and biological engineering have had a profound impact on the way I approach
research. I've drawn a lot of inspiration from the remarkable energy and enthusiasm with which
you teach, and I hope to imbibe these qualities towards my career in academia. Thanks also for
encouraging and supporting me throughout this thesis research.
To S. Raguram: our numerous long discussions on protein science have been deeply
inspiring and will remain etched as few of the best times of my graduate life. Thanks for keeping
me grounded, while always encouraging me to think beyond, and patiently supporting my flights
of imagination with kind words however naive my thoughts. In you, I found a mentor with an
identical background and vision, which provided me strength in times of self-doubt and further
energy when things went well. I look forward to our building on the solid PCAIN-based
foundations we've established.
To Dr. David Eavarone and Dr. Toomas Haller, it was a pleasure working with both of
you on the development of the Voxels platform. I'd like to specially thank David for the patient
guidance and focus provided during the initial stages of the project.
To Dr. Vikas Prabhakar, Dr. Ishan Capila, Dr. James Myette, Dr. Zachary Shriver, and
Dr. Jonathan Behr: sincere thanks for the powerful set of experimental tools and protocols
developed as part of the GAG enzyme toolkit, that provided a fertile ground for developing
homology-based models to study enzyme structure-function relationships. These tools were
immensely beneficial for the progress we made during the first few years of this Thesis research.
To Dr. Karthik Viswanathan: it was an incredible experience learning the fundamentals
of experimental molecular biology from you. It was due to your mentorship that I got exposure
to hands-on molecular biology, and will always remember those few months fondly. Thanks
sincerely, for your exceptional patience in steering me through the several new and fascinating
aspects of experimental protocols. Thanks also for the numerous long lunch sessions that helped
me better understand graduate life nuances.
To Dr. Aarthi Chandrasekaran: thanks for being an amazing mentor during the many
stressful events of my first few years in the lab. Talking to you made it all seem so easy; and for
that I am truly grateful.
To Dr. Kannan Tharakaraman: one of the earliest lessons I learnt as a graduate student
was "time spent with Kannan is time well spent". Thanks sincerely, for making the last four
years an exciting, informative, and enjoyable experience. The two weeks of intense, burning-the-
midnight-oil, research frenzy that we undertook together during the outbreak of the 2009 HiNi
"Swine Flu" influenza pandemic virus, culminating in our integrated sequence-structure
understanding of the virus and our subsequent submission to Nature Biotechnology, was one of
the most fast-paced phases of this Thesis research. For this and the several other brainstorming
sessions we've had on various projects, I am most grateful.
To Dr. Vidya Subramanian: thanks for the many wonderful discussions on protein
engineering, and I look forward to all the emerging excitement in our horizon.
To Kenneth Warnock, Neel Patel, Stephanie Yaung, Ganesh Chock, and Molly Eileen
Cain -- my exceptional UROP students -- sincere thanks for your brilliant hard work. It has been
a genuine pleasure working with each of you, and you've all enriched my graduate life in many
special ways. Added thanks to Ken -- my first UROP student -- for his remarkable efforts in
piecing together the several gigabytes of evolutionary information from the protein fold universe
towards building our PCAIN database, as well as the numerous long philosophical discussions
on intriguing topics such as the creation-evolution balance, origins of life, computers as man's
greatest evolutionary strengths, suppressing evolution of drug-resistant viruses, and decoding
protein misfolding in the context of neurodegenerative diseases.
To the wonderful MIT Biological Engineeringfaculty, a big thanks. To Dr. Forest White,
Dr. Ernest Fraenkel, and Dr. Neda Bagheri: it was a genuine pleasure teaching 20.320 with you.
Thanks for the incredible opportunity to teach and learn. To Dr. Doug Lauffenburger: special
thanks for always being supportive and encouraging of my academic and research pursuits. To
Dr. John Essiggman: thanks for making learning biochemistry so much fun - I will always
remember your lectures fondly.
To my exceptional TAs, Dr. Jared Toettcher, Dr. Mikhail Shapiro, and Dr. Victor
Lelyveld: it was an incredible experience learning from the three of you -- thanks for making
grad school courses so much fun. To my ever-helpful BE grad seniors, especially Dr. Shan Wu,
thanks for helping me find my place in BE, coming from a vastly different academic
background.
To Ada Ziolkowski: sincere thanks for your patient and timely help throughout the last
five years. Thanks also to Dalia Fares, Mariann Murray, and Linda Bragman, for facilitating the
various administrative aspects during the course of this Thesis.
To members of the Sasisekharan group, BE colleagues, MIT friends, IT friends, and
schoolfriendsfrom India: thanks for making the whole ride memorable. To all my teachers right
from school to college: none of this would have been remotely possible if not for your patient
nurturing and loving guidance.
To my father Mr. K Soundararajan, mother Mrs. S. Anjana Jayanthi, and grandparents:
you have been instrumental for all things good in my life. To my brother Harish Chandra: you
have been a phenomenal "co-passenger" in the ride called life, particularly a remarkable
colleague during all our conversations on science and technology; and I wish you the best as you
embark on your PhD in Molecular Biology at Trinity/Cambridge/LMB. To my in-laws and
family: thanks for all the support and well-wishes.
To my ever-loving wife Barghavi: my past, present, future, and beyond; my here, there,
and everywhere; are all what they are, because of you.
To Dr. Viswanathan Sasisekharan, my teacher, mentor, and father-figure, who made me
realize that imagination is, but the only limit of Science: for all things that have been said and
remain unsaid... this Thesis is dedicated to you.
Venkataramanan Soundararajan
April 2010
Cambridge, Massachusetts, USA
Table of Contents
Abstract..............................................................................................................................................5
1 Introduction .................................................................................................................................... 15
1. 1 M otiv ation ............................................................................................................................ 15
1.2 Biopolymers in nanotechnology ....................................................................................... 16
1.3 Biopolymers in glycobiology ........................................................................................... 27
1.4 Summary and specific objectives .................................................................................... 47
2 Deducing Structure-Function Relationships of Biopolymers in Cancer Nanotechnology ... 53
2.1 Predicting kinetics of anti-cancer drug release from polymeric nanoparticles ................. 54
Published m anuscript ...................................................................................................... 66
2.2 Harnessing Nanotechnology to target the Cancer Cell Immortality Spectrum ................. 71
Published m anuscript ...................................................................................................... 88
Published m anuscript ......................................................................................................... 103
3 Recombinant Enzymatic Tools for Decoding GAG Polymer Fine Structure ......................... 122
3.1 Decoding the structure-function relationships of GAG enzymes ....................................... 123
3.2 Structure-function relationship of Chondroitinase ABC-I from Proteus Vulgaris.............124
Published m anuscript ......................................................................................................... 127
3.3 Structure-function relationship of 6-0-Sulfatase from Flavobacterium Heparinum...........140
Published m anuscript ......................................................................................................... 144
3.4 Structure-function relationship of N-Sulfamidase from Flavobacterium Heparinum.........156
Published m anuscript ......................................................................................................... 159
4 Influenza Virus Surface Proteins Interactions with Host Sialylated Branched Glycans........172
4 .1 Introduction ........................................................................................................................ 173
Published m anuscript ......................................................................................................... 188
Supplem entary inform ation ................................................................................................ 192
5 De novo Protein Structure Prediction and Lectin Sequence-to-Function Assignment...........197
5.1 Pursuit of the Elusive Protein Fold Code: Implications of Ab Initio Mapping of Gene
Sequences to Folded Protein Structures ............................................................................ 198
5.2 Anfinsen's Dogma in the Post-Genomics Era: Significance and Implications of the Twilight
Z one of H om ology ............................................................................................................. 199
5.3 Nature as a Tinkerer: How Evolutionary Tinkering Challenges Illuminating the Twilight
Z one of H om ology ............................................................................................................. 200
5.4 The Twilight Zone of Glycobiology: The Need for, and Challenges Posing, Ab initio GBP
Structure Prediction ............................................................................................................ 203
5.5 Evolutionary Tinkering as Noise Masking De Novo Deduction of Fold Codes: The Signal-
to-Noise Ratio of Molecular Biology ................................................................................. 209
5.6 The Core of it All: Shielding from Water as a Factor Mitigating Evolutionary Tinkering in
P rotein F old s.......................................................................................................................2 10
5.7 Mining Protein Contact Maps from the Multi-dimensional Protein Universe .................... 211
5.8 Introduction to the (p,w) Landscape of Protein Structural Folds: A Valuable Tool for
Homology Modeling in the Twilight Zone.........................................................................212
Published m anuscript ......................................................................................................... 2 18
Bibliography ........................................................................................................................................ 232
List of Figures
1.1 M echanisms of polymeric matrix degradation ......................................................................... 17
1.2 M odes of polym eric m atrix erosion ........................................................................................... 18
1.3 Active targeting of nanoparticles to tumor-specific over-expressed receptors .......................... 19
1.4 The broad-spectrum of Nanotechnology based approaches for targeting Cancer .................... 20
1.5 Release of agents from drug encapsulated and drug-conjugated polymeric nanoparticles ..... 22
1.6 Synergistic, additive, antagonistic, and unknown interactions between common cancer drugs ....23
1.7 Diverse drug release profiles from the same polymer-drug combination of nanoparticles ..... 24
1.8 C lassification of glycans.................................................................................................................25
1.9 Chemical structures of GAG disaccharide repeat units ............................................................ 28
1.10 Known GAG-protein interactions and their biological roles......................................................30
1.11 The Non-templated Biosynthesis of GAGs ............................................................................. 31
1.12 Ribbon rendering of chondroitinase B ...................................................................................... 33
1.13 Contrast of the endolytic mode of HepAC with exolytic mode of ArthroAC............................34
1.14 Molecular surface rendering of cABCI depicting its structural complex with DS .................... 35
1.15 Sequential degradation and processing of heparin and HSGAGs by GAG enzymes ............... 36
1.16 Depiction of FGF bound to H SGAG ......................................................................................... 39
1.17 Chem ical diversity of branched glycans .................................................................................. 40
1.18 Classes of lectins and their glycan specificities ....................................................................... 41
1.19 Protein structural topologies for extracellular domains in lectin classes ................................... 42
1.20 Influenza virus HA engagement of cone topology and umbrella topology glycans...................43
1.21 Breakdown of homology modeling in the twilight zone of low sequence identity ................... 44
2.1 Mode of clearance and chemical structure of polymers in anti-cancer applications...................52
2.2 The 2-D Pixel-based models contrasted with 3-D Voxel-based whole nanoparticle model. ...... 55
2.3 Contrast of the neighborhoods of pixels (2-D) and voxels (3-D)...............................................57
2.4 The limited computational cost associated with 3-D voxel simulation of nanoparticles. ........... 55
2.5 Correlation between experimental and model results for drug release from nanoparticles.........60
2.6 The Cancer Cell Imm ortality Spectrum ..................................................................................... 67
2.7 The versatile degradation lifetimes of polymeric nanoparticles............................................... 68
2.8 Structures of receptor molecules that are over-expressed in breast cancer cells........................69
2.9 Estimated levels of over-expressed Breast Cancer receptor molecules ..................................... 70
2.10 Structure of Nanocell delivery system . ..................................................................................... 72
2.11 Simulation of polymeric nanoparticle degradation and erosion with time.................................73
2.12 Simulation of bulk eroding polymeric nanoparticle degradation and erosion...........................74
2.13 Extension of 2-D and 3-D modeling platforms to simulate surface eroding microparticles .......... 75
2.14 Spatial compartmentalization at nanoscales and microscales ................................................... 76
2.15 Simulation of agglomer size distribution with time at fixed agglomeration factor values......77
2.16 Variation of agglomeration factor (AF) on the size of agglomer clusters formed is computed.....78
2.17 Simulation of agglomeration with the extended Voxel platform ............................................... 79
3.1 A lignm ent of the chondroitinase enzym es .................................................................................... 119
3.2 Docking of 14mer C4S (green) to cABCII (gray) highlights collision regions . .......................... 129
3.3 Analysis of collision region contributions towards exolytic mode of cABCII ............................. 130
3.4 Ramachandran plot verification of the developed cABCII homology model .............................. 132
3.5 Structural model of 6-0-sulfatase with docked glucosamine monosaccharide ............................ 135
3.6 Function of H SGAG processing enzym es .................................................................................... 149
3.7 Known Nitrogen-Sulfur bond cleaving enzymes and their chemical mechanism.........................150
4.1 Influenza V irus Lifecycle ............................................................................................................. 166
4.2 Influenza Hemagglutinin (HA) and Neuraminidase (NA) serotypes . ......................................... 167
4.3 MALDI-MS glycan profile of Human Bronchical Epithelial (HBE) cells...................................168
4.4 Cone topology (left) and umbrella topology (right) glycans bind influenza HA ......................... 169
4.5 The glycan-binding and membrane fusion facilitating sites on Influenza HA. ............................ 171
4.6 Chemical structures of sialic acid (boxed) and popular influenza NA inhibitors.........................172
4.7 Crystal structure rendering of the 1918 pandemic HINI NA with Sialic Acid...........................173
4.8 Chemical structures of Adamantane derivatives inhibiting influenza M2 protein ........................ 174
4.9 The hydrophobic amantadine-binding pocket on Influenza M2 protein. ..................................... 175
4.10 Amantadine docked to homology model of 2009 HINI virus MP2 protein ............................... 176
4.11 Rimantadine docked to homology model of 2009 HINI virus MP2 protein ............................. 177
4.12 Influenza Z oonoses ...................................................................................................................... 178
4.13 Host and lineage origins for the proteins of the 2009 H1N1 "swine flu" virus............................179
4.14 Rimantadine docked to homology model of 2009 HINI virus MP2 protein ............................. 177
4.15 Influenza Z oonoses ...................................................................................................................... 178
5.1 Decoding Biological Information Flow in Nature's Lego Set: The Elusive Protein Fold Code.... 189
5.2 Estimated Evolutionary Sequence Divergence of Protein Fold Families......................................193
5.3 The Full-Spectrum of Known Protein Architectures in the Biological Universe...........................194
5.4 Function-driven Evolutionary Tinkering: CDR Loops of Antibody p-Sandwich Folds ............... 196
5.5 Poor intra-fold pairwise sequence identities of GBPs...................................................................198
5.6 Chemical and Structural Diversity of Glycans Binding to 0-trefoil Proteins.................................199
5.7 Classification of p-trefoil fold protein domains into GBPs and non-GBPs....................................200
5.8 Inaccurate structure prediction by current homology modeling tools in the twilight zone ........... 201
5.9 Depiction of Signal-to-Noise Ratio (SNR) of Molecular Biology ................................................ 202
5.10 Protein core/scaffold, surface residues, peptide bonds, and water molecules..............................203
5.11 Protein Contact Maps from architectures in the protein universe ................................................ 204
5.12 Structure-based multiple sequence alignment of p-trefoil protein fold family.............................205
5.13 The PCAIN-based methodology for protein fold and structure prediction ............................ 206-07
5.14 Examples of structures obtained with PCAIN approach to homology modeling ........................ 208
5.15 Structures predicted based on PCAIN methodology for CASP target sequences ........................ 209
13
List of Tables
1.1 Polymeric biomaterials classified according to mode of in vivo clearance ................................. 15
1.2 Degradation lifetimes of hydrolysis-susceptible polymers ........................................................ 16
1.3 Classes of GAGs and their disaccharide building blocks............................................................27
1.4 The diversity of protein fold families that constitute GBPs ....................................................... 45
4.1 Available Crystal Structures of Influenza Proteins Compiled from the PDB ................................ 170
5.1 Diversity of the commonly occurring fold families in Glycan-binding proteins ........................... 197
14
1. Introduction
1.1. Motivation
Structure is a key determinant of function in biopolymeric molecules. With the exception
of the most simple biopolymers however, the structure-function relationships for several of the
more complex biopolymers has been challenging to decode [1-3]. This Thesis is motivated by
the growing needs from biological, biotechnological, and medical applications, that call for the
elucidation of structure-function relationships of complex biopolymers [4-10].
The first part of this Thesis is motivated by the need for uncovering the factors governing
hydrolysis kinetics of synthetic biopolymers and their interplay with water and drug molecules
[11-16]. The main application is developing tools for integrated "spatiotemporally" regulated
targeting of polymeric nanoparticle vehicles for fighting Cancer. Spatiotemporal regulation of
polymeric nanoparticle vehicles requires understanding structure-function relationships at both
polymeric nanoparticle scales (e.g. for predicting nanoparticle fragmentation) and molecular
scales (e.g. for predicting receptor-ligand structural fit) [17-20]. It is envisioned that the
developed tools would enable prediction of chemotherapeutic drug release kinetics for a wide
variety of FDA approved materials, thus advancing nanotechnology-based cancer treatment.
The second part of this Thesis pertains is motivated by the tremendous biological
significance of decoding factors governing the interaction of complex polysaccharides (glycans)
with polypeptides (proteins) [21-24]. Glycans are structurally complex and chemically
heterogeneous carbohydrates present at the interface of a cell and its environment [25-27].
Glycan-binding proteins (GBPs) specifically recognize these structurally diverse glycans and
modulate several biological processes ranging from cell-cell communication, intracellular
signaling and catalysis to disease, defense and infection [28-32]. Decoding glycan-protein
interactions has been met with several challenges in the past, that this thesis aims to overcome
[33-50]. Specifically: (a.) the non-template driven biosynthesis and high information density of
glycans complicates elucidation of glycan fine structure; (b.) the fuzzy and often multivalent
nature of glycan-protein interactions hinders traditional biomolecular interaction readouts; and
(c.) the exceptionally high evolutionary sequence divergence of glycan-binding proteins presents
tremendous difficulties for ab-initio characterization of the native structural fold and glycan-
binding properties directly from sequence. It is envisioned that developing tools that overcome
these challenges will permit characterizing biologically salient glycan-protein interactions.
1.2 Biopolymers in Nanotechnology
1.2.1 Biopolymers in medical applications
The 2 0 h century witnessed tremendous progress in the synthesis of polymeric materials
derived from biological molecules, termed biopolymers [51-54]. Biopolymers are typically
suitable for in vivo use owing to their non-toxic, non-carcinogenic, non-mutagenic, non-
allergenic, and non-inflammatory properties [55-60]. Polymers are classified as biodegradable,
bioeliminable or permanent, depending on the mode of their in vivo clearance (Table 1.1) [61].
Biodegradable materials are initially in the solid or gel phase and are thereafter broken
down into natural metabolites within the body by hydrolytic or enzymatic activity [62-64].
PLGA is an example of a biodegradable material that has been approved for clinical use by the
Food and Drug Administration (FDA) [65]. PLGA is completely hydrolyzed into lactic acid and
glycolic acid which are components of the Kreb's cycle and are hence naturally metabolized by
the body [66]. The biomaterial revolution of the 20th century was born out of the realization that
instability of biodegradable polymers in solution that promotes erosion of their matrices is highly
desirable for achieving temporal regulation in biotechnology, pharmaceutical, and medical
applications [67-70].
One of the first medical applications of biodegradable polymers -- approved around mid-
20th century --- was sutures composed of poly lactic acid (PLA), poly glycolic acid (PGA), and
poly lactic-co-glycolic acid (PLGA) [71]. Following this, several other biodegradable polymeric
materials such as polydioxanone, polytrimethylene carbonate, polycaprolactone, polyanhydrides,
polyorthoesters, and polyphosphazenes have become popular for a multitude of medical
applications [72-80]. Some of these other salient medical applications of biodegradable polymers
include dental devices, orthopedic fixation devices, cardiovascular devices such as stents and
grafts, tissue staples, anastomosis rings for intestinal resection, ligating clips, drug delivery
vehicles, in vivo imaging devices, and tissue-engineering scaffolds [81-90].
At the heart of each of these medical applications is the precise regulation in temporal
kinetics of polymer degradation and opportunities for molecular/cellular targeting made available
by the advent of nanotechnology [91-95]. The next two sections introduce factors governing the
temporal regulation of biopolymer degradation kinetics and the spatial targeting of nano-devices
to cells of interest within the human body.
Table 1.1 Polymeric biomaterials classified according to mode of in vivo clearance
Clearance mode Polymer Chemical structure
Biodegradable
poly(glycolic acid)
poly(lactic acid)
poly(lactide-co-glycolide)
poly(6-caprolactone)
0
0 n
0
CH3
0
5 n
poly(malic acid)
poly(ethylene carbonate)
poly(propylene carbonate)
poly(anhydride)
HO C, 0
O 0
R 0
R=H/CH3
( 0 rR "
O 0
CEN
poly(alkyl cyanoacrylate)
Bioeliminable COOR
poly(ethylene oxide)
n
CH3
poly(methyl methacrylate)
poly(hydroxyethyl methacrylate) COOR
Permanent/Implant R = CH3 / CH2CH2OH
poly(N-isopropyl acrylamide) CONHR
R = CH(CH 3)2
1.2.2 Temporal regulation ofpolymer degradation kinetics and its biomedical applications
Why is temporal regulation of polymer degradation desirable for biomedical
applications? The answer lies in the inherent importan e of time as a key moderating factor in
biomedical treatments. For example, a biodegradable implant that has been carefully engineered
to degrade at the rate of bone healing can serve to optimally transfer load from the implant to the
healing bone, thus negating the need for a second surgery to remove the implant [96]. Yet
another example that highlights the importance of polymer degradation kinetics is drug delivery.
It is well known that the controlled release of drugs is key to achieving maximal therapeutic
efficacy [97]. This necessitates factoring the desired polymer degradation kinetics -- and as a
consequence the drug release rate -- into the design of therapeutic delivery vehicles.
The duration of therapy for various diseases ranges from a few hours to several months
[96]. Application-specific drug delivery devices constituted of biodegradable polymers have
been developed across the therapeutic duration spectrum in recent years (Table 1.2) [96]. The
characteristic degradation half lives of biodegradable polymers varies from a few minutes to
several years based upon the ease of their hydrolysis [97]. Matrices composed of biodegradable
polymers degrade by cross-link, side chain, or backbone degradation (Figure 1.1), and the
polymer molecular weight plays an important role in determining the average degradation
lifetimes [97]. Other characteristics of biodegradable polymers that are known to influence their
hydrolysis rate include hydrophobicity, steric effects (local structure, glass transition),
microstructure (porosity, phase separation, crystallinity), oligomer solubility, autocatalysis, and
pH of the medium [97].
Table 1.2 Degradation lifetimes of hydrolysis-susceptible polymers
Polymer class Degradation half life
Polyanhydrides < 10 minutes
Polyorthoesters ~ 5 hours
Polyesters ~ 20 months
Polyphosphazenes ~ 5 years
Polyamides > 50,000 years
Crosslink Backbone Side chain
degradation degradation degradation
Figure. 1.1. Mechanisms of polymeric matrix degradation
Biodegradable polymeric devices are classified as bulk eroding or surface eroding based
on the progress of hydrolysis and degradation (Figure 1.2) [70]. Bulk eroding polymer matrices
undergo uniform, instantaneous wetting and degradation happens throughout the bulk of the
matrix, whereas water diffuses much more slowly into surface-eroding polymer matrices and
degradation hence happens only at the exposed surface of these matrices [70]. The drug release
profile associated with surface-eroding polymer matrices is generally mono-phasic whereas bulk
eroding polymer matrices display more biphasic release profiles with a distinct initial "burst
release" phase [98]. During the burst phase, bulk eroding nanoparticles release a significant
volume of their drug payload and this is undesirable for therapeutic applications [18]. However,
drug molecules may be chemically conjugated to polymer molecules to ensure non-burst release
and such vehicles are known as drug-conjugated polymeric devices [18]. The effects of chemical
drug conjugation to polymers is described in a later section pertaining to chemotherapy, where
such techniques have been extensively explored for the purpose of sustained drug release [98].
In addition to temporal regulation, the ease of chemical conjugation of biopolymers to
other synthetic or organic molecules with highly specific interaction spectrums permits their
precise targeting to cells or tissues of interest [97]. This spatial targeting of biopolymers is
particularly effective for nanoscale devices owing to the several related advantageous properties
of these "small scale devices" [96-98], as discussed in the following section.
. . ............... ..  ......................... 
Surface erosion
= - Intact polymer
Bulk erosion Dded polymer
Eroded polymer
Time
Figure. 1.2. Modes of polymeric matrix erosion
1.2.3 Spatial regulation ofpolymeric device targeting: Emergence of biomedical nanotechnology
A nanometer is one billionth of a meter and devices that are less than hundreds of
nanometers in dimension are known as nanoscale devices or nano-devices. These devices are
typically smaller than human cells and are able to achieve cellular entry [97]. Such devices can
further readily interact with biological macromolecules owing to their comparable dimensions
[97]. Nanotechnology, hence, presents an unprecedented insight into the complex regulatory and
signaling network of biomolecular interactions that constitute all cellular functions. A broad-
spectrum of novel nanotechnology based techniques have been proposed for fighting various
diseases, giving rise to the promising field of biomedical nanotechnology [96-98].
The exquisite sensitivity offered by nanotechnology in terms of the ability to monitor
sub-cellular compartments and biological molecules in vivo, has presented clinicians with a
paradigm shift in the diagnosis of diseases at their most elementary stages [99]. The design of
nanoscale devices for detection and diagnosis has motivated a broad-spectrum of advancements
in molecular sensing, nano-electromechanical systems (NEMS), nano-fluidics, and ultrasensitive
imaging technologies [97]. On the therapeutic front also, nanotechnology is revolutionizing the
spatiotemporally regulated delivery of drugs to precisely target cells and molecules of interest
[96]. For instance, the shift from macro- to nano- scale drug delivery systems in recent decades
has been driven by improvements in polymer formulation technology and evidence that medical
applications such as chemotherapy are significantly enhanced by the use of biopolymeric
nanoscale delivery vehicles [98].
.............   .. .............. -
One of the biggest achievements of nanotechnology in the context of biomedicine is in
spatial targeting of nano-devices with drug and imaging agent payloads precisely to the tissues,
cells, and molecules of interest [20]. Such a mode of spatial localization of nano-devices within
the human body is referred as active targeting and involves the chemical conjugation of targeting
ligands such as polysaccharides, antibodies, peptides, nucleic acid aptamers, or other small biomolecules,
to the surface of nanodevices [96]. For the purposes of active targeting, biomolecules are carefully
screened to identify potential targeting ligands that bind selectively to receptors that are unique to, or over
expressed in, the cells of interest (Figure 1.3) [97].
Active targeting is particularly important in the context of tumor therapy for minimizing toxicity
and ensuring maximal delivery of chemotherapeutic drugs to cancer cells [20]. Taken together with the
concomitant developments on biopolymeric device engineering fronts that permits precise
temporal regulation in drug release, as described previously, tremendous opportunities are
emerging for integrated spatiotemporally regulated diagnostics and therapeutics for combating
cancer on various fronts (Figure 1.4) [96-99]. These emerging opportunities for nanotechnology
in targeting cancer are discussed in the following section.
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Figure 1.3 Active targeting of nanoparticles to tumor-specific over-expressed receptors
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1.2.4 Biodegradable polymeric nano-devices in anti-cancer applications
The development of nanoscale systems for targeted delivery of drugs to cancer cells is a
major focus of chemotherapy, primarily for the purpose of toxicity reduction [20]. Nanoscale
systems that are smaller than 200 nm in diameter effectively navigate through the leaky tumor
microvasculature and aggregate selectively within the tumor interstitial space [62]. They are
thereafter contained within the tumor microenvironment owing to the dysfunctional lymphatic
drainage [63]. Devices that rely primarily on this enhanced permeation and retention (EPR) for
delivering drugs to tumors are known as passively targeted or auto-targeted systems [64]. Active
targeting, as defined earlier, involves conjugation of targeting ligands -- that bind selectively to
receptors over-expressed in cancerous cells -- to surface of nano-devices (Figure 1.3) [96-98].
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Figure 1.4. The broad-spectrum of Nanotechnology based approaches for targeting Cancer
The conjugation of appropriate tumor-specific targeting molecules onto drug-
encapsulated nano-devices ensures selective delivery of the agent to cancerous cells and hence
minimal toxicity to noncancerous cells [96]. Although passive and active targeting are both
helpful for directing nanoscale devices to tumor tissues, the latter mode is associated with greater
reduction in chemotherapeutic toxicity, specifically to healthy cells in the immediate
neighborhood of tumor cells [97].
Chemical conjugation is also useful in the context of drug and polymer molecules for the
purpose of prolonging the release duration (sustained release), as mentioned earlier [18].
Sustained release of agents over several weeks is required for many applications such as
monitoring of the tumor microenvironment and anti-cancer drug delivery [100, 101]. The
chemical conjugation of drug molecules to polymer fragments prevents rapid dissolution of the
drug into the medium [18]. The mechanism governing sustained release from drug-conjugated
polymeric nanoparticles is as follows (Figure 1.5). Upon repeated hydrolytic or enzymatic
cleavage of the polymer backbones, the fragments become increasingly smaller in size. The
dissolution of the drug-polymer conjugates commences only after the molecular weight of these
fragments decreases below a certain threshold that is characteristic of the polymer. The dissolved
drug molecules then begin diffusing out of the nanoparticle.
An added advantage of drug-conjugated nanoparticles is the absence of the initial burst
release phase which, as was discussed earlier, is characteristic of drug-encapsulated polymeric
nanoparticles [18]. Burst release in the latter occurs primarily because of the near-instantaneous
efflux of medium-exposed drug molecules present in the vicinity of the carrier surface. In the
case of drug-conjugated polymeric nanoparticles, the chemical binding of the drug molecules to
the polymer backbone prevents instantaneous diffusion of even these medium-exposed drug
molecules on the carrier surface.
Drug-conjugated polymeric nanoparticle systems have been successfully used for the
sustained delivery of chemotherapeutic agents to several cancer types [18, 96-98]. For example,
PLGA-doxorubicin nanoconjugates have been employed to effectively deliver the
chemotherapeutic drug doxorubicin to tumors over several weeks [18]. Additionally, the
polymers constituting the nanoparticles may be surface functionalized with PEG and tumor-
targeting molecules, similar to other nano-devices as described earlier [96-98].
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Figure 1.5. Burst release of agents from drug encapsulated polymeric nanoparticles
contrasted with sustained release of agents from drug-conjugated polymeric nanoparticles
Another unique aspect of cancer therapy is the requirement for drugs combinations owing
to the complexity of the disease and failure of single-shot approaches to provide effective
treatment [102-122]. Cancer is a complex disease that arises from the dysregulation of several
biological networks that are frequently interconnected [105-108]. Consequently, the single drug-
single target approach of mono-therapies is often less effective than combination chemotherapies
that can synergistically target multiple processes simultaneously [102-122]. This is verified by
assessments of numerous successful clinical combination therapies for cancer. Therapeutic
synergy involves one or more of the following effects - multiplicative increase of cancer cell
death, decreased dosage requirement of each drug, reduced toxicity, and minimized development
of drug resistance [102]. The last three effects are a natural consequence of using multiple drugs
because the decreased requirement for each drug alleviates issues of toxicity and drug resistance.
A compilation of synergistic interactions amongst some of the commonly administered cancer
drugs indicates an abundance of mechanistic synergy that can be harnessed by combination
therapies (Figure 1.6) [102-122].
However, the effective administration of combination therapies requires very precise
spatiotemporal control in the release of each drug owing to the sensitivity associated with
functional rewiring of cellular biochemical signaling networks [96]. This in turn calls for the
design of sophisticated nanoscale delivery platforms that can carry multiple payloads and
disburse them selectively to the cancerous tissues in a spatially and temporally regulated fashion
[97-99]. The next section outlines the challenges associated with the design of spatiotemporally
regulated polymeric nanoparticle systems and the need for computational nanotechnology
platforms for overcoming the challenges towards ushering in an era of novel nano-devices for
fighting cancer.
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Figure 1.6. Synergistic (U), additive ( ), antagonistic (U), and currently unknown (0)
interactions between common cancer drugs. The following three letter abbreviations are used
for the drugs: Capecitabine (Xeloda@), Cyclophosphamide (Cytoxan@), Docetaxel (Taxotere@),
Doxorubicin (Adriamycin®), Epirubicin (Pharmorubicin@), Fluorouracil (5FU), Gemcitabine
(Gemzar@), Lapatinib (Tyverb@), Letrozole (Femara@), Methotrexate (MTX), Mitoxantrone,
Paclitaxel (Taxol@), Tamoxifen (Nalvodex@), _Tastuzumab (Herceptin®).
1.2.5 Challenges in predicting drug release kinetics of polymeric nanoparticles: Emergence of
computational nanotechnology
The rapid progression from micro- to nano- scale drug delivery systems in recent years
has been in part due to improvements in polymer formulation technology as well as
accumulating evidence that medical applications such as chemotherapy are significantly
enhanced by the use of nanoscale delivery vehicles [19-21, 69, 123]. However, because drug
release profiles differ based on the polymer, drug, and design parameters, the availability of
computational models to understand and predict drug release is very valuable for the extension
and optimization of existing drug delivery technologies [98]. While several models have been
reported in the literature to describe drug release and particle breakdown for macro- and micro-
scale polymer-based delivery vehicles [14-17, 124], there is an absence of such models in the
nano- realm that is of great importance to cancer therapy, as outlined earlier. From the studies on
polymer degradation, it is clear that there are a number of factors that influence drug release
kinetics including water and drug diffusion, drug dissolution, polymer molecular weight, particle
size and geometry, polymer degradation, micro-environment pH changes, autocatalysis, polymer
swelling, and more [124-126]. Incorporation of these factors is further complicated by a still
incomplete understanding of the extent to which they each influence the kinetics of drug release
[98]. As a result of this complex interplay between water, polymer, and drug molecules within
the milieu of nanoparticles, the prediction of degradation kinetics of polymeric nanoparticles and
rates of drug release has been extremely challenging [98].
However, such prediction of drug release kinetics from polymeric nanoparticles is key to
optimizing the design process in terms of time and finances, as well as ensuring the highest
therapeutic efficacy and maximal feedback vis-a-vis optimal release rates for different tumor
types [17, 69]. Furthermore, a broad-spectrum of drug release rates are observed for the same
polymer and anti-cancer drug combination (Figure 1.7), thus suggesting that several intricate
factors are involves in determining release rates from polymeric nanoparticles, and necessitating
the developing of an effective predictive tool [98].
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Figure 1.7. Extremely diverse drug release profiles from the same combination of polymer
(PLGA) and drug (dexamethasone) employed in polymeric nanoparticle based anti-cancer
systems necessitates the development of computational models that can accurately predict
the kinetics of drug release from polymeric nano-devices.
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Computational nanotechnology is quickly emerging as a fertile ground for the
development of models to understand theoretical nanosciences and designing new nanoscale
technologies for targeting Cancer [127]. Computational nanotechnology refers to the design of
models for elucidating the mechanistic underpinnings of nanoscale phenomena. In Chapter 2 of
this thesis, a novel platform based on the principles of computational nanotechnology is
introduced for overcoming the challenges described herein and provide accurate predictions on
the drug release kinetics from polymeric nanoparticles [98]. The efficacy of this platform is
demonstrated on a wide variety of polymer, drug, and cancer types, thus validating the utility and
versatility of the technique [96, 97].
1.3 Biopolymers in Glycobiology
1.3.1 Glycans and glycan-binding proteins: Biological roles and classification into families
Glycans are structurally and chemically heterogeneous carbohydrates present at the cell-
extracellular matrix (ECM) interface [128-141]. There is increasing evidence for the role of
glycans in several physiological and pathological processes like cell growth, development,
tumorigenesis, infection, anticoagulation, immunity, and cell-cell/cell-ECM communication
[142-159]. Glycans can be broadly classified according to their backbone chemical structure into
(a.) branched sugars - these are presented as N-linked or O-linked glycosylations on
glycoproteins/glycolipids, and (b.) linear sugars - a majority of which are glycosaminoglycans
(GAGs) that contain long polymers O-linked to a core protein forming proteoglycan aggregates
(Figure 1.8) [160-173]. While glycans modulate biological processes generically by virtue of
their mass, shape, charge, or other physical properties, several of their more specific functions
are attributed to their recognition by glycan-binding proteins (GBPs) [174-177]. Owing to their
ubiquitous presence at the cell-ECM interface, glycans interact with numerous GBPs such as
growth factors, cytokines, immune receptors, and enzymes (Figure 1.8) [178-180]. GBPs hence
serve to decipher the Glycome of biological systems by recognizing and binding specific glycans
from the cell's array of complex polysaccharides [181-185]. The underlying glycan-protein
interactions are typically characterized by a rich spectrum of specificities, avidities and affinities,
allowing for the precise moderation of several different biological processes [186-198]. GBPs
are classified as GAG-binding proteins and lectins [199-205].
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Figure 1.8. Glycans are classified as simple and complex, and as linear (GAGs) and
branched, as shown. GAGs interact with GAG-binding proteins and are processed by GAG
enzymes, whereas Lectins interact with simple and branched glycans. The Consortium for
Functional Glycomics (CFG) nomenclature is adopted for depicting glycans. This picture
was adapted from: The Essentials of Glycobiology by A. Varki et. aL, CSH Press, 2004.
The following sections describes each class of glycans and GBPs, as well as the salient
biological roles of glycan-protein interactions.
1.3.2 GAGs and biological implications of their interaction with GBPs and GAG enzymes
The Glycosaminoglycan (GAG) family is further classified according to the dissacharide
repeat units composed of hexosamine (galactosamine/glucosamine), hexose (galactose) and
hexuronic acid (glucuronic acid/iduronic acid) as well as varied patterns of sulfations (2-0-
sulfate/6-0-sulfate/4-Osulfate/N-sulfate), acetylations (N-acetyl) and linkage geometries such as
p1-3/p1-4/al-4 (Table 1.3) [206-209]. Of these, the heparin/heparan sulfate GAGs (HSGAGs)
and chondroitin sulfate GAGs (CSGAGs) are two most prevelent GAG families [210-214].
........ ... . . ......
Table 1.3 Classes of GAGs and their disaccharide building blocks
Category Disaccharide U H Modifications
X - sulfated
Heparin/Heparan U2X (w1,4) HNY,3X,6X (al,4) IdoA/GlcA Glucosamine Y - acetylated/
Sulfate (HSGAG)
sulfated
Chondroitin Sulfate
(CSGAG) / Dermatan U2X (01,3) HNAc,4X,6X (P1,4) IdoA/GlcA Galactosamine X - sulfated
Sulfate (DSGAG)
Keratan Gal6X (p1,4) HNAc,6X (p1,3) Gal Glucosamine X - sulfated
Hyaluronic Acid GlcA (p1,3)HNAc (p1,4) GlcA Glucosamine None
Chondroitin sulfate GAGs (CSGAGs) and dermatan sulfate GAGs (DSGAGs) belong to
a family of GAGs known as galactosaminoglycans or GalAGs (Figure 1.9) [215-218]. GalAGs
are linear polysaccharides of 1-3 linked repeating disaccharide units. The disaccharide units
consist of a uronic acid (a-L-iduronic acid; IdoA or p-D-glucuronic acid; GlcA) linked 1-3 to a
p-D-N-acetyl-galactosamine (GalNAc) [219-222]. Each disaccharide unit can additionally
possess variations in the form of sulfation at the 2-0 and 3-0 positions of the uronic acid and 4-
0 and 6-0 positions of the GalNAc [223-227].
Heparin and heparan sulfate glycosaminoglycans (HSGAGs) comprise an important
polysaccharide constituent of many proteoglycans [228-230]. These glycans are linear polymers
based on the variably repeating disaccharide unit (uronic acid 1-4 glucosamine)n, where 'n'
represents a variably repeating number, typically 10-200 (Figure 1.9) [231-233]. As present in
nature, these sugars possess an extensive chemical heterogeneity that is largely attributed to the
mosaic arrangement of 0- and N-linked sulfates present at different positions along each sugar
chain [234-236]. Additional structural variations include the presence of N-linked acetates at the
glucosamine C2 position as well as epimerization of the uronic acid C5 carboxylate to form
eithers-D-glucuronic acid or a-L-iduronic acid [237-239]. HSGAGs are present as structurally
defined binding epitopes on the cell surface and hence also play an important role in microbial
pathogenesis [240-242].
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Figure 1.9. Chemical structures of GAG disaccharide repeat units
GAGs are present in an environment comprised of a variety of proteins, such as growth
factors, cytokines, morphogens, and enzymes (Figure 1.10) [243]. GAGs play a critical role in
assembling protein-protein complexes such as growth factor-receptor or enzyme-inhibitor
aggregates on the cell surface and in the extracellular matrix that are directly involved in
initiating cell signaling events or inhibiting biochemical pathways [244]. Furthermore,
extracellular GAGs can sequester proteins and enzymes and present them to the appropriate site
for activation [245]. Thus, for a given high-affinity GAG-protein interaction, the positioning of
the protein-binding oligosaccharide motifs along the GAG chain determines if an active complex
is assembled at the cell surface or an inactive complex is sequestered in the matrix [247].
High-affinity GAG-protein interactions are not the only biologically significant ones
(Figure 1.10) [248]. GAGs have been shown to play important roles in maintaining morphogen
gradients across a cell or tissue, which has been implicated in developmental processes [249].
Maintaining a gradient in the concentration of growth factors or morphogens involves graded
affinities between different GAG sequences and the protein [250]. Thus, the nature of GAG-
protein interactions coupled with their sequence diversity enables GAGs to fine-tune (analog
modulation) the activity of proteins, unlike DNA-protein interactions, which block expression of
a protein, completely activating or inhibiting (digital regulation) protein function [251].
GAG binding proteins and their biological roles GAG oligosaccharide specificity
Ce growth and development
FGF-HSGAG: FGF-oligomerization, assembling FGF-FGFR FGF-1 - HSGAG: -(I2S_HNS,6S)n- n > 2 for binding
complexes leading to receptor oligomerization and cell >5 for FGF-mediated cell signaling
signaling. Cell growth and development, angiogenesis.
FGF-2 - HSGAG: -[l2S-HNS,6Xln- n > 2 for binding
>5 for FGF-mediated cell signaling. Sulfation at 6-0
position is not required for binding but may be
required for cell signaling
HGF/SF-dermatan: hepatocyte regeneration, morphogenesis, I-HNAcAS-I-HNAc.4S-I-HNAc.4S-I-HNAc4S
cell motility, tumorigenesis and metastasis.
Midkine, pleotrophin-chondroitin: neuronal adhesion, -(G-HNAe.4S.6S)n- or -(G2s-HNAe,6S)n-
migration, and neurite outgrowth.
Other growth factors/Morphogens: FGFs (1-21), TGF 0,
VEGF, PDGF, EGF Amphiregulin, Betacellulin, Neuregulin,
IGF II, Activin, Sonic Hedgehog, Sprouty peptides, Wnts
(1-13), BMP-2, 4.
Antinagidation and antithrnbosis
AT-HIl-heparin: enhances factor Xa and Ia inhibition. -(HNAc,6S-G-HNS,3S,6S-I2S-HNS,6S)-
Annexin V-heparin: enhances protein oligomerization. -(I2s-HNS,6S)n-
HCF II-DS: inhibition of factor Ila and factor Ila-fibrin I2s-HNAc.4S-I2s-HNAc4S-I2s-HNAc4S
complex.
Other factors/proteases: factor Xa, Ila, Thrombomodulin
Mitrobialpathogenesis
HSV-1-heparin AU-HNS-12S-HNAc-I2S(orG2-S)-HNS-12S-HNH2,3S,6S
FMDV-heparin 
-(I2s-HNS,6S)n-
VCP-heparin 
-(I2S-HNS.6S)n-
Inflammation/immne response
Cytokines/adhesion: interleukins, GM-CSF, Interferony, Inflammation/immune response
TNF-a, Angiostatin, Endostatin, L-selectin, N-CAM, AC-1,
PECAIM-1, CXC, Bac-5,7, PR-39.
Figure 1.10. Known GAG-protein interactions and their biological roles. This picture was
adapted from: R. Raman et. aL, Annual Review of Biomedical Engineering, 2006.
In addition to GAG-binding proteins, GAGs also interact with, and are processed by
several GAG enzymes [252]. In fact, fundamental to understanding GAG structure-activity
relationships is the appreciation that polydispersity of GAG fine structure is not random, but is
the end product of a complex and concerted biosynthetic pathway involving numerous modifying
enzymes (Figure 1.11) [253-255]. The relative expression levels and specific activities of GAG
enzymes are regulated in a cell- and tissue-specific fashion [256]. This programmed diversity of
GAG structure ultimately plays out at a functional level, namely through the dynamic regulation
of numerous biochemical signaling pathways relating to processes like cell growth,
differentiation, death, intercellular communication, adhesion and tissue morphogenesis [257].
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Figure 1.11 The Non-templated Biosynthesis of GAGs. This picture was adapted from: R.
Raman et. aL, Annual Review of Biomedical Engineering, 2006.
In contrast to the complex enzymatic process by which GAGs are synthesized, GAG
catabolism is considerably more straightforward, both in the scope of its purpose and the means
by which it is carried out at the biochemical level [258]. Both bacterial and mammalian cells
produce enzymes that degrade GAGs [259]. In microbes, GAG degradation processes are
utilized by some soil bacteria, like Pedobacter heparinus, for metabolizing GAGs, whereas in
others, like Streptococcus pneumonia, the degradation of GAGs in the ECM enhances the
virulence of the microbe [260]. The bacterial depolymerizing enzymes are lyases that cleave the
glycosidic linkage between a hexosamine and an uronic acid through the p-elimination
mechanism [261]. The lyase action leaves a 4,5 unsaturated linkage on the nonreducing end
uronic acid, which has a characteristic absorbance at 232 nm. The overall sequence of GAG
degradation in bacteria involves the depolymerization of GAG chains by the heparinases and
chondroitinases down to di- and tetrasaccharide fragments [262]. These small fragments are then
acted on by the exolytic sulfatases, such as AU 2-0 sulfatase, A4,5 glycuronidase, N-sulfamidase
(HSGAG), GlcNAc 3-0 sulfatase, GlcNAc 6-0 sulfatase, GalNAc 4-0 sulfatase, and GalNAc 6-
0 sulfatase [263].
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The mammalian GAG-degrading enzymes, including heparanases and hyaluronidases,
are glycosidases that hydrolyze the glycosidic linkage and retain the epimeric state of the uronic
acid in the products formed [264]. The human heparanase I enzyme has been demonstrated to
cleave the GlcA-GlcNS,3S,6S linkage within the oligosaccharide motif -GlcNAc,6S-GlcA-
GlcNS,3S,6S-IdoA2S-GlcNS,6S-, where the 2-0 sulfation on the adjacent IdoA plays a key role
in the activity of the enzyme [265]. The GAG catabolic pathway involves depolymerization of
the endocytosed GAG chains by heparanases and hyaluronidases and desulfation of the smaller
fragments by lysosomal sulfatases, which are exolytic enzymes analogous to the bacterial
sulfatases [266]. In addition to the lysosomal exolytic sulfatases, the endolytic sulfatases appear
to cleave the 6-0 sulfate group from GlcNAc and GlcNS monosaccharides in mature HSGAGs
at the cell-ECM interface [267]. These endosulfatases represent a novel family of enzymes that
modify extracellular GAG chains [268].
The next few sections focus on the different GAG enzyme families, the spectrum of
substrates they process, and the biological functions of these enzymes.
1.3.3 The chondroitinase family of GAG enzymes
Chondroitinases are a family of lyases that depolymerize a wide variety of GalAG
substrates (Figure 1.9) [269]. Chondroitinases have been classified broadly into three
subfamilies. Chondroitinase AC depolymerizes chondroitin-4-sulfate and chondroitin-6-sulfate,
whereas chondroitinase B depolymerizes dermatan sulfate as its sole substrate [270-273].
Chondroitinase ABC has the broadest substrate specificity in that it depolymerizes both CS and
DS substrates [274].
Chondroitinases have been employed in attempts to promote functional locomotor
recovery following trauma to the central nervous system [275]. The application of cABCI at the
site of central nervous system injury is believed to prune CS chains from proteoglycans localized
to the glial scar [276]. The absence of these CS chains, inhibitory to axon regeneration, facilitates
neural outgrowth and reconstruction of damaged tissue. However, the use of chondroitinases as
therapeutics is limited because of the lack of availability of pure and contaminant-free enzyme
[277-279]. Further, chondroitinase enzymes are often difficult to handle, because of thermal
instability and spontaneous proteolysis, as reported by various studies [280].
Chondroitinase AC (cAC) and chondroitinase B (c'B) from the soil bacterium Pedobacter
heparinus have been characterized extensively in terms of their enzymatic activity and substrate
specificity [281].
AB
Figure 1.12 (A.) Ribbon rendering of chondroitinase B - DShexa complex; (B.) Molecular
surface of chondroitinase B showing the three DS oligosaccharides near the active site. This
picture was adapted from: W. Huang et aL 1999.
The crystal structure and co-crystal structure of cB with its DS substrate (Figure 1.12)
together with site-directed mutagenesis of its putative active site residues provided detailed
insights into its substrate processing and also revealed a calcium-dependent catalytic activity
[282]. The co-crystal structures of cAC with different CS and DS oligosaccharide substrate
complexes (Figure 1.13) led to the proposal of multiple scenarios in which the active site
residues contributed to the catalytic activity of the enzyme [283]. The crystal structure of another
cAC from Artrhobacter aurescens and its co-crystal structure with CS substrates (Figure 1.13)
provided molecular insights into the active site of this enzyme and also its exolytic mode of
action compared with the endolytic mode of cAC from P. heparinus [284]. Two distinct broad
substrate specificity GalAG-degrading chondroitinase ABC lyases, cABCI and cABCII, have
been identified in Proteus vulgaris [285]. In fact, the ability of the conventional enzyme known
as "chondroitinase ABC" to catalyze the complete depolymerization of GalAG substrates to
disaccharides is actually the result of the joint action of cABCI and cABCII [286]. Recently,
cABCI from P. vulgaris was characterized in terms of its active site, the role of divalent cations
in processing CS and DS substrates, and its endolytic mode of action (Figure 1.14) [287].
Figure 1.13 (A.) Contrast of the endolytic mode of action of HepAC (shown with the
tetrasaccharide substrate complex) and the (B.) Exolytic mode of action of ArthroAC
(shown with the tetrasaccharide substrate complex and the insertions in the sequence
capping the substrate binding site highlighted green). This picture was adapted from: V. V.
Lunin et al 2004.
Building on these previous studies, in the second part of this thesis, the cloning,
recombinant expression, and integrated biochemical-structural characterization of chondroitinase
ABC-II (cABCII) from P. vulgaris is. described. The development of such a contaminant free,
recombinant bacterial cABCII will be a valuable tool for the isolation and structural
characterization of GAGs, which includes decoding their primary sequence, and also therapies
pertaining to CNS recovery after injury [288]. The native forms of chondroitinase ABC purified
from soil bacteria have been used in the past for the isolation and characterization of GAGs in
these applications [289, 290]. However, the utility of these native enzymes has been impeded by
contaminating activities of other enzymes that co-purify with the target enzyme. Cross-
contamination of enzyme activities limits the accurate assignment of sequence information
obtained from depolymerization of the parent GAG chain [289, 290]. To circumvent these issues,
in this thesis, cABCII is cloned, recombinantly expressed, and biochemically as well as
structurally characterized in detail, so as to enhance the utility of the developed enzyme tool for
fine structural characterization of CSGAGs and DSGAGs.
. . ...... .... . .....................
Figure 1.14 Molecular surface rendering of cABCI depicting its structural complex with
DS and highlighting the active site residues. This picture was adapted from: V. Prabhakar
et. aL 2005.
1.3.4 Heparin and heparan sulfate processing GAG enzymes
Heparinases I, II, and III (hep I, II, and III) have been cloned from P. heparinus and have
been recombinantly expressed in Escherichia coli (Figure 1.15) [291-293]. These enzymes have
been characterized extensively in terms of the critical amino acids involved in substrate binding
and catalysis, involvement of divalent cations in enzymatic activity, substrate specificities, and
action pattern toward defined HSGAG substrates [294-296]. Hep I prefers to cleave substrates
starting from the nonreducing end (exolytic), and continues to depolymerize (processive) at
successive cleavable linkages toward the reducing end. Hep I was shown to cleave -GlcNS,6X-
12S- linkages in highly sulfated regions of HSGAG chains. Hep II from P. heparinus has the
broadest substrate specificity among the heparinases. Biochemical investigation of this enzyme
has revealed two distinct active sites involved in the processing of regions of high sulfation and
low sulfation, respectively [297-299]. The action pattern of hep II is distinct from that of hep I.
Specifically, studies indicate that hep II processing proceeds through an endolytic and
nonrandom mechanism. In addition, hep II releases intermediates, unlike hep I, which
processively cleaves its substrate. Hep III has an orthogonal specificity compared to that of hep I,
in that it cleaves GlcNAc,6X-G or GlcNS,6X-G linkages in regions of low sulfation in HSGAGs.
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Figure 1.15 Sequential degradation and functional-group processing of heparin and
HSGAGs by GAG enzymes. This picture is obtained from: R. Raman et al, Annual Review
of Biomedical Engineering, 2006.
Building on the efforts to develop enzymatic tools for HSGAGs, additional exolytic
HSGAG-degrading enzymes (Figure 1.15) were cloned from P. heparinus and recombinantly
expressed [300-302]. The first of these enzymes was the A4,5 glycuronidase, which cleaves an
unsulfated A4,5 unsaturated uronic acid at the nonreducing end of heparinase-depolymerized
oligosaccharides [303-305]. Using the AU-HNS,6S disaccharide substrate, the conditions for
optimal activity of this enzyme have been determined [306]. The second enzyme, the 2-0
sulfatase, cleaves the 2-0 sulfate group of AU. Using a homology modeled structure of P.
heparinus 2-0 sulfatase, the structural basis for exolytic activity and substrate specificity of this
enzyme has been recently determined [307-309]. The unsaturated A4,5 linkage was shown to be
critical for the activity of the enzyme. Furthermore, it was shown that the 2-0 sulfatase generated
the substrates for the A4,5 glycuronidase because the 2-0 sulfate group inhibited glycuronidase
activity. These enzymes have since been used in tandem with the heparinases for the
compositional analysis of heparin [309-311].
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In the second part of this thesis, the cloning, recombinant expression, purification, and
integrated biochemical-structural characterization of 6-0 sulfatase (cleaves 6-0 sulfate of
glucosamine) [312] and N-sulfamidase (cleaves N-sulfate of the glucosamine) [313] enzymes are
described, this illuminating the entire HSGAG degradation pathway (Figure 1.15). Homology
modeling (comparative protein modeling) is used to predict the structure of these enzymes in this
study, since crystal structures of heparinase, sulfatase, and other enzymes have been extremely
challenging to elucidate, whereas high-resolution homologous structures are already available to
serve as templates.
Indeed, homology-based modeling tools are emerging as attractive tools for predicting
the structure-function relationships of GAG enzymes universally, as outlined in the next section.
1.3.5 Need for determining the structure-function relationships of GBPs and GAG enzymes:
Emergence of homology modeling
From the examples of GAG-protein interactions described above, it is clear that the
specificity of biomolecular interactions goes beyond the GAG primary sequence. In the heparin-
antithrombin-III (AT-III) complex, the specificity is precisely defined at the level of the
pentasaccharide sequence [26, 45, 155]. Any modifications to this sequence are detrimental to
the binding and activation of AT-III. On the other hand, in the case of growth factor binding, it is
more challenging to define specificity at the level of a single oligosaccharide motif like the
pentasaccharide. Recently, the preferences of different FGFs for defined HSGAG sequences
were studied using a library of octasaccharides [38, 156, 233, 241]. The authors concluded that
they were unable to determine a highly specific motif for each FGF similar to the
pentasaccharide sequence that binds to AT-Ill. Further, they concluded that there is a significant
overlap in the specificities of different FGFs to different HSGAG sequences and challenged the
notion of specificity in these interactions. Intuitively, these differences can be rationalized in the
context of the biological pathways involving these interactions. The coagulation cascade requires
a tight regulation in a short time span, which involves activation or inhibition of enzymes (digital
regulation). On the other hand, interactions involving cell growth and development require some
level of degeneracy in the GAG sequence space to accommodate longer time frames for the
signaling events as well as maintaining graded affinities for generating morphogen gradients.
Going beyond the sequence space into the 3-D structure space, it is possible to define
specificity of GAG-protein interactions as the optimal fit of a GAG structure into the GAG-
binding site of the protein. This fit is governed by the ionic interactions of the sulfate and
carboxylate groups of GAGs with the basic amino acids on the protein as well as the van der
Waals contacts made by the GAG chain with the binding site of the protein. The topology and
distribution of the basic amino acids of the GAG binding site on the protein influence its
specificity in the molecular recognition of GAG sequences. Thus, specificity as defined by
structural fit or molecular recognition can be viewed in the 3-D space for GAGs in terms of
conformation of the polysaccharide backbone and the orientation of the sulfate groups. It is
possible for more than one GAG sequence to satisfy the constraints imposed by the structural fit
of the GAG chain to the protein. Thus it is important to understand how the primary GAG
sequence translates into a specific GAG conformation and topology (i.e., sulfate and carboxylate
groups). Because GAGs are typically known to adopt a linear extended conformation with
helical symmetry, it is more manageable to relate their primary sequence to 3-D structure (unlike
the challenging problem of protein structure prediction). However, since elucidating GAG-
protein interactions requires structures of both GAGs and proteins to be deciphered, and
considering the several challenges with obtaining crystal structures of GAG enzymes as outlined
earlier, there is an emerging need to develop tools to address protein structure prediction as well.
Further to the prediction of GBP structure, is the elucidation of factors motivating
glycan-binding specificity. It is notable that the concept of protein-protein interaction network
analysis has revolutionized the field of biology by changing the traditional single-protein-single-
function notion to the powerful "systems" approach to biomolecular interaction analysis [314-
316]. In this post-genomics period where there is increasing evidence of the role of protein-
polysaccharide interactions in modulating key biological processes, there is great focus in
adopting "systems" engineering approaches to decode the structure-function relationships
mediating glycan-protein interaction specificity. There is much lesser knowledge presently about
the factors that are responsible for specificity of glycan-protein interactions as compared to
protein-protein and protein-DNA interactions, owing to the distinctively complex information
density of polysaccharides and their multi-layered interplay with proteins, as discussed earlier.
GAG-protein interactions such as Fibroblast growth factor (FGF) interaction with HSGAGs
(Figure 1.16) are also comparatively well characterized through structure-function and site-
specificity studies as compared to lectins (that bind to smaller, simple or branched glycans).
Figure 1.16 Depiction of FGF (C = gray; 0 = red; N = blue) bound to HSGAG (green) with the
HSGAG-binding site residues and binding surface on FGF highlighted in pink.
The FGF is a huge family of p-trefoil fold proteins that have been indicated as important
modulators of cancer and other diseases [38, 156, 233, 241]. The beta-trefoil fold itself is
extensive across GBPs, and is found co-complexed with several diverse glycans (including
heparin in the case of FGF). An analysis of each of these protein-glycan complexes is performed
towards the latter half of the second part of this thesis that pertains to developing tools for
predicting glycan-binding protein structure.
In addition to GAGs that are linear glycans, branched glycans are also key mediators of
important biological processes, as mentioned earlier. The next section focuses on branched
glycans and the biological functions arising from their interactions with GBPs (lectins).
1.3.5 Branched glycans and their interactions with Lectins
Branched glycans are present as N-linked and O-linked glycosylation on glycoproteins or
on glycolipids (Figure 1.17) [317-321]. There are three major classes of N-linked glycans: high-
mannose, complex, and hybrid [322-326]. High-mannose glycans are two N-acetylglucosamines
with many mannose residues. Complex glycans contain almost any number of the other types of
monosaccharides, including more than the original two N-acetylglucosamines. The
oligosaccharide chain is attached by oligosaccharyltransferase enzymes to asparagine occurring
in the tripeptide sequence Asn-X-Ser or Asn-X-Thr (where X could be any amino acid except
proline) [327-331]. This sequence has come to be known as a glycosylation sequon.
a. a3/6a a2a3 a3/04
a33
134 03
a2 a2 a2 p4
146 2 04/6 2 /
a3 a6 2
a3 a6 a6a6
a3 $3 13 p3
3 -p3 6 p3 p-3 $6
Asn Asn Asn Ser/Thr Ser/Thr Ser/Thr Ser/Thr
High mannose Hybrid Complex Core 1 Core 2 Core 3 Core 4
N-linked glycans 0-linked glycans
Glycan OMannose O Galactose UN-acetyl glucosamine 0 N-acetyl galactosamine
nomenclature + N-acetyl neuraminic acid *N-glycolyl neuraminic acid
Figure 1.17 Chemical diversity of branched glycans. This picture is adapted from: The
Essentials of Glycobiology, A. Varki et al, CSH Press, 2004.
O-linked glycosylation may involve the addition of N-acetyl-galactosamine (0-GalNAc
type), fucose (0-fucose type), glucose (0-glucose type), N-acetyl-glucosamine (0-GlcNAc
type), mannose (0-mannose), or other moieties, to serine or threonine residues by enzymes [332-
337]. This may be followed by addition of other monosaccharides. O-linked glycans of each of
these types occur in various tissues within the human body and are involves in several important
biological functions [338-345].
Glycan-binding proteins (GBPs), also called as Lectins, decode the glycome of biological
systems by recognizing and binding specific glycans from the cell's array of information dense
polysaccharides [346]. The structural diversity in GBPs mirrors the chemical heterogeneity, non-
template driven biosynthesis and high information density of the ligand glycan molecules [347-
349]. GBPs bind to N-linked and O-linked glycans and mediate cell adhesion, trafficking, and
signaling events in inflammation and immune responses [350]. GBPs also act as receptors for
viruses, bacteria and other microbes that use the glycans attached to cell-surface glycoproteins as
ligands for the host-cell GBPs [351].
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Figure 1.18 Classes of lectins and their glycan specificities. This picture is adapted from:
The Essentials of Glycobiology, A. Varki et al, CSH Press, 2004.
The glycan binding sites on lectins typically accommodate mono- to tetrasaccharide
glycan ligand motifs [352]. The underlying glycan-protein interactions are characterized by a
rich spectrum of specificities, avidities and affinities [353, 354]. The interaction between any
single glycan binding site and the glycan motif is low affinity with values in the micro- to
millimolar range [355]. Most of the physiological glycan-lectin interactions, however, are
multivalent involving binding of an ensemble of glycan motifs to multimeric carbohydrate
recognition domains (CRDs) formed by association of lectins [356, 357]. Lectins are either
expressed as soluble or membrane-bound proteins in the monomeric or multimeric forms with
multiple glycan binding sites [358]. Also, lectins can either be dispersed on the cell surface or
localized in a microenvironment such as microvilli or clathrin-coated pits [359, 360].
The main classes of lectins include C-type lectins, S-type lectins (Galectins), P-type
lectins, and I-type lectins (Siglecs) (Figure 1.18) [361]. These lectins possess diverse
organization of protein topologies in their extracellular domains that house the CRDs (Figure
1.19) [362].
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Figure 1.19 The protein structural topologies for the extracellular domains in the main
classes of lectins are depicted. Nomenclature is as follows: CL (C-type lectin CRD); SL (S-
type lectin CRD); MP (P-type lectin CR9); IL (I-type lectin CR9); EG (EGF-like); Ig [I2]
(Immunoglobulin C-set); TM (transmembrane region); C3 (complement regulatory
repeat). T his picture is adapted from: The Essentials of Glycobiology, A. Varki et a!, CSH
Press, 2004.
Several crystal structures of lectins from various biological sources with their cognate
glycan ligands have been elucidated, allowing for an exploration of lectin-glycan interactions at
the level of atomic resolution [363-365]. Along these lines, the following principles regarding
lectin binding sites have emerged as a consensus from numerous previous studies [366-371].
First, the binding sites are of relatively low affinity and are found in shallow indentations on the
surface of the lectins. Second, selectivity is mostly achieved via a combination of hydrogen
bonds (involving the hydroxyl groups of the sugars) and by van der Waals' packing of the
hydrophobic face of monosaccharide rings against aromatic amino acid side chains. Third,
further selectivity may be achieved by additional contacts between the saccharide and the
protein, sometimes involving bridging water molecules or divalent cations. Finally, the actual
region of contact between the saccharide and the polypeptide typically involves only one to three
monosaccharide residues. As a consequence of all of the above, these lectin-binding sites tend to
be of relatively low affinity, but of high specificity [372-374]. The ability of such low-affinity
sites to mediate biologically relevant interactions in the intact system thus appears to require
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multivalency. These unique and important characteristics of lectins make the study of lectin
biology both interesting and significant.
One of the biological systems in which lectin binding to branched glycans becomes
particularly significant is in the context of influenza virus surface hemagglutinin (HA) binding to
the epithelial cell surface branched sialylated glycans (Figure 1.20) [317-324]. The Spanish
influenza pandemic of 1918 caused by the HIN1 subtype virus resulted in ~20 million to 50
million deaths worldwide [325-331]. The emergence of avian influenza H5N1 viruses that are
able to infect humans (>300 known cases) and produce a high mortality rate (~200 deaths) has
raised serious global health concerns [332-337]. Significantly, adaptation of these viruses for
efficient human-human transmission could result in a new influenza pandemic, a public health
disaster of tragic proportions [338-341].
The evolution of pandemic viruses involves crossing-over of avian influenza viruses
(natural host) to humans and adaptation to the human host for subsequent infection and human-
human transmission [342]. This cross-over is believed to involve mutations in HA that switch its
glycan receptor preference from cone topology a2-3 sialylated (a2-3) to umbrella topology a2-6
sialylated (a2-6) glycans found abundantly in human upper respiratory epithelia [343]. The
human upper respiratory tract a2-6 receptor adaptation of HA is a critical step in permitting the
viruses to infect and efficiently replicate in these tissues, leading to rapid human-human
transmission [344].
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Figure 1.20 Influenza virus Hemagglutinin (HA) engagement of (A.) host surface a2,3
linked sialylated glycans with cone topology; and (B.) host surface a2,6 linked sialylated
glycans with umbrella topology. This picture is adapted from: The A. Chandrashekaran et
al, Nature Biotechnology 2008.
The recent incidence and spread in humans of the 2009 pandemic "swine flu" virus has
raised global concerns regarding its virulence, human-human transmission, and anti-viral drug
resistance properties [375]. The main cause of the so-called swine flu has been identified as
human infection by influenza A viruses of a new H1Nl (hemagglutinin 1, neuraminidase 1)
subtype, or '2009 H1N1 strain' [376]. The first cases of human infection were reported in April in
the Mexican town of La Gloria in Veracruz; soon after, reported infections occurred in areas of
southern California and Texas of USA [377]. In the latter half of this thesis, using a
representative 2009 H1N1 strain as our starting point and our intricate understanding of
homology modeling and glycan-protein interaction analysis tools, the likely human adaptation,
transmissibility, virulence, and resistance characteristics of these viruses are investigated [378].
Our ability to engineer lectins with desired specificity for important therapeutic
applications (such as treatment of influenza and other hypermutative RNA viruses) also rests
upon deducing and exploiting the factors that dictate the glycan-binding specificity of GBPs
[353-361]. Such protein engineering applications require the development of precise tools for
deducing the structures and functions of the protein of interest [362-364]. However, elucidation
of GBP structure is rife with several challenges on both experimental and computational fronts
[363-369]. As outlined earlier, it is not always possible to experimentally determine GBP
structure since many of these are transmembrane molecules and there are challenges associated
with their expression and crystallization [368-371]. The challenges on the computational front,
on the other hand, are a consequence of the extreme evolutionary sequence divergence of lectins
(twilight zone) presents hurdles for conventional homology modeling protocols [363-374].
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Figure 1.21 Breakdown of homology modeling in the twilight zone of low sequence identity
The next section discusses these challenges facing prediction of GBP structure by
homology modeling and the emerging need for development of new tools for this application.
1.3.6 Challenges facing GBP structure prediction: Need for new homology modeling tools
The elucidation of GBP structure is not only fundamental to the characterizing key
structure-function relationships like their glycan-recognition specificity, but also for designing
novel GBPs for biological or pharmaceutical applications. Given the numerous challenges facing
experimental structure determination of GBPs, homology modeling is emerging as a desirable
alternative. Homology modeling is an in-silico molecular modeling methodology that builds the
structure of 'target' protein based on a 'template' with high sequence identity [379-381].
Although there are plenty of outstanding homology modeling servers and tools, the application
of these to structure prediction of GBPs has been limited due to several roadblocks [382-386].
One major limitation is the generally poor sequence identity (even less than 10%) that prevails in
GBP fold families, believed to be a consequence of large evolutionary sequence drift caused by
the binding of several chemically heterogeneous and structurally diverse glycans to GBPs of the
same fold (Figure 1.17). Since homology modeling produces significant inaccuracies in the
'twilight zone' of less than 25% target-template sequence identity (Figure 1.21) -- such as entire
folds mispredicted [387-390] -- it is challenging to identify the fold of GBP sequences de novo.
Additionally, glycan-binding proteins are composed of a diverse array of protein folds,
that further challenges elucidation of folds from sequence de novo (Table 1.4). Since fold
identification is the first towards template selection, target-template alignment, and structural
coordinates assignment in homology modeling [391-397], the application of conventional
homology modeling tools to GBPs becomes further complicated.
In order to address these challenges and develop a tool for GBP structure prediction, in
this Thesis, evolutionarily conserved regions of proteins are examined to decode "non-tinkered"
information that is characteristic of each fold family. Such "fold signature" information is then
utilized towards accurate identification of protein folds directly from sequence and for the
purposes of selecting an optimal template molecule. The latter half of the second part of this
thesis focuses on the development of this new tools that can extend the application of homology
modeling to the twilight zone of low identity, thereby providing a new platform for high-
throughput GBP structural modeling
Table 1.4 The diversity of protein fold families that constitute GBPs
Glycan-binding Proteins (GBPs) Fold family (aI/q/a3)
Mannose-binding proteins, Snake coagglutinins, Surfactant C-type lectin-like (ap)
proteins, Tetranectins, Selectins, DC-SIGNs, CD69, CD94
Calnexins, Galectins, Lectin leg-like, Concanavalin A-like (1)
Legume lectins, Pentraxins
Fibroblast growth factors, Ricin B-like lectins, Agglutinins, p-trefoil (P)
Glycosidases, Neurotoxins, Ribosome-inactivating proteins
Mannose-binding lectins, Delta-endotoxins, p-prism (P)
Vitelline membrane outer-layer proteins
E set domains, Fibronectins, Immunoglobulins, Tenascins 0-sandwich (P)
Antithrombins, Heparin co-factors, Protein C inhibitors Serpins (ap)
Amylases, Chitinases, Glycanases TIM beta/alpha barrel (ap)
Angiogens RNase A-like (ap)
Hevein-like lectins Knottin (1)
Receptor associated proteins RAP domain-like (a)
Apolipoproteins Four-helical up-and-down bundle (a)
Tachylectins, Fucose-specific lectins p-propeller (P)
1.4 Summary and Specific Objectives
Understanding structure is central to decoding the function of biopolymers. In this Thesis,
new tools are introduced for investigating the structure-function relationships of biopolymers in
nanotechnology and glycobiology, thus furthering their biological, biotechnological, and medical
applications.
Advances in nanotechnology have led to an active interest in developing multifunctional
biopolymer-based nanoscale platforms capable of sensing the molecular signatures of
tumorigenesis (the birth and development of cancer) and delivering therapeutics specifically to
cancerous cells in order to simultaneously reduce toxicity and increase efficacy. Pioneering
contributions to polymer-drug formulation technology have particularly enhanced these efforts
by providing for distinct advantages such as sustained release, increased circulation lifetime,
specific localization to tumor microenvironments, and biocompatible vehicles. There is growing
evidence that (i.) precise targeting of surface-functionalized nanoparticles to over expressed
receptors on tumor cells (spatial control), combined with (ii.) rational design of polymer-drug
formulations for modulation of factors influencing the release profiles of nanoparticle-
encapsulated drugs (temporal control), could together offer dramatic therapeutic benefit. Hence,
there is emerging interest in the development of molecular modeling and computational
nanotechnology tools for the design of such spatiotemporally-regulated anticancer systems.
Specifically, embedding temporal control into the release of anti-cancer drugs is extremely
challenging owing to the influenza of several distinct phenomena such as polymer hydrolysis,
polymer degradation, polymer erosion, drug dissolution, drug diffusion, nanoparticle
fragmentation, and microenvironmental physicochemical changes. Hence, this Thesis introduces
a new tool for modeling polymeric nanoparticle degradation and the release of chemotherapeutic
agents from such vehicles. The spatiotemporally regulated release of FDA-approved anti-cancer
drugs from FDA-approved polymeric systems with the Nanocell technology developed by our
group is demonstrated, with compelling results of nanoparticle formulation and tumor shrinkage.
On the glycobiology front, this Thesis builds on the solid foundation of several previous
studies from our group that have provided significant impetus to the development and
standardization of Glycomics. In this post-genomic era, Glycomics is emerging as an exciting
area of research in cellular and molecular biology, with numerous salient roles of glycans in
fundamental biological processes being discovered. It is clear from these studies that the
biochemical structure of glycans is a chief factor governing the specificity and affinity of their
interaction with biologically significant proteins such as morphogens, growth factors, cytokines,
chemokines, enzymes, and numerous other signaling molecules. However, decoding structure-
function relationships mediating glycan-protein interactions has encountered several unique
challenges owing to many factors including high information density, chemical heterogeneity,
and lack of amplification tools for glycans; their multivalent and "fuzzy" interaction with GBPs;
and the rampant lack of homology between functionally-related GBPs that challenges de novo
fold characterization for these proteins. Advancing the field of Glycomics hence requires the
development of new tools to address the key challenges associated with decoding the structure-
function relationships governing glycan-protein interactions.
With these as the primary goals, the specific objectives of this thesis are as outlined
below. The rest of the thesis is organized as follows. The development of a new whole-
nanoparticle modeling platform for predicting drug release kinetics from polymeric nanoparticles
and its application to enhance the potency of chemotherapy to different tumors is described in
Chapter 2. The engineering and structure-function characterization of the recombinant bacterial
enzymatic tools Chondroitinase ABC-II, 6-0-Sulfatase, and N-Sulfamidase for decoding the fine
structure of complex linear glycans and facilitating GAG sequencing are described in Chapter 3.
In Chapter 4, the structure-function relationships governing interactions of branched glycans
with lectins is investigated, specifically in the context of Influenza virus hemagglutinin binding
to host cell surface sialylated glycans, using the 2009 H1N1 pandemic influenza virus as a model
system. This thesis concludes with Chapter 5 wherein the development of a novel tool for the de
novo prediction of protein fold and structure directly from sequence is described, along with
applications of this tool for GBP structure prediction towards facilitating the high-throughput
decoding of structure-function relationships governing protein-glycan interactions.
Specific objectives of the Thesis
1. Develop a new platform for predicting the kinetics of drug release from polymeric
nanoparticles and apply this towards achieving spatiotemporally regulated targeting of
anti-cancer drugs to tumor tissues for maximal therapeutic efficacy (Chapter 2).
* Predict drug release profiles from polymeric nanoparticles constituted of FDA-
approved polymer-drug combinations.
* Investigate the biological significance of temporally regulated release of anti-
cancer drugs to tumor tissues.
* Understand the scope of extending the developed platform towards other
spatiotemporally regulated nanotechnology devices for targeting the broad
spectrum of diverse attributes that together constitute the "Cancer Cell
Immortality Spectrum".
2. Develop and structurally-biochemically characterize recombinant enzymatic tools
for elucidating GAG structure and decoding GAG-protein interactions (Chapter 3).
* Develop and biochemically characterize the structure-function relationship
mediating substrate specificity, active site residue functions, mode and
mechanism of action, for Chondroitinase ABC-II from Proteus Vulgaris.
* Develop and biochemically characterize the structure-function relationship
mediating substrate specificity, active site residue functions, sequence of
processing, mode and mechanism of action, for 6-0-Sulfatase from
Flavobacterium Heparinum.
* Develop and biochemically characterize the structure-function relationship
mediating substrate specificity, active site residue functions, sequence of
processing, mode and mechanism of action, for N-Sulfamidase from
Flavobacterium Heparinum. Also understand the structural basis for novel
nitrogen-sulfur bond cleavage by this enzyme as opposed to oxygen-sulfur
bond cleavage by all other known sulfatases.
Specific objectives of the Thesis (continued)
3. Understand the structure-function relationship mediating the interaction of branched
sialylated host cell surface glycans with influenza virus surface lectins and apply this
knowledge to examine the virulence, transmissibility, and anti-viral resistance of the
2009 HIN1 "Swine Flu" influenza virus (Chapter 4).
" Model the hemagglutinin (HA) structure of 2009 HINI influenza virus to
investigate the human adaptation and receptor binding of the present pandemic.
" Model and analyze the neuraminidase (NA) structure of the 2009 HIN1
influenza virus to elucidate the structure basis for its binding to sialic acid and
understand the potential for emergence of viruses resistant to the popular anti-
virals tamifu and relenza.
" Model the PB2 and M2 structures and analyze the information content of all
other remnant genes of the 2009 H1N1 influenza virus to predict the human-to-
human transmission, resistance to adamantane derivative anti-virals, and the
overall virulence of the present "swine flu" pandemic.
4. Develop a novel tool for de novo prediction of protein fold and structure directly
from its sequence and apply this to shed light on homology modeling in the twilight
zone, thus providing for new opportunities to model GBP structure (Chapter 5).
" Analyze evolutionarily non-tinkered regions of proteins to elucidate "fold
signatures" that can be used for high-throughput assignment of protein folds to
amino acid sequences de novo.
" Understand the biological implications of rampant twilight zone of homology
in GBPs and explore opportunities for modeling biologically or medically
salient GBPs and understanding their interaction with glycans.
* Investigate the universal applicability of the developed protein structure
prediction protocol and explore its utility for illuminating the twilight zone in
biologically salient examples from fields such as immunology, protein science,
and glycobiology.
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2. Deducing Structure-Function Relationships of Biopolymers
in Cancer Nanotechnology
Summary
This chapter focuses on developing tools for decoding the factors governing
kinetics of drug release from polymeric nanoparticles and applying this towards
enhancing the efficacy of chemotherapeutic treatments.
Specifically, a 'Voxel' based whole nanoparticle simulation platform that can
account for the complex parameters modulating drug release was developed, to model
the kinetics of biopolymer degradation upon hydrolysis and the formation of erosion
channels thereof It was observed that the developed Voxel platform could accurately
predict all phases of the experimentally-determined kinetics for polymeric matrix erosion
and drug release. The platform was also able to provide insight into the fragmentation of
polymeric nanoparticles upon formation of erosion channels, with unprecedented
resolution. The platform was further able to incorporate the effects of chemical drug-
conjugation to polymer molecules, this providing ample application to anti-cancer
sustained drug release kinetics prediction. The Voxel platform hence emerged as a
versatile method to delineate the effects of all nanoparticle design parameters
quantitatively. The successful deployment of the Voxel method to predict the temporally-
regulated release -- of FDA-approved anti-cancer drugs (including doxorubicin and
dexamethasone) from nanoparticles constituted of the FDA-approved biopolymer PLGA -
- was demonstrated with the Voxel-optimized nanocell platform, with compelling results
vis-a-vis tumor volume shrinkage.
These studies resulted in 3 peer reviewed publications in (i.) The Journal of
Nanoscience and Nanotechnology; (ii.) Macromolecular Rapid Communications; and
(iii.) Handbook of Nanophysics: Nanomedicine and Nanorobotics.
2.1 Predicting kinetics of anti-cancer drug release from polymeric nanoparticles
2.1.1 Need for computational models to understand factors governing biopolymer
hydrolysis and nanoparticle erosion
The use of polymeric nanoparticles as drug delivery devices is becoming
increasingly prevalent in a variety of biological and therapeutic applications [11]. There
is accumulating evidence that chemotherapeutic treatments are significantly enhanced by
the temporally regulated release of drugs from polymeric devices [12]. The temporal
kinetics of drug release from polymeric devices is dependent on most of the
physicochemical properties of the polymeric biomaterials involved [13]. These are
typically classified based on their mode of clearance (if at all) from the body (Figure 4a)
[14]. Biodegradable polymers are broken down and metabolized within the body,
bioeliminable polymers remain structurally intact but are cleared by the renal filtering
system (kidneys), and permanent polymers are used for long term in-vivo implants [15].
Of these, there has been great interest in the use of biodegradable polymeric nanoparticles
for cancer treatment [16].
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Fig. 2.1 Mode of clearance and structure of polymers in anti-cancer applications.
Despite their widespread use in Cancer diagnostics and therapeutics, the factors
influencing the kinetics of drug release from polymeric nanoparticles are still not
quantitatively understood [17]. Given that drug release profiles depend on a wide variety
of design parameters that moderate the interplay between polymer, drug, and water
molecules, this in turn challenges the high-throughput engineering of anti-cancer
polymer-based nanoscale devices [18].
Recently, the availability of computational models to understand and predict drug
release from macroscale polymer matrices has become popular for the extension and
optimization of existing drug delivery technologies [11-20]. However, since the
mechanism of drug release from nanoparticles differs from that of macro-particles even
when both vehicles have the same polymer-drug composition, direct application of
existing methods to nanoparticles is challenging [14-19]. For instance, drug diffusion
through the polymer matrix has been shown to be slower in nanoparticles than in
microparticles, and this may be due to more dense internal structures as a result of
fabrication techniques or the neutralization of autocatalysis-enhanced diffusion
phenomenon at the smaller length scales [16-18]. Such nanoscale-unique properties
compound the development of models to predict drug release kinetics from polymeric
nanoparticles.
Hence, there is a need for a platform for simulation of polymeric nanoparticle
erosion and chemotherapeutic drug release thereof.
2.1.2 Utility of PLGA and other biopolymers in design of anti-cancer nanoparticles:
Challenges in ab-initio optimization of design parameters
The most frequently used biodegradable polymers for anti-cancer applications
include the polyesters poly(lactic acid) and poly(glycolic acid), or PLA and PGA
respectively, among several other biocompatible polymer families (Figure 2.1) [398]. As
PLA and PGA are introduced, they are eventually hydrolytically degraded and form
acidic oligomers and monomers, effectively dropping the pH [17]. The acidic pH
contributes further to the hydrolysis, eventually reducing the polymeric network via
various degradation mechanisms that allow the encapsulated drug to be released.
By fine-tuning the physicochemical characteristics of the polymer, it is possible to
obtain a high level of control over the kinetics of drug release [17]. Polymer size,
composition, and chain length have all been shown to have profound effects on the
properties of the biomaterial device, and are each easily tailored [11-19]. It is also
possible to create co-polymers, or polymers of multiple monomeric species, allowing for
a nearly infinite number of customizable attributes [15-17]. These traits allow researchers
to "fine tune" properties such as the stability, pH, solubility, and tensile strength of
nanoscale polymeric devices. By encapsulating or conjugating different drugs to different
polymers, it is possible to create a multitude of temporal release characteristics [17]. In
fact, the use of different polymer classes allows for absolutely diverse temporal control,
ranging from minutes to months [96-98]. This is highly beneficial, as it allows specific
temporal control that can be altered for each drug used in the nano-complex. Such
spatiotemporal control features of polymeric nano-devices also permit the creation of
novel treatments that would otherwise be impossible. For example, highly toxic drugs
that would normally prove fatal may be successfully delivered almost exclusively to
tumors, effectively broadening the scope of drugs that can be administered by severely
reducing off-target effects. This is evidenced by the fact that nanoparticle-based cancer
therapeutics are already showing some promise from clinical trials [96, 97].
However, given the several parameters that influence the kinetics of polymer
degradation, it is important to accurately zero in on the design parameters for polymer
nanoparticles [98]. For this purpose, the development of predictive computational models
is key, as outlined earlier. Here, we introduce a 3-D whole-nanoparticle simulation
platform for this very purpose.
2.1.3 Development of a platform for prediction of polymeric nanoparticle erosion and
drug release: From pixels to voxels
Monte Carlo models based on 'pixel degradation' have been proposed to simulate
polymer erosion and subsequent drug release from microparticles as depicted pictorially
herein (Figure 2.2) [14, 70, 126]. The pixel model mechanism as initially proposed is
simple, reliable and pragmatic. Although much advancement has emerged since the
initial use of pixels for polymer erosion modeling [15-20], there remains remarkable
scope for sophistication. The pixel models have not considered key factors such as
average polymer molecular weight, monomer composition, geometry of the particle or
physical breakdown of the polymer particle following progressive erosion [98]. Some
recent extensions to the pixel model have also made assumptions that decrease the
versatility of Monte Carlo simulations such as the use of discrete polymer and drug pixels
or linear drug pixel degradation lifetimes [15-20]. The decrease in versatility prevents
their use for simulating drug-conjugated polymer particles and other such hybrid vehicles
that are becoming increasingly popular in anti-cancer drug delivery [18]. Moreover, with
the exception of the most recent Monte Carlo models that account for the complete
particle, the earlier models had restricted themselves to just the microenvironment around
the particle-medium interface and generalized the results to the system at large. Finally,
since the concept of 'pixel volume' does not exist, two dimensional models cannot
account for density, morphology and distribution of the pores, polymers and drugs inside
the device. These limitations greatly undermines the potential of pixel models and
necessitates 3-D modeling (Figure 2.2).
An outstanding motivation to consider the 'third dimension' stems from the
observation that pixel models work with the principle of 'neighboring unit effect', that is,
the combined influence of immediate neighbors on any polymer matrix pixel of interest.
But two dimensional modeling accounts for only eight immediate neighbors whereas
three dimensional models could potentially account for all twenty six immediate
neighbors as shown pictorially (Figure 2.3). Further, the difference in number of
neighbors (NoN) between 2-D and 3-D increases drastically as we consider more distant
neighbors (Figure 2.3). The development and application of future Monte Carlo models
would require accurate calculation of the neighboring unit effect and this necessitates
consideration of all three dimensions.
Voxel is the volume element which represents data on a regular grid in 3-D space
and is analogous to pixels that are area elements representing 2-D data (Figure 2.3)
[399].
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Figure 2.3 The 2-D Pixel-based Monte Carlo models of microparticles contrasted
with the 3-D Voxel-based whole nanoparticle model introduced herein
Voxels are particularly attractive and time-optimized for computational
nanotechnology applications because the number of voxels required for nanoscale
modeling is far lesser than that required at micro- and higher-scales (Figure 2.4).
Considering the recent advances in processing power and the relatively small value of
voxels to pixels ratio (VPR) for nanoparticles the computational cost associated with
voxels modeling is comparable to pixels modeling. Considering all of the above factors,
we focused on the development of voxels based three-dimensional spherical model that
can predict drug release from polymeric nanoparticles.
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Figure 2.3 (Top) Contrast of the neighborhoods of pixels (2-D) and voxels (3-D)
shows the 8 versus 26 immediate "Number of Neighbors (NoNs)"; and (Bottom) The
drastic increase in progressive number of neighbors from 1-D to 2-D to 3-D is
shown.
I ................... "I'll -1  1.-1:::::::- ----- - - - - =
................
.................. 
------
710 ... .....
8..........
.. .. 
2 .....
0......
6000 D si
4
Particle
Microparticles Dimension
6000
2000 4000
S9 ' 0 0 20 Resolutio
Very Low VPR
Nanoparticles
Figure 2.4 The limited computational cost associated with 3-D Voxel-based simulations at
the nanoscales for polymeric nanoparticles is in sharp contrast to significantly higher
computational cost associated with 3-D Voxel-based simulations at the microscales for
polymeric microparticles.
2.1.4 Predicting release of the anti-cancer drug doxorubicin from spherical PLGA
nanoparticles with the Voxelplatform
For the purposes of the Voxels model introduced herein, recent findings from
nanoscale experiments that revealed that the reduced drug diffusivity in nanoparticles
limits the influence of diffusion to the interface between polymer and the external
aqueous environment was utilized [11-15]. The model hence simulates drug release after
degradation of surrounding polymer and the formation of an erosion channel to the
particle surface, given that once the drug diffuses into the exposed erosion channel, the
drug is released due to the small distances necessary to travel to the particle surface at the
nanoscales. Using this framework, drug release from bulk eroding nanoparticles was
modeled based upon a three dimensional Voxel based Monte Carlo simulation of polymer
erosion.
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In a recent study, Yoo et. al. compared the release of the anti-cancer drug
doxorubicin from drug-encapsulated and drug-conjugated PLGA nanoparticles [18] and
this data is used here to highlight the efficiency of the Voxel method predictions. A more
detailed analysis of the Voxel model predictions for other anti-cancer drugs such as
Dexamethasone is presented in the publication following this section. The computed
simulation result of cumulative drug release from doxorubicin encapsulated PLGA
nanoparticles is shown as a blue line (Figure 2.5 A), along with the corresponding
experimental data (green dots). The simulation was then performed for the case of
doxorubicin-conjugated PLGA nanoparticles and the correlation between experimental
data points (orange dots) and voxel model results (red line) are also shown (Figure 2.5
A). The high degree of correlation between voxel model results and experimental data
points validates the model and proves its versatility in simulating both drug encapsulated
and drug-conjugated polymer nanoparticles.
The predictive potential of the voxel model was also explored through the
variation in molecular weight of the polymer constituting the nanoparticle. This factor is
known to play an important role in controlling the rate of drug release, however as
discussed earlier, none of the pixel-based models have accounted for polymer molecular
weight variance. The data from an earlier study of cumulative drug release from 200nm
sized nanoparticles composed of dox-PLGA5005 conjugates (of molecular weight 5000)
and dox-PLGA5010 conjugates (of molecular weight 10000) was used to verify the
predicted model results. The experimental data for cumulative doxorubicin release from
dox-PLGA5005 nanoparticles (blue dots) and dox-PLGA5010 nanoparticles (red dots) is
shown (Figure 2.5 B). The voxel model results corresponding to dox-PLGA5005 (green
line) and dox-PLGA5010 (orange line) are also shown (Figure 2.5 B). The same figure
also displays both the experimental data (gray dots) and model results (black line) for
cumulative release from doxorubicin encapsulated PLGA nanoparticles. The predicted
model results correlate extremely well with the experimental data for both drug
encapsulated and drug-conjugated polymeric nanoparticles of varying PLGA molecular
weights, thereby demonstrating the predictive capability of three dimensional voxel
modeling.
An analysis of the simulation results shows that cumulative doxorubicin release is
nearly bi-phasic for drug encapsulated nanoparticles, with an initial burst release (~50%
of total drug volume) that is then followed by a relatively slower release phase.
Comparison with cumulative doxorubicin release from drug-conjugated nanoparticles
shows that the sustained release profile does not have the initial burst phase, but has an
increased rate between 8 to 16 days indicating tri-phasic release. This tri-phasic release is
characteristic of PLGA particles that undergo bulk erosion driven by percolation effects
and autocatalysis [70]. The burst phase is absent in drug-conjugated nanoparticles owing
to the chemical bond between polymer matrix and the drug molecules even in the
proximity of the nanosphere surface. This hypothesis was confirmed with the voxels
model by analyzing the exposed surface area to volume ratio (AVR) which has been
indicated to influence polymer erosion kinetics. The quantization of AVR variation was
possible owing to the three dimensional whole-nanosphere nature of the voxels model.
The dynamic variation of the exposed surface area and remnant volume of the
nanosphere (Figure 2.5 C) and the computed AVR variation (Figure 2.5 D) are also
shown. The variation of surface area, volume and AVR for different average polymer
molecular weights has also been investigated in these figures. There appears to be
substantial increase in AVR dynamics for PLGA5005 nanoparticles as compared to
nanoparticles of higher average molecular weights. This predicated result correlates with
our earlier analysis of the significance of AVR in determining the burst release and
subsequent rate of sustained release. It is interesting to note that physical properties
associated with polymer molecules have such a significant impact on nanosphere erosion
kinetics.
In order to use computational nanotechnology for investigating hitherto
unexplored nanoscale phenomena, the influence of nanoparticle size on drug release and
average dynamic size of bulk-eroding nanoparticles was studied. These effects have not
been empirically studied owing to the technological bottlenecks associated with
nanoscale observation and experimentation that were discussed earlier.
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Figure 2.5 (a.) The correlation between experimental data and voxel model results for
doxorubicin release from DE and DC nanoparticles is shown. The known parameter
values from literature are PLGA50-50 polymer crystallinity = 0, nanoparticle diameter =
300nm, weight average molecular weight = 8020 and degradation rate constant = -
0.121/day. The model parameters values obtained for PLGA by curve-fitting are a = 23,
b = 3 and p = -0.5. (b.) The predictions by the voxels model for cumulative drug release
from nanoparticles with PLGA of varying molecular weights are correlated with
experimental data . (c.) The dynamics of exposed nanoparticle surface area and remnant
volume are computed with the voxels model for varying PLGA molecular weights. (d.)
The Area to Volume Ratio (AVR) dynamics is computed using the voxels model for
PLGA of varying molecular weights. (e.) The variation of cumulative doxorubicin release
with time as a function of nanoparticle size is relatively difficult to calculate empirically.
Here this variation is computed using the voxels model for DE nanoparticles. (f.) The
variation of cumulative doxorubicin release with time is computed from drug-conjugated
polymeric nanoparticles for DC nanoparticles.
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The predicted release from doxorubicin encapsulated and doxorubicin-conjugated
PLGA nanoparticles of varying sizes (100-700 nm) respectively are shown (Figure 2.5
E-F). Experimental data is only available for 300nm sized nanoparticles and this is also
shown (black dots) in the same figures. From these results, one can observe that increase
in size of nanoparticle causes general decrease in rate of predicted drug release. This
observation may be explained by the increase in average drug diffusion path length with
increase in particle size for polymer matrices such as PLGA that erode substantially
throughout their bulk. In the case of drug encapsulated nanoparticles (Figure 2.5 E), the
magnitude of predicted burst release appears to decrease from 89% for 100nm sized
nanoparticles to 22% for 700nm sized microparticle. This correlates with experimental
data on microparticles for which burst release was documented to diminish with increase
in particle size.
These results of this section provide proof-of-principle demonstration regarding
the potential of three dimensional voxel models for analysis and prediction of polymeric
nanoparticle erosion kinetics, using the anti-cancer drug doxorubicin and FDA-approved
biopolymer PLGA as examples. The voxels computational platform emerges to be
reliable as demonstrated by its accuracy in prediction of key nano-material properties.
The model's versatility was also successfully exhibited by precise simulation of drug
encapsulated as well as drug-conjugated nanoparticles. The following publication
discusses the application of the Voxel platform for simulating the release of another
popular anti-inflammatory drug, dexamethasone, thus demonstrating the more broader
and potentially universal applicability of this platform for nanoparticle erosion and drug
release predictions.
2.1.5 Published manuscript
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The use of polymeric nanoparticles as drug delivery devices is becoming increasingly prevalent in
a variety of therapeutic applications. Despite their widespread clinical use, the factors influencing
the release profiles of nanoparticle-encapsulated drugs are still not quantitatively understood. We
present here a new, semi-empirical model of drug release from polymeric nanoparticles using a
formulation of dexamethasone encapsulated within poly(lactic-co-glycolic acid) to set model param-
eters. We introduce a three-dimensional voxel-based framework for Monte Carlo simulations that
enables direct investigation of the entire spherical nanoparticle during particle degradation and drug
release. Due to implementation of this model at the nanoscale, we utilize assumptions that sim-
plify the model while still allowing multi-phase drug release to be simulated with good correlation
to experimental results. In the future, emerging mechanistic understandings of nanoparticle drug
release may be integrated into this simulation framework to increase predictive power.
Keywords: Nanoparticles, Monte Carlo Model, Drug Release.
The shift from micro- to nano- scale drug delivery sys-
tems in recent decades has been driven by improvements
in polymer formulation technology and evidence that med-
ical applications such as chemotherapy are significantly
enhanced by the use of nanoscale delivery vehicles."
Because drug release profiles differ based on the poly-
mer, drug, and design parameters, the availability of com-
putational models to understand and predict drug release
is valuable for the extension and optimization of existing
drug delivery technologies.
Several models have been reported in the literature to
describe drug release and particle breakdown for polymer-
based delivery vehicles." It is clear from these studies
that the number of factors influencing drug release is too
unwieldy for a single model to incorporate. Such factors
include water and drug diffusion, drug dissolution, poly-
mer molecular weight, particle size and geometry, polymer
degradation, micro-environment pH changes, autocataly-
sis, polymer swelling, and more." 1 Incorporation of these
factors is further complicated by a still incomplete under-
standing of the extent to which they each influence the
kinetics of drug release. Previous modeling approaches
*Author to whom cormspondence should be addressed.
tThese authors contributed equally to this work.
have been limited by necessity to incorporating the fac-
tors most influential to drug release or polymer breakdown
for a particular delivery system.10 Despite this limitation,
computational models have still successfully simulated
complex multi-phase drug release profiles from polymeric
microparticles."-2 Few studies have extended these mod-
els to polymeric nanoparticles, though these are becoming
prominent in therapeutic applications. 16
The mechanism of drug release from nanoparticles may
differ from that of microparticles even when both vehi-
cles have the same polymer composition. Drug diffusion
through the polymer matrix has been shown to be slower in
nanoparticles than in microparticles, and this may be due
to more dense internal structures as a result of fabrication
techniques or the neutralization of autocatalysis-enhanced
diffusion phenomenon at the smaller length scales.'- 17
For the purposes of our model, we postulate that the
reduced drug diffusivity in nanoparticles limits the influ-
ence of diffusion in the model to the interface between
polymer and the external aqueous environment. That is,
we assume that drug release occurs only after degradation
of surrounding polymer and the formation of an erosion
channel to the particle surface. Once the drug diffuses into
the exposed erosion channel, the drug is considered to be
released due to the small distances necessary to travel to
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the particle surface at the nanoscale. Using this framework,
we model drug release from bulk eroding nanoparticles
based upon a three dimensional Monte Carlo simulation
of polymer erosion.
For the Monte Carlo simulation presented here, entire
spherical nanoparticles are represented using voxels.
A voxel is the volume element which represents data on
a regular grid in three dimensional space and is analo-
gous to a pixel which is the area element representing
data in two dimensions.18 Previous two dimensional mod-
els have depicted drug release from a pixel as dependent
upon the state of the pixel's immediate 8 neighbors.' 2" 4 In
this three dimensional voxel-based model, we assess the
influence of the 18 neighbors most immediately surround-
ing the voxel in order to give the best representation of a
sphere (Fig. 1). The State Diagram (Fig. 2) describes the
sirmulation algorithm governing voxel dynamic state tran-
sitions (x, ,) and voxel drug release. Assuming a homo-
geneous mixture of drug and polymer, each voxel begins
with a voxel dynamic state (x, ,.) of 1. The lifetime of
individual voxels follows a Poisson's distribution given by:
T j.~)= -ln(s/A) (1)
where s is a random number and 1/A is the half life of
the polymer system. Expiration of this lifetime changes the
voxel dynamic state (xi ,,) to zero and the polymer is con-
sidered degraded. In order for the polymer to be considered
eroded, access to the aqueous environment via an erosion
channel from the surface of the nanoparticle is required.
Such a channel is formed when at least one of the 18 imrme-
diate neighboring voxels is eroded, i.e., any of the neigh-
bor's dynamic voxel state (x1, ) becomes -1.
We formulated poly(lactic-co-glycolic acid) (PLGA)
nanoparticles encapsulating the hydrophobic agent dexam-
ethasone as described in Figure 3. Hydrolysable polymers
such asPLGA are often used in the forrmlation of nanopar-
ticles as they combine sustained drug release with complete
biodegradability.' The polymer half life (1/A) is approx-
imated at 0.121 days from previous measurements in the
literature2 In order to run the model sirmlation, we used
the drug release data from this forrmlation to fit values for
two parameters: the number of voxels (N) that compose
each nanoparticle and a parameter (K) that integrates the
influence of mass transport phenomenon into the simula-
tion. The parameter K (value between 0 and 1) measures
the likelihood of drug release from an intact voxel into
an aqueous erosion channel upon exposure, and represents
the cormbined contributions of drug diffusion and dissolu-
tion on drug release at this interface. The parameter N is
related to the physical size of the particle and also controls
the surface area to volume ratio. Polymeric nanoparticles
have a higher surface area to volume ratio than microparti-
cles which may lead to a more pronounced relative initial
burst of drug release.
The experimental release profile of dexamethasone from
PLGA nanoparticles shows an initial burst release of 40%
over the first ~25 hours. A more sustained phase of drug
release occurs over the next -120 hours resulting in com-
plete release of encapsulated drug by 150 hours. The
model sirmulation was a good match to experimental drug
release with a coefficient of determination (R2) value of
0.96 (Fig. 3). We are also able to use our model simu-
lation to investigate physical properties of the voxelated
nanosphere during erosion by exploring the fragment size
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Fig. 1. Geometric implications of pixel and voel neighborhoods. The distance (d) between the center of a pixel (in 2D) or vael (in 3D) and the
center of its immediate neighbors is .1 or 42 or /3 units. The center to center distance factor (CCDF) and spherical volume ratio (SVR) are used to
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distribution and average size of the nanoparticles over time
(Fig. 4(a)). Percolation-driven particle breakdown due to
bulk erosion is shown to occur after 150 hours, and go does
not appear to play a dominant role in drug release. A plot
of nanoparticle surface area/volurm with respect to tirm
(Fig. 4(b)) indicates an initial lag prior to the formation
of erosion channels. This corresponds well with the lag
before the change in phase of experimental drug release
from initial burst to sustained release (Fig. 3).
The potential of extending this model to additional drug
formulations is explored through variation in the param-
eter K (Fig. 5). The influence of K is restricted to drug
release at the interface of polymer and the external aque-
ous environment. A K value of 1 corresponds to immediate
drug release from an exposed intact voxel into an erosion
channel, and the resultant rapid drug release profile is con-
sistent with that of a highly hydrophilic dmg.?3 A K value
of 0 indicates that drug release from an exposed intact
voxel does not occur until the voxel is degraded, and the
resultant sustained drug release profile is consistent with
J. Nanosci. Nanotechnol. 10, 1-5,2010
that of a polymer-conjugated drug 2 Values of K between
0 and 1 correspond with intermediate capacities for drug
release from an exposed intact vaxel, and the resultant
rulti-phase drug release profiles are consistent with that
of a hydrophobic drug as presented here.
Because all processes that influence drug release are
not yet quantitatively understood, there is value to the use
of semi-empirical cormputational models able to sirmulate
rmlti-phase drug release profiles. Use of the model pre-
sented here does not require knowledge of physical param-
eters such as polymer porosity, drug solubility, and drug
diffusivity which are often not available or can be difficult
to measure. Voxelation of the entire nanoparticle facilitates
the extension of this platform to non-symmetrical vehi-
cle forrmulations as well as non-uniform drug and polymer
distributions. Variation of the parameter K demonstrates
the versatility of this model for simulating release of
hydrophilic, hydrophobic, and polymer-conjugated drugs.
This model was intended as a proof of principle, however
in the future emerging mechanistic understandings of
3
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Mg, 3. Dexamethasone release from PLGA nanoparticles in vitro.
Nanoparticles were formulated using a modified emulsion-solvent evap-
oratim technique.Y- Briefly, 25 mg of dexamethasone and 50 mg of
PLGA were allowed to dissolve completely in 2.5 mL acetone before
addition of 0.5 mL methanol and emulsification into an aqueous 2% PVA
solution with sonication. Nanoparticles were separated from free drug by
ultracentrifuagation and were demonstrated to have a mean particle diam-
eter of 115 nm by dynamic light scattering. Drug release was quantified
by HPLC after dialysis against PBS at 37 'C with gentle shaking. Sim-
ulations of drug release were coded using the C programming language
and were performed 100 times with mean values shown. Experimental
results are means +/- s.e.m. (n = 3). Parameters: N = 5497 voxels,
K =0.5.
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Fig. 4. Simulation of drug release and nanoparticle fragmentation.
(a) Model representation of nanoparticle fragmentation: black scatter
represents variability between different simulations, blue line represents
average fragment size. (b) Simulation results for surface area (exposed
voxel area) and volume (voxel count) during nanoparticle fragmentation.
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Rg, 5. Influence of the model parameter K on drug release. Simu-
lation results for K values between 0 and 1 demonstrate the capacity
of the model fr simulating the release of drugs with distinct diffu-
sion and dissolution characteristics. Model parameters: N = 5497 voxels,
iterations = 100.
phenomenon influencing nanoparticle drug release may be
incorporated to further increase accuracy and strengthen
predictive power.
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2.2 Harnessing Nanotechnology to target the Cancer Cell Immortality Spectrum
2.2.1 The Cancer Cell Immortality Spectrum
Tumorigenesis is a complex process with multiple pathways of progression, and
"normal" cells typically require several mutations in order to overcome regulatory
mechanisms and metamorphose into tumorous cells. These mutations may be explained
by survival of the fittest, wherein cells that acquire mutations promoting increased cell
division rate or longevity maybe more likely to produce daughter cells harboring
selective proliferation advantages. Some of the common pro-tumorigenic mutations
include the following: mutations that increase function of an oncogene (pro-growth/pro-
division/pro-life), mutations that decrease function of a tumor suppressor gene
(prodeath/anti-growth), or mutations that decrease function of a surveillance gene (DNA
repair/cell cycle control). Individuals carrying one or more congenital mutations in these
pathways are predisposed to particularly rapid progression of tumorigenesis. The
combined genetic mutations in cancer cells rapidly manifest at the level of tumor tissues
and are typified by a combination of characteristics that we refer to as factors I-X of the
"Cancer Cell Immortality Spectrum" (Figure 2.6).
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Figure 2.6 The Cancer Cell Immortality Spectrum
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Fundamental to the cancer cell immortality spectrum are the discussed genetic
mutations that promote cell growth and/or reduce cell death, culminating in the formation
of tumor predisposed cells (factors I, II, IX). The deregulation of DNA repair and cell
cycle control are other key factors that occur throughout tumorigenesis, accelerating its
progression via faster mutation and replication rates (factor III). As the tumor tissue
grows, it requires additional space, oxygen, and nutrients, necessitating the invasion of
local tissue through the degradation of the ECM (factor IV) and the formation of new
blood vessels through the production of angiogenic growth factors (factor V). Any anti-
growth signals that are produced by the organism during this stage can be countered by
mutations in tumor cells that reduce effects of such signals (factor VI). Cancer treatment
involves use of chemotherapeutic agents (e.g., cytotoxic drugs) for destroying cancer
cells and inhibiting further growth of the tumor tissue. However, tumors are able to
acquire mutations that render them resistant to chemotherapy (factor VII). This,
combined with their ability to overcome senescence through methods such as over-
expression of telomerase, causes cancer cells to become immortal (factor X). As the
tumor continues to expand, malignant cells detach from the primary tumor and begin to
degrade proteins in the surrounding ECM. This allows cancerous cells to escape from the
matrix, enter the blood stream or lymph system, and migrate to other cells via a process
termed metastasis (factor VIII). Such multi-drug resistant, immortal, metastatic tumors
are responsible for a majority of the present cancer-related deaths.
Given that cancer is motivated by all ten hallmarks of the cancer cell immortality
spectrum discussed herein, it becomes critical to adopt a multi-pronged therapeutic
approach to tumor treatment. Such combination therapeutics approaches, however,
require precise temporal regulation in the release kinetics of the multiple drugs involved
in order to achieve maximal "synergy" and optimal therapeutic efficacy in their
application (Figure 2.7).
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Figure 2.7 The versatile degradation lifetimes of polymeric nanoparticles taken
together with the availability of several anti-cancer drugs allows careful tailoring of
temporal release characteristics.
2.2.2 Receptor-ligand structural fit as the basis for spatial targeting of polymeric
nanoparticles to tumor cells
The conjugation of appropriate tumor-specific targeting molecules onto drug
encapsulated nano-devices ensures selective delivery of the agent to cancerous cells and
hence minimal toxicity to non-cancerous cells, as described earlier. Additionally, the
potency of nano-devices for cancer treatment is generally enhanced due to the fact that
several localization techniques involve binding to tumor over-expressed cell surface
receptors that are themselves important for cell growth (Figure 2.8). This is because
tumor cell surface receptors are often endocytosed upon binding, thus providing a method
for intra-cellular delivery of the nano-complex while simultaneously "competing" with
the natural growth signals, thereby inhibiting their biochemical signaling.
As a specific example, folate receptor a (FRa) is over-expressed on the surface of
certain cancer cells, but is naturally expressed only on the apical (away from the blood)
surface of epithelial cells, making it a unique target for therapy. This has allowed the use
of folate-conjugated nanoparticles for both imaging and the delivery of drugs. Once the
receptor binds a ligand, such as folate, it is taken into the cell via receptor-mediated
endocytosis, escapes from the endosome, and is recycled back to the surface after
releasing its ligand within the cell. However, one can imagine a technique in which the
ligand remains bound to the receptor after depositing the drug, effectively inactivating or
reducing the growth receptor pathway.
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Figure 2.8 Structures of receptor molecules that are over-expressed in Breast
Cancer cells. (a.) Fibroblast growth factor receptor (FGFR) is over-expressed in sarcoma
and breast cancers; (b.) Interleukin-13 (IL-13) receptor is over-expressed in skin and
brain cancers; (c.) Vascular endothelial growth factor receptor (VEGFR) is over-
expressed in colorectal, ovarian, pancreatic, and breast cancers; (d.) Androgen receptor is
over-expressed in prostate cancer; (e.) Insulin-like growth factor-i receptor (IGF1R) is
over-expiessed in cervical cancer; (f.) Neuropilin-1 (NRP-1) is over-expressed in breast,
colon, prostate, and pituitary cancers; (g.) Epidermal growth factor receptor 2 (EGFR-2)
is over-expressed in pancreatic, bladder, cervical, breast, and stomach cancers; and (h.)
Estrogen receptor alpha (ERa) is over-expressed in breast and ovarian cancers.
This highlights an important dynamic in drug delivery since any localization
technique targeting a growth factor receptor has the unique ability to temporarily disrupt
pro-growth in a completely drug-independent manner. Estimated levels of cell surface
receptor over-expression in breast cancer is compiled from literature and presented herein
to highlight the importance of targeting these receptors in localizing the delivery of
chemotherapeutic agents specifically to tumor cells (Figure 2.9). Additionally, several
such over-expressed cell surface receptors are known for various cancers and is presented
herein along with the incidence of over-expression (Table 2.1).
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Figure 2.9 Estimated levels of over-expressed Breast Cancer receptor molecules
2.2.3 Voxel model optimization of the polymeric nanoparticle core of Nanocell delivery
systems
A "Trojan horse" approach using a multi-compartment, multi-functional
nanoscale system has recently been proposed to exploit the full potential of
nanotechnology for targeting cancers. This strategy is based on a delivery system called
the "nanocell" (Figure 2.10), so named because of its visual resemblance to a cell and its
nanoscale dimensions. A nuclear polymeric nanoparticle conjugated to a
chemotherapeutic agent was encapsulated within a PEG-phospholipid block-copolymer
envelope that contained a vascular disruption agent (VDA). Thus, a nanoscale vehicle
with two drugs was designed, with customizable release profiles.
.........................
Table 2.1 Over-expressed cell surface receptors classified according to incidence of cancer
Over-expressed cell surface receptor
Estrogen receptor alpha (ERa)
Progesterone receptor (PR)
Human epidermal growth factor receptor 2 (HER2)
Endothelin-A receptor (ETAR)
Platelet derived growth factor receptor (PDGFR)
Fibroblast growth factor receptor 2 (FGFR-2)
Heparin Sulfate Glycosaminoglycan (HSGAG)
Neuropilin-1 (NRP-1)
Androgen receptor (AR)
Insulin-like growth factor- 1 receptor (IGF1R)
G-Protein coupled receptor (GPCR)
Cannabinoid-specific receptors (CBR)
Chemokine Receptor (CXCR4)
Vascular endothelial growth factor receptor (VEGFR)
Interleukin-13 (IL-13) receptor
Cancer type (incidence)
Breast (70%), Ovary
Breast (64%), Uterus
Pancreas (26%), Bladder
(44%), Cervix (77%), Breast
(30%), Stomach
Breast (45.3%), Ovary
Liver (22.1%), Breast
(39.2%)
Sarcoma, Breast (5-10%)
Breast, Colon, Prostate,
Pituitary
Prostate (43%)
Cervix
Brain (57%), Stomach,
Prostate (60%)
Liver (62%)
Skin
Colorectal , Ovary,
Pancreas, Breast
Skin, Brain
As the nanocells are lodged into the tumor tissue by active or passive targeting,
the envelope quickly breaks down, releasing both the conjugated nanoparticle and the
free VDA into the tumor. The VDA induces vascular collapse, effectively trapping the
nanoparticle-chemotheraputic conjugation within the tumor, allowing the
chemotherapeutic agent to undergo sustained release without being able to leave the
tumor microenvironment.
PEG
Tmor-targeting
.. molecules
Anti-angiogenetic drug
And-cancer drug conjugated enclosed in hydrophobic
to polymeic nanoparticle liposome outer layer
for sustained release
Figure 2.10 Structure of Nanocell delivery system highlighting the polymeric
nanoparticle core for which the Voxel platform can be used to optimize drug release
kinetics
As demonstrated in the last section, the Voxel modeling platform is useful for
predicting the release of drugs encapsulated and conjugated to polymeric nanoparticles.
Hence, the Voxel platform was used to model the degradation and erosion kinetics of
PLGA nanoparticles conjugated chemically to the anti-cancer agent of interest. A
simulation of the progression in degradation and erosion processes within the polymeric
nanoparticle was performed, based on the Voxel model results for this system (Figure
2.11). It can be seen from the simulation results that the polymeric nanoparticle is
degraded in bulk throughout the vehicle (including the central core) right from the start of
the simulation, but erosion only proceeds from the solvent-exposed surface towards the
core with progression of time.
............. .
Figure 2.11 Simulation of polymeric nanoparticle degradation and erosion with time,
with intact polymer (gray), degraded polymer (red), and eroded polymer (blue).
This simulation result is hence in agreement with the Voxel model results that
predicted Bulk Erosion of PLGA nanoparticles owing to instantaneous diffusion of water
molecules and uniform wetting of the entire vehicle, followed by more gradual
erosion/fragmentation that accelerated with development of erosion channels from the
surface of the vehicle. As mentioned earlier, bulk eroding polymeric matrices such as
those composed of PLGA, have been traditionally simulated using 2-D of pixels grids
(left) with intact polymers (black), degraded polymers (gray) and eroded pores (white)
depicted as shown (Figure 2.12), but these pixel Models cannot account for volumes. On
the other hand, the 3-D Voxel-based simulation platform (right) is able to include the
effect of volumes of the biomaterials, pores, and drugs as depicted herein with intact
(pink/black) and eroded (blue) polymers highlighted (Figure 2.12).
Polymer matrices undergo either surface erosion or bulk erosion, depending on
their dimension and material properties. Smaller particles (e.g. nanoparticles) that are
uniformly wetted by water throughout undergo bulk erosion, while larger particles (e.g.
microparticles) that are wetted by water only on their surfaces undergo surface erosion.
The rate of erosion is primarily governed by percolation kinetics in the case of bulk
erosion but is instead governed by the progress of the eroding surface in the case of
surface erosion. Both surface eroding and bulk eroding drug-conjugated matrices have
been employed extensively in sustained release therapeutic applications.
The Voxel model platform was also successfully extended to PLGA
microparticles that undergo surface erosion, as shown. Similarly to bulk erosion, the
simulations of surface erosion of microparticles was also inclusive of volumes of
biomaterials, pores, and drugs, and provided incredible insight into the process of
polymeric matrix surface erosion (Figure 2.13). From the voxel platform simulation of
microparticle surface erosion (Figure 2.13), it can be seen that, unlike bulk erosion
(Figure 2.12) wherein instantaneous and uniform wetting of the vehicle promoted
degradation throughout the vehicle (including the core), in the case of surface erosion,
degradation by hydrolysis of polymers is initially restricted to the solvent-exposed
surface and only with time does it progress towards the core. Such differences in water
molecule diffusion, polymer hydrolysis, polymer degradation, nanoparticle erosion, and
nanoparticle fragmentation are hence adequately captured by the Voxel model for both
surface and bulk eroding polymeric particles.
Time = 0.5 days Time = 5 days
Time = 10 days Time = 15 days
Time = 20 days Time = 25 days
Time = 0.5 days
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Figure 2.12 Simulation of bulk eroding polymeric nanoparticle degradation and
erosion with the 2-D pixel (left) and 3-D voxel (right) modeling platforms.
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Figure 2.13 Extension of the pixel and voxel modeling platforms to simulation surface
eroding polymeric microparticle degradation and erosion. The 2-D pixel (left) and 3-D
voxel (right) modeling platform simulation results are shown besides each other for
contrast
Some of the limitations of pixel based models that emerges from the Voxel
platform results are noted herein. It is observed that pixels cannot account adequately for
material properties that require volume based grid specification, such as dissolution
kinetics, conjugation density, and neighborhood-based effects. Hence, for instance,
existing pixel based models cannot directly be applied to analyze drug-conjugated
polymeric nanoparticles. Some recent extensions to the pixel degradation model, have
also assumed discrete polymer and drug pixels to simulate drug release. This would
however be physically meaningful only for extremely dense grids and decrease the power
of the pixel approach to modeling. Another disadvantage of pixel based polymer
modeling is that of over-simplification which leads to a decrease in versatility. An
................. 
......  .... . . .. . .........
.............  ....................
example of this is the assumption of linear distributions to obtain the lifetimes of discrete
drug pixels. The assumptions of symmetry and eight neighboring pixel influence further
limits their application. While 2-D pixel models serve as an excellent platform to design
more sophisticated and realistic computational models, by themselves they are unsuitable
for nano-scale phenomenon analysis, which is best captured using volume dependent
parameters. There have also been indications of substantial differences in 2-D versus 3-D
modeling in other applications such as tumor vasculature modeling. The group proposed
an invasion-percolation 2-D model and have noted that 2-D modeling shows
discrepancies in simulation of physical phenomena, but was still preferred because at that
time 3-D modeling was too computationally unwieldy. The recent advances in
computational processing power prompted revisiting 3-D modeling with the Voxel
platform and as demonstrated in the last few sections, this has eliminated the limitations
of 2-D modeling outlined herein.
2.2.4 From nano to micro: Adaptation of the Voxel platform for modeling polymeric
agglomer-based anti-cancer applications
Along the dimension scale from "nano to micro", the phenomenon of
agglomeration, or the coming together of individual nanoscale particles to form clusters
(or agglomers), becomes increasingly important due to the high surface energies
involved. A computational platform that integrates the nanoscale voxels platform, which
currently pertains to single nanoparticles, with multi-nanoparticle simulations wherein
inter-particle forces are accounted for, hence becomes important (Figure 2.14). It is
found that such an extension to the Voxel platform enables simulation of a diverse array
of polymeric vehicles with spatial compartmentalization including quantum dots, core-
shell nanoparticles, and nanomer clusters (at the nanoscales) and agglomers (at the
microscales). By varying the interparticle forces with a suitable agglomeration factor
parameter as shown, it was possible to tease apart these forces and compute quantitative
estimates of their influence on factors that govern polymeric agglomeration (Figure
2.15).
Figure 2.15 Spatial compartmentalization at nanoscales (quantum dots, core-shell
nanoparticles, and nanomer clusters) and microscales (agglomers).
Furthermore, the size of agglomers are key to their applications for the treatment
of specific cancers. For instance, treatment of lung cancers and associated inflammation
and infections with large agglomers delivered as aerosol formulations has been explored.
Such aerosol formulations typically require several hundred polymeric nanoparticles or
liposomes to agglomerate together. In most of these scenarios, designing nanoscale
agglomers of smaller sizes (e.g. agglomer of size 2 or 3 nanoparticles) is required to
ensure that these are specifically localized to the tumor microenvironment (owing to the
dimensions of the pores in the "leaky" tumor microvasculature). In order to facilitate the
precise engineering of such nano-complexes for application to tumor treatment, the
extended Voxels simulation platform was used to analyze the concentrations of
agglomers of the required size as a function of time as shown (Figure 2.16). Thus, the
outlined extensions of the voxels-based 3-D simulation platform allow for integrated
modeling of polymeric nano- and micro- particle behavior in the context of their anti-
cancer applications.
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Figure 2.15 Simulation of agglomer size distribution with time at fixed
agglomeration factor (AF) values is used to predict time spans when desired
agglomer clusters will occur.
Quantitative insight into polymeric particle agglomeration kinetics may be
derived from the above computations. For instance, from the above simulations, it can be
deduced tht time = 19 units and agglomeration factor = 0.6 (- 60% activated PEG density
on lipsome) appears ideal for obtaining one-on-one binding of PEGylated liposomes. The
'agglomeration factor' has been specifically defined to account for material properties and
mechanistic forces to facilitate such computations.
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Figure 2.16 Effect of variation of agglomeration factor (AF) on the size of agglomer
clusters formed is computed, so that polymer characteristics may be appropriately
tailored for desired agglomer sizes.
The results indicate that very fine degrees of precise 1-1 bonding can be achieved
by controlling the: a.) temperature and, b.) time of reaction -- factors that may be of value
in engineering polymeric vehicles of desired spatial compartmentalization. The entire
Monte Carlo simulation of polymer agglomeration (Figure 2.17) provides further insight
into the dynamics of individual particles and their association into larger agglomers.
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Multifunctional Nanoscale Platforms for
Targeting of the Cancer Cell Immortality
Spectrum
Venkataramanan Soundararajan, Kenneth Warnock, Ram Sasisekharan*
In the post-genomic era, "omics" platforms and cancer systems biology are greatly advancing
our knowledge of the molecular and cellular underpinnings of cancer. In this article, we
begin by outlining the factors governing the development of cancer (tumorigenesis) and use
this framework to motivate the need for systems-approaches to cancer diagnostics and
therapeutics. We review recent efforts to tap into the remarkable potential of nanotechnology
for (i) systems-surveillance (or "sensing") of the molecular signatures of tumorigenesis, and (ii)
spatiotemporally-regulated delivery (or "targeting") of combination therapeutics to cancer
cells. Specifically, we highlight the salient role of polymeric biomaterials and describe the
physicochermical characteristics that render them attractive for the design of such nanoscale
platforms. We conclude with discussions
on the emerging role of macromolecular
biophysics and computational nano- S
technology in engineering spatiotem-
porally-regulated anti-cancer systems. Nanoscale and Macromolecular Simulation Platform for Design and Testing
Introduction
Cancer is one of the leading causes of death, accounting for
nearly 13% of annual mortality according to the World
Health Organization (WHO), and it is estimated that
another 25 million people are presently living with cancer
around the worldL1 While these numbers are certainly
alarming, recent reports ominously predict that these are
likely to double within the next two decades. 2 ]
Tumorigenesis, or the development of cancer, is a
multistep process that begins with the malignant trans-
formation of innocuous cells owing to a combination of
genetic predisposition factors and sustained physical/
chemical/biological carcinogenic exposure?35 4 1 MalignantIV. Soundararajan, K. Warnock, R. Sasisekharan
Harvard-MIT Division of Health Sciences and Technology,
Department of Biological Engineering, Koch Institute for
Integrative Cancer Research, Massachusetts Institute of
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cells are typified by a variety of characteristics, including
increased replicative potential, evasion of programmed cell
death (apoptosis), self-sufficiency in growth signals,
insensitivity to anti-growth signals, sustained blood vessel
development (angiogenesis), loss of cellular repair mechan-
isms, evolution of multi-drug resistance, destruction of
adjacent tissues (invasion), non-adherence to universal
aging (senescence), and spread to non-neighboring
organelles (metastasis).5-6 These factors work in synergy
to promote the rapid progression of the disease from cells to
tissues and organs. Detecting cancer at its earliest
stages and adopting a personalized, combination thera-
peutics approach targeting many of these factors hence
becomes critical for effective treatment of the disease.[
78 1
This in turn necessitates the development of high-
sensitivity, multi-functional, diagnostic and therapeutic
platforms for ultra-precise measurement and manipula-
tion at molecular, cellular, and tissue levels9-111
Advances in nanotechnology have led to an active
interest in developing multifunctional nanoscale plat-
forms capable of sensing the molecular signatures of
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tumorigenesis and delivering therapeutics specifically to
cancerous cells in order to simultaneously reduce toxicity
and increase efficacy 61 Pioneering contributions to polymer-
drug formulation technology have particularly enhanced
these efforts by providing for distinct advantages such as
sustained release, increased circulation lifetime, specific
localizationtotumor microenvironments, andbiocompatible
vehicles.1 2-1 4 1 There is growing evidence that (i) precise
targeting of surface-functionalized nanoparticles to over-
expressed receptors ontumor cells (spatial control), combined
with (ii.) rational design of polymer-drug formulations for
modulation of factors influencing the release profiles of
nanoparticle-encapsulated drugs (temporal control), could
together offer dramatic therapeutic benefit 1 1 71 Hence,
there is emerging interest in the development of molecular
modeling and computational nanotechnology tools for
the design of such spatiotemporally-regulated anticancer
systems.[1 -2 4
In this article, we provide a perspective on nanoscale
polymeric systems for cancer diagnostics and combination
therapeutics, and macromolecular modeling platforms for
engineering these systems.
Cancer Cell Immortality Spectrum
Tumorigenesis is a complex process with multiple path-
ways of progression, and "normal" cells typically require
Macromol. Rapid Commun. 2010, 31, 202-216
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several mutations in orderto overcome regulatory mechan-
isms and metamorphose into tumorous cellsJ3.2s] These
mutations may be explained by survival of the fittest,
wherein cells that acquire mutations promoting increased
cell division rate or longevity maybe more likelyto produce
daughter cells harboring selective proliferation advan-
tages.161 Some of the common pro-tumorigenic mutations
include the following: mutations that increase function of
an oncogene (pro-growth/pro-division/pro-life), mutations
that decrease function of a tumor suppressor gene (pro-
death/anti-growth), or mutations that decrease function of
a surveillance gene (DNA repair/cell cycle control). 27 1
Individuals carrying one or more congenital mutations in
these pathways are predisposed to particularly rapid
progression of tumorigenesis. [31
The combined genetic mutations in cancer cells rapidly
manifest at the level of tumor tissues and are typified by a
combination of characteristics that we refer to as factors I-X
of the "cancer cell immortality spectrum" (Figure la).
Fundamental to this spectrum are the discussed genetic
mutations that promote cell growth and/or reduce cell
death, culminating in the formation of tumor predisposed
cells (factors I, II, IX). The deregulation of DNA repair and cell
cycle control are other key factors that occur throughout
tumorigenesis, accelerating its progression via faster muta-
tion and replication rates (factor III)[4,28] As the tumor tissue
grows, it requires additional space, oxygen, and nutrients,
www.mrc-journal.de 203
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necessitating the invasion of local tissue through the
degradation of the extracellular matrix (ECM) (factor IV)
and the formation of new blood vessels through the pro-
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Cut off tumor blood supply
with anti-angiogenetic drugs
Reverse multi-drug resistance and
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take in anti-cancer drugs % %
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tumor monitoring
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with drug A (0 )
Longer lifetime
polymeric nanoparticle
with drug B (9 )
-00 
*1
'N _
ShotA Shot B
Surface functionalizationwith tumor-
cell specific targeting molecules
Target migratory metastatic tumor cells by
monitoring lymphatic and other inter-organelle
tumor cell transport networks
Shorter lifetime
polymeric nanoparticle
with drug A ( 0)
Longer lifetime
polymeric nanoparticle
with drug A( 0)
e 0*e*
(.0001
Figure ?. Cancer cell immortality spectrum: hallmark of the multi-pronged systems-approach to nanoscale combination chemotherapy.
a) Contrast of the normal cell cycle that balances cell division and cell death with the ten traits that render immortality to cancer cells.
b) Pictorial depiction of multifunctional anti-tumor nanoparticles that house drug cocktails for combating cancer on several fronts
simultaneously. c) The versatile degradation lifetimes of polymeric nanoparticles taken together with the availability of several anti-cancer
drugs allows careful tailoring of temporal release characteristics. The same system with a single drug can also be used for multiple shots as
shown.
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that reduce or eliminate the effects of such signals (factor
VI) [29]
Cancer treatment generally involves the use of che-
motherapeutic agents (e.g., cytotoxic drugs) for destroying
cancer cells and inhibiting further growth of the tumor
tissue. However, tumors are able to acquire mutations that
render them resistant to chemotherapy or other types of
drugs (factor VII)Po-"32 This, combined with their ability to
overcome senescence through methods such as over-
expression of telomerase, causes cancer cells to become
immortal (factor X). 33' As the tumor continues to expand,
malignant cells detach from the primary tumor and begin
to degrade proteins in the surrounding ECM. This allows
cancerous cells to escape from the matrix, enter the blood
stream or lymph system, and migrate to other cells via a
process termed metastasis (factor VIII). Such multi-drug
resistant, immortal, metastatic tumors are responsible for a
majority of the present cancer-related deaths.[3,6,2s-331
Giventhat cancer is motivated by allten hallmarks of the
cancer cell immortality spectrum discussed herein, it
becomes critical to adopt a multi-pronged therapeutic
approachtotumortreatment (Figure lb). Such combination
therapeutics approaches, however, require precise tem-
poral regulationinthe release kinetics ofthe multiple drugs
involved in order to achieve maximal "synergy" and
optimal therapeutic efficacy in their application
(Figure 1c). The following section discusses methods for
integrated targeting of the cancer cell immortality spec-
trum with combination therapies.
Cancer Combination Therapeutics
Combination therapeutics refersto thetreatment of disease
with a variety of drugs and treatments, as opposed to a
single drug or treatment?341 Three significant aspects have
prompted scientists to search for treatments that involve
drug combinations. The first is the concept of synergy, or
the idea that the combined benefit of multiple drugs can be
several orders of magnitude greater than the sum of the
benefits of the individual drugs.E34 1 Several different models
for synergistic effects have been described and are reviewed
extensively elsewhere.[-38] The synergistic effects of cancer
drugs (Figure 2) have found some success in recent years with
promising results from multiple clinical trials. 39 1
The second major driving force of the multi-drug
transition has been the emergence of drug resistance.[30 33 1
As anti-cancer drugs are introducedto tumors,this creates a
strong selective pressure for the tumor cells to acquire
mutations that grants resistance against the drug. While a
vast majority of the tumor may be eliminated by the drug,
unless the population is completely destroyed, small sets of
cells may survive by acquiring mutations that protect them
from the drug, reproduce, and create a drug resistant
Macromol Rapid Commun. 2010, 31, 202-216
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Figure z Synergistic (0, additive (DU), antagonistic (K, and
currently unknown ([]) interactions between common cancer
drugs. The following three letter abbreviations are used
for the drugs: Cagecitabine (Xeloda*), _lophosphamide
(Cytoxan*Y), Docetaxel (Taxotere*), Doxorubicin (Adriamycin*),
Epirubicin (Pharmorubicin*), Fluorouracil (5FU), Gemcitabine
(Gemnzar*&), Lapatinib (Tyverb*), Letrozole (Femara*), Wghotrex-
ate (MTX), Mitoxantrone, Paclitaxel (TaxoP@), Tamoxifen (NaIvo-
dexl) Trastuzumab (Herceptin*).
population. This threat is even greater for cancer because
most tumors' DNA repair mechanisms are impaired (factor
III),[3.2-291 thus providing for opportunities to rapidly
acquire new mutations and develop drug resistance before
the drug eliminates the tumor. As a specific example, about
70% of all ovarian cancers are resistant to the drug
paclitaxal, and virtually all cases are resistant following
relapse.E451 Hence, unless the cancer proceeds to complete
remission, its ability to acquire new mutations and the
selective pressure to develop drug resistance will almost
guarantee that resistance occurs.
Cells are also capable of gaining resistance against a wide
range of drugs through a variety of mechanisms, such as
increased drug efflux, enzymatic deactivation, and decreased
cell permeability"A 7 1 This multi-drug resistance (MDR)
creates an enormous challenge, as it renders most current
cancer treatment options futile. However, nanotechnology is
emerging as an attractive option for countering MDR, as
evidenced by the development of nanocarriers capable of
simultaneously affecting cellular pH, lowering apoptotic
threshold, and introducing resistance modulators. 4 1
The third and final factor in the need for a multi-drug
approach is due to the inherent complexity of cancer. As
described in the previous section, tumorigenesis arises
from a complex set of mutations involving multiple
Journak
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biological systems, making mono-therapy cures less lik
solutions.[3.2s29341 Given that a single drug that simu
neously modulates growth, angiogenesis, apoptosis, met
tasis, cell signaling, and other key factors of the cancer'
immortality spectrum is very unlikely, a drug cocktail
synergistic targeting of multiple factors provides a m
pragmatic form of cancer treatment.
However, there are two significant challenges associa
with combination therapeutics - (i) possible antagonii
cross-interaction of drugs,[48^91 and (ii) the creation of no
platforms for the spatiotemporal delivery of combinat
drug cocktails 50-58 1 In order to address the possibilit)
cross-interactions in combination cocktails, massive effc
are underway to map out the synergistic, antagonistic, a
additive interactions between the universal set of d
combinations.[591 While the potential for combinat
therapeutics is likely to expand as new drug cocktails
tested and approved, the development of novel mu
functional platforms for delivering these drug combi
tions in a spatiotemporally regulated fashion is still v
much in its infancy. With the emergence of nanotechi
ogy, there is great interest in the development of si
multifunctional nanoscale platforms for the delivery
synergistic combination therapeutics.
Multifunctional nanoscale platforms for target
cancer are being engineered for two related applicatic
namely, timely detection (diagnostics) and treatm
(therapeutics). As mentioned earlier, detection of can
at its earliest stages is essential for effective treatmen
the disease, and the ability of nanoscale systems to mon
cellular microenvironments and sub-cellular compartme
with high sensitivity provides unprecedented opportuni
for the timely recognitionof tumor metamorphosis.[6-71 In
following two sections we first review some of the emerg
nano-devices for cancer diagnostics, and follow wit]
discussion of multifunctional nanoscale platforms capabl
simultaneously targeting multiple factors of the cancer
immortality spectrum.
The Nanotechnology Era and its Implicatior
for Cancer Systems-Surveillance
One of the greatest challenges in cancer treatment is be
able to accurately diagnose and characterize the multi
stages of cancer in a cost-effective, low-risk, high-accur
manner. Certain current methods, such as biopsies,
incredibly invasive, while alternatives can be relath
inaccurate.1 61 For example, there is a 20% chance that,
woman will be incorrectly diagnosed with breast car
over the course of a decade with yearly mammogr
testing.[601 Inaccurate diagnoses can introduce grave ri
to patients who are not given treatment for a disease t
have (false negative), as well as to patients who
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.ely recommended treatment for a disease they do not actually
Ita- have (false positive). Additionally, an inaccurate diagnosis
:as- creates a significant financial burden. Effective and timely
cell detection of cancer requires remarkable finesse in diag-
for nostic capabilities, an attribute that has become increas-
ore ingly feasible since the emergence of nanotechnology.
A systems-based approach to nanotechnology has the
ted potential to monitor cancer at ali stages of the disease,
stic including initial diagnosis, subsequent treatment, and
vel detection of relapse. [611 Several methods for high-
ion resolution, high-accuracy nanoscale cancer detection have
rof been explored and are described exhaustively in our recent
)rts chapter. 61 For example, femtomolar quantities of known
ind celi-surface tumor markers may be detected through the
rug use of semi-conductors, such as nanowires (NWs), nanotu-
ion bules (NTs), and nano cantlevers. 62631 Similarly, the
are presence of specific point mutations can be identified
ilti- throughthe use of gold nanoparticles capable of monitoring
na- changes in the binding pallterns of any protein of
ery interest.64l Likewise, the versatility of quantum dots
1o1- (Q~s) makes them principal candidates for systems-based
Lich cancer detection, as they have already been utilized for
of imaging cells, [561tracking signaling pathways,6] identi-
tying celi-cell interactions, 6 81 and detecting metastasis. 6 91
ing As with any new medical technology, the in vivo use of QDs
ins, for cancer detection requires monitoring for ethical, safety,
ent and regulatory issues. 7O] Along these lines, the safety
icer associated with several new nanobiotechnology-based
tof products, including in vivo use of QDs for tumor detection,
itor is presently being evaluated by the FDA. 171] Pending their
nts approval, it is possible to envision the creation of a
ties nanoscale platform capable of monitoring tumor progres-
the sion through each of the factors in the cancer celi
ing immortality spectrum. Such a systems-based diagnostic
.i a tool would prove invaluable for both researchers and
e of clinicians by providing a comprehensive framework for
cell studying progression of the disease and treating patients.
Another emerging area of interest in tumor diagnosis is
characterization of morphological and biochemical mod-
ifications that occur in the extracellular environment (ECM)
L5 of cells during tumorigenesis, given the increasing evidence
for role of the ECM in modulating various stages of
cancer. 772 -7 61 For example, glycosaminoglycans (GAGs)
ing are long, linear (unbranched) polysaccharides, abundant
Lple in the ECMK that are known to modulate numerous
acy biological processes including angiogenesis, apo ptosis,
are and tumor growth. 72-74 1 A change in the level of activity
rely of GAG-modifying lyases has been implicated in the
mny progression of various diseases including cancer. 72 77 1 For
icer instance, the increase of heparanase activity in myeloma
'am patients enables monitoring of heparanase activity as a
.sks strategic tumor surveillance option? 7'7 87 1 unfortunately, in
hey vivo detection of heparanase activity is chalienging, owing
are to the fact that lyase activity is typically measured by
journals
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monitoring absorbance at 232nm and most biological
mate-rials interfere with this absorbance. 77~8 However,
GAG-conjugated gold nanoparticles have recently been
used to shift the absorbance spectra, thus providing an
interference-free in vivo assay for tumor detection and
surveillance thereafter.77
The success of these nanoscale technologies arises from
the ability to easily manipulate the localization properties
of the nanoscale complexes. Due to the diversity of
localization methods available, including DNA/RNA apta-
mers,[182 immunoliposomes,[" 1 lipidoids,181 and receptor-
based ligands,[8 51 nanotechnology allows an unprece-
dented level of precision and accuracy for spatial localiza-
tion (e.g. nuclear, endosomal, lysosomal, cytoplasmic, cell
surface, extra cellular, etc). Thus, a high-resolution "detec-
tion" nano-component can be combined with a high-
precision localization component to offer systems-scale
tumor surveillance.
While these nanoscale systems are furthering our ability
for widespread cancer surveillance, there is critical need for
multifunctional platforms that can enable spatiotempo-
rally regulated delivery of combination therapeutics to the
detected cancer tissues. Due to their versatile physico-
chemical properties, surface-functionalized polymeric
nanoparticles are emerging as front-runners in nanoscale
anti-cancer platform design.[6-71 The next section focuses
on the localization of surface-functionalized polymeric
nanoparticles by biomolecular "targeting" techniques and
the physiochemical properties of polymeric biomaterials
used in the development of these devices for spatiotempo-
rally regulated anti-cancer combination therapeutics.
Spatiotemporal Control in Targeted Delivery
of Nanoscale Polymeric Devices
As discussed earlier, the various factors constituting the
development of cancer necessitate the creation of multi-
pronged therapeutics capable of "combating" tumors on
several different fronts. By designing a platform with the
ability to localize several drugs to the same tumortissue in a
spatiotemporally regulated fashion, it is theoretically
possible to address each of the traits in the cancer cell
immortality spectrum. Unfortunately spatiotemporal reg-
ulation is challenging from a design perspective, since the
volume of the platform is constrained to a few hundred
nanometers so that the device may permeate the "leaky"
tumor microvasculature"1 -7 5 Although a single platform
capable of "full spectrum" anti-cancer therapeutic delivery
is yet to be designed, great strides have already been made
in the creation of nanoscale multifunctional therapeutics
platforms.[61
The use of multifunctional nanoscale platforms for
cancer treatment is enhanced due to the fact that several
Macromol Rapid Commun. 2010, 31, 202-216
@ 2010 WILEY-VcH Verlag GmbH & co. KGaA, Weinheim
localization techniques involve binding to tumor over-
expressed cell surface receptors, many of which are
important for cell growth (Figure 3). This is because tumor
cell surface receptors are often endocytosed upon binding,
thus providing a method for intra-cellular delivery of the
nano-complex while simultaneously competing with the
natural growth signals, thereby inhibiting their biochem-
ical signaling.[7 )
As a specific example, folate receptor a (FRa) is over-
expressed on the surface of certain cancer cells, but is
naturally expressed only on the apical (away from
the blood) surface of epithelial cells,[8 61 making it a unique
target for therapy. This has allowed the use of folate-
conjugated nanoparticles for both imaging and the delivery
of drugs. 8,) Once the receptor binds a ligand, such as
folate, it is taken into the cell via receptor-mediated
endocytosis, escapes from the endosome, and is recycled
back to the surface after releasing its ligand within the
cell. [89.90 However, one can imagine a technique in which
the ligand remains bound to the receptor after depositing the
drug, effectively inactivating or reducing the growth receptor
pathway. This highlights an important dynamic in drug
delivery since any localization technique targeting a growth
factor receptor has the unique ability to temporarily disrupt
pro-growth in a completely drug-independent manner.
Gold nanoparticles, another common drug delivery
platform, also contain inherent properties that have been
exploited to treat cancer in a multipronged fashion.6 1 Gold
nanoparticles are known to emit heat when exposed to
near-infrared laser light, and since cancer cells are highly
susceptible to heat, gold nanoparticles canbe delivered into
cancer to create localized hyperthermia.191- 9 3 This technol-
ogy has since been expanded by combining the nanopar-
ticles with additional drugs, such as the apoptosis-inducing
factor TNFa, allowing for a dual treatment with drugs and
hyperthermia19 1 By adding a high affinity growth
receptor ligand analogue to the nanoparticle, it would be
possible to impair the growth receptors and induce
hyperthermia without the presence of an actual chemical
drug. The use of a single drug encapsulated within gold
nanoparticles can hence potentially influence at least three
of the components of the cancer cell immortality spectrum,
and by combining several other drugs, it would be possible
to simultaneously treat additional aspects ofthe tumor on a
system-wide scale.
Although great advances have been made in the
utilization of non-drug components of nano-complexes
to aid as "adjuvants" in cancer treatment,[1 an effective
generic multifunctional platform must be able to deliver
drugs with highly regulated spatiotemporal control.
Nanotechnology has recently begun to address this
problem, and drug delivery designs using polymeric
nanoparticles are becoming increasingly popular. How-
ever, by themselves, polymeric nanoparticles typically
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Breast cancer receptor over expression levels
" Estrogen receptor * Progesterone receptor
" Epidermal growth factor receptor * Endothelin-A receptor
" Platelet derived growth factor receptor 0 Fibroblast growth factor receptor 2
Figure 3. Over expressed tumor cell surface receptor molecules. a) Fibroblast growth factor receptor (FGFR) is over-expressed in sarcoma and
breast cancers. b) Interleukin-13 (IL-13) receptor is over-expressed in skin and brain cancers. c) Vascular endothelial growth factor receptor
(VEGFR) is over-expressed in colorectal, ovarian, pancreatic, and breast cancers. d) Androgen receptor is over-expressed in prostate cancer.
e) Insulin-like growth factor-i receptor (IGF1R) is over-expressed in cervical cancer. f) Neuropilin-i (NRP-1) is over-expressed in breast, colon,
prostate, and pituitary cancers. g) Epidermal growth factor receptor 2 (EGFR-2) is over-expressed in pancreatic, bladder, cervical, breast, and
stomach cancers. h) Estrogen receptor alpha (ERa) is over-expressed in breast and ovarian cancers. i) Estimated levels of cell surface receptor
over-expression in breast cancer.
release a significant portion of their drug payload in a ra
"burst" manner, severely limiting the propensity
temporal control.6,71 Fortunately, recent advances
nanotechnology have allowed sustained drug release c
several weeks, for instance, by conjugating the d
molecule to polymeric nanoparticles 2 0'9 2 1 Likewise, mi
ple pulses of drug can be delivered by implanting a sir
polymeric microchip."9 31 Thus, it is possible to achieve b
sustained release (useful for long-term drugs and surv
lance molecules) and controlled pulses of drug rele
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pid (useful for drugs like chemotherapeutics). Taken together
for with the previously outlined "targeting" aspects, this
in creates a tunable "spatiotemporal" component to drug
iver delivery with nanoscale polymeric devices.
rug The temporal kinetics of drug release from polymeric
ilti- devices is dependent on the physicochemical properties of
igle the polymeric biomaterials involved. [7 -:31 These are typi-
oth cally classified based on their mode of clearance (if at all)
reil- from the body (Figure 4a). Biodegradable polymers are
!ase broken down and metabolized within the body, bioelimin-
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Figure 4. Characteristics of nanoscale polymeric biomaterials. a) Classification of polymeric biomaterials as biodegradable, bioeliminable
and permanent/implant based on their mode of clearance within the body. b) Chemical structures of popular biocompatible polymers.
c) Mechanisms of polymer degradation. d) Degradation lifetimes of biocompatible polymers.
able polymers remain structurally intact but are cleared by
the renal filtering system (kidneys), and permanent
polymers are used for long term in-vivo implants.[6] Of
these, there has been great interest in the use of biodegrad-
able polymeric nanoparticles for cancer treatment.
The most frequentlyusedbiodegradable polymers include
the polyesters poly(lactic acid) and poly(glycolic acid), or PLA
and PGA respectively, among several other biocompatible
polymer families (Figure 4b).191 As PLA and PGA are
introduced, they are eventually hydrolytically degraded
and form acidic oligomers and monomers, effectively
dropping the pH.[951 The acidic pH contributes further to
Macromol. Rapid Commun. 2010, 31 202-216
0 2010 WILEY-VcH Verlag GmbH & co. KGaA, Weinheim
the hydrolysis, eventually reducing the polymeric network
via various degradation mechanisms (Figure 4c) that allow
the encapsulated drug to be released.19 6
1
Byfine-tuning the physicochemical characteristics of the
polymer, it is possible to obtain a high level of control over
the kinetics of drug release. -l Polymer size, composition,
and chain length have all been shown to have profound
effects on the properties of the biomaterial device, and are
each easily tailored. It is also possible to create co-polymers,
or polymers of multiple monomeric species, allowing for a
nearly infinite number of customizable attributes. These
traits allow researchers to "fine tune" properties such as the
lounas
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stability, pH, solubility, and tensile strength of nanosc
polymeric devices.[97' 98 1
By encapsulating or conjugating different drugs
different polymers, it is possible to create a multitude
temporal release characteristics such as those visuali:
earlier (Figure 1c). In fact, the use of different polymer clas
allows for absolutely diverse temporal control, ranging fr
minutes to months (Figure 4d).E61 This is highly beneficial, a
allows specific temporal control that can be altered for e,
drug used in the nano-complex.
The spatiotemporal control features of polymeric na
devices also allow for the creation of novel treatments t]
would otherwise be impossible.J713'991 For example, hig
toxic drugs that would normally prove fatal have be
successfully delivered almost exclusively to tum
effectively broadening the scope of drugs that can
administered by remarkable reduction of non-specific,
target effects100 In fact, it is notable that nanoparti
based cancer therapeutics are already showing so
promise from clinical trials. For instance, a recen
concluded clinical trial (phase-I) in recurrent prostr
cancer patients confirmed safe in vivo administration
magnetic nanoparticles for production of "localized he
(targeted temperature increase) capable of killing tun
cells upon stimulation by a magnetic field.1' 01 1
However, most of the previously discussed nanosc
devices only target individual hallmarks of the cancer
immortality spectrum. Recognizing that the use of nan
cale polymeric devices allows for a complex combinatior
treatments, we began exploring the design of nanosc
platforms for combination therapeutics that could sirr
taneously target multiple hallmarks of the cancer
immortality spectrum. The following sections discuss so
of our recent progress in the development of such mu
functional nanoscale platforms for integrated targeting
the cancer cell immortality spectrum.
Multicompartmental and Mutifunctional
Nanocells for Integrated Targeting of
Manifold Factors in the Cancer Cell
Immortality Spectrum
As discussed previously, angiogenesis, or the growth of n
blood vessels, is an important component of cancer, a
allows oversized tumors to receive additional blo
Vascular disrupting agents (VDAs) comprise a class
cancer drugs that simultaneously disrupt angiogene
while shutting down the existing vasculature [102
theory, this should eliminate the oxygen supply of'
tumor, leading to hypoxia and eventual necrosis;
practice, VDAs have been able to slow the growth
tumors, but have not emerged as the "magic bullet" agai
cancer treatment as was originally expected. Although
Macromol. Rapid Commun. 2010, 31, 202-216
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ale individual effectiveness of VDAs has been limited, the
combination of VDAs with chemotherapy has produced
to positive results, with over 10 different VDAs currently in
of clinical trials. [C3104] Although simultaneous delivery of
zed VDAs and chemnotherapeutics possesses enormous ther-
ses apeutic potential, the underlying attributes of both classes
om of drugs raise unique obstacles for effective transport.
is it The first of three major challenges is that chemother-
ich apeutic agents are traditionally delivered to the tumor via
the bloodstream. Since the purpose of VDAs is to effectively
no- shut down the surrounding vasculature, this severely
hiat reduces the amount of chemotherapeutic drug that can
hly reach the tumor if it is delivered after vascular disruption
!en has begun. The second problem is that as tumor cells
irs, become hypoxic, they over-express hypoxia-inducible
be factor-la (HIF). a), which in turn inhibits the pro-apoptotic
Atf effect of chemotherapeutic drugs. 101 Although the combi-
:lIe- nation of VDAs and chemnotherapeutics is highly synergis-
me tic, it contains an inherent disadvantage. This is because
itly vascular shutdown by VDAs reduces the amount of
ate chemotherapeutic drug that reaches the tumor, increasing
* of the amount of drug required for therapeutic efficacy and
at" escalating systemic toxicity. Finally, the optimal amount of
ntor drug delivered and duration of treatment for both classes
are completely different. Whereas VDAs typically require
ale long-term administration to prevent angiogenesis, che-
:ell motherapy is given in high doses over short treatment
.os- cycles, highlighting the need for separate customizable
Iof release kinetics. 10 6 ]
'ale A "Trojan horse" approach using a multi-compartment,
Lul- multi-functional nanoscale system has recently been
^ell proposed to overcome these challenges. 1 0 21 This strategy
me is based on a delivery system Called the "nanocell"
ilti- (Figure 5), so named because of its visual resemblance to
of a cell and its nanoscale dimensions. A nuclear polymeric
nanoparticle conjugated to a chemotherapeutic agent was
encapsulated within a pegylated-phospholipid block-
copolymer envelope that already contained a VDA. Thus,
an integrated nanoscale plafformwithtwo drugs of varying
function was designed, each with its own customnizable
release profile.
As the nanocells are lodged into the tumor tissue by
active or passive targeting, the envelope quickly breaks
ew down, releasing both the conjugated nanoparticle and the
s it free VDA into the tumor. The VDA induces vascular collapse,
od. effectively trapping the nanop art icle-chemot heraputic
of conjugation within the tumor, allowing the chemother-
nis apeutic agent to undergo sustained release without being
In able to escape the tumor micro environmie nt.
the To demonstrate the effectiveness of this integrated
in multifunctional nanoscale platform, the cytotoxic che-
of motherapeutic drug doxorubicin was conjugatedto aPLGA-
nst fabricated nanoparticle. The conjugated nanoparticle was
the then nucleated inside the VDA drug comb rest atin-laden
Journals
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Nanoscale combination therapeutic device engineering
PEG
Inner hydrophilic drug-conjugated .
polymeric nanoparticle encloses
anti-cancer agent for sustained release
Tumor targeting molecule
I
Outer hydrophobic lipid layer
encloses anti-angiogenetic drug
Figure 5. Design of a multifunctional and mult icompartmental nanoscale platform for integrated targeting of manifold factors in the cancer
cell immortality spectrum. The nanocell is a multi-compartmental nanoscale system engineered for dual-attack on angiogenesis and cancer
cell proliferation. The outer liposomal layer being hydrophobic encloses the anti-angiogenetic drug such as chrombetastatin which isI released first, followed by the inner polymeric nanoparticle layer
tumor tissue.
phospholipid block-copolymer envelope composed of PEG-
DSPE, phosphotidylcholine, and cholesterol (Figure 5a). A
tumor-endothelium co-culture bioassay'"1 revealed that
unlike controls, the nanocells were able to shut down the
vasculature surrounding tumor cells in 12 hours and
completely ablate the tumor in 30 hours, thus proving
the effectiveness of this nanoscale platform for integrated
targeting of tumor cells and angiogenesis ex vitro.
The in vivo capacity of the platform was demonstrated
by introducing nanocells into mice with either B16/F10
melanomas or Lewis lung carcinoma. Compared to single-
drug, no-drug, and non-temporally restrained multi-drug
controls, nanocells significantly reduced tumor size,
increased apoptosis rates, decreased the amount of HIF1-
a and VEGF, reduced the amount of overall system toxicity,
and increased the overall survival rates of the mice. These
data indicate that the use of nanocells is far more effective
than using either drug alone or simultaneously delivering
both drugs encapsulated in the same liposome without the
polymeric nanoparticle.
Thus, the multicompartmental and multifunctional
nanocell platform (Figure 5) allows for accurate control of
both the spatial and temporal targeting, and is also able to
overcome the hypoxia-induced resistance to chemother-
apeutic drugs 0 2 1 Because the nanoparticle-chemothera-
peutic conjugate is trapped within the tumor, the nanocell
also significantly alleviates off-targetcytotoxic side-effects,
making it safer than traditional chemotherapy. Addition-
ally, nanocells are able to achieve even greater specificity
throughthe incorporation of cell surface receptors, receptor
ligands, antibodies, or aptamers. This extra layer of
targeting ensures that the nanocells reaches their appro-
priate molecular target. This could further limit the already
low off-target effects, potentially allowing the use of
Macromol. Rapid Commun. 2010, 31, 202-216
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releasing the anti-cancer agent from within the blood vessel deprived
otherwise highly toxic cancer drugs. Moreover, this would
allow an additional level of treatment, as both the
polymeric nanoparticle and the targeting component
could be used therapeutically in drug-independent man-
ners as previously discussed. Finally, the physicochemical
properties of nanocells are easily tailored, allowing for a
high degree of customization in delivery rates, drug
payloads, and specificity. Since every tumor type reacts
differently to each of these parameters, the ability to
customize treatments is both beneficial and required for the
nanocell to function as a universal multi-drug delivery
platform.
As future advancements to the nanocell platform, it is
envisioned that strategic drug combinations may be tested
as payloads to further the potency of the platform and
influence many or all factors of the cancer immortality
spectrum. A major challenge to the extension and
optimization of the nanocell delivery platform is the still
incomplete understanding of the complex interaction of
factors relevant to drug release from polymer formulations.
As a result, there is a growing need for better modeling and
simulation platforms to further the understanding and
predictive capabilities of drug release. In the following
section, we discuss the recent progress of integrated
nanoscale modeling and simulation platforms.
Development of In-Silica Platforms for
Computational Nanotechnology and
Macromolecular Simulations
Recent work has emphasized the dramatic therapeutic
benefits obtained through rational control over the design
parameters of polymer-drug formulations.6.7,20 1 Rational
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design of nanoscale polymeric systems for the optimization
of delivery strategies requires further understanding of the
complex interaction of factors relevant to drug release from
polymer formulations. -1 0 8 13 As a result, thereis agrowing
need for better models to understand and predict phenom-
ena such as polymer degradation and nanoparticle erosion.
Existing models, however, have been limited in their
application to predict drug release from nanoparticles. They
typically utilize simplified two dimensional simulation
structures to limit computational cost at the expense of
accuracy, and they are additionally structured almost
exclusively from microparticle-drug release data[108 1
1 3 1
Recently, a three dimensional platform11 41 has been
proposed for modeling and simulating drug release from
polymeric nanoparticles (Figure 6a). This model was
based on selective incorporation of known nanoscale
mechanistic phenomenon pertinent to polymeric devices
and parameter integration from material, computational,
and pharmaceutical nanotechnologies. As part of this
study, a three-dimensional voxe"5 1 (portmanteau of
"volume" and "pixel") based framework for Monte Carlo
simulation was proposed (Figure 6b), that enables direct
investigation of the entire spherical nanoparticle during
various phases of particle degradation and drug release.
Drug release from an experimental formulation of the
chemotherapeutic agent dexamethasone encapsulated
within poly(lactic-co-glycolic acid) nanoparticles was
studied, and good correlation to the simulation results
was observedJ' 1 41 This semi-empirical platform was also
used to obtain insights into the classical bulk erosion
(Figure 6b) and surface erosion (Figure 6c) mechanisms of
polymeric matrix degradation and erosion. The 3-D
nanoscale platform permitted inclusion of volumes of
the polymers, drugs, and pores, and its versatility allowed
a) Nanoscale and macromolecular simulation platform for design and testing
b) Bulk erosion simulation on
2-D (left) and 3-D (right) grids
C) Surface erosion simulation on
2-D (left) and 3-D (right) grids
Time - 0.5 days Time - 5 days Time - 0.5 days Time - 5 day Time -0. day The - 5 Ms Thee -0.5 days Time - 5 day
Time -10 days Time -15 days Time - 10 days Time - 15 days The - 10 days Time -15 daya TIme -10 days Time - i days
Time - 20 days Thee - 25 das Time - 20 days Time - 25 days Time - 20 daysTime-s 25 days Time - 20 days Time - 25 days
Figure 6. The nanoscale simulation platform developed as part of our multi-pronged approach to targeting the cancer cell immortality
spectrum. a) Whole nanoparticle simulation using the 3D platform to study the physicochemical behavior of nanoscale polymer matrices
enclosing or conjugated to drug molecules of interest. In this depiction of the platform herein, the progress of polymer degradation (red)
and erosion (blue) in a bulk eroding polymeric nanoparticle (gray) is shown. b) Bulk eroding polymeric matrices are traditionally simulated
using 2-D grids (left) with intact polymers (black), degraded polymers (gray) and eroded pores (white) but these cannot account for volumes,
whereas the 3-D simulation platform (right) is able to include the effect of volumes of the biomaterials, pores, and drugs as depicted herein
with intact (pink/black) and eroded (blue) polymers colored. c) Similarly to bulk erosion, surface erosion of microparticles and nanoparticles
is also simulated inclusive of volumes of biomaterials, pores, and drugs, with the 3D simulation platform.
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easy incorporation of physicochemical parameters that are
important for predictive power.
Along the dimension scale from "nano" to "micro", the
phenomenon of agglomeration, or the coming together of
individual nanoscale particles to form clusters (or agglom-
ers), becomes increasingly important due to the high
a)
The
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surface energies involved.J1 6"'l A computational plat-
form that integrates the nanoscale voxels platform, which
currently pertains to single nanoparticles, with multi-
nanoparticle simulations wherein interparticle forces are
accounted for, hence becomes important (Figure 7a). By
varying the interparticle forces with a suitable agglomera-
Microscale Aggloers
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Figure 7. From nanomers to agglomers. a) Spatial compartmentalization at nanoscales (quantum dots, core-shell nanoparticles, and
nanomer clusters) and microscales (agglomers) is depicted pictorially. b) Simulation of agglomer size distribution with time can be
computed at fixed agglomeration factor (AF) values to predict time spanswhen desired agglomer clusters will occur. c) Effect of variation of
agglomeration factor (AF) on the size of agglomer clusters formed can be computed as shown and polymer characteristics may be
appropriately tailored for desired agglomer sizes.
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tion factor parameter as shown, it is possible to tease apart
these forces and compute quantitative estimates of their
influence (Figure 7b). Furthermore, the size of the agglomers
is key to their applications for the treatment of specific
cancers.6] For instance, treatment of lung cancers
and associated inflammation and infections with large
agglomers delivered as aerosol formulations has been
explored.11 18 1 2 01 Such aerosol formulations typically
require several hundred polymeric nanoparticles or lipo-
somes to agglomerate together. In most of these scenarios,
designing nanoscale agglomers of smaller sizes (e.g.
agglomer of 2 or 3 nanoparticles) is required to ensure that
these are specifically localized to the tumor microenviron-
ment (owing to the dimensions of the pores in the "leaky"
tumor microvasculature). [6,7,118-1211 In order to facilitate
the precise engineering of such nano-complexes for
application to tumor treatment, simulation platforms
can be used to analyze the concentrations of agglomers
of the required size as a function of time as shown
(Figure 7c). Thus, the outlined extensions of the voxels-
based 3-D simulation platform will allow for integrated
modeling of polymeric nano- and micro- particle behavior
in the context of their anti-cancer application.
Given that several phenomena including water and drug
diffusion, drug dissolution, drug solubility, particle size and
geometry, polymer degradation kinetics, porosity, swelling,
average molecular weight of polymer, micro-
environmental pH changes, and autocatalysis have all
been shown to influence drug release from polymeric
devices, there is tremendous value to the development of
computational models for predicting multi-phase drug
release kinetics. With the advent of more such 3-D
computational platforms for engineering nanoscale
devices, it is reasonable to expect further progress in our
ability to temporally regulate release kinetics. Concomi-
tantly, the virtual explosion of high-resolution 3-D
structures for over-expressed cancer cell surface receptors
made possible by significant strides in high-throughput
x-ray crystallography, structural genomics, and homology-
based (comparative) modeling, is continually enabling new
opportunities for targeting nanoscale devices to tumor
specific signatures. Taken together, the exquisite spatial
and temporal regulation of diagnostic and therapeutic
agent delivery from nanoscale platforms is likelyto present
novel methods in the foreseeable future for integrated
targeting of the many factors in the cancer cell immortality
spectrum.
Conclusion
There is an emerging understanding that the technology
used to deliver drugs for fighting cancer is as important as
the drugs themselves for obtaining maximal therapeutic
Macromol. Rapid commun. 2010, 31, 202-216
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benefit. The field of nanotechnology is notable for its
application to cancer chemotherapy, and pioneering work
in nanoparticle-drug formulation has resulted in therapies
with longer blood circulation, increased tumor uptake, and
enhanced anti-tumor action. However, cancer is a complex
disease for which the "magic bullet" single-drug treatment
is increasingly appearing unlikely to succeed, and hence,
there is great interest in exploration of combination
therapeutics for cancer treatment. In this article, we have
outlined the molecular underpinnings of tumors using the
cancer cell immortality spectrum and motivated the need
for a combination therapeutic approach to cancer treat-
ment. We then described emerging nanoscale platforms for
both cancer diagnosis and therapeutics, emphasizing the
novel approaches that target multiple factors of the cancer
cell immortalityspectrum. With the development of further
such multifunctional nanoscale platforms, it is envisioned
that the search for the elusive cancer cure will culminate in
potent, cost-effective, minimal side-effect solutions to this
dreaded disease.
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34.1 Introduction
There exists a delicate balance between life and death within all
biological systems. It is estimated that an average of 60 billion
cells undergo programmed cell death or apoptosis per day in the
adult human body, counterbalancing cell division (Alberts 1983).
This equilibrium facilitates the maintenance of an optimal den-
sity of cells in healthy tissue. Cancer or tumor is a disproportion
that is pathologically characterized by uncontrollable cell divi-
sion and apoptosis evasion. Tumors are sustained by reservoirs
of pro-growth signals and additionally have a distinct insen-
sitivity to anti-growth signals (Hanahan and Weinberg 2000).
Tumor tissues thrive on angiogenesis, which is the construction
of new blood vessels. These hastily erected blood vessels ensure
adequate supply of nutrients and oxygen for the greedy cancer
cell colonies (Figg and Folkman 2008). Expanding tumors are
typified by an obstinate lack of boundary consciousness and
they often impinge on neighboring organelles, disrupting their
normal function. Cancer cells, like pathogens, are further capa-
ble of metastasizing to non-neighboring organs by hitching onto
34-1
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lymphatic or blood vessels. Metastasis, which is characteristic
of malignant tumors, permits the rapid colonization of multiple
organs with tumor-favoring microenvironments (Harold 2001).
Such an irrepressible spread of the disease is usually responsible
for the eventual death of the organism.
A number of cancer-causing agents, also known as carcino-
gens, have been identified (Milman and Weisburger 1994).
Sustained exposure to carcinogens causes irreparable genetic
mutations, which increases the risk of cancer development. The
carcinogenic potential of materials such as asbestos, arsenic,
coal tar, heavy metals, tobacco, and dyes as well as environmen-
tal risk factors such as exposure to ultraviolet radiation is well
characterized. Further, some pathogens have been recognized as
cancer-causative agents (Table 34.1). For example, chronic infec-
tion with the human papillomavirus (HPV) has been linked
with cervical cancer development (Wu 2004). Carcinogenic
synergies between multiple agents have also been recorded. For
instance, carcinogenic synergy between hepatitis B virus and
aflatoxin has been observed to drastically amplify the possibil-
ity of liver cancer development (Zur Hausen et al. 2006). Owing
to the ubiquitous presence of carcinogens as well as numerous
cases of congenital susceptibility to cancer, the prevention of the
disease in its totality is extremely challenging.
The detection of cancer at its earliest stages is essential for the
effective treatment of the disease. The ability to monitor cellular
microenvironments and subcellular compartments with high
sensitivity is in turn fundamental to the timely recognition of
tumorous metamorphosis. This necessitates the miniaturiza-
tion of sensing technology. Furthermore, miniaturization is also
essential for the design of effective anticancer therapeutic sys-
tems because the systemic administration of chemotherapy or
anticancer chemicals results in high levels of toxicity to healthy
tissues. With the advent of nanotechnology, there has been a
surge of attempts to "sense" molecular signatures of cancer at its
onset and "target" therapeutics to cancer cells.
TABLE 34.1 Pathogens with Suspected Roles in Promoting
Carcinogenesis
Pathogen Family Cancer Type
Hepatitis B virus (HBV) Hepadnaviridae Liver
Hepatitis C virus (HCV) Hepadnaviridae Liver
Human papilloma virus (HPV) Papillomaviridae Cervix, anus, vulva,
oropharynx
Simian virus 40 (SV40) Polyomaviridae Lung
Herpes simplex virus-2 (HSV-2) Herpesviridae Cervix
Epstein-Barr virus (EBV) Herpesviridae Nasopharynx blood
Human T-lymphotropic virus Retroviridae Blood, bone marrow
(HTLV)
Helicobacter pylori Helicobacteraceae Stomach, pancreas
Salmonella typhi Enterobacteriaceae Gallbladder
Streptococcus bovis Streptococcaceae Colorectum
Chlamydia pneunoniae Chlamydiaceae Lung
Mycoplasma Mycoplasmataceae Stomach, intestine,
colon, esophagus
A nanometer is one billionth of a meter and devices that are
less than hundreds of nanometers in dimension are known
as nanodevices. Nanoscale devices are typically smaller than
human cells and are able to achieve cellular entry. Such devices
can further readily interact with biological macromolecules
owing to their comparable dimensions. Nanotechnology, hence,
presents an unprecedented insight into the complex regulatory
and signaling network of biomolecular interactions that moti-
vate cancerous transformation of normal cells. Nanotechnology
has also provided significant impetus to the development of
promising approaches for fighting cancer on various fronts
(Figure 34.1).
This chapter describes the full spectrum of nanodevices for
molecular diagnostics and therapeutics, specifically highlighting
the state-of-the-art nanoscale techniques for targeting cancer.
On the diagnostics front, the development of nanoscale systems
for the molecular sensing of tumorigenesis fingerprints and for
in vivo imaging of the tumor microenvironment is discussed. On
the therapeutics front, the development of nanoscale platforms
for targeted drug delivery, combination chemotherapy, and sus-
tained drug release is described. Nanoscale systems for other
purposes such as multidrug resistance reversal and personalized
medicine are then discussed with emphasis on the significance
of computational nanotechnology in this post-genomic era. The
chapter concludes with a summary of opportunities and chal-
lenges involving the translation of nanoscale anticancer devices
to the clinical realm.
34.2 Nanoscale Molecular Sensing
and Early Malignancy Detection
The exquisite sensitivity of nanoscale technology and its ability
to monitor subcellular compartments presents clinicians with
a paradigm shift in the identification of tumors at elementary
stages (Amiji 2006). The design of nanoscale carcinogenesis
detection systems is motivated by advancements in molecular
sensing, nanoelectromechanical systems (NEMS), nanofluidics,
and ultrasensitive imaging technologies. This section showcases
these emerging nanoscale opportunities for the timely detection
of cancer.
34.2.1 Molecular Combing for Unearthing
Genomic Instability
Molecular combing is a prospective high-resolution technology
that provides for the linearization and alignment of deoxyri-
bonucleic acid (DNA) molecules thus permitting a thorough
analysis of the encoded genetic information. This technique is
useful for unearthing mutated genomic domains that may have
been missed by conventional sequencing-based screens in can-
cer patients (Weitzman 2001). Since conventional screenings
produce considerable proportion of false negative diagnoses,
"cancer combing" is a major step forward toward the develop-
ment of foolproof procedures for the identification of mutations
that arise during the genesis of cancer.
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FIGURE 34.1 Compilation of nanoscale platforms for early tumor detection, in vivo imaging of tumor microenvironmrent, targeted drug deliv-
ery, sustained release, long-term tumor monitoring, combination chemotherapy, body-on-a-chip, and biomedical informatics.
34.2.2 Nanomechanical Cellular Analysis
with Atomic Force Microscopy
The atomic force microscope (AFM) can be used to measure the
stiffness and elasticity of materials at nanoscale resolutions with
high precision. The AFM has been employed to show that lung,
breast, and pancreatic tumor cells are all substantially softerthan
normal cells (Cross et al. 2007). Such studies enable the rational
differentiation of cancer cells from noncancerous cells of the
same tissue microenvironment, in spite of their general similar-
ity in shape. These studies also contribute to our understanding
of the change in mechanical properties underlying each cellular
phenotypic event that constitutes carcinogenesis. However, the
translation of these in vitro studies to viable in vivo platforms
would be paramount to the deployment of cellular elasticity
sensing platforms in real-time tumor detection applications.
34.2.3 Tumor Signal Sensing with
Nanoelectromechanical Systems
NEMS are nanoscale devices that are constructed out of com-
ponents such as nanocantilevers, nanosieves, nanowires, and
nanochannels. These devices are useful for the collection and
analysis of biological signals. NEMS can aid in the timely
detection of rare molecular signals associated with malig-
nancy (Cui et al. 2001). For example, nanowire sensor arrays
with surface receptors are demonstrated to recognize even
femtomolar concentrations of carcino embryonic antigen and
prostate -specific antigen from as few as ten tumor cells (Zheng
et al. 2005). This ability to identify tumor molecular markers
at small concentrations holds immense potential for the early
detection of malignancy.
34.2.4 Tumor Signal Amplification with
Superparamagnetic Nanoparticles
Superparamagnetic materials are generally nonmagnetic mate-
rials that are composed of small, randomly oriented ferro-
magnetic clusters. However, when an external magnetic field
is applied, thermal fluctuations aid in orienting the clusters
resulting in "switching on" of the materials magnetism (Bean
and Livingston 1959). Magnetic resonance imaging or MRI
involves scanning materials with externally applied magnetic
fields. Superparamagnetic materials are ideal candidates for the
amplification of low-amplitude tumor signals owing to their
polarization during MRI scans. This property of superparamag-
netic nanoparticles has been used for noninvasive illumination
of the anatomical contours of brain tumors in the early stages of
development (Simberg et al. 2007). Tumor signal amplification
with superparamagnetic nanoparticles has also been helpful in
locating tumor colonies that may not appear on conventional
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MRI scans owing to the associated poor signal-to-noise (SNR)
ratio. This high-sensitivity technology is useful for the timely
and accurate detection of cancer.
34.2.5 Ultrasensitive Nanoscale
Imaging Technology
Conventional optical interferometer systems use resolution-
limited, Fourier transform spectroscopy (FTS) to monitor sig-
nals from biological samples. Although this provides for faster
signal processing and more affordable system design, FTS
is unsuitable for nanoscale sensing which by its very nature,
demands extremely high resolutions for sensitive scanning.
Terahertz spectroscopy systems designed with quantum cascade
structures employ far-infrared radiation to extract molecular
spectral information with very high resolutions (Ferguson and
Zhang 2002). This ultrasensitive imaging technology offers some
insight into the native conformations of biomolecules, many of
which have collective vibration modes in the terahertz range.
One of the applications of this technology is the biomolecular
characterization of tumor protein-ligand interactions and this is
beneficial for the early detection of cancer (Menikh et al. 2002).
The following section examines tumor-specific nanoscale
imaging systems.
34.3 In Vivo Imaging of the
Tumor Microenvironment
with Nanoscale Systems
Nanoscale devices are commonly employed for many medical
imaging applications (West et al. 2006). Owing to their smaller
dimensions compared to the relatively larger pores on the leaky
tumor microvasculature, nanoscale devices preferentially accu-
mulate within tumor tissues. This "auto-targeting" of nano-
scale devices enables localization of the imaging agent in tumor
microenvironments. Nanoscale imaging provides compelling
snapshots of the biological mechanisms governing tumor matu-
ration while also enabling effective monitoring of disease spread
and assessment of therapeutic efficacy. This section discusses
the use of nanoscale systems for in vivo imaging of the tumor
microenvironment.
34.3.1 Quantum Dots
Quantum dots (QDs) are nanoparticles less than l0nm in
diameter, possessing unique optical, chemical, and electronic
characteristics. These include improved signal intensity, nar-
row emission spectra, good photo-stability, single-wavelength
excitation of multiple colors, size-tunable light emission, resis-
tance to photo-bleaching, and ease of surface functionalization
(Bruchez and Hotz 2007). Such distinctive properties render
QDs as ideal fluorescent probes for the simultaneous illumina-
tion of multiple subcellular compartments with high resolution,
appreciable sensitivity, and agreeable color contrast. A variety
of QD probes have been developed for monitoring the tumor
microenvironment. These probes are generally composed of an
amphiphilic polymer matrix encapsulated within QDs that are
surface-functionalized with tumor-targeting ligands. The pow-
erful combination of ultrasensitivity and ultraprecise targeting
enables high-resolution imaging of tumor cells and subcellular
structures.
34.3.2 PEGylated Quantum Dots
Polymeric QDs have limited in vivo lifetimes (-minutes).
However, they may be optimized for imaging tumors by ensur-
ing adequate circulation time and sustained fluorescence over
longer periods. The conjugation of polyethylene glycol (PEG)
molecules to the QD polymer coat produces a manifold increase
in their lifetime. The resulting fluorescent signal from PEGylated
QDs also lasts for several months after injection into the blood
stream. This increased lifetime of PEGylated QDs is due to the
presence of a hydration shell around the device that improves
its ability to resist pressure (Allen et al. 2002). The hydration
sphere in turn is stabilized by a rich n etwork of hydrogen bonds
between PEG and water molecules. Furthermore, the excellent
structural fit of PEG with the tetrahedral lattice of water mol-
ecules enhances the stability of the hydration sphere. Given their
greatly increased circulation lifetime, PEGylated QDs are ideal
tools for sustained monitoring of tumor cells.
34.3.3 Immunofluorescent Label-
Conjugated Quantum Dots
PEGylated QDs can conveniently be conjugated to biomolecules
through covalent chemical bonding. These conjugated QDs
allow for selective labeling of cell surface receptors, cytoskel-
eton components, nuclear antigens, and other biomolecules.
Immunofluorescent labeling is one technique by which the
molecular footprint of tumors may be mapped to aid in the
design of appropriate therapeutic systems. For instance, QDs
linked with streptavidin and immunoglobin molecules have
been used to selectively label the Her2 receptors on the surface
of live breast cancer cells (Wu et al. 2003). Such selective immu-
nofluorescent labeling of tumor biomarkers helps to track the
progress of the disease and to evaluate the efficacy of therapeutic
regimens.
34.3.4 Bioluminescent Quantum Dots
QDs generally require blue light for efficient excitation. However,
the visible frequency range has low tissue-penetration capability
and is associated with random excitation of endogenous fluo-
rophores resulting in high levels of background noise (Arnone
et al. 2000). Bioluminescent QDs can auto-fluoresce and there-
fore do not call for any external excitation. Bioluminescence
is the phenomenon of light production involving the conver-
sion of biochemical energy to light energy in organisms such
as fireflies, glow worms, honey mushrooms, gulper eels, coral,
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and vibrionaceae. Bioluminescence resonance energy transfer
(BRET) is a technology that is prevalently used in a variety of bio-
technological applications for harnessing bioluminescence from
natural and genetically engineered organisms (Shrestha and Deo
2006). BRET involves the transformation of a naturally occur-
ring fluorophore protein such as luciferase into a bioluminescent
probe by conjugating it with QDs. Since fluorophores such as
luciferase are of fragile structure, bioluminescent QDs are likely
to possess constrained fluorescent activity and highly reduced
circulation lifetimes. In order to retain the activity of these auto-
fluorescent devices, synthetic biology techniques are employed
to design stable variants of the luciferase gene. Furthermore,
genetically engineered fluorophores may be tailored to emit light
of shorter wavelength than the natural firefly luciferase protein,
thereby synergizing better with the absorption spectrum of QDs.
Bioluminescent QDs are powerful tools for probing the anatomi-
cal contours of living systems provided the in vivo resistance to
degradation by host immune system is enhanced.
34.3.5 Cysteine-Coated Quantum
Dot Nanocrystals
Coating of QD nanocrystals generally causes variations in their
optical properties that adversely affect their pharmacokinet-
ics. However, coating of QD nanocrystals with the sulfur-rich
cysteine amino acid renders them bright and stable (Liu et al.
2007). The cysteine coating also prevents the undesirable adsorp-
tion of random serum proteins onto the QD surface that typically
leads to enlargement and distortion. Furthermore, unbound
QDs are rapidly cleared via the kidney's filtering mechanisms.
This suppresses the otherwise rampant background noise con-
tribution of unbound QDs. Cysteine-coated QD nanocrystals
are hence particularly useful for the in vivo imaging of microen-
vironments wherein the tumor signal-to-background noise ratio
is generally low.
34.3.6 Luminescent Carbon Nanotubes
Carbon nanotubes (CNTs) are cylindrical carbon allotropes of
length-to-diameter ratios greater than a million. These nano-
structures are characterized by extraordinary strength, chemi-
cal inertness, and thermal conductivity (Reich et al. 2004).
Hybrid nanostructures of CNTs conjugated to luminescent
QDs are used to selectively illuminate cancer cells. An added
advantage of these hybrid nanostructures is the additional cav-
ity volume present within the CNT where substantial payloads
of anticancer drug can be stored. The successful translation of
these luminescent CNTs to clinical trials would require toxicity
assays relating to long-term CNT exposure.
34.3.7 Nanoscale Polymeric Matrices
Polymeric matrices are highly versatile, biocompatible, biode-
gradable devices that are extensively used for in vivo imaging
applications and a well known example is poly-lactic-co-glycolic
acid (LaVan et al. 2003). These devices also offer the advantages
of high agent encapsulation efficiency and specific accumulation
within tumor sites. Moreover, polymeric matrices can be conve-
niently surface-conjugated to polyethylene glycol (PEG) mole-
cules for increasing their circulation lifetime and functionalized
with tumor-targeting molecules for homing the device specifi-
cally to tumor sites (Aubin-Tam and Hamad-Schifferli 2008).
These characteristics that render polymeric matrices attractive
for in vivo imaging are also responsible for the extensive use of
these devices as targeted drug delivery vehicles.
The following section describes the design of targeted nano-
scale drug delivery systems with emphasis on the recently dis-
covered biomaterials and technologies that are being utilized for
anticancer applications.
34.4 Targeting the Nanoscale Delivery
of Chemotherapy to Tumors
The development of nanoscale systems for targeted delivery of
drugs to cancer cells is a major focus of chemotherapy, primar-
ily for the purpose of toxicity reduction. Nanoscale systems
that are smaller than 200nm in diameter effectively navigate
through the leaky tumor microvasculature and aggregate selec-
tively within the tumor interstitial space. They are thereafter
contained within the tumor microenvironment owing to the
dysfunctional lymphatic drainage. Devices that rely primarily
on this enhanced permeation and retention (EPR) for deliver-
ing drugs to tumors are known as passively targeted or auto-
targeted systems. Active targeting, on the other hand, implies
that targeting ligands such as polysaccharides, antibodies, pep-
tides, nucleic acid aptamers, or other small biomolecules are
conjugated to the surface of the nanodevice. Biomolecules are
carefully screened to identify potential targeting ligands that
bind selectively to receptors that are unique to, or overexpressed
in, cancerous cells. A compilation of overexpressed cell surface
receptors in various tumor types is presented (Table 34.2). The
conjugation of appropriate tumor-specific targeting molecules
onto drug-encapsulated nanodevices ensures selective delivery
of the agent to cancerous cells and hence minimal toxicity to
noncancerous cells (Figure 34.2). Although passive and active
targeting are both helpful for directing nanoscale devices to
tumor tissues, the latter mode is associated with greater reduc-
tion in chemotherapeutic toxicity, specifically to healthy cells in
the immediate neighborhood of tumor cells. This section out-
lines the advancements in targeting the nanoscale delivery of
anticancer drugs.
34.4.1 Biodegradable Polymeric Nanoparticles
The duration of therapy for various diseases ranges from a few
hours to several months. Application-specific injectable drug
delivery devices are being developed across this therapeutic
duration spectrum (Chasin and Langer 1990). These devices are
typically constituted of polymeric materials that are suitable for
in vivo use, that is, nontoxic, noncarcinogenic, nonmutagenic,
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TABLE 34.2 Overexpressed Cell Surface Receptors Classified
According to Incidence of Ca ncer Type
Cancer Type (Incidence
Overexpressed Cell Surface Receptor If Available)
Estrogen receptor alpha (ERo) Breast (70%),ovary
Progesterone receptor (PR) Breast (64%), uterus
Human epidermal growth factor receptor Pancreas (26%), bladder (44%),
2 (HER2) Cervix (77%),breast (30%),
stomach
Endothelin-A receptor (ETAR) Breast (45.3%), ovary
Platelet-derived growth factor receptor Liver (221%), breast (39.2%)
(PDGFR)
Fibroblast growth factor receptor 2 Sarcoma, breast (5%-10%)
(PGFR-2)
Heparin Sulfate Glycosaminoglycan
(HSGAG)
Neuropilin-1 (NRP-1) Breast, colon, prostate, pituitary
Androgen receptor (AR) Prostate (43%)
Insulin-like growth factor-1 receptor Cervix
(IGFR)
G-Protein coupled receptor (GPCR) Brain (57%),stomach,
prostate (60%)
Cannabinoid-specific receptors (CBR) Liver (62%)
Chemokine receptor (CXCR4) Skin
Vascular endothelial growth factor Colorectal, ovary pancreas,
receptor (VEGFR) breast
Interleuln-13 (IL-13) receptor Skin, brain
no nallergenic, and non inflammatory. Materials satisfying
these criteria are classified as biodegradable, bioelimable or
permanent, depending on the mode of their in vivo clearance
Extra cellular matrix (E%)
(Table 34.3). Biodegradable materials are initially in the solid
or gel phase and are thereafter broken down into natural
metabolites within the body by hydrolytic or enzymatic activ-
ity (Hasirci et aL. 2001). PLGA is an example of a biodegradable
material that has been approved for clinical use by the Food
and Drug Administration (FDA). PLGA is completely hydro-
lyzed into lactic acid and glycolic acid which are components
of the Kreb's cycle and are hence naturally metabolized by the
body. The characteristic degradation half lives of biodegrad-
able polymers varies from a few minutes to several years based
upon the ease of hydrolysis (Table 34.4). Matrices composed
of biodegradable polymers degrade by cross-link, side chain,
or backbone degradation and the polymer molecular weight
plays an important role in determining the average degrada-
tion lifetimes (Figure 34.3a). Other characteristics of biode-
gradable polymers that are known to influence their hydrolysis
rate include hydrophobicity, steric effects (local structure,
glass transition), microstructure (porosity, phase separation,
crystallinity), oligomer solubility, autocatalysis, and pH of the
medium (Kumar 2007). Biodegradable polymeric devices are
classified as bulk or surface eroding based on the hydrolysis
and diffusion rates (von Burkersroda et aL 2002). Bulk erod-
ing polymer matrices undergo uniform, instantaneous wetting
and degradation happens throughout the bulk of the matrix,
whereas water diffuses much more slowly into surface-erod-
ing polymer matrices and degradation hence happens only
at the exposed surface of these matrices (Figure 34.3b). The
drug release profile associated with surface-eroding polymer
matrices is generally monophasic whereas bulk eroding poly-
mer matrices display more biphasic release profiles with a
distinct initial "burst release" phase. During the burst phase,
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FIGURE 34.2 Active targeting of nanoparticles to turnor-specific overexpressed receptors.
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TABLE 34.3 Polymeric Biomaterials Classified According to Mode of In Vivo Clearance
Clearance Mode Polymer Chemical Structure
Biodegradable Poly(glycolic acid) 0
0
n
Poly(lactic acid)
Poly(lactide-co-glycolide)
Poly(c-caprolactone)
Poly(malic acid)
Poly(ethylene carbonate)
Poly(propylene carbonate)
Poly(anhydride)
Bioeliminable Poly(alkyl cyanoacrylate)
Poly(ethylene oxide)
Perm anent/implant Poly(methyl methacrylate)
poly(hydroxyethyl methacrylate)
Poly(N-isopropyl acrylamide)
0
0
n
CH,
0 0
m n
0 0
0
0
HO 0
C O
0
O 0
R 0
R = H/CH.7
HO
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r 
n
C OR
0 0 n
CH3
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TABLE 34.4 Degradation Lifetimes
of Hydrolysis-Susceptible Polymers
Polymer Class Degradation Half-Life
Polyanhydrides <10 min
Polyorthoesters -5 h
Polyesters -20 months
Polyphosphazenes -5 years
Polyamides >50,000 years
bulk eroding nanoparticles release a significant volume of their
drug payload and this is undesirable for therapeutic applica-
tions (Langer and Folkman 1978). However, drug molecules
may be conjugated chemically to polymer molecules to ensure
non-burst release.
34.4.2 Liposomes, Micelles,
and Polymerosomes
Liposomes are nanoscale spheres composed of one or more
bilayer, self-assembled, concentric lipid membranes which can
be used to encapsulate various biological molecules. Micelles are
self-assembled, spherical lipid monolayers with a hydrophobic
core-hydrophilic shell architecture. Polymerosomes are com-
posed of synthetic polymer amphiphiles and are structurally
similar to liposomes. Certain characteristics of these lipid-based
carriers enable their use for chemotherapeutic drug delivery.
These include biodegradability, biocompatibility, drug insula-
tion, ease of surface functionalization, and, encapsulation of
- -. -
-~ - -~ -~' ~)L \j\f~~~; iii P > T.
___ 'I-,'
Crosslink
degradation
Backbone
degradation
- - .- .- - - -, - - -
- -, ..
- - -. -
-
- - Y
~ -
~ ~-. ~- ~-
drugs with wide-spectrum physicochemical properties (Peer
et al. 2007). Furthermore, some of these carriers can be loaded
with multiple drug combinations. For example, the inner cavity
of liposomes being aqueous is ideal for encapsulating hydrophilic
drugs, while the volume between successive lipid membranes
is well suited for housing relatively hydrophobic drugs (Figure
34.4a). While these advantages have resulted in extensive deploy-
ment of lipid-based nanoscale carriers in therapeutic applica-
tions, the synthesis of these carriers remains cumbersome. This
challenge is overcome by the use of lipidoid libraries.
34.4.3 Lipidoid Libraries
The time-intensive synthesis of liposomes is a major limita-
tion to the throughput of this class of delivery system. Lipidoid
libraries are designed by the rapid and parallel combination of
amino molecules with alkyl-akrylates and alkyl-acrylamides.
This multiplexed synthesis is capable of producing more than a
1000 different lipid-like structures in an accelerated manner
(Akinc et al. 2008). Lipidoids are a viable platform for the tar-
geted intracellular delivery of short strands of ribonucleic acid
(RNA). The targeted approach is necessary because direct intro-
duction of RNA into the bloodstream results in its breakdown
by the body's immune system. The RNA may be engineered to
block the action of selectively targeted oncogenes, while leaving
other cellular mechanisms intact. This exquisite specificity offers
a new tool for harnessing the potential of RNA interference
(RNAi) which is aimed at suppressing the expression of specific
proteins that have been associated with cancer.
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34.4.4 Immunoliposomes
Antibodiesor immunoglobulins are proteins used by the immune
system to identify and neutralize bacteria, viruses, and other for-
eign bodies. The chemical conjugation ofmonoclonal antibodies
to the distal ends of PEGylated liposomes yields immunolipo-
somes (Figure 34.4b). These are useful both for the intracellular
targeting of therapeutic nucleotides aimed at malignant cells as
well as for roping in the immune systems arsenal (Kontermann
2006). Moreover, unlike liposomes that are incapable of perme-
ating the blood-brain barrier composed of the brain capillary
endothelial wall, immunoliposomes undergo receptor-mediated
transcytosis. This has been used to successfully deliver small
molecule anticancer drugs such as doxorubicin to brain tumors
(Huwyler et al. 1996).
34.4.5 Dendrimers
Dendrimers are synthetic organic macromolecules structured
like branched trees (Figure 34.4c). The fabrication of these
macromolecules is relatively new to polymer sciences (Tomalia
and Frechet 2003). Dendrimers are classified as bioeliminable
because they are cleared rapidly from blood by thekidneys owing
to their nanoscale (<10 nm) dimensions. They are also water sol-
uble, have well-defined chemical structures, and are completely
biocompatible. Dendrimers can also be conveniently conjugated
with appropriate targeting molecules with moderate affinity and
high avidity. The term "avidity" refers to multivalent collective
binding. High avidity of multi-ligand conjugated dendrimer
nanovehicles is responsible for manifold increase in their target-
ing ability (Hong et al. 2007). The moderate affinity of dendrim-
ers is important because high binding affinity of nanocarriers to
their targets decreases the probability of their tissue penetration
due to "binding-site barrier" effects. Although dendrimers are
well suited for targeted drug delivery applications, their mass
production is a challenging task.
34.4.6 Natural and Synthetic Viral Capsids
Capsids are protein shells of viruses consisting of several oligo-
meric units. These are structured as icosahedrons (20 equilat-
eral triangular faces) or other complex geometries and house the
viralgenetic matter (Figure 34.4d). Like carbon buckyballs, viral
capsids self-assemble into near-spherical geometries with high
surface area-to-volume ratios (Wagner and Hewlett 2004). The
specificity of biomolecular interactions between glycoproteins
on the host cell surface and the virus coat dictates cellular entry,
implying that certain cells are intrinsically more susceptible
to infection with certain vectors. This is the rationale behind
cell-specific targeted gene therapy with viral vectors (Table
34.5). Furthermore, vectors can be tailored for tumor-centric
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TABLE 34.5 Tumor Targeting with Viral Capsids and Vectors
Viral Family Type Capsid Target Molecules Tumor Type
Adenoviridae DNA Icosahedral Urokinase-type plasminogen activator Skin, prostate
Matrix metalloproteinases (MMP)
Herpesviridae DNA Icosahedral Urokinase-type plasminogen activator Brain
Matrix metalloproteinases (MMP)
Poxviridae DNA Complex Urokinase-type plasminogen activator Liver
Reoviridae RNA Icosahedral Matrix metalloproteinases (MMP) Skin
Picornaviridae RNA Icosahedral
Rhabdoviridae RNA Helical Matrix metalloproteinases (MMP) Skin
Paramyxoviridae RNA Helical Signaling lymphocytic activation Bladder, skin, ovary,
molecule brain
Membrane cofactor protein (MCP)
applications by appropriately modulating the capsid surface gly-
coproteins. For instance, the incorporation of tumor-targeting
peptides onto the capsids of recombinant adeno-associated
human parvovirus transforms this typically broad-range infec-
tive vector into a tumor-specific delivery vehicle (Grifman et al.
2001). The advantageous features of viral capsids such as their
stable structure, target specificity, and ease of surface functional-
ization have also prompted the design of synthetic nano-capsids
for drug delivery applications (Cattaneo et al. 2008).
34.4.7 Targeted Nanoshells
Nanoshells are nanoscale concentric spheres with a core-shell
architecture that provides for the accommodation of multiple
drugs as payload (Figure 34.4e). The core-shell dimensions can
further be manipulated, allowing for the fine-tuning of key opti-
cal properties of the device, such as light absorption at different
wavelengths. Nanoshells that are surface functionalized with tar-
geting biological molecules are able to seek out and bind selectively
to the surface receptors of cancerous cells. Illumination of these
tumor-bound nanoshells with infrared light leads to increase in
their temperature and this is useful to selectively destroy tumor
cells (Hirsch et al. 2003). Thermal treatment of tumors with IR
and targeted nanoshells does not have the toxic side effects of che-
motherapy such as fatigue, immune suppression, and hair loss.
34.4.8 Striped Nanoparticles
While gold nanoparticles coated with alternating bands of two
different molecular "stripes" are able to enter cells, random coat-
ing of these molecules onto nanoparticles does not enable their
internalization (Verma et al. 2008). Furthermore, while gold
nanoparticles sans the molecular stripes rupture membranes
leading to cell death, nanoparticles with the stripes are able to
internalize nondestructively. It is proposed that similar material
properties of striped nanoparticles and cell surfaces may play a
critical role in mediating the former's nondestructive cellular
entry (Jackson et al. 2004). Striped nanoparticles are hence ideal
for targeting the delivery of anticancer drugs to the cytoplasm
of tumor cells.
34.4.9 Biomimetic Smart Material Nanodevices
Materials may be classified as "regular" or "smart" depend-
ing on their ability to adapt to external stimuli. The properties
of smart materials can be significantly altered in a controlled
manner using specific external stimuli to which the material is
sensitive. Regular materials, on the other hand, are able to offer
only their characteristic and often limited set of properties
(Langer and Tirrell 2004). Most regular materials (e.g., steel)
are a sharp contrast to biological materials that show definitive
adaptability to environmental stimuli (e.g., plants spreading out
to maximize the area exposed to sunlight). Biomimetics refers
to the engineering of stimulus-responsive smart systems based
upon design principles borrowed from the study of biological
materials (Campbell 1995). The ability to quantitatively predict
the change in properties of smart materials with varying exter-
nal stimulus is beneficial for the rationale design of respon-
sive materials for biomedical applications. There are numerous
examples of nanoscale "smart" anticancer technologies (Table
34.6). However, many of these technologies are associated with
safety concerns relating to deployment of smart materials in
vivo. One exception is stimulus -responsive nanogels that are
biodegradable and hence safe for in vivo use.
34.4.10 Hydrogels
Hydrogels are water-soluble, cross-linked networks that swell
with water inflow (Figure 34.4f). Hydrogels are classified accord-
ing to the kind of chemical bonding involved. Ease of chemical
modification, in situ formability and biodegradability are some
of the properties that make hydrogels desirable for drug delivery
(Khademhosseini et al. 2006). Moreover hydrogels can be read-
ily tailored with recognition sites such as adhesion or collagenase
sequences for a variety of biological applications (Mann et al.
2001). Further, the environmental responsiveness of hydrogels
to stimuli such as change in pH, ionic strength, or presence of
analytes, is very useful for the regulation of network swelling.
This in turn controls the kinetics of drug release from hydrogels.
For instance, pH-responsive nanoscale hydrogels or nanogels
maybe designed to swell specifically within the relatively acidic
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TABLE 34.6 Stimulus-Responsive Smart Materials in Nanoscale Antitumor Applications
Material Stimulus Variable Antitumor Applications
Piezoelectric Force Voltage Sensing of tumor cells
Shape memory alloy/polymer Temperature Shape Controlled drug release
Magnetic shape memory alloy Magnetic field Anti-inflammatory drug delivery
pH-sensitive polymers pH Volume Targeted drug delivery
Electrorheostatic Electric field Controlled drug release
Magnetorheostatic Magnetic field Viscosity Tumor cell separation
Non-Newtonian fluid Force
Halochromic pH High-contrast imaging
Electrochromic Electric field Subcellular imaging
Thermochromic Temperature Color Tumor microenvironment monitoring
Photochromic Light intensity
Supramolecular assemblies Metastasis and angiogenesis detection
Chemically cross-linked hydrogels Enzymes Entropy Agent encapsulation in nanoparticles
Enzyme-Tresponsive surfaces Combination chemotherapy
environment of cancer cells thereby releasing the drug payload in
a targeted and controlled manner (Lee et al. 2008). While hydro-
gels are useful for delivery of drugs over short durations, their
widespread therapeutic use is challenged by difficulties in obtain-
ing sustained release. Some of the other nanoscale systems with
sustained drug release capabilities are discussed in the following
section.
34.5 Nanoscale Systems for
Sustained Drug Release
and Tumor Monitoring
Sustained release of agents over several weeks is required for
many applications such as monitoring of the tumor microen-
vironment and anticancer drug delivery (Langer and Folkman
1978). The design of nanoscale systems that are tailored for
sustained release applications is outlined in this section.
34.5.1 Drug-Conjugated Polymeric
Nanoparticles
The chemical conjugation of drug molecules to polymer frag-
ments prevents rapid dissolution of the drug into the medium.
The mechanism governing sustained release from drug-conju-
gated polymeric nanoparticles is as follows (Figure 34.5a). Upon
repeated hydrolytic or enzymatic cleavage of the polymer back-
bones, the fragments become increasingly smaller in size. The
dissolution of the drug-polymer conjugates commences only
after the molecular weight of these fragments decreases below
a certain threshold that is characteristic of the polymer. The
dissolved drug molecules then begin diffusing out of the nano-
particle. An added advantage of drug-conjugated nanoparticles
is the absence of the initial burst release phase which, as was
discussed earlier, is characteristic of drug-encapsulated poly-
meric nanoparticles. Burst release in the latter occurs primarily
because of the near-instantaneous efflux of medium-exposed
drug molecules present in the vicinity of the carrier surface
(Figure 34.5a). In the case of drug-conjugated polymeric nano-
particles, the chemical binding ofthe drug molecules to the poly-
mer backbone prevents instantaneous diffusion of even these
medium-exposed drug molecules on the carrier surface. Drug-
conjugated polymeric nanoparticle systems have been used for
the sustained delivery of chemotherapeutic agents. For example,
PLGA-doxorubicin nanoconjugates have been employed to
effectively deliver the chemotherapeutic drug doxorubicin to
tumors over several weeks (Yoo et al. 2000). Additionally, the
polymers constituting the nanoparticles may be surface func-
tionalized with PEG and tumor-targeting molecules, similar to
other nanodevices. While the use of drug-conjugated polymeric
nanoparticles is associated with these multiple advantages,
implants of nanoscale devices help in attaining a more locally
targeted delivery in the immediate neighborhood of the implan-
tation site (Grayson et al. 2003).
34.5.2 Nanochip Implants
Polymeric multi-reservoir microchips are designed for tem-
porally controlled local release of multiple agents over several
weeks (Grayson et al. 2003). By varying the enclosing "gate"
characteristics that determine the kinetics of polymer matrix
hydrolysis, unique temporal release profiles are obtained for
each drug contained within the chip reservoirs. Polymeric
nanochips serve as preprogrammed implants for the sustained
and controlled release of combination chemotherapy or for
simultaneous delivery of drugs and imaging agents for parallel
therapy and monitoring. However, tumor sites are not always
conducive for procedures such as implantation and it hence
becomes important to develop minimally invasive platforms
for sustained combination chemotherapy. The following section
examines such technologies that are driving nanoscale combi-
nation chemotherapy.
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34.6 Nanoscale Combination
Therapy: Angiogenesis,
Metastasis, and Beyond
Cancer is a complex disease that arises from the dysregulation
of several biological networks that are frequently interconnected
(Keith et al. 2005). Consequently, the single drug-single target
approach of monotherapies is often less effective than combi-
nation chemotherapies that can synergistically target multiple
processes simultaneously. This is verified by assessments of
numerous successful clinical combination therapies for cancer
(Zimmerman et aL 2007). Therapeutic synergy involves one or
more of the following effects-multiplicative increase of cancer
cell death, decreased dosage requirement of each drug, reduced
toxicity, and minimized development of drug resistance (Chou
2006). The last three effects are a natural consequence of using
multiple drugs because the decreased requirement for each drug
alleviates issues of toxicity and drug resistance. Acompilation of
synergistic interactions amongst some of the commonly admin-
istered cancer drugs indicates an abundance of mechanistic syn-
ergy that can be harnessedby combination therapies (Table 34.7).
However, the effective administration of combination therapies
requires very precise spatiotemporal control in the release of
each drug owing to the sensitivity associated with functional
rewiring of cellular biochemical signaling networks. This in turn
calls for the design of sophisticated nanoscale delivery platforms
that can carry multiple payloads and disburse them selectively
to the cancerous tissues at appropriate times. This section exam-
ines such nanoscale platforms for the administration of cancer
combination chemotherapy.
34.6.1 Nanocells
Antiangiogenesis drugs curb the growth of new blood vessels
thereby starving the cancer colony of oxygen and nutrients.
This limits the expansion of tumor tissues. However, delivery
of just antiangiogenesis drugs does not suffice to defeat cancer
owing to subsequent systemic hypertoxicity (Folkman 1996).
Moreover, the destruction of tumor blood supply by antiangio-
genesis drugs cuts off potential routes for the delivery of che-
motherapeutic agents (Carmeliet and Jain 2000). The design of
the nanocell is based upon the principle that the chemothera-
peutic agent could be released from within the tumor after its
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0 Eroded
Release
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blood supply is restricted (Sengupta et al. 2005). The nanocell
is a dual-compartment device that derives its name from its
resemblance to a cell (Figure 34.5b). The device is composed
of an outer PEGylated liposomal vesicle enclosing a poly-
meric nanoparticle in its interior. The antiangiogenesis drug is
encapsulated within the lipid layers and the interior polymeric
nanoparticle houses the chemotherapeutic agent. Owing to the
nanoscale dimensions of this device and the predominance
of enhanced permeation and retention (EPR) in the tumor
microenvironment as outlined earlier, the nanocells are selec-
tively targeted to tumor tissues. Once the nanocells are lodged
within the tumors, the outer layer releases the antiangiogenesis
agent thereby cutting off tumor blood supply. The sustained
release of the chemotherapeutic agent then commences from
within the tumor tissue. Combination chemotherapy with
nanocells is more efficient than nanoscale monotherapy and
conventional combination chemotherapy in inhibiting tumor
growth. The nanocell platform can be further extended to
house drugs that target other features of cancer such as drug
resistance (Sengupta and Sasisekharan 2007).
34.6.2 Nanoscale Modulation of
Tumor Extracellular Matrix
The surface of cancer cells is rich in a plethora of complex poly-
saccharides such as heparan sulfate glycosaminoglycans (GAGs)
that are known to regulate tumorigenesis, tumor progression,
neovascularization, and metastasis (Sasisekharan et al. 2002).
Furthermore, the extracellular matrix (ECM) is composed
of macromolecular networks that restrict liberal transport of
materials thereby limiting the efficiency of anticancer systems
(Goodman et al. 2007). The ECM and cell surface can be modu-
lated with enzymes such as collagenase that degrades collagen
fibers or heparanase that degrades heparan sulfate GAGs. These
ECM-modulating enzymes play critical roles in several aspects
of tumor biology (Liu and Sasisekharan 2005). The combination
of anticancer and antiangiogenetic drugs with such enzymes that
alter the ECM is hence crucial for maximally synergistic thera-
peutic benefit. For instance, conjugation of collagenase onto the
surface of nanoparticles for site-specific degradation of collagen
networks produces manifold increase in nanoparticle mobility
and internalization (Goodman et al. 2007).
34.6.3 Chemo-Thermal Combo-Therapy
with Targeted Gold Nanoparticles
Targeted thermal therapy generally inhibits expansion of tumor
tissues and antitumor drugs are more adept at killing cancerous
cells at elevated temperatures (Everts et al. 2006). Gold nano-
particles have the ability to transduce light into heat and this
property appears promising for two-pronged chemo-thermal
combination therapy. For example, targeted gold nanoparticles
can carry drugs as payload and concomitantly transduce light to
heat in the tumor microenvironment resulting in more efficient
antitumor activity (Visaria et al. 2006).
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34.6.4 Combination Gene Therapy
for Synergistic Targeting
of Multiple Pathways
Monotherapies typically target specific genes involved in spe-
cific pathways responsible for motivating cancer. Combination
therapies on the other hand target multiple genetic pathways
and harness the resulting synergy to produce a multiplicative
increase in cancer cell death (Keith et al. 2005). However, the
use of nanoscale platforms for controlled delivery is paramount
to realizing the full potential of combination gene therapy. For
instance, controlled delivery of multiple tumor-suppressor genes
with nanoparticle-based systems is more effective than the indi-
vidual monotherapies in treating cancer (Deng et al. 2007).
34.6.5 Nanoscale Combo-Therapies for
Targeting Metastasis and Angiogenesis
Metastasis from cancer colonies are significantly more diffi-
cult to detect and treat than the primary tumor itself. However,
since newly formed metastatic tumor colonies thrive on the
development of fresh blood vessels by angiogenesis, nanopar-
ticle-based systems may be used to target drugs specifically
to the sites of maximal blood vessel formation (Murphy et al.
2008). The targeting approach involves sensing the gradients of
pro-angiogenetic factors and directing the nanoparticle-based
systems toward increasing concentrations of these factors. This
integrated approach to treatment of metastasis and angiogen-
esis with nanoparticle-based systems is more effective than
monotherapies in suppressing the spread of malignancy.
34.6.6 Fighting Intractable Tumors with
Nanoparticle-Based Combo-Therapies
Cancer cells develop resistance to anticancer agents leading to the
formation of intractable tumors. However, pretreatment ofintrac-
table tumors with subtherapeutic levels of a potent but highly
toxic anticancer agent followed by nanoparticle-based delivery
of a second anticancer agent sensitizes tumors cells to the latter
(Kano et al. 2007). Nanoscale systems enable the administration
of such drug cocktails with precise spatiotemporal targeting.
The following section focuses on nanoscale systems for tumor
drug resistance reversal.
to the internalization of drugs since it utilizes a different set of
receptors that are not modified by MDR (Figure 34.6b). This sec-
tion focuses on nanoscale strategies for MDR reversal.
34.7.1 Direct Intracellular Ceramide
Delivery with Polymeric
Nanoparticles and Liposomes
Ceramide is the pro-apoptotic mediator that is suppressed by the
overexpression of glucosyl ceramide synthase (GCS) enzyme in
drug-resistant tumor cells. Intravenous injection of ceramide is
not feasible owing to high systemic toxicity, necessitating nano-
scale-targeted delivery of ceramide directly to the cytoplasm of
cancer cells. Nanoparticles that are co-encapsulated with cer-
amide and an anticancer drug are effective in reversing MDR
and killing tumor cells that are normally insensitive to the anti-
cancer drug. For instance, co-encapsulation of ceramide and
paclitaxel in polymeric nanoparticles promotes apoptotic sig-
naling in human ovarian cancer cells with MDR and results in
nearly 100-fold increase in their chemotherapeutic sensitization
(Devalapally et al. 2008). Nanoliposomal formulations of pro-
apoptotic ceramide and the anticancer drug sorafenib are also
able to completely eliminate breast and skin cancer cell lines in
vitro (Tran et al. 2008). While ceramide inhibits MDR, sorafenib
attacks angiogenesis and promotes apoptosis. Liposomes and
polymeric nanoparticles are hence useful for direct cytoplasmic
delivery of MDR reversing agents and pro -apoptotic drugs.
34.7.2 Nanoscale Electrochemotherapy
Electrochemotherapy is a relatively new cancer treatment
modality. This form of therapy uses electric pulses to increase the
permeability of cancer cell membranes, followed by the delivery
of chemotherapeutic agents. For instance, electroporation com-
bined with delivery of bleomycin is effective in increasing the
membrane permeability and promoting the internalization of
bleomycin molecules into a variety of cancer cell lines in vitro
(Gothelf et al. 2003). However, electrochemotherapy as an in
vivo MDR-treatment modality will be practicable only upon
adapting the electroporation technology on targeted, safe thera-
peutic platforms (Wagner 2007). The following section discusses
the development of integrated platforms for testing a variety of
combination drug cocktails.
34.7 Drug Resistance Reversal in 34.8 Body-on-a-Chip: Systems
Tumor Cells with Nanotechnology AD
Approach to Drug Testing
Multi drug resistance (MDR) is a property of certain pathological on Integrated Platforms
bacterial and tumor cells that successfuly defy a wide spectrum
of potent apoptosis -inflicting drugs (Krishan and Arya 2002).
Increased drug efflux, enzymatic drug deactivation, increased
membrane permeability, altered drug molecule receptor sites,
and creation of compensatory metabolic pathways are some of
the mechanisms employed by tumor cells to attain MDR (Figure
34.6a). Nanoparticle -based delivery provides an alternative route
Microfluidics is the study of fluid behavior at microscales.
Microfluidic chips have been designed to host a variety of
human cells and mimic different body tissues (Shuler and Xu
2007). This effectively bridges in vitro and in vivo testing by sim-
ulating full-fledged tissue microenvironments. Such integrated
body-on-a-chip platforms allow for the targeted screening
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FIGURE 34.6 (See color insert following page xxx.) (a) MDR mechanisms; (b) nanoparticle-based delivery for circumvention of MDR.
and selection of the best-suited drugs instead of the conven-
tional shot-in-the-dark approach. These platforms are useful
to test the efficacy and toxicity of preclinical, anticancer drugs,
thereby saving time and money associated with conventional
drug screening processes. Furthermore, this technology holds
promise for "personalized medicine" wherein patient-specific
information is used to predetermine drug efficacy and side
effects prior to actual administration.
34.9 Theoretical and Computational
Nanotechnology
Computational nanotechnology refers to the design of models
for elucidating the mechanistic underpinnings ofnanoscale phe-
nomena. An understanding of theoretical nanosciences is fun-
damental to designing new nanoscale technologies for targeting
cancer (Rieth and Schommers 2006). This section discusses a
few integrated semiempirical models of nanoscale systems for
anticancer applications.
34.9.1 Modeling Polymeric Nanoparticle
Erosion and Drug Release
The degradation kinetics of polymeric networks within polymer-
based nanoscale and microscale delivery systems determines the
rate of drug release. Several computational models have been
developed to simulate hydrolysis-driven erosion of polymeric
matrices (Siepmann and Gopferich 2001). Many of these mod-
els employ two-dimensional pixel grids to represent polymeric
matrices and associate the pixels with a degradation lifetime that
is derived from the characteristic rate constant of hydrolysis for
that polymer. Such pixel-based Monte Carlo (MC) simulations
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have been successful in predicting the mechanistic underpin-
nings of polymer hydrolysis and have also been used to quan-
titatively estimate matrix erosion kinetics, porosity changes,
microenvironmental pH variations, and drug release rates.
34.9.2 Multiscale Spatiotemporal
Modeling of Nanoparticle
Penetration in Tumor Spheroids
The tissue-penetration efficiency of nanoparticles increases
with the use of collagenase enzyme to modulate the extracel-
lular environment. Semiempirical, multiscale models of nano-
particle penetration into tumor spheroids are able to accurately
predict the spatiotemporal distribution profiles of nanoparticles
of various dimensions (Goodman et al. 2007). Furthermore,
tissue-specific circulation of the agents released from the nano-
particles can also be estimated from these models. Multiscale
models provide a platform to bridge molecular-, cellular-, and
tissue-level phenomena that prevail in tumor microenviron-
ments. Multiscale models also collectively contribute to our
understanding of tumor architectures and how they impinge on
the efficiency of nanoparticle-based delivery systems.
34.10 Summary
There is an emerging understanding that a systems approach
to targeting cancer will be fundamental to the development of
effective diagnostic, therapeutic, and preventive tools (Hartwell
et al. 2006). In this post-genomic era, proteomics (Timms 2008),
glycomics (Raman et al. 2005) and other "omics" platforms are
greatly advancing our knowledge of the molecular and cellular
underpinnings of cancer. In order to transform this knowledge
into modular, multifunctional, and potent nanoscale devices for
fighting cancer, the National Cancer Institute (NCI) has estab-
lished the "Alliance for nanotechnology in cancer" (http://nano.
cancer.gov/). Other countries have similarly embarked on the
nano-war against cancer, resulting in a spurt of innovative anti-
cancer approaches. However, seamless integration of anticancer
efforts in nanotechnology, bioinformatics, and modern molecu-
lar biology forsuccessful clinical application is in its infancy. Cost
efficacy, high throughput, standardization in design, develop-
ment of benchmarks, long-term toxicity studies, and creation of
opportunities for synergistic interaction of engineers, biologists,
and physicians are some future milestones toward the assimila-
tion of nano-oncology into mainstream clinical biomedicine.
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3. Recombinant Enzymatic Tools for Decoding
Glycosaminoglycan Polymer Fine Structure
Summary
This chapter focuses on development of recombinant bacterial enzymatic tools for
decoding the structure-function relationships of glycosaminoglycan (GAG) enzymes. An
integrated biochemical-analytical approach was adopted to characterize the structure-function
relationships (including saccharide substrate specificity, enzyme active site, mode and
mechanism of action)for the following GAG enzymes:
(a.) Chondroitinase ABC-II (cABCII) from Proteus vulgaris;
The development and characterization of this contaminant-free cABCII emerges as a tool
to decode biologically significant structure-function relationships of DS and CSGAGs. The
results also offer new therapeutic strategies for tissue repair and recovery after injury.
(b.) Heparin/Heiparan sulfate 6-0-sulfatase from Flavobacterium heparinum;
The findings from this study provide a framework that enables the use of 6-0-sulfatase as
a tool for HSGAG structure-activity studies and expands our biochemical and structural
understanding of this important class of oxygen-sulfur bond cleaving enzymes.
(c.) Heparin/Heparan sulfate N-sulfamidase from Flavobacterium heparinum
The development and characterization of this recombinant, contaminant-free N-
sulfamidase enzyme potentiates in vitro reconstruction of the complete and defined exolytic
sequence for the heparin and heparan sulfate GAG degradation pathway. This "HSGAG enzyme
toolkit" is particularly powerful for application in tandem toward the exo-sequencing of
HSGAG-derived oligosaccharides.
The developed enzymes have been integrated into the GAG databases of the Consortium
for Functional Glycomics (CFG) for data mining and polysaccharide sequencing applications.
These studies resulted in 3 peer reviewed publications in (i.) Journal of Biological
Chemistrv (October 2008); (ii.) Journal of Biological Chemistry (September 2009): and (iii.)
Journal of Biological Chemistry (September 2009).
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3.1 Decoding the structure-function relationships of GAG enzymes
There has been substantial progress in two key areas to address the challenge of
elucidating GAG structure-function relationships [43-46]. The first area pertains to the
development of sensitive analytical methodologies using mass spectrometry (MS), HPLC,
capillary electrophoresis (CE) and NMR techniques. These methodologies have been able to
detect and characterize even femtomolar to picomolar amounts of GAG samples. Generally, only
this much amount can be isolated and purified from biological sources such as cells and tissues.
The second area pertains to the development of bacterial enzymes as tools to
depolymerize GAGs at specific linkages [43-46]. The development of enzymatic tools involves
recombinant expression and purification followed by detailed characterization of substrate
activity that in turn enables rational engineering of these enzymes with desired specificity. Much
of the past efforts in these directions have focused on investigating the structure-activity
relationships of bacterial GAG-depolymerizing lyases starting with the heparanases (a family of
GAG lyases from Pedobacter heparinus that depolymerize heparin and heparan sulfate GAGs or
HSGAGs) [47-50]. After successful development of heparinases as tools to characterize
HSGAGs, investigations began on another family of lyases - the chondroitinases [43-46].
As described earlier, chondroitinases are classified broadly into three sub-families -
chondroitinase-AC (cAC), chondroitinase-B (cB) and chondroitinase-ABC (cABC). cAC
depolymerizes chondroitin-4-sulfate (C4S) and chondroitin-6-sulfate (C6S) whereas cB
depolymerizes dermatan sulfate as its sole substrate. cABC has the broadest substrate specificity
as it depolymerizes both CS and DS substrates. cABC has been employed in attempts to promote
functional locomotor recovery following trauma to the central nervous system in a mouse model.
The application of cABC I at the site of brain injury is believed to prune CS chains from
proteoglycans localized to the glial scar [206]. The absence of these CS chains, inhibitory to
axon regeneration, facilitates neural outgrowth and reconstruction of damaged brain tissue.
Recently, starting with a structural framework, our group had synthesized the
recombinant Chondroitinase ABC I (cABC I) from Proteus Vulgaris, identified its active site,
and investigated its structure-function relationship biochemically [267, 268]. Chondroitinase
ABC II (cABC II), also from P.vulgaris degrades CS, DS, and hyaluronan substrates via an
eliminative cleavage reaction resulting in oligosaccharides with D4, 5-unsaturated uronic acid
residues at the non-reducing end. An approach similar to the method adopted for characterizing
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cABCI is required to elucidate the structure-function relationship of the cABCII enzyme, and
this work is described in the first part of this chapter.
Upon successful characterization of the chondroitinases, the sulfatase enzymes that are
downstream to lyases (such as heparinases and chondroitinases) were isolated and characterized
by our group and others [155, 255, 260-263]. These sulfatases selectively de-sulfate
polysaccharide substrates. Recently, our group reported the molecular cloning and recombinant
expression of 2-0-sulfatase as a soluble, highly active enzyme from Pedobacter heparinus and
concomitant structural analysis was also performed. At the protein level, the bacterial 2-0-
sulfatase was found to possess considerable sequence homology to other members of a large
sulfatase family, especially within its amino terminus, where a highly conserved sulfatase
domain was located. Within this domain, the critical active site cysteine that is predicted to be
chemically modified as a formylglycine (in vivo) was identified by sequence homology.
Further, two other proteins were identified by our group that were found to exhibit a
kinetic preference for highly sulfated glucosamines within each disaccharide unit, especially
those possessing 6-0-sulfate and N-sulfate groups. Upon further investigation two new sulfatases
were discovered, namely, the 6-0 Sulfatase and the N-Sulfamidase enzymes. Determination of
the structure-function relationships by integrated biochemical-structural methods is reported for
these two new enzymes in the second and third parts of this chapter.
3.2 Structure-function relationship of Chondroitinase ABC-TI from Proteus Vulgaris
3.2.1 Brief overview of motivation, methodology, and principalfindings
Chondroitin lyases (or chondroitinases) are a family of enzymes that depolymerize
chondroitin sulfate (CS) and dermatan sulfate (DS) galactosaminoglycans, which have gained
prominence as important players in central nervous system biology [206]. Two distinct
chondroitinase ABC enzymes, cABCI and cABCII, were identified in Proteus vulgaris.
Recently, cABCI was cloned, recombinantly expressed, and extensively characterized
structurally and biochemically by our group [267, 268]. Building on our previous efforts, this
study focuses on the recombinant expression, purification, biochemical characterization, and
understanding the structure-function relationship of cABCII. Using an efficient system of
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Escherichia coli-mediated expression and purification, recombinant cABCII was obtained, and
the conditions for its optimal activity were examined.
A homology-based structural model of cABCII and its complexes with CS
oligosaccharides was constructed. For this purpose, alignment of cABCI, cABCII, PhcAC and
AacAC (Figure 3.1) was computed and revealed that cABCII has generally high sequence
identity with cABCI, barring two prominent insertions of large loop regions (green) on both
sides of the active site residues (blue, pink, red). The crystal structure of cABCI from P. vulgaris
(Protein Data Bank code 1HNO) complexed to DSGAG were obtained from the protein data bank
(PDB). In the case of cAC, two distinct structures were available -- one from Artrhobacter
aurescens (AacAC; Protein Data Bank code 1RW9) complexed with CSGAG substrate and the
other from Pedobacter heparinus (PhcAC; Protein Data Bank code 1CB8) complexed with
DSGAG substrate. Both of these share the same structural fold with cABCI and were obtained
from the PDB to serve as additional templates for the purpose of homology modeling.
This developed structural model of cABCII provided molecular insights and predictions
into the product profile of the enzyme, that could then be readily compared with that of cABCI.
The critical active site residues involved in the catalytic activity of cABCII identified based on
the structural model were validated experimentally using site-directed mutagenesis and kinetic
characterization of the mutants. Based on the developed homology model of cABCII, we
predicted an exolytic mode of action for this enzyme, in contrast with the endolytic mode of
action of cABCI. Similarly, the structural model of cABCII suggested a preference of smaller
substrated owing to a more constrained active site from both sides of the groove. These
predictions made from analyzing the homology model of cABCII were then verified
experimentally. Specifically, the kinetic parameters and mode of action of the enzyme were
characterized using CS and DS substrates. The profile of products formed by action of cABCII
on different substrates was compared with product profile of cABCI, and the predicted smaller-
substrate preference of cABCII was verified. It was also determined that cABCII was able to
efficiently cleave a DS tetrasaccharide that was resistant to cleavage by cABCI, showing that
cABCII has more a broad specific spectrum than cABCI. Similarly, the experimental results also
validated the predicted exolytic mode of action of cABCII, by showing that cABCII only cleaves
substrates at the nonreducing end of the polysaccharide.
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The development of this contaminant-free, recombinant cABCII enzyme provides a new
tool to decode the biologically important structure-function relationship of CS and DS GalAGs
and offers novel therapeutic strategies for recovery after central nervous system injury.
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AwAC AEFAALR4RW'DQ!TGRN\'IQAGDPDFAAITALNNKAAD-LAKLDAAAG . RTS\'FTDLSLAKD -................ AEMVTTYTRLSQLATAW
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cABC7l MIKSLLMLPDYQQRQQALAQLQSWLNKTILSSKG-VAGGFKSDGSIF S-OHY-PA KDAFGGLAPSVYALSDSPFRLSTSAHERLKDVLL-KMRIYTKE-TQIPVVL
eABC1 HLALLLLEPDDQKRINLVNTFSHYITGALTQVPPGGKDOLRPDGTA VE-GNY-PG FPAFKNASQLIYLLRDTPFSVGESGWNNLKKAMV-SAWIYS-N-PEVOLPL
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cABlI PDLNLYQ tAESQSTNSTITYK- --GIWKLTTPQPGlIIKH-HHNNTLITTTT--IQATPT\I
ABCJ PDLNMTR ------------- QKAATPVTINVTIN- - -GKWGSADNSEVEYQ'- SIDNTELTFTS --YFGIPQEI
PacAC PLQK -------------------------------- -EKTAVLSIRDLKT ------------- -GYTNRVE IDFPQQEFAGAT'EL
Ae*A. PTOK -....----- .....----- .... --- - AAGLTLTLPEGTWS'V LEGAGTLOTDADGRSTLTLDTTG--LSGKTKLI
Figure 3.1 Alignment of the chondroitinase enzymes, highlighting the two prominent N-
terminal and C-terminal additional residues in cABCII (green) as well as the active side
residues (blue, pink, red).
3.2.2 Published manuscript
Prabhakar, V., Capila, I., Soundararajan, V., Raman, R., Sasisekharan, R. (2009) Recombinant
expression, purification, and biochemical characterization of chondroitinase ABC II from
Proteus vulgaris. Journal ofBiological Chemistry, 284(2), pp. 974-982.
Specific contributions of this Thesis research to the publication: Developed the homology-
based structural model for cABCII and predicted its structure-function relationship in terms
of substrate specificity, active site residue functions, mode and mechanism of action, which
were all validated subsequently by targeted experiments.
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Chondroitin lyases (or chondroitinases) are a family of
enzymes that depolymerize chondroitin sulfate (CS) and derma-
tan sulfate (DS) galactosaminoglycans, which have gained
prominence as important players in central nervous system biol-
ogy. Two distinct chondroitinase ABC enzymes, cABCI and
cABCII, were identified in Proteus vulgaris. Recently, cABCI
was cloned, recombinantly expressed, and extensively charac-
terized structurally and biochemically. This study focuses on
recombinant expression, purification, biochemical character-
ization, and understanding the structure-function relationship
of cABCII. The biochemical parameters for optimal activity and
kinetic parameters associated with processing of various CS and
DS substrates were determined. The profile of products formed
by action of cABCII on different substrates was compared with
product profile of cABCI. A homology-based structural model
of cABCII and its complexes with CS oligosaccharides was con-
structed. This structural model provided molecular insights
into the experimentally observed differences in the product pro-
file of cABCII as compared with that of cABCI. The critical
active site residues involved in the catalytic activity of cABCII
identified based on the structural model were validated using
site-directed mutagenesis and kinetic characterization of the
mutants. The development of such a contaminant-free cABCII
enzyme provides additional tools to decode the biologically
important structure-function relationship of CS and DS galac-
tosaminoglycans and offers novel therapeutic strategies for
recovery after central nervous system injury.
Chondroitin sulfate (CS) 3 and dermatan sulfate (DS) belong
to a family of glycosaminoglycans) known as galactosaminogly-
cans (GalAGs). GaIAGs are linear polysaccharides of 1-4-
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linked repeating disaccharide units. The disaccharide units
consist of a uronic acid (a-L-iduronic acid; IdoA or -D-glucu-
ronic acid; GlcA) linked 1--3 to a J-D-N-acetyl-galactosamine
(GalNAc). Each disaccharide unit can additionally possess vari-
ations in the form of sulfation at the 2-0 and 3-0 positions of
the uronic acid and 4-0 and 6-0 positions of the GalNAc (1).
GalAG-depolymerizing chondroitinases have been classified
broadly into three subfamilies. Chondroitinase AC depolymer-
izes chondroitin-4-sulfate (C4S) and chondroitin-6-sulfate
(C6S), whereas chondroitinase B depolymerizes dermatan sul-
fate as its sole substrate (2-9). Chondroitinase ABC has the
broadest substrate specificity in that it depolymerizes both CS
and DS substrates (10-12). Chondroitinases have been
employed in attempts to promote functional locomotor recov-
ery following trauma to the central nervous system (13-15).
The application of cABCI at the site of central nervous system
injury is believed to prune CS chains from proteoglycans local-
ized to the glial scar. The absence of these CS chains, inhibitory
to axon regeneration, facilitates neural outgrowth and recon-
struction of damaged tissue. However, the use of chondroiti-
nases as therapeutics is limited because of the lack of availability
of pure and contaminant-free enzyme. Further, chondroitinase
enzymes are often difficult to handle, because of thermal insta-
bility and spontaneous proteolysis, as reported by various
groups (12, 16, 17).
Chondroitinase AC (cAC) and chondroitinase B from
Pedobacter heparinus have been characterized extensively in
terms of their enzymatic activity and substrate specificity. The
crystal structure and co-crystal structure of chondroitinase B
with its DS substrate together with site-directed mutagenesis of
its putative active site residues provided detailed insights into
its substrate processing and also revealed a calcium-dependent
catalytic activity (3, 6, 8). The co-crystal structures of cAC with
different CS and DS oligosaccharide substrate complexes led to
the proposal of multiple scenarios in which the active site resi-
dues contributed to the catalytic activity of the enzyme (7). The
crystal structure of another cAC from Artrhobacter aurescens
and its co-crystal structure with CS substrates provided molec-
ular insights into the active site of this enzyme and also its
exolytic mode of action compared with the endolytic mode of
cAC from P. heparinus (4).
Two distinct broad substrate specificity GalAG-degrading
chondroitinase ABC lyases, cABCI and cABCII, have been
identified in Proteus vulgaris (12). In fact, the ability of the con-
ventional enzyme known as "chondroitinase ABC" to catalyze
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the complete depolymerization of GaIAG substrates to disac-
charides is actually the result of the joint action of cABCI and
cABCII. Recently, cABCI from P. vulgaris was cloned, recom-
binantly expressed, and characterized biochemically in terms of
its active site and the role of divalent cations in processing CS
and DS substrates (10, 18).
Building on our previous efforts, the present study describes
the cloning, recombinant expression, and biochemical charac-
terization of cABCII from P. vulgaris. Using an efficient system
of Escherichia coli-mediated expression and purification,
recombinant cABCII was obtained, and the conditions for its
optimal activity were examined. The kinetic parameters and
mode of action of the enzyme were characterized using CS and
DS substrates. In contrast to cABCI, which is predominantly an
endolytic enzyme, cABCII is an exolytic enzyme that cleaves
the substrate only at the nonreducing end of the polysaccha-
ride. Furthermore, cABCII was able to efficiently cleave a DS
tetrasaccharide that was resistant to cleavage by cABCI (10).
The structural basis for the role of the active site residues in
enzymatic activity and exolytic processing of cABCII was fur-
ther elucidated using homology-based structural models of the
enzyme-substrate complexes constructed using the cABC I and
cAC crystal structures (4, 7, 11) as templates. The establish-
ment of a contaminant-free recombinant cABCII and detailed
characterization of its structure-function relationship enables
using this enzyme in a variety of biotechnological applications
that include sequencing biologically important GaIAG motifs
and augmenting therapeutic strategies to reverse central nerv-
ous system deficit.
EXPERIMENTAL PROCEDURES
Isolating Chondroitinase ABC IIfrom P. vulgaris-Genomic
DNA was isolated from cultures of P. vulgaris (ATCC 6896)
using a DNeasy purification kit (Qiagen). The primers were
designed based on the available sequence of the gene for both
the full-length and mature versions (19). Forward primers were
designed so as to incorporate an NdeI restriction site; the
reverse primer was designed to incorporate BamHI and XhoI
restriction sites. This allowed cloning into a pET-28a vector
(Novagen). The primers for cloning cABCII had the sequences:
5'-CATATGCTAATAAAAAACCCTTTAGCCC-3' (forward
primer for the full-length gene), 5'-CATATGTTACCCACTC-
TGTCTCATGAAGC-3' (forward primer for the truncated
gene-excluding signal sequence), and 5'-GGATCCTCG-
AGTTACTTAACTAAATTAATAACAGTAGG-3' (reverse
primer). It should be noted that for the truncated gene an addi-
tional methionine was introduced into the primer sequence to
allow for translation of the protein product. This causes an
increment in the numbering of the residues by one for the final
protein product thus produced. PCR was run using genomic
DNA as template with an extension time of 3 min. The PCR
product was ligated into the pCR 4-TOPO vector using the
TOPO TA cloning kit (Invitrogen) and transformed into
TOP10E coli cells. Plasmid DNA was isolated, and the cABCII
gene was excised by exploiting the NdeI and XhoI restriction
sites. The excised gene was ligated into similarly digested
pET28a. These ligation products were transformed into
DHSa E. coli cells. Plasmid DNA isolated from the colonies
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was screened by restriction digestion for incorporation of
the cABCII gene. Sequencing was also undertaken to con-
firm incorporation of the gene. E. coli cells (BL21(DE3))
were transformed with plasmid DNA for expression.
Protein Preparation--Recombinant cABCII was expressed in
E. coli using an adapted version of a previous approach (5, 18).
The pET28a expression system contains an inducible T7 pro-
moter, as well as an N-terminal six-histidine tag for facile puri-
fication. Cultures of Luria-Bertani broth containing kanamycin
were inoculated, induced with 1 m isopropyl-j3-D-thiogalac-
topyranoside in mid-log phase (A6 00 = -0.8), and incubated at
room temperature overnight. Centrifugation was used to har-
vest the cells, and the supernatant was discarded. The cell pellet
was kept on ice and resuspended in 50 mm Tris, 250 mm NaCl,
10 mm imidazole, pH 7.9 (binding buffer), and then lysed by
sonication. Soluble protein was collected by centrifugation at
15,000 X g for 15 min at 4 *C. The soluble lysate was sequen-
tially filtered through a 0.8-gm membrane and then a 0.45-gm
membrane. A 5-ml Hi-Trap Metal Chelate column (GE Health-
care) was prepared by charging with 200 mm NiSO4 and treat-
ment with binding buffer. The protein was loaded onto the
column, washed with a buffer containing 100 imn Tris, 250 mm
NaCl, and 50 mm imidazole, and eluted into a similar buffer
with increased imidazole (250 mm). The six-histidine tag was
removed using a thrombin capture kit (Novagen) as previously
described (20). The presence and purity of the proteins was
assessed by standard methods using SDS-polyacrylamide gel
electrophoresis. Protein concentration was measured using the
Bradford assay (Bio-Rad) with bovine serum albumin (Sigma)
as a standard.
Site-directed Mutagenesis-A QuikChange site-directed
mutagenesis kit (Stratagene) was used with plasmid DNA tem-
plate to induce mutations in the cABCII clone. As previously
described (18), plasmid denaturation and annealing of custom-
crafted complementary oligonucleotide primers were used to
introduce mutations. The primers were designed as follows (all
primers are read in the 5' -+3' orientation): the 5' 123T primer
had the sequence GAA GGT GAA TTA CCC AAT ACC CTT
ACC ACT TC and the 3' 123T primer had the sequence GA
AGT GGT AAG GGT ATT GGG TAA TTC ACC TTC; the 5'
G247V primer had the sequence TGG GAA AAA TTG GTG
TTA ACA CAA CAC GCT GAT GGC and the 3' G247V
primer had the sequence GCC ATC AGC GTG TTG TGT
TAA CAC CAA TTT TTC CCA; the 5' R356W primer had the
sequence CC AGA GAA CTT TTT GAT GCA TGG TTT ATT
GGC CGT C and the 3' R356W primer had the sequence G
ACG GCC AAT AAA CCA TGC ATC AAA AAG TTC TCT
GG; the 5' D389N primer had the sequence GGA CGT ATT
TTT GAA AAA AAT AAT GAA ATT GTT GAT GCA AAT
GTC and the 3' D389N primer had the sequence GAC ATT
TGC ATC AAC AAT TTC ATT ATT TTT TTC AAA AAT
ACG TCC; and the 5' H490R primer had the sequence CGC
TTA TCT ACT TCA GCA CAT GAG CGT TTA AAA GAT G
and the 3' H490R primer had the sequence C ATC TTT TAA
ACG CTCATG TGC TGAAGT AGA TAA GCG. Extension of
the primers in a PCR machine with Pfu Turbo DNA polymerase
followed. The mutated plasmids were transformed into XL1-
Blue supercompetent cells. The plasmids were prepared using a
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Qiagen miniprep kit. Each clone was sequenced to confirm the
presence of the desired mutation. Plasmid DNA was used to
transform BL21 (DE3) E. coli. In addition to the mutants
described above, other mutations in residues believed to be
important for enzyme activity were also made. The primer
sequences for each of the mutants are listed below. The H344A
mutant primers have the sequences 5'-CGA GGA AGT GGT
TAT CAA ATT ATT ACT GCT GTT GGT TAC CAA ACC-3'
and 5'-GGT TTG GTA ACC AAC AGC AGT AAT AAT TTG
ATA ACC ACT TCC TCG-3'. The H453A mutant primers
have the sequences 5'-CT GAT GGT TCT ATT TTT GCC
CAT TCA CAA CAT TAC CCC GC-3' and 5'-GC GGG GTA
ATG TTG TGAATG GGCAAAAAT AGAACCATCAG-3'.
The H454A mutant primers have the sequences 5'-C AAA
TCT GAT GGT TCT ATT TTT CAC GCT TCA CAA CAT
TAC CCC GC-3' and 5'-GC GGG CTA ATG TTG TGA AGC
GTG AAA AAT AGA ACC ATC AGA TTT G-3'. The H457A
mutant primers have the sequences 5'-CAC CAT TCA CAA
GCT TAC CCC GCT TAT GCT AAA GAT GC-3' and 5'-GC
ATC TTT AGC ATA AGC GGGGTA AGC TTG TGA ATG
GTG-3'. The Y461A mutant primers have the sequences 5'-CA
CAA CAT TAC CCC GCT GCT GCT AAA GAT GCA TTT
GGT GG-3' and 5'-CC ACC AAA TGC AT C TTT AGC AGC
AGC GGG GTA ATG TTG TG-3'. The R514A mutant primers
have the sequences 5'-CCT GTG GTA TTA AGT GGT GCT
CAT CCA ACT GGG TTG C-3' and 5'-G CAA CCC AGT
TGG ATG AGC ACC ACT TAA TAC CAC AGG-3'. The
E609A mutant primers have the sequences 5'-AGC CGT TAT
CTT GTT GGT AAT GCT AGC TAT GAA AAT AAC AAC
CGT-3' and 5'-ACG GTT GTT ATT TTC ATA GCT AGC
ATT ACC AAC AAG ATA ACG GCT-3'.
Composition Analysis of Products from cABCII Processing of
CS and DS Substrates-To investigate the composition of the
final products of cABCII digestion, capillary electrophoresis
was performed as previously described (6). Substrates included
C6S from shark cartilage (Sigma), DS from porcine intestinal
mucosa (Sigma), and C4S from sturgeon notochord (Seika-
gaku). Exhaustive overnight digestions of substrate by cABCII
were analyzed using a Hewlett Packard three-dimensional cap-
illary electrophoresis instrument with an extended path length
cell. A voltage of 30 kV was applied using reverse polarity. Oli-
gosaccharides were injected into the capillary using hydrody-
namic pressure. They were detected using an ultraviolet detec-
tor set to 232 nm.
Biochemical Characterization of Chondroitinase ABC II
Activity-Substrates (C6S and DS) were dissolved at 1 mg/ml
concentration in various buffers to determine the relative
effects of pH, temperature, ionic strength, and sodium acetate
concentration on enzyme activity, as previously described (18).
Chondroitin from shark cartilage (Seikagaku), hyaluronan from
human umbilical cord (Sigma), heparin (Celsus), heparan sul-
fate (Celsus), and keratan sulfate (Sigma) were also used in
these studies. For activity experiments, 2 tl of enzyme was
placed in 248 pl of 50 mM Tris/HCl, pH 8.0, and reacted with 1
mg/ml substrate at 37 'C (0.25 mg/ml for hyaluronan). Product
formation was monitored as an increase in absorbance at 232
nm as a function of time in a SpectraMax 190 (Molecular
Devices) 96-well quartz format. For kinetic assays, 1 sl of
enzyme (0.2-1.0 4g//l) was added to 249 sl of a solution con-
taining a GalAG substrate. Substrate concentration ranged
from 0.1 to 5 mg/ml. Product formation was monitored by
measuring the absorbance at 232 nm every 2 s. Kinetic param-
eters were determined using the initial rate of product forma-
tion and calculated as previously described based on Michaelis-
Menten and Hanes techniques (18).
Modeling the Theoretical cABCII-Substrate Structural
Complex-The crystal structure of cABCI from P. vulgaris
(Protein Data Bank code 1HNO) was used as a template to
obtain the model of cABCII. Initial inspection of the sequence
alignment between cABCI and cABCII revealed that cABCII
had multiple insertions of large loop regions as compared with
cABCI. In addition to cABCI, the crystal structures of distinct
cACs (which share the same structural fold with cABCI) fromP.
heparinus (PhcAC; Protein Data Bank code 1CB8) and from A.
aurescens (AacAC; Protein Data Bank code 1RW9) were also
used to model the loop regions in cABCII that aligned with
either of the cACs. The structural superimposition of cABCI
and these distinct cACs was obtained using combinatorial
extension-Monte Carlo (CE-MC) multiple structural align-
ment tool (21) (supplemental Fig. Sl).A homology-based struc-
tural model of cABCII was generated usingthe homology mod-
ule of Insightll v2005 (Accelrys, San Diego, CA). The deletions
in the modeled structure were closed by constrained minimiza-
tion upon holding most of the structure rigid, except for regions
close to the deletion site. This was followed by 300 iterations of
steepest descent and 400 iterations of conjugate gradient min-
imization without including charges. The loops and side chains
of all of the residues were then allowed to move freely by per-
forming 500 iterations of steepest descent minimization. The
refined structure was then subjected to 500 iterations of steep-
est descent minimization without including charges and 500
iterations of conjugate gradient minimization including
charges to obtain the final predicted model of the cABCII
enzyme. The final model of cAB CII was validated using Whatif
web-based interfaces and the Ramachandran plot explorer
(supplemental Fig. S2).
A C4S Tetrasaccharide Substrate, (GlcA-GalNAc,4S)2, was
docked into the putative active site of cABCII using the follow-
ing approach. The SuperPose version 1.0 server (22) was used to
superimpose the co-crystal structure of cAC-CS tetrasaccha-
ride complex (Protein Data Bank code 1HMW) with the mod-
eled cABCII structure. The CS tetrasaccharide in this cAC
complex had a uronic acid with a A4,5 unsaturated linkage at
the nonreducing end. The starting model of the C4S tetrasac-
charide inthe cABCIIactive site was therefore derived from the
coordinates of a C4S hexasaccharide (Protein Data Bank code
1C4S), which was superimposed on the CS substrate inthe cAC
co-crystal structure. The enzyme-substrate complex was sub-
ject to minimization without charges with 400 steps of steepest
descent and 600 steps of conjugate-gradient methods. This was
followed by another 500 steps, each of steepest descent and
conjugate-gradient methods with charges. To constrain the
ring torsion angles to maintain the ring conformation of the
tetrasaccharides during the process of energy minimization, a
force constant of 7000 kcal/mol was utilized. To evaluate the
exolytic versus endolytic propensity of cABCII in comparison
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FIGURE 1. Cloning, recombinant expression, and purification of cABCII. A, expression and purification of
cABCiI. Lane 1, Invitrogen SeeBlue Plus2 prestained standard; lane 2, cell pellet; lane 3, crude lysate; lane 4,
empty; lane 5, recombinant cABC 11l cABC 11 migrates in close proximity to the 97-kDa standard band. B, the
original (*) expressed cABCil product had negligible activity against C6S substrate. By implementing sequen-
tial mutagenesis steps, a clonewas produced that, when expressed, provided cABCII (0) that cleaved C6S at far
greater rates.
with that of cABCI, an octasaccharide C4S substrate, (GicA-
GaINAc,4S)4, was also docked in a similar fashion (described
above) into putative active sites of cABCI and cABCII, respec-
tively. The octasaccharide was generated from the coordinates
of a C4S hexasaccharide (Protein Data Bank code 1C4S) by
adding another, GlcA-GalNAc,4S, to the reducing end of the
hexasaccharide.
The viewer, builder, and discover modules of InsightII v2005
(Accelrys) were used for the visualization, structure building,
and energy minimization, respectively. The AMBER force field
(Amber95) provided with the Discover module was used to
assign the potentials for both the enzyme and substrate. The
parameters for sulfates and sulfamate groups in glycosamin-
oglycans described previously (23) were incorporated into this
force fieldto assign potentials fortheC4Ssubstrates.A distance-
dependent dielectric constant of 4*r and scaling of 0.5 for the
p1-4 cross terms were used in the discover module for the
AMBER force field-based simulations according to the specifi-
cations in the InsightII manual.
RESULTS
Cloning Expression, and Purification of cABCII-Two ver-
sions of the cABCII gene were cloned from P. vulgaris DNA: a
full-length version and a truncated version that corresponds
to the mature form of the enzyme, that is, without its puta-
tive leader sequence. These cABCII transcripts are -3 kb in
length-rather large, but still at an appropriate size to toler-
ate amplification via standard polymerase chain reaction
techniques. Following cloning into a TOPO vector, the PCR
product was subcloned into the pET28a expression vector.
This facilitates E. coli-mediated uptake of the transcript and,
ultimately, expression of the protein. Chondroitinase ABC II
was expressed in E. coli as described under "Experimental
Procedures." Purification over a charged Ni2 resin was pos-
sible because of the incorporation of an N-terminal His 6 tag.
As described in our earlier studies
on recombinant cABCI (18), we
faced similar challenges because
of the discrepancies between our
cABCII transcript and the sequence
reported previously (19). The
codons of concern occupy positions
23 (our clone contains isoleucine
instead of threonine), 247 (glycine
instead of valine), 356 (arginine in-
stead of tryptophan), 389 (aspartic
acid instead of asparagine), and 490
(histidine instead of arginine). After
unsuccessfully trying out different
measures to minimize transcript
discrepancies (including the use of
various high fidelity polymerases),
sequential site-directed mutagene-
sis was successfully employed to
achieve the desired DNA sequence.
Chondroitinase ABC II was
expressed as a fusion protein with
an N-terminal His6 tag. Expression
was induced in the log phase by the addition of isopropyl-#-D-
thiogalactopyranoside. Purification of cABCII generated in
excess of 50 mg of protein/500 ml of culture. SDS/PAGE anal-
ysis (Fig. 1A) confirmed the presence of highly pure cABCII at
~100 kDa, consistent with previously reported masses of the
enzyme (12). Expression of the full-length cABCII clone gener-
ated a proteinlargely present in the insoluble fraction. The yield
of soluble enzyme was greatly improved by the engineered
removal of the hydrophobic N-terminal signal sequence. We
then turned our attention to the truncated dones, both the
original sequence and the transcript that underwent our
sequential mutagenesis resolution. The recombinant protein
with the sequence discrepancies was unable to effectively proc-
ess Ga1AG substrates (Fig. 1B). The expression and purification
of the modified cABCII gene, on the other hand, generated a
protein product with reinvigorated functionality as demon-
strated by the observed cleavage of chondroitin-6-sulfate (Fig.
1B).
Biochemical Conditionsfor Optimal Enzyme Activity-After
establishing the active recombinant cABCII, the reaction con-
ditions for optimal cleavage of GaIAGs were investigated.
These reaction parameters included temperature, pH, ionic
strength, and buffer system. For C6S substrate, cABCII demon-
strated maximal processing at 37 'C, with a greater than 50%
decline in activity at 42 'C (Fig. 2A). Chondroitinase ABC II
similarly acted on DS substrate maximally at 37 *C, with a 50%
drop at 42 'C (Fig. 2A). Activity against both substrates fell dra-
matically in excess of 45'C. For both C6S and DS substrates,
37 'C was chosen as the optimal temperature for biochemical
experiments.
A Tris buffer system was chosen for biochemical experi-
ments because it permitted greater activity relative to phos-
phate buffer (data not shown). The recombinant enzyme dem-
onstrated maximal activity at pH 8.0 for C6S. For DS, maximal
activity occurred in the range from pH 8.0 to 8.5 (Fig. 2B).
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FIGURE 2. Chondroltinase ABC 11 biochemical reaction conditions. A, effecto
profile in Tris buffer system. C, salt effect on cABCII processing using sodium c
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TABLE 1
Specific activity of recombinant chondroltinase ABC lion
glycosaminoglycan substrates
Specific activity was determined by monitoring the increase in absorbance at 232
nm for 5 min. The initial rate of increase in A2mm .. was determined for each sub-
strate. The enzyme activity in units (1 unit = 1 pimol product formed/min) was
calculated from the initial rate using e = 3800 M- 1 for reaction products at pH 8.0,
ND, not determined.
Substrate Specific activity
mi!iuntsigprotein
Chondroitin-6-sulfate 29,000
Chondroitin-4-sulfate 18,000
Dermatan sulfate 17,000
Chondroitin 5400
Chondroitin sulfate D 4900
Chondroitin sulfate E 4900
Hyaluronan ND
Heparin/heparan sulfate ND
Keratan sulfate ND
TABLE 2
Kinetic analysis of chondroltinase ABC 11 with various substrates
The values are the means of at least three experiments - standard deviation.
Substrate K. k. k/K,,
PA min- pwalm n
Chondroitin-6-sulfate 9.8 ± 2.1 1300 113 132
Dermatan sulfate 19.2 -2.9 1150 26 60
Chondroitin-4-sulfate 16.1 : 4.2 1000 60 60
Chondroitinase ABC II processing of GaIAG substrates is
greatly curtailed below pH 7.5 and above pH 8.8. For purposes
of simplicity, pH 8.0 was taken as the optimal pH for biochem-
ical studies for both C6S and DS in a Tris buffer system.
For cABCI, ionic strength proved to be an important deter-
minant in the processing of GaIAG substrates (18). In the case
of cABCII, -100 mm NaCl reduced processing by 50% for both
p.0 9.2 .4 &S && 9.0
pH
f reaction temperature. B, pH
hioride titration. D, salt effect
C6S and DS substrates (Fig. 2C).
Processing of C6S and DS is virtu-
ally eliminated in excess of 250 mM
NaCl. Furthermore, the addition of
-50 mi sodium acetate for C6S
and 100 mm sodium acetate for DS
activates cABCII-mediated proc-
essing (Fig. 2D). Depolymerization
of GalAG substrate by cABCII is
nearly completely inhibited at 500
mm sodium acetate. Therefore,
unlike cABCI, which required -50
mM of NaCl for C6S processing (and
125 mm for DS) (18), for cABCIL the
presence of NaCl in the buffer actu-
ally decreases the activity.
Galactosaminoglycan Processing
by cABCII-The specific activity of
the recombinant cABCII was tested
against a full panel of glycosamin-
oglycan substrates (Table 1). The
results suggest that cABCII is most
proficient in degrading C6S, C4S,
and DS substrates. It was not possi-
ble to detect reaction progression
for hyaluronan, possibly because of
low cleavage rate and nonoptimal
pH for this substrate. As expected, other glycosaminoglycan
families, like heparin and heparan sulfate (which contain glu-
cosamine instead of galactosamine), were not processed by
cABCII. Comparison of cABCII activity with that of cABCI (18)
shows that cABCI more efficiently processes CS (-10-fold) and
DS (more than 7-fold) than cABCII. Kinetic parameters for
recombinant cABCII acting on C6S, DS, and C4S are summa-
rized in Table 2. These measurements were obtained from the
initial reaction rates against each substrate using both Michae-
lis-Menten and Hanes analysis. The turnover numbers for
cABCII were experimentally determined to be 1300, 1150, and
1000 min' for C6S, DS, and C4S, respectively. The catalytic
efficiency was highest against C6S substrate (132 LM-l min-')
and comparable for DS and C4S (both 60 pkM-1 min-').
The depolymerization of GaIAG substrates by cABCII was
further scrutinized with capillary electrophoresis. These stud-
ies allow for the characterization ofthe final products of cABCII
digestion following a 20-h exhaustive reaction at 37*C and
therefore represent an end point assay for cABCII activity. For
all of the substrates examined, the product profile contains an
overwhelming proportion of disaccharide products (Fig. 3). For
C6S, the dominant product is a 6-0-sulfated disaccharide. For
C4S, the major product is a 4-0-sulfated disaccharide. With
DS, a mixture of disaccharide products includes two mono-
sulfated species, the 4-0-sulfated DS disaccharide and the 6-0-
sulfated DS disaccharide, and a doubly sulfated disaccharide,
the 4-0- and 6-0-di-sulfated disaccharide. It should also be
noted that the amount of disaccharide released in each of
these end point assays is considerably less (as measured by the
double bonds generated, i.e. A,2 2 m) when compared with those
released by cABCI processing of these substrates. Comparison of
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FIGURE 3.Product profile analysisof recombinant chondroktinase ABC IL
Product profiles for cABCIlacting on C6S (A), C4S (B),and DS (Q. Shown in inset
of Cisthe processing of DS by cABCI.Chondroitinase ABC I is unable to cleave
DS tetrasaccharide fragments (indicated by Tetra in the peak label) despite
the addition of more enzyme and longer digestion period, whereas cABCII
processing of DS results only in disaccharides. ADi4S, AUA-GalNAc,4S; ADi6S,
AUA-GaINAc6S; ADi4S6S, AUA-GaINAc,4S6S. Impurities in commercial sub-
strate preparations result in the ADi4S peak in electrophoretogram (A) and
the ADi6S peak in electrophoretogram (B).
the processing of DS by cABCI and cABCII (Fig. 3C, inset) indi-
cated that although cABCI processing resulted in a resistant tet-
rasaccharide AUA-GalNAc,4S-IdoA-GalNAc,4S (10), cABCII
action on DS substrates forms only disaccharide products.
Structural Investigation of the Active Site Residues and Mode
of Action of cABC11-The crystal structures of cABCI, PhcAC,
and AacAC were used as templates to obtain a homology-based
structural model of cABCII and its complex with the substrate
(Fig. 4). The resulting model therefore adopted a multi-domain
structure (similar to thatof cABCI and the cACs) comprising an
N-terminal (3-domain with a jellyroll fold, the catalytic a-helix
domain (incomplete toroid (a/a)S-fold), and a C-terminalanti-
parallel P-sheet domain. To contrast the active site and posi-
tioning of the substrate within cABCII, the obtained model was
superimposed on the enzyme-substrate co-crystal structures of
the cAC enzymes (see "Experimental Procedures"). This super-
imposition showed that the critical active site residues were
conserved and aligned spatially (supplemental Fig. Si). Com-
parison of cABC structures with that of cACs showed that the
substrate binding and the active site of the cABCs formed a
wider groove to accommodate a broad range of CS and DS
substrates. The notable differences in the structures of cABCI
and cABCII were in two specific loop regions Ile"-Thrm' and
Gly9"-Leu9 3' that were present in cABCII and not cABCI
(supplemental Fig. Si). The presence of extra loop regions in
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lII224-Thr231
FIGURE 4. Homology-based structural model of cABCI-C4S tetrasaccha-
ride complex. Shown in the figure is the Ca trace (cartoon representation) of
cABCIl (gray)-C4S tetrasaccharide (colored by atom:carbon and sulfur,yellow;
oxygen, red; nitrogen, blue) superimposed on the cABCI template (Ca trace
colored pink), which was used in the homology modeling. The active site
groove of the enzyme is zoomed in for clarity. The distinct additional loop
regions in the active site grooveof cABCII,11e224-Thr"23 and Gly9 14-Leu' 37, are
colored in brick red. The critical active site tetrad residues that structur-
ally coincide are labeled using their numbering in cABCIland the single alpha-
bet codefor clarity (Arg and His are colored blue, Glu is colored red, and Tyr is
colored magenta). This figure was generated using PyMol software.
AacAC compared with that of PhcAC has been implicated to
account for the predominant exolytic activity of AacAC as
against the endolytic activity of PhcAC (4). To better under-
stand the role of the loop regions in cABCII in substrate proc-
essing, an octasaccharide of C4S was docked into the putative
active site of cABCII. Assuming that the GalNAc,4S-GIcA
cleavable linkage occupied subsites -1 and + 1, respectively,
the sugars on the nonreducing end of the cleavable linkage
occupied -2, -3, and -4 positions, whereas the sugars on the
reducing end occupied +2, +3, and +4 positions.
In the docked model of the cABCII-octasaccharide complex,
the sugars at the nonreducing end -3 and -4 positions had
unfavorable steric contacts with the Ile 22-Thr 31 loop region
(Fig. 5). Also, it appeared that for a long oligosaccharide (octa
and higher) to be accommodated into the active site of cABCII,
the chain would have to bend out of the active site groove. The
cABCI active site groove, on the other hand, is open at both
reducing and nonreducing ends of the substrate and hence is
readily able to accommodate longer oligosaccharide substrates
in the active site. Together the above observations offer an
explanation based on the structural model for the ability of
cABCII to process smaller oligosaccharides such as tetrasac-
charides more efficiently than cABCI. Further, these observa-
tions also support the notion that cABCII processes its sub-
strates in a predominantly exolytic fashion starting from the
nonreducing end.
To understand the interactions of cABCII with its substrates,
a C4S tetrasaccharide was docked into the putative active site of
cABCII (see "Experimental Procedures"). It has been shown
previously that a tetrad of residues including Arg, His, Tyr, and
Glu play a critical role in the lyase activity of cABCI and the
cACs. The analogous tetrad of residues in cABCII (that struc-
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FIGURE 5. Structural rationalleforweolytic action of cABCil versus endolytic
figure Is the Connolly surface rendering of cABCI (top In pink) and cABCII (botto
chari de (shown as a stick model) docked into their putative active sites (gener ate
left and right is the active site groove seen from the nonreducing and reduci
respectively. Note that the octasaccharide is readily accommodated In the acti
hand, the access for the octasaccharide appears to be constricted toward the n
site groove of cABCIL
TABLE 3
Kinetic analysis of chondroltinase ABC |1 site-directed mutants with
different substrates
The values,where measurable, are the means of at least three experiments stand-
ard deviation. NDA, no detectable activity. MDA, minimally detectable activity
(activity was too lowto allow for reliable determination ofkinetic parameters).
Chondroitin-6-sulfate Dermatan sulfate
Ezyme K., km ka/1 Km kK. t k.IK/
pu mn mip-' pminn- -p,
cABCII 9.8 t2.1 1300 ±113 132 19.2 ± 2.9 1150 ± 26 60
H348A NDA NDA NDA NDA NDA NDA
H452A 7.0 ± 1.5 10.1 ± 1.9 1.4 9.1 ± 4.2 4.3 ± 0.5 0.5
H453A NDA NDA NDA NDA NDA NDA
H456A 10.4 2.4 428 2 51 41 7.6± 1.9 144 ±17 19
Y460A NDA NDA NDA NDA NDA NDA
RS13A NDA NDA NDA NDA NDA NDA
E608A NDA NDA NDA MDA MDA MDA
turally aligned with cABCI and cACs) are Args13, His" 3, Tyr'60,
and Glu60 (Fig. 6). Although Glu' does appear to be directly
involved in the contact with the sugar, it is positioned to make
critical hydrogen bonding interactions with His' 53 and Arg 1",
thus positioning these residues for their activity (Fig. 6).In addi-
tion to these critical active site residues, there are several other
residues that are proximal to the CS substrate and hence could
play a key role in positioning the substrate for enzyme action.
The residue His"s2 proximal to His'5 3 is on the opposite side of
Arg" 3 in the base of the groove and is positioned to interact
with carboxyl group of the GIcA in the cleavage site. Residues
His3"3 and Tyr 34 on the top side of the grove (opposite to the
catalytic tetrad at the base) are positioned to interact with GIcA
and GaINAc,4S in the +1 and +2 subsites and hence could play
a critical role in anchoring the substrate in the active site. The
residues His"' and His5 1' are prox-
imal to the 4-sulfate group of the
GlcNAc4S residue at the -1
subsite.
Site-directed Mutagenesis and
Kinetic Characterization of the Pu-
tative Active Site Residues-
Based on the above structural model
of cABC[I-CS tetrasaccharide com-
plex, a putative catalytic tetrad,
His' 5 3, Tyr* 0, Arg 13, and Glu6*,
and the other residues in the active
site that are positioned to interact
with the substrate such as His34 3,
His'5 2, and His'" were identified.
To probe the contribution of these
residues to enzymatic activity, they
were mutated to alanines, and the
resulting enzyme products were
assayed for activity on chondrotin-
ctilonofcABCI.Shown in the 6-sulfate and dermatan sulfate sub-
rn in gray) with a C4S octasac- strates (Table 3). The results show
d using PyMol). Shown on the that mutants H453A, Y460A,
ng end of the octasaccharide
ve site of cABCI. On the other R513A, and E608A all show no
onreducing end in the active detectable activity on either C6S or
DS, consistent with their designa-
tion as the critical catalytic tetrad
required for enzyme activity. H452A shows similar K values to
the wild type enzyme but a greatly (1 00-fold) reduced catalytic
efficiency. On the other hand, mutation of His'" to alanine has
limited effect on overall catalytic efficiency (-3-fold reduc-
tion), indicating that this residue likely does not play an impor-
tant role in catalysis. Surprisingly, mutation of His3  to alanine
also yields an enzyme that shows no detectable activity on C6S
and DS, suggesting that His3 c3 plays a critical role in the enzy-
matic activity in addition to the catalytic tetrad.
DISCUSSION
This report is the first to describe the expression and charac-
terization of a stable, highly active, conta~inant-free recombi-
nant chondroitinase ABC II from P. vudganis. The sequence
anomalies in the original clone resulted in a catalytically inac-
tive enzyme, although these anomalies were not in the critical
active site residues (Fig. 1B). It is therefore likely for these
sequence differences to affect the overall stability of the
enzyme, which in ta results in an inactive enzyme. Fixing
these anomalies resulted in a fully active recombinant enzyme
that efficiently processed both CS and DS substrates. This
recombinant cABCii was examined structurally and biochem-
ically, including reaction conditions to maximize enzyme effi-
cacy, the product profle following digestion of GalAG sub-
strates, kinetic analysis, substrate specificity, mode of action
analysis, and structural insights into the active site-substrate
interactions. Comparison of substrate processing of cABCII
with that of cABCI showed that cABCI does cleave GaAG sub-
strates at superior rates to cABC; however, depolymerization
mediated by cABCII proceeds bya course distinct from cABCI.
Chondroitinase ABC I seems to prefer longer chain substrates
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Gu6s
FIGURE 6. C ritical residues Involved In catalytic action of cABCIl. A shows ste
ride (carbon, cyan; oxygen, red; nitrogen, blue; sulfur,yellow) substrate docked In
structural model of cABCII. The groove is shown as a cartoon model generated
that are positioned to Interact with the substrate are also shown In the following(purple); and Asp, Glu (red). 8 shows a two-dimensional schematic of the chem
charide and its interactions with the critical residues in the active site. The suga
and +2 from nonreducing to reducing end of the C4S substrate wherethe cleava
and GIcA In the -1 and +1 sites, respectively. The tetrad of residues His,53,
conserved in cABCI, PhcAC, and AacAC and have been shown to play a critical
these enzymes.
and cleaves in a predominantly endolytic fashion (10, 12).
Chondroitinase ABC II, on the other hand, appears to cleave
shorter oligosaccharide substrates more efficiently in a pre-
dominantly exolytic fashion, resulting only in disaccharide
products. The presence of these distinct cABCs offers the bac-
teria the ability to rapidly process GalAG substrates where
cABCI would cleave the naturally occurring long GalAG
polysaccharides and cABCII would then act on the smaller oil-
abled the identification of critical
.o residues involved in the enzymatic
OH activity. This combined analysis fur-
iN ther suggests the likely role of these
active site residues in catalytic
action of the enzyme. A tetrad of
residues including His453, Tyr4 0,
'rr61O Argnt 3, and Glu648 in cABCII was
structurally conserved in cABCI
and the cACs. The corresponding
tetrad in cABCI has been shown to
be critical for enzyme activity (10).
reo view of a C4S tetrasaccha- The mutation of any of these four
to the active site groove ofthe critical residues to Ala resulted in a
using PyMol, and the residues inactive
colors: His, Arg, Lys (blue); Tyr
Ica I structure of C4S tetrasac- 3), which strongly supports the cen-
rs are numbered -2, -1, + 1, tral role of this tetrad in the catalytic
ge occurs between GaINAc,4S
Tyr*4, Argm, and Glu* are . The proximity of
role In the catalytic activity of Hiay 3 to the C5 proton of the GlcA
in the structural model suggests the
role of His1 3 as a general base for
abstraction of the C5 proton. The proximity of Tyr"4 to the
glycosidic linkage between GalNAc,4S-GlcA makes it an ideal
candidate for protonating the GalNAc sugar after cleavage. The
neutralization of the carboxylate group to increase the lability
of the C5 proton can potentially be accomplished by the Arg 13
residue. Furthermore, Areg3, His452, and His2 3 are all equally
likely candidates for the stabilization of the uronic acid C5 car-
banion intermediate formed after proton abstraction. As men-
JANUARY 9, 2009-VOLUME 284-NUMBER 2
Arg349
HNNrNH2
HN
NH2,
Tyr346 hM13
N
............... _ -_ _ -::::::::::::::::::::::: --------
gosaccharide fragments from
cABCIprocessingto generate disac-
charides that can be readily utilized
for bacterial metabolism. The pro-
posed exolytic mechanism of
cABCII and its ability to efficiently
process smaller GalAG substrates is
also supported by the structural
model of the cABCII-C4S octasac-
charide complex. In this model the
two extra loop regions, Ile"4-
Thrm1 and Gly"91 -Leu 937, in cAB-
CII appear to constrict the active
site groove specifically on the non-
reducing side of the substrate. This
groove constriction restricts the
access of internal cleavable linkages
in a long GaIAG chain and thus
points to a predominant exolytic
mode of action for cABCII. The
structural basis for differences in
the activity of cABCI and cABCII is
similar to the framework proposed
for endolytic action of PhcAC versus
exolytic action of AacAC (4, 9).
A combination of the theoretical
structural model ofthe enzyme-C4S
tetrasaccharide substrate complex
and site-directed mutagenesis en-
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tioned earlier, Glu6 08 is not directly involved in interactions
with the substrate, but it is positioned to interact with both
His"s and ArgS13 via hydrogen bonding. Hence mutation of
Glu6 1 to Ala disrupts these interactions and is therefore unfa-
vorable for the optimal positioning of these critical residues for
catalytic activity. Earlier studies (2, 10, 24) implicate distinct
interactions of cABCI with CS and DS substrates. The same
scenario holds good for cABCII because of the structurally
conserved active site tetrad. Therefore, the proposed roles of
the tetrad in catalytic activity of cABCII could potentially be
interchanged to accommodate a broad range of CS and DS
substrates.
In addition to the tetrad, it was surprising to note that the
H343A mutant completely lost the catalytic activity toward
both CS and DS substrates (Table 3). This residue is positioned
on the top side of the active site groove opposite the tetrad,
which is at the base of the groove (Fig. 6). In the structural
model of cABCII described in this study, His3 is not as prox-
imal as the tetrad to the substrate. However, the model devel-
oped in this study is based primarily on the uncomplexed
cABCI enzyme. Therefore, it is possible that in the presence of
the substrate the active site groove could become more
"closed," which would position HisMs proximal to the CS atom
of the GlcA where it could play a critical role in either neutral-
izing the carboxylate group or stabilizing the CS carbanion
transition state.
This understanding of the structure and mechanism of
action of cABCII extends our understanding of precisely how
these lyases function and how various structural features con-
tribute to the depolymerization process. The distinct substrate
processing ability of cABCII enables its use as an additional
valuable resource in technologies directed at determining the
fine structural elements of biologically relevant GaIAGs. These
enzymes may further be useful directly in strategies to interfere
with GalAG function in vivo, for example, in neural regenera-
tion therapeutics and other such biomedical applications.
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3.2.3 Understanding chondroitinase ABC II preference for smaller GAG substrates and exolytic
mode of action by glycan-docking
Docking of 14mer C4S polysaccharide to the developed homology-based cABCII
structural model was performed to further understand the enzyme's preference for smaller GAG
substrates and its exolytic mode of action. Upon successive minimizations of the enzyme-
substrate complex, the molecular surface was plotted (gray) and two distinct collision regions
(denoted CR-i and CR-2 respectively) were identified on the cABCII structure that impinge on
the long polysaccharide substrate (Figure 3.2). The CR-1 region was identified as residues 231-
243 (reducing end) and the CR-2 region was identified as residues 910-924 (non-reducing end).
These two collision regions together render a small-substrate, exolytic preference to cABCII.
These docking results are in agreement with the experimental results presented in the publication
preceding this section.
Figure 3.2 Docking of 14mer C4S (green) to cABCII (gray) highlights collision regions (red)
that make cABCII exolytic with preference for smaller polysaccharide substrates.
.... .... . . . ... . .........   ...........  ... 
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Figure 3.3 Analysis of collision region contributions towards exolytic mode by deletion of
CR-1 (top row; orange), CR-2 (middle row; blue), and CR-1+CR-2 (bottom row; pink)
- - - .. - .. W - .- -11- .............. ..
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The first mutant cABCII structure (Figure 3.3; orange) was generated by deletion of
residues 224-241 from CR-1 upon which multiple rounds of energy minimizations were
performed on the mutant enzyme-substrate complex. Although this mutant structure was
observed to be sterically unhindered in the reducing end (where CR-i originally existed), there
was still remnant steric hindrance on the non-reducing end (proximal to CR-2). Therefore, it
appears that CR-i contributes lesser towards the exolytic mode of action and small-substrate
preference of cABCII. The second mutant cABC-II structure (Figure 3.3; blue) was generated
by deletion of residues 912-937 from CR-2 upon which multiple rounds of energy minimizations
were performed on the mutant enzyme-substrate complex. This mutant structure is unhindered
on the non-reducing end (where CR-2 originally existed) and does not impinge on residues 233-
242 of CR-i. This implies that CR-2 is the major contributor to the experimentally observed
exolytic mode and small-substrate preference of cABCII. A third mutant cABCII structure
(Figure 3.3; pink) was generated by deletion of both residues 224-241 from CR-1 and residues
912-937 from CR-2, as a frame of reference. Energy minimizations were subsequently
performed on the mutant enzyme-substrate complex. From an observation of this molecular
surface, it is clear that there are no steric hindrances on either the reducing or the non-reducing
end and this in turn implies that in the absence of CR-1 and CR-2, cABCII mutants may be
endolytic similar to the experimentally observed endolytic mode of cABCI.
3.2.4 Additional verification of the cABCI homology model with the (<p, V) plot
The homology-based structural model of cABCII and all mutants were verified with the
(p, xV) Plot. The (P, xV) plots for cABCII structural model and cABCI crystal structures computed
are shown herein (Figure 3.4). These (e, y) plots show that the conformations of most of the
residues in both cABCI and cABCII are within the allowed regions. To check whether the
conformation of the critical active site residues in cABCII are within the allowed region (Figure
3.4), the Ramachandran Plot explorer 1.0 software (http://boscoh.com/ramaplot/) was used to
analyze the conformational maps (shown in bottom-left) of these residues (shown in bottom-
right). This analysis shows that the conformation of the active site residues in the cABCII
structural model fall in the permitted regions of the (9, xv) plot, thus providing additional
verification for the developed homology model of this enzyme.
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Figure 3.4 Ramachandran plot verification of the developed cABCII homology model
Having thus deduced the structure-function relationship of the CSGAG and DSGAG
cleaving chondroitinase ABC II enzyme from Proteus vulgaris, we next proceeded to clone,
recombinantly express, and biochemically-structurally characterize the heparin and HSGAG
processing 6-0-sulfatase and N-sulfamidase enzymes from Flavobacterium heparinum, as
described in the next two sections of this chapter.
... ......................................................................................................................................... -- _________
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3.3 Structure-function relationship of 6-0-Sulfatase from Flavobacterium Heparinum
3.3.1 Brief overview of motivation, methodology, and principalfindings
Sequential HSGAG degradation has been demonstrated in several microorganisms, which
depend on these sulfated polysaccharides not only as a carbon source but often as a means of
scavenging inorganic sulfate [218, 255, 266]. The Gram-negative soil bacterium Flavobacterium
heparinum (a.k.a. Pedobacter heparinus) is an excellent example of this process. As such this
organism has proven to be a rich biological source for the isolation and molecular cloning of
several GAG degrading enzymes [21, 25]. Like the enzymes of the lysosomal pathway, many of
the flavobacterial enzymes possess well defined substrate specificity.
Given the manifold biological applications of other HSGAG-degrading enzymes we had
previously derived from F. heparinum, including the heparinases as well as the 4,5-
glycuronidase and the 2-0-sulfatase [21, 25, 218, 255, 266], we reasoned that cloning and
characterization of additional downstream sulfatases would enable the development of important
tools for more specifically investigating HSGAG structure. This is especially relevant given
extensive experimental evidence that points to the regulated expression of endolytic HSGAG
desulfating enzymes (especially 6-0-sulfatase) and their secretion into the extracellular matrix as
a mechanism of modulating GAG structures critical for protein interactions. Thus, the use of
HSGAG degrading and desulfating enzymes as analytical tools is central to unlocking the
structural basis of HSGAG function and their potential use in generating structure-specific,
bioactive glycans for therapeutic applications [35]. To utilize these enzymes correctly and
efficiently requires not only a detailed understanding of the biochemistry of these enzymes; it
also requires their ample availability for in vitro use. Both of these criteria already have been
satisfied in structure-function studies of several HSGAG-related degrading enzymes, such as
heparinase I, heparinase II, a unique unsaturated glycuronidase, and the 2-0-sulfatase [21, 25,
218, 255, 266].
Recently, our group cloned and identified an additional sulfatases downstream to these
enzymes, namely the 6-0-sulfatase. The enzyme was cloned from the gram-negative soil
bacterium Flavobacterium heparinum, recombinantly expressed in Escherichia coli in a soluble,
active form, and identified as a specific HSGAG sulfatase. So as to investigate the mechanism of
action of the enzyme through biochemical and structural studies, a homology based structural
model of -O-sulfatse was developed. For this purpose, ClustalW was used to perform multiple
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sequence alignment of 6-Osulfatase with bacterial and lysosomal enzymes from the highly
conserved sulfatase family. The crystal structures of human arylsulfatase A (PDB code: 1AUK),
human arylsulfatase B (PDB code: 1FSU) and P. aeruginosa arylsulfatase B (PDB code: 1HDH)
were obtained and structure-based multiple superposition was performed using CE-MC and
SuperPose tools. Human arylsulfatase A was used as a template for homology-based modeling
with Insight II molecular simulations package (Accelrys, San Diego, CA) and the preliminary
coordinates of 6-Osulfatase were obtained. The AMBER force field was used to assign the
potentials for the structure. The homology module of Insight II was used to model the loop
regions of the structure and discover module was used to close the deletions in the model, by
constraining most of the structure while permitting the regions in the proximity of the deletion
site to move freely during multiple iterations of steepest descent and conjugate gradient
minimization. The loop regions and side-chains of all residues were then allowed to move freely
while performing further iterations of steepest descent minimization and the refined structure
was finally subjected to more iterations of steepest descent minimization without including
charges and conjugate gradient minimization including charges to obtain the final predicted
model of 6-0-Sulfatase. The structures of GlcNS, GlcNS,6S and GlcNS,3S,6S monosaccharides
were then obtained into the builder module of Insight II by appropriate modifications to the
coordinates of heparin structure (lHPN) from the PDB. Owing to these monosaccharides being
the possible natural substrates for the 6-0-sulfatase enzyme, these were docked to the enzyme
model for molecular analysis. In order to further verify the substrate specificity of the enzyme,
the coordinates of chondroitin sulfate were obtained from its crystal structure (PDB code 1C4S)
and imported into the builder module of Insight II to generate the structural models of the
GalNAc,6S and GalNAc,6S,4S monosaccharides. The initial orientation of the different
substrates in the groove of the enzyme active site was facilitated by the highly conserved
position of the cleavable sulfate group relative to Oyl of the geminal diol as observed from the
crystal structures of the sulfatase enzyme family. The potentials for all structures were assigned
using the AMBER force field modified to include carbohydrates with sulfate and sulfamate
groups. Following this, the enzyme-substrate complexes were subjected to optimization with
minimization. In order to constrain the ring torsion angles to maintain the ring conformation of
the monosaccharides during the process of minimization, a force constant was utilized. The final
homology-based model structural model of the 6-0-sulfatase enzyme-substrate complexes were
this obtained for further analysis (Figure 3.5).
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Figure 3.5 Structural model of 6-0-sulfatase with docked glucosamine monosaccharide
As detailed in the manuscript that follows, all predictions made from analysis of the
homology-based molecular modeling studies regarding the substrate specificity of the F.
heparinum 6-0-sulfatase enzyme, its mode of action, kinetic properties, active-site topology,
substrate specificity, role of divalent metal ions, and key enzyme-substrate interactions, were
verified by targeted biochemical and molecular biology experiments. Taken together, the
structural and biochemical studies indicate that 6-0-sulfatase is a predominantly exolytic enzyme
that specifically acts on N-sulfated or N-acetylated 6-0-sulfated glucosamines present at the non-
reducing end of HSGAG oligosaccharide substrates. This requirement for the N-acetyl or N-
sulfo groups on the glucosamine substrate can be explained through eliciting favorable
interactions with key residues within the active site of the enzyme, using the homology model
developed. These findings provide a framework that enables the use of 6-0-sulfatase as a tool for
HSGAG structure-activity studies as well as expand the horizons of biochemical-structural
understanding of this key class of oxygen-sulfur bond cleaving enzymes.
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Myette, J.R.., Soundararajan, V., Shriver, Z., Raman, R., Sasisekharan, R. (2009)
Heparin/Heparan Sulfate 6-0-Sulfatase From Flavobacterium Heparinum: Integrated Structural
And Biochemical Investigation Of Enzyme Active Site And Substrate Specificity. Journal of
Biological Chemistry, 284(50), pp. 35177-35188.
Specific contributions of this Thesis research to the publication: Developed the homology-
based structural model for 6-0-sulfatase and predicted its structure-function relationship in
terms of substrate specificity, active site residue functions, role of divalent metal ions, mode
and mechanism of action, which were all validated subsequently by targeted experiments.
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Heparin and heparan sulfate glycosaminoglycans (HSGAGs)
comprise a chemically heterogeneous class of sulfated polysac-
charides. The development of structure-activity relationships
for this class of polysaccharides requires the identification and
characterization of degrading enzymes with defined substrate
specificity and enzymatic activity. Toward this end, we report
here the molecular cloning and extensive structure-function
analysis of a 6-0-sulfatase from the Gram-negative bacterium
Flavobacterium heparinum. In addition, we report the recombi-
nant expression of this enzyme in Escherichia coli in a soluble,
active form and identify it as a specific HSGAG sulfatase. We
further define the mechanism of action of the enzyme through
biochemical and structural studies. Through the use of defined
substrates, we investigate the kinetic properties of the enzyme.
This analysis was complemented by homology-based molecular
modeling studies that sought to rationalize the substrate speci-
ficity of the enzyme and mode of action through an analysis of
the active-site topology of the enzyme including identifying key
enzyme-substrate interactions and assigning key amino acids
within the active site of the enzyme. Taken together, our struc-
tural and biochemical studies indicate that 6-0-sulfatase is a
predominantly exolytic enzyme that specifically acts on N-sul-
fated or N-acetylated 6-0-sulfated glucosamines present at the
non-reducing end of HSGAG oligosaccharide substrates. This
requirement for the N-acetyl or N-sulfo groups on the glucosa-
mine substrate can be explained through eliciting favorable
interactions with key residues within the active site of the
enzyme. These findings provide a framework that enables the
use of 6-0-sulfatase as a tool for HSGAG structure-activity stud-
ies as well as expand our biochemical and structural under-
standing of this important class of enzymes.
Heparan sulfate glycosaminoglycans (HSGAGs)3 comprise
an important polysaccharide constituent of many proteogly-
* Thisworkwas supported, In whole or In part, by National institutes of Health
Grant GM57073.
Present Address: Momenta Pharmaceuticals, 675 West Kendall St., Cam-
bridge, MA 02142.
2 To whom correspondence should be addressed: 77 Massachusetts Ave., Rm.
16-561, Cambridge, MA 02139. Fax: 617-258-9409; E-mail: rams@mit.edu.
'The abbreviations used are: HSGAG, heparin/heparan sulfate glycosami-
noglycan; AU, A4,5- unsaturated uronic acid; GICNS,65, N-, 6-0-disulfated
a-D-glucosa mine; GIcNS,35,6S, N-, 6-0-, 3-0-trisulfated a-D-gilucosa mine;
GlcNAC6S, N-acetylated, 6-0-sulfated a-D-glucosamlne; GalNAC6s, N-acety-
lated, 6-0-sulfated P-o-galactosamine; 4-MU, 4-methylumbelliferyl; CE,
cans (see Ref. 1, for a review). These glycans are linear polymers
based on the variably repeating disaccharide unit (uronic acid
1-4 glucosamine),,, where n represents a variably repeating
number (typically 10-200). As present in nature, these sugars
possess an extensive chemical heterogeneity that is largely
attributed to the mosaic arrangement of 0- and N-linked
sulfates present at different positions along each sugar chain (2,
3). Additional structural variations include the presence of
N-linked acetates at the glucosamine C2 position as well as
epimerization of the uronic acid C5 carboxylate to form either
)3-D-glucuronic acid or a-L-iduronic acid. Fundamental to
understanding HSGAG structure-activity relationships is the
appreciation that polydispersity of the glycan fine structure is
not random. Instead, it is the end product of a complex and
concerted biosynthetic pathway involving numerous modifying
enzymes, whose relative expression levels and specific activities
are regulated in a cell- and tissue-specific fashion. This pro-
grammed diversity of HSGAG structure (4) ultimately plays out
at a functional level, namely through the dynamic regulation of
numerous biochemical signaling pathways (2) relating to such
processes as cell growth and differentiation (5), cell death (6,7),
intercellular communication, adhesion and tissue morphogen-
esis (8). HSGAGs are present as structurally defined binding
epitopes on the cell surface and hence also play an important
role in microbial pathogenesis (9, 10).
In contrast to the complex enzymatic process by which these
polysaccharides are made, it appears that their catabolism is
considerably more straightforward, both in the scope of its pur-
pose and the means bywhich it is carried out at the biochemical
level. Sequential HSGAG degradation has been demonstrated
in several microorganisms (11-13), which depend on these sul-
fated polysaccharides not only as a carbon source but often as a
means of scavenging inorganic sulfate (14). The Gram-negative
soil bacterium Flavobacterium heparinum (a.k.a. Pedobacter
heparinus) is an excellent example of this process. As such this
organism has proven to be a rich biological source for the
isolation and molecular cloning of several GAG degrading
enzymes (15, 16). Like the enzymes of the lysosomal pathway,
many of theflavobacterial enzymes possess well defined sub-
strate specificity. Given the utility of other HSGAG-degrading
capillary electrophoresis; LC/MSD, liquid chromatography/mass selective
detector; MIES, 4-morpholineethanesulfonic acid; MO PS, 3-(N-morpholino)-
propanesulfonic acid; ESI, electrospray Ionization; MS, mass spectrometry;
ORF, open reading frame; PDB, Protein data bank.
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enzymes derived from F. heparinum, including the heparinases
as well as the A4,5-glycuronidase (17) and the 2-0-sulfatase
(18), we reasoned that cloning and characterization of addi-
tional sulfatases would enable the development of important
tools for investigating HSGAG structure. This is especially rel-
evant given extensive experimental evidence that points to the
regulated expression of endolytic HSGAG desulfating enzymes
(especially 6-0-sulfatase) and their secretion into the extracel-
lular matrix as a mechanism of modulating GAG structures
critical for protein interactions (19, 20). Therefore, the use of
HSGAG degrading enzymes as analytical tools is central to
unlocking the structural basis of HSGAG function and their
potential use in generating structure-specific, bioactive glycans
for therapeutic applications (21). To utilize these enzymes cor-
rectly and efficiently requires not only a detailed understanding
of the biochemistry of these enzymes; it also requires their
ample availability for in vitro use. Both of these criteria already
have been satisfied in structure-function studies of several
HSGAG-related degrading enzymes, such as heparinase 1 (22),
heparinase 11(23), a unique unsaturated glycuronidase (17), and
the 2-0-sulfatase (24). We have been able to clone and identify
two additional sulfatases downstream to these enzymes,
namely the 6-0-sulfatase and N-sulfamidase.
In this study, we report the molecular cloning and recombi-
nant expression in Escherichia coli of the F. heparinum sulfo-
hydrolase, namely the glucosamine 6-0-sulfatase, and in the
accompanying manuscript (39) we report detailed studies on
the N-sulfamidase as well as a model for how the 2-0- and
6-0-sulfatases, and N-sulfamidase work in concert. In both
studies, we also present detailed molecular structural modeling
and biochemical analyses of the recombinant enzyme as it
relates to substrate specificity, optimal reaction conditions, and
the role of divalent metal ions in the action of the enzyme.
Taken together with our previous studies regarding other
members of the heparinase-sulfatase family of enzymes, we
have now unraveled the complete framework for HSGAG deg-
radation in F. heparinum.
EXPERIMENTAL PROCEDURES
Reagents-Fluorescent glucopyranoside substrates 4-meth-
yllumbelliferyl-a/3-D-glucopyranoside (4-MU-a-D-Glc and
4-MU-3-D-Glc) were purchased from EMD Biosciences, Inc.
(San Diego, CA). 6-0-Sulfated fluorogenic glycopyranoside
derivatives were obtained through Toronto Research Chem-
icals (Toronto, Canada). Glucosamine and galactosamine
monosaccharides, and arylsulfate substrates 4-catechol-sul-
fate and 4-methyllumbelliferyl-sulfate were purchased from
Sigma. Exo-glucosidases were purchased from MP Biomedi-
cals (Irvine, CA). Materials for genonic library construction
and screening were obtained from Stratagene (La Jolla, CA).
Reagents for site-directed mutagenesis were also obtained
from Stratagene. PCR enzymes, TOP10 chemically compe-
tent cells, and oligonucleotide primers were obtained from
Invitrogen. Additional molecular cloning reagents were pur-
chased from New England Biolabs (Beverly, MA) or the man-
ufacturers listed.
Molecular Cloning of Flavobacterial 6-0-Sulfatase-The fla-
vobacterial sulfatase gene was cloned by PCR from a kZAPII
flavobacterial genomic library originally screened using DNA
hybridization probes specific to the 2-0-sulfatase (18). Library
construction, hybridization screening, and phage excision were
as described. An overlapping clone was expanded by chromo-
somal walking and restriction mapping using the Lambda
DASH II genomic cloning kit (Stratagene) for the ligation of
size-fractionated genomic DNA (generated by partial Sau3AI
digestion). 2-0-Sulfatase-positive clones from an amplified
library were plaque purified through three successive rounds,
and the DNA were purified from a high titer lysate using stand-
ard techniques. For DNA sequencing, recombinant phage DNA
was subcloned into pBluescript SK±. The coding sequence of
the putative sulfatase gene (described throughout this paper as
orfb) was identified bythe canonical PFAM (25) sulfatase family
identifier (CXPXRXXXXS/TG) and subsequently PCR ampli-
fied using the following primer set for orfb (6-0-sulfatase),
5'-GAA TTC ATA TGG GTA AAT TGA AAT TAA TTT
TA-3' (forward) and 5'-GGA T CC TCG AGT TAT AAA GCT
TCA GTT GGA TTC GT-3' (reverse). The amplified gene was
subcloned into the T7-based bacterial expression vector
pET28a (Novagen) as an NdeI-XhoI cassette (restriction sites
underlined). Cloning as such allowed the gene to be expressed
as an NH 2-terminal His6 fusion with an intervening thrombin
cleavage site for facile removal of this tag following protein
purification.
Bacterial Expression and Protein Purification-Recombinant
protein expression in E. coli strain BL21(DE3) and one-step
affinity purification by nickel chelation chromatography were as
described for the 2-0-sulfatase (18). The prediction of the
NH2-terminal signal sequence and putative cleavage site for the
protein was made by the computational method of von Heijne
(26). Engineering and expression of the truncated protein
(minus signal sequence) was as described above for the full-
length gene with the exception of substituting the 5' primer
that was used in the original P CR amplification step. The inter-
nal primer included 5'-TCT AGA CAT ATG TCT TGC CAG
CAG CCT AAA C-3' for orfb with the NdeI site underlined. As
such, the orjb gene sequence begins at Met-18. Removal of the
His 6 tag was achieved by site-specific protease cleavage using
the thrombin cleavage capture kit (Novagen). Proteolysis con-
ditions were generally as described for other recombinantly
expressed flavobacterial heparin-degrading enzymes (17, 18).
Following concentration of orb by ultrafiltration, the cleaved
protein was dialyzed against 4 liters of 50 mm Tris, pH 7.5, and
0.1 M NaCl, 4 *C, overnight using a 3-ml slide-a-lyzer cassette
with a 10,000 molecular weight cutoff (Pierce).
Final protein concentration was determined calorimetrically
using the Bradford assay (Bio-Rad) and confirmed by UV
absorption spectroscopy using theoretical molar extinction
coefficients (E280) of 94,730 M~1 (61,572 Da) for the NH2-ter-
minal truncated orJb (6-0-sulfatase). This value was calculated
for the thrombin-cleaved protein lacking a His6 purification
tag. The enzyme was stored at 4 'C at a concentration of -10
mg/ml and full enzyme activitywas retained for several months
under these conditions.
Site-directed Mutagenesis of Putative 6-0-Sulfatase Active
Site Residues-Based on homology modeling of the 6-0-sulfat-
ase (described below), three residues were initially chosen for
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mutagenesis: Cys-80, Asp-186, and Asp-374. All three residues
were mutated to alanines. Site-directed mutagenesis was com-
pleted by thermal cycling using the QuikChange' method
(Stratagene) generally as recommended by the manufacturer.
The same pET28 (His 6) vector used for bacterial expression of
the wild type 6-0-sulfatase was likewise used as the template
for linear amplification. The following oligonucleotide primer
pairs (forward and reverse) were used: 5'-CTG TTT TGT AAC
CAA TGC AGT Tgc CGG GCC ATC CAG GGC TAC-3',
5'-GTA GCC CTG GAT GGC CCG gcA ACT GCA TTG GTT
ACA AAA CAG-3' (C80A); 5'-C CTT GAA AAA AGG GAC
CAT GcT AAA CCC TTT CTG ATG ATT TAC-3', 5'-G TAA
ATC ATC AGA AAG GGT TTA gCA TGG TCC CTT TTT
TCAAGG-3' (D186A); 5'-CCATT ATT GTC TAT ACT TCC
GcT CAG GGC TTT TAT TTG GGT G-3', 5'-CA CCC AAA
TAA AAG CCC TGA gCG GAA GTA TAG ACA ATA ATG
G-3'. Base pair changes are noted in lowercase, boldface type.
Parental DNA was restricted using DpnI. Mutated DNA was
transformed into XL Blue chemically competent cells. Targeted
mutations were confirmed by direct DNA sequencing of both
strands.
Arylsulfatase Assay-Arylsulfatase activity was measured
independently using two chromogenic substrates, 4-catechol
sulfate and 4-methylumbelliferyl sulfate. The catechol sub-
strate assay was conducted generally as described (27). Briefly,
10 mm substrate was incubated with -30 pm recombinant
enzyme overnight (12-15 h) at 37 'C in a 100-jl reaction vol-
ume that included 50 mM MES, pH 7.0, and 2 mm CaC12. Reac-
tions were quenched by the addition of 5 sl of 5 M NaOH, and
colorimetric activity was determined spectroscopically at 515
nm. The fluorimetric arylsulfatase assay using 4-methylumbel-
liferyl sulfate was as described (28) with some modifications.
Reaction conditions included 10 pM enzyme, 2 mm 4-meth-
ylumbelliferyl sulfate, 50 mm sodium acetate, pH 6.0, and 5 mm
CaCl2 in a 20-p.1 reaction volume. Enzyme incubation temper-
ature was 30 'C. Activity was measured as a function of time
ranging from 3 to 24 h; the reactions were quenched by the
addition of 200 pl of 0.5 M Na2CO 3, pH 10.7. Detection of
fluorescent methylumbelliferone was measured at this alkaline
pH using a SpectraMax microtiter plate reader (GE Healthcare)
set at excitation and emission wavelengths of 360 and 440 nm,
respectively. Fluorescence intensity was corrected against
background (minus enzyme control). In both assays, 0.5 units of
arylsulfatase from Aerobacter aerogenes (Sigma) were used as a
positive control.
Pilot 6-0-Sulfatase Assay-Initial assessment of substrate
specificity and pH optima was made using a capillary electro-
phoresis-based assay for the detection of desulfated products.
Preliminary enzyme activity was measured against the follow-
ing series of fluorescently derivatized, monosulfated gluco- and
galactopyranosides: 4-MU-GlcNAc,6s, 4-MU-GlCNS, 4-MU-
GalNAc,6S, and 4-MU-Gal 6S (where Glc refers to glucosamine
and Gal refers to galactose). Standard reactions included 1 m
substrate, 1-10 ptm enzyme, 50 mm sodium acetate, pH 5.5- 6.5,
and 5 mM CaCl2 in a 20-pd reaction volume. For the pilot exper-
iment, exhaustive reactions involved overnight incubations at
30 'C. Enzyme was inactivated by heat denaturation at 95 'C for
10 min, followed by a 10-fold dilution into water. Reaction
products were resolved by capillary electrophoresis using a
25-cm long, 75-gm inner diameter fused silica capillary (Agi-
lent Technologies). Electrophoresis was carried out under neg-
ative polarity by applying a voltage of -15 kV (-1.2 watts) for
10 min. Substrate desulfation was measured as a percentage of
substrate depletion relative to a minus enzyme control as mon-
itored by the loss of UV absorbance at 315 nm detected at -4
min. A standard capillary electrophoresis buffer included 50
mm Tris and 10 gm dextran sulfate (average molecular mass of
10,000 Da) adjusted to pH 2.0 with phosphoric acid.
The effect of pH was likewise measured by capillary electro-
phoresis using the following three sets of buffers with overlap-
ping pH ranging from 4.5 to 8.0: 50 mm sodium citrate at 4.5,
5.0, and 5.5; 50 mm MES at 5.5, 6.0, 6.5, and 7.0; and 50 mm
MOPS at 6.5, 7.0, 7.5, and 8.0. Reactions included 1 im
enzyme, 2 mm 4-MU-GlcNAc,6S, 50 mM buffer, and 5 mm
CaCl2 in a 20-p1 reaction volume. Assay was initiated by the
addition of 2 p1 of a 1OX enzyme stock to 18 pl of preheated
reaction mixture. Reactions were carried out at 30 'C for 60
min and quenched by heat and dilution as described. The
ability of the enzyme to desulfate unsaturated heparin and
chondroitin disaccharides was assessed essentially as described for
CE-based compositional analyses of enzymatically generated gly-
cosaminoglycan di- and tetrasaccharides (29). For these studies,
the following disaccharide substrates were tested: AUGlcNA,6s,
AU2SGlCNAc,6S, AUGlCNS, AUGlcNS,6S, AU2SGlCNS,6S> and
AUGalNAc,6S. Reactions included 500 tm substrate, 10 ptm
enzyme, 50 mm sodium acetate, pH 6.5, and ±2 mm CaCl 2 in
a 20-pl reaction volume.
Coupled Enzyme Assay for the Determination of Biochemical
Reaction Conditions and Steady-state Kinetics-Indirect meas-
urement of enzyme activity was also made using a fluorimetri-
cally based plate assay in which the prerequisite desulfation of
the appropriate glucopyranoside 1-+4-methlybelliferone sub-
strate by the 6-0-sulfatase was coupled to the glucosidase-me-
diated hydrolysis of the stereo-specific 1-+4-glycosidic linkage
between the pyranose ring and the adjoining fluorophore.
Release of the free fluorophore (4-MU) was monitored spectro-
scopically as described above for the arylsulfatase assay using
4-MU sulfate. Hydrolysis of the substrate 4-MU-D3-n-GlcNAc,6s
at the 6-OH position was coupled to 3-glucosidase purified
from sweet almonds (MP Biomedicals, catalogue number
195197). The efficacy of the coupled assay was contingent on
the intrinsically poor ability that the glucosidase possesses for
hydrolyzing the glycosidic bond when the adjoining glucosa-
mine is modified by a sulfate. The presumption of the sulfatase
activitybeing the rate-limiting step was established experimen-
tally. Reaction conditions were optimized to satisfy three crite-
ria: 1) linear readout of the fluorescent signal that was directly
proportional to sulfatase activity; 2) quantitative release of
4-MU by glucosidase activity under the biochemical conditions
examined; and 3) negligible fluorescent quenching of free
chromophore.
The standard reaction conditions for the assay included 2 pm
recombinant enzyme, 50 mm sodium acetate buffer, p H 5.5, and
5 mM CaCl2 in a 20-pl reaction volume. The 4-MU-GlcNAc,6S
substrate concentration was varied from 0.1 to 2 mm. Each well
of a microtiter plate (prechilled on ice) was treated with 2 td of
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enzyme, followed by gentle vortexing of the plate and spin
down of the well contents for 1 min at 500 X g and 4 'C. The
assay was initiated by transferring the 96-well plate to a heating
block preequilibrated at 30 'C. The incubation of the 6-0-sul-
fatase enzyme was carried out at 30 *C for 20 min, after which
the enzyme activity was inactivated by heat denaturation
(95 'C, 10 min). For the glucosidase enzyme, the microtiter plate
was once again chilled on ice and 40 units of /3-glucosidase was
added to each well. These were followed by vortex of the plate for
mixing and spin down at 500 X g for 1 min at 4 'C. The contents
were then transferred to a heating block preequilibrated at 37 *C.
Incubation proceeded for 60 min prior to beingquenched with 200
pl of 0.5 M Na2CO 3, pH 10.7. Reactionswere transferred to ablack
96-well, flat-bottom fluoroimmunoassay plate and fluorescence
measured as described above for the detection of free 4-MU. Flu-
orescent signal was adjusted to background (minus sulfatase con-
trol). For /-glucosidase, this background hydrolysis was somewhat
dependent on the initial 4-MU-GlcNAc,6s concentration, but was
typically less than 10%. Molar conversion of product was extrapo-
lated from a standard curve generated from various concentra-
tions of 4-MU from 0 to 300 Mm. Michaelis-Menten kinetics was
extrapolated from V0 versus substrate concentration plots fit by
non-linear regression to pseudo-first order kinetics and all
obtained data represent the mean of three experimental trials.
The coupled enzyme assay was also used for the assessment
of enzyme activity for select site-directed mutants. Enzyme
activity was measured kinetically using a single saturating con-
centration (2 mm) of fluorescently labeled substrate. Results are
reported as % activity relative to the wild type enzyme.
Compositional Analyses ofSulfatase-treatedHeparin-20 Mg
of heparin was preincubated with 10 pM 6-0-sulfatase for 8 h at
30 'C in a 20-p1 reaction volume that included 25 mm sodium
acetate, pH 7.0, and 2 mM calcium acetate, pH 7.0. Following
this preincubation, the enzyme was inactivated by heat dena-
turation at 95 'C for 10 min, and heparin was exhaustively
digested overnight at 37 'C by the addition of 2 M1 of a concen-
trated enzyme mixture containing heparinase I and III. Subse-
quent CE-based compositional analyses of heparinase-derived
disaccharides were completed as described (17).
Electrospray Ionization (ESI)-Mass Spectrometry of Sulfated
Glucosamine Monosaccharides-Electrospray ionization-mass
spectrometry was performed in the negative ion mode using an
Agilent 1100 Series VL LC/MSD trap. For simplicity, the sam-
ples were prepared by adding MeOH directly to the enzymatic
reaction mixtures without purification, and directly injected
into the source of the mass spectrometer using a syringe pump
at a rate of -8 Ml/min. The SPS function of the software (LC/
MSD Trap Software 4.1 Build 143, MSD Trap Control Version
5.0 Build 65) was used to tune the instrument, with the target
mass set to the mass of the substrate, the sample stability set to
50%, and the drive level set to 100%. Data were acquired over
the scan range of m/z 100-2200 by accumulating 30,000 ions
per scan. Capillary voltage was set to 3000 V. Nitrogenwas used
as the drying gas, whereas helium was used as the nebulizing
gas, with flow rates of 5 and 15 liters/min, respectively. In each
case a minimum of 10 spectra were averaged. Substrate speci-
ficity was determined using unlabeled glucosamide monosac-
charide substrates with various substitutions at the 2-N, 3-OH,
and 6-OH positions. Reactions were carried out with 2.5 mM
substrate, 5 mm CaCl2, 1 gM enzyme, and 50 mm acetate buffer
at pH 5.5 and 37 'C. Reactions were quenched by diluting the
samples 1:4inMeOH. The carrier solvent was H20:MeOH (1:4,
v/v). In the experiments, 4-MU-GlcNS was added prior to
injection as the internal standard to monitor ionization and
mass accuracy in source and trap.
Homology Modeling of 6-0-Sulfatase and Docking of
Substrates-ClustalW (33) was used to perform multiple
sequence alignment of 6-0-sulfatase with bacterial and lysoso-
mal enzymes from the highly conserved sulfatase family (Fig. 1).
The crystal structures of human arylsulfatase A (PDB code
1AUK), human arylsulfatase B (PDB code 1FSU), and P. aerugi-
nosa arylsulfatase B (PDB code 1HDH) were obtained and
structure-based multiple superposition was performed using
CE-MC (30) and SuperPose (31) tools. A homology-based
structural model of the 6-0-sulfatase was generated using the
Homology module of Insightll version 2005 (Accelrys, San
Diego, CA) using human arylsulfatase A as a template. The
deletions in the modeled structure were closed by constrained
minimization upon holding most of the structure rigid, except
for regions close to the deletion site during 300 iterations of
steepest descent and 500 iterations of conjugate gradient min-
imization without including charges. The loops and side chains
of all residues were then allowed to move freely by performing
500 iterations of steepest descent minimization. The refined
structure was then subjected to 500 iterations of steepest
descent minimization without including charges and 500 iter-
ations of conjugate gradient minimization including charges to
obtain the final predicted model of the enzyme.
The structures of GlcNS, GlCNS,6S, and GlcNs,3s,6s monosac-
charides were obtained by appropriate modifications to the
coordinates of the heparin structure (PDB 1HPN). These mon-
osaccharide substrates were docked to the enzyme. To further
verify the substrate specificity of the enzyme, the coordinates of
chondroitin sulfate were obtained from its crystal structure
(PDB code 1C4S) to generate the structural models of the mono-
saccharides GalNAc,6s and GalNAc,6s,4s. The initial orientation
of the different substrates in the groove of the enzyme active
site was facilitated by the highly conserved position of the cleav-
able sulfate group relative to Oy-1 of the geminal diol as
observed from the crystal structures of the sulfatase enzyme
family. The glycosidic and exocyclic torsion angles were then
adjusted manually upon fixing the 6-0-sulfate group to elimi-
nate unfavorable steric contacts with the amino acids of the
enzyme active site. Following this, the enzyme-substrate com-
plexes were subjected to optimization with 400 steps of steepest
descent followed by 500 steps of Newton-Raphson minimiza-
tion including charges. To constrain the ring torsion angles to
maintain the ring conformation of the monosaccharides during
the process of energy minimization, a force constant of 7000
kcal/mol was utilized. Most of the enzyme was held rigidly,
whereas regions constituting the active site were allowed to
move freely.
The Viewer, Builder, and Discover modules of Insight1I ver-
sion 2005 (Accelrys) were used for visualization, structure
building, and energy minimization, respectively. The potentials
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FIGURE 1. Multiple sequence alignment of the sulfatases using ClustaW. The flavobacterial 6-sulfatase
enzyme is a member of a large sulfatase family. The putative active site is boxed, with the critically modified
Cys-80 noted by an asterisk. Invariant residues are shaded in dark gray, those with partial identity in light gray,
and conservative substitutions in charcoal. Multiple sequence alignment was generated by ClustalW (1) using
only select sequences identified from a BLASTP search of the protein data base. Enzymes with the following
GenBank accession numbers are abbreviated as follows: F. heparinum 6-O-sulfatase (FH6S); F. heparinum 2-0-
sulfatase (FH2S); Pseudomonas aeruginosa arylsulfatase (PARS, GenBank code CAA88421); human N-acetyl-
galactosamine-6-sulfate sulfatase or chondroitin 6-sulfatase (HGal6S, GenBank code AAC51350); human cere-
broside-3-sulfate sulfatase or arylsulfatase A (HARSA, GenBank code AAC51350); human
N-acetylgalactosamine-4 sulfate sulfatase or arylsulfatase B (HARSB, GenBank code AAC51350).
for all structures were assigned using the AMBER force field
modified to include carbohydrates with sulfate and sulfamate
groups. The AMBER force field (Amber95) provided with the
Discover module was used to assign the potentials for both the
enzyme and substrate. The parameters for sulfates and sulfa-
mate groups in glycosaminoglycans described previously (32)
were incorporated into this force field to assign the potentials
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- - - - - - - - - - - - - - - - - - - -
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LQICCHPGCTPRPACCHCPDPHA-------------
YFPAQDPRCDPKATGVWGPWM---------------
the genetically engineered removal of the amino-terminal sig-
nal sequence of the protein. Exclusion of this domain had little
deleterious effect on the specific activity of the enzyme (data
not shown). At the same time, replacement of this NH2-termi-
nal peptide with a histidine (His6 ) tag facilitated purification of
the recombinant protein in essentially a single chromato-
graphic step to greater than 80% purity (data not shown). Sub-
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for the sulfated monosaccharide
substrates. A distance-dependent
dielectric constant of 4'r and scaling
of 0.5 for the p1-4 cross-terms were
used in the Discover module for the
AMBER force field-based simula-
tions according to specifications in
the Insightll manual.
RESULTS
Molecular Cloning and Recombi-
nant Expression of F. heparinum
Sulfatase Gene-The sulfatase gene
described in this study was first
identified through the screening of a
genomic library with hybridization
probes directed toward the fla-
vobacterial 2-O-sulfatase (18). An
overlapping phagemid clone identi-
fied during this process was ex-
panded by chromosomal walking
and restriction mapping. Sequence
analyses of this genomic region
revealed a sizeable open reading
frame of 1647 base pairs (described
hereafter as orfb). The gene se-
quence putatively encodes a protein
of 545 amino acids in length starting
at the initiating Met. The sequence
does not possess an obvious Shine-
Delgarno ribosomal binding site
within 10 nucleotides of the initiat-
ing ATG codon. A closer examina-
tion of the sequence at the protein
level revealed several important
features. The flavobacterial orjb
possesses an NH.-terminal hydro-
phobic signal peptide and the corre-
sponding cleavage site sequence
predicted by the von Heijne method
for Grain-negative bacteria (26).
The orfb gene product is character-
ized by a theoretical pl of 8.6 and
also contains the canonical sulfatase
domain as described by the Protein
Family (PFAM) identifier PF 000884
(see "Discussion").
The putative sulfatase gene was
robustly expressed in E. coli as a sol-
uble enzyme. Satisfactory expres-
sion of the soluble enzyme required
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sequent thrombin cleavage of the histidine tag was carried out
as described under "Experimental Procedures." These ANH2-
terminal truncations (lacking both the native signal sequence
and NH2-His 6 tag) were used in all subsequent biochemical
characterizations of the sulfatase. The apparent molecular mass
of the recombinant protein based on SDS-PAGE was consistent
with its theoretical molecular mass calculated from the amino
acid composition (orfb gene product, 61,572 Da).
Biochemical Characterization of Recombinant HSGAG 6-0-
Sulfatase: Preliminary Determination of Monosaccharide Sub-
strate Specificity-As a first step in biochemical characteriza-
tion of the orfb sulfatase, we examined whether this enzyme,
similar to the previously characterized 2-0-sulfatase (18), can
function as a generic arylsulfatase. Both enzyme activities were
tested against 4-catechol sulfate and 4-MU sulfate, two differ-
ent aromatic sulfate esters commonly used as substrates to
make this assessment. The 2-0-sulfatase exhibited an apprecia-
ble level of hydrolytic activity relative to a known arylsulfatase
from A. aerogenes, which served as a positive control (data not
shown). The orjb sulfatase partly hydrolyzed the 4-MU sulfate
at a much slower but discernible rate. To further test our pre-
diction that the orfb sulfatase acts on carbohydrates, in partic-
ular, heparin and heparan sulfate, we used a modified substrate
wherein the sulfated hexosamine was linked 1-4 (a or )3) to
4-MU. The presence of this chromophore allowed us to directly
monitor desulfation of the monosaccharide by capillary elec-
trophoresis. Four monosulfated substrates were tested, all of
which were commercially available. These included the two
"heparin" monosaccharides 4-MU-GlCNS,6s and 4-MU-GlcNS
in addition to the 6-0-sulfated galactose sugars 4-MU-Gal 6s
and 4-MU-GaNAc,6s (corresponding to the monosaccharide
constituents of keratan sulfate and chondroitin/dermatan sul-
fate, respectively). In this analysis, the orfb sulfatase was found
to be specific for the 6-0-sulfated glucosamine (Fig. 2A) and did
not act upon either of the two 6-0-sulfated galactose sugars.
We further investigated the substrate specificity of this enzyme
by examining the influence of various substitutions at the 2-
amino, 3-OH, and 6-OH positions of the glucosamine. In these
experiments, desulfation of non-derivatized monosaccharide
substrates was detected and quantified by ESI-mass spectrom-
etry. In this analysis, the enzyme acted specifically on the 6-0-
sulfate position and required a substituted amine (acetate or
sulfate) at the 2-amino position. A comparative kinetic analysis
of the two corresponding substrates (GlcNAc,6S versus GIcNS,6S)
indicated only a modest preference of the enzyme for the
monosulfated substrate (Fig. 2C) based on initial kinetic pro-
files. The enzyme was also completely inhibited bythe presence
of a 3-0-sulfate group (data not shown). Based on these find-
ings, we defined the or/b as a heparin/heparin sulfate 6-0-sul-
fatase. To investigate these experimental observations in
greater detail, we proceeded to analyze the purified recombi-
nant enzyme using a combination of more detailed biochemical
and structural studies.
The CE-based assay was also used to determine the p H opti-
mum for the enzyme. The 6-0-sulfatase enzyme exhibited
slightly acidic pH optima (between 5.5 and 6.5) and showed
higher activity in acetate buffer when compared with sulfonate
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FIGURE 2. Substrate specificity of recombinant 6-0-sulfatase.A,the specific-
ity of the 6-0-sulfatase as heparin/heparan desulfating enzyme. Desulfation of
4-MU-Gal6s (0, 4-MU-GalNAsS (fi), or4-MU-GCkNA6s (fil and iv bythe recombinant6-0-sulfatase was followed by capillary electrophoresis. Exclusive desulfation of
4-MU-GlcN&Es by 6-0-sulfatase Is evidenced by a singular disappearance of
absorbance at 315 nm In electrophoretogram ll (that normally appears at -4
min). Minus enzyme control is shown in iv. Electrophoretograms are offset for
illustrative purposes.B, time course analyses of recombinant 6-0-sulfatase activ-
ity using three different, 6-osulfated monosaccharide substrates (each at 2.5
mM). GkcNAcS (0), GIcNss (0), and 4-M U-GIcNAC6s (A) are Indicated. C, close-up ofthe initial kinetics out to 30 mn. Desulfation kineticswere measured by ESI-mass
spectrometry as described under "Experimental Procedures."
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buffers, such as MES and MOPS when examined over this same
pH range.
Optimization of in Vitro Reaction Conditions-Having iden-
tified a suitable chromogenic substrate for the recombinant sul-
fatase, we also used this substrate to further develop a fluores-
cence-based plate assay as the means to define the optimal in
vitro reaction conditions for 6-0-sulfatase. We investigated
parameters such as ionic strength and the effect of divalent
metal ions as well as steady-state enzyme kinetics. We chose a
coupled enzyme assay in which the recombinant sulfatase
served as the primary (product limiting) enzyme and j-gluco-
sidase served as the secondary enzyme. Use of this second
enzyme permitted the indirect detection of relative sulfatase
activity by means of the stoichiometric release of free 4-MU,
which served as the fluorescent signal. This coupled assay for
the 6-0-sulfatase was validated in control experiments demon-
strating only modest hydrolysis by the glucosidase of the
11->4-MU glycosidic linkage of the sulfated glucosamine. The
6-0-sulfatase was sensitive to increasing ionic strength as mea-
sured by the addition of NaCl and 50% inhibition was observed
at -200 mm NaCl with less than 20% activity remaining at 1 M
NaCl relative to the zero NaCl control. Moreover, 6-O-sulfatase
was inhibited by the addition of sulfate or phosphate, and
between these anions, phosphate was clearly a more effective
inhibitor with 50% inhibition of 6-0-sulfatase activity observed
at -2 mM PO- compared with -20 mM SO2.
Structural Investigation of Substrate Binding and Enzyme
Action of the 6-0-Sulfatase-Having defined the basic bio-
chemistry of the 6-0-sulfatase, we sought to provide a struc-
tural context to our findings. A homology based structural
model of 6-0-sulfatase was constructed. A representative dis-
ulfated monosaccharide GlcNS. 6S was docked into the putative
active site of the enzyme to investigate the molecular interac-
tions between the enzyme and the substrate (Fig. 3). The critical
active site residues at the base of the sugar binding pocket
involved in the positioning of the sulfate group and the sulfate-
ester bond cleavage are structurally conserved among the dif-
ferent sulfatases (highlighted in bold in Table 1). The functional
roles of these conserved residues in the sulfate-ester hydrolysis
mechanism were assigned (Table 2) based on the analysis of
the enzyme-substrate complex as well as on the assigned
roles of their structurally conserved residues in the other
sulfatases (33-35).
Apart from the conserved residues, the other residues in the
proximity of the active site are Asp-186, Lys-187, Pro-188, Phe-
189, Thr-300, Trp-307, Tyr-378, and His-507. These residues
are not structurally conserved in the other sulfatases and there-
fore they potentially play a unique role in the substrate speci-
ficity of the 6-0-sulfatase. Indeed, examination of the crystal
structures for other, non-HSGAG sulfatases, indicates that
there is no equivalent for these residues (Table 1). Furthermore,
many of these residues are present as a part of the additional
loop regions in the 6-0-sulfatase as compared with the other
sulfatases. The presence of these additional loop regions makes
the substrate-binding groove of 6-0-sulfatase more constricted
as compared with the other sulfatases. This narrow substrate
binding groove taken together with these additional residues
are likely to restrict the processing of GlcNAc/NS.6S sugar present
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FIGURE 3. Homology-based structural model of the 6-0-sulfatase-sub-
strate complex. Top, stereo view of the active site of the enzyme (backbone
shown as gray schematic) and the side chain of the critical active site amino
acids. The amino acids are colored using the following scheme: Glu and Asp,
red; His, Lys, and Arg, darkblue;CGln and Asn, lightblue;Trpand Phe, brown; Ser
and Thr, orange; active site L-C-a-formylglycine (FGly), cyan. The GkNs.65 sub-
strate is shown in stick representation and colored by atom (C, green; 0, red; S,
yellow; N, dark blue). Bottom, schematic of the active site (with the key amino
acids labeled), the location of the divalent cation Ca , and the substrate. The
dotted line indicates the intermolecular enzyme-substrate interactions.
either as a monosaccharide or at the non-reducing end of a
short oligosaccharide (exolytic processing of substrate).
It was observed that Phe-189 and Tyr-378 are positioned to
stack the pyranose sugar ring and thus lock the substrate in the
active site. Asp-186 is positioned to make favorable contacts
with the amine group in both GicNS,6s and (iCNAc,6S substrates.
Due to its role in substrate binding, mutation of Asp-186 to
alanine resulted in a modest decrease in 6-0-sulfatase activity
relative to the wild type (Table 3), consistent with the fact that
multiple contacts are important for orientation of substrate and
stabilization of its binding. His-507 on the other hand interacts
with the equatorial 4-OH of the Glc pyranose sugar. Among the
GlcNS6s and GcNAC,6S substrates, the N-acetyl group contain-
ing substrate is likely to make a higher number of favorable
contacts because of the planarity of the acetyl group and the
stacking of the CH, group with the hydrophobic Trp-307 and
Pro-188 residues. This observation provides a structural basis
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TABLE 1
Structure-based comparison of sulfatase active site residues
Structural alignment of the modeled 6-O-sulfatase with the other sulfatases was
obtained using the SuperPose tool (25). Residues that are highly conserved are
displayed in boldface and non-conserved residues are listed in normal font. Regions
of deletion are marked with the minus sign. Amino acids of 6-0-sulfatase that could
potentially be involved in substrate binding are denoted with the asterisk.
6-0-Sulfatase 2-0-Sulfatase Arylsulfatase Aryisulfatase Arylsulfatase
(F heparinum) (F heparinum) A (human) B (human) (P. aeruginosa)
cys-o Cys-82 Cys-69 Cys-91 Cys-51
Arg-84 Arg-86 Arg-73 Arg-95 Arg-55
Lys-128 Lys-134 Lys-123 Lys-145 Lys-113
His-130 His-136 His-125 His-147 His-115
Lys-387 Lys-308 Lys-302 Lys-318 Lys-375
Gln-306 Gln-237 His-229 His-242 His-211
Asp-40 Asp-42 Asp-29 Asp-53 Asp-13
Asp-41 Gin-43 Asp-30 Asp-54 Asp-14
Asp-374 Asp-295 Asp-281 Asp-300 Asp-317
Gln-375 His-296 Asn-282 Asn-301 Asn-318
Asp-186* - - - -
Lys-187* - - - -
Phe-189* - - -
Thr--300* - -
Tyr-378* - Arg-288 Ala-307 Ls-325
His-507* - His-405 Ser-403 -
Trp-307 Lys-238 Tyr-230 Glu-243 Trp-212
TABLE 2
Functional assignment of 6-O-sulfatase active site residues
Amino acids listed in this table were identified by inspection of the 6-0-sulfatase
model proposed in Fig. 3. The critical active site cysteine is shown in boldface.
Amino acids
Sulfate ester hydrolysis
FGly-80
Arg-84, His-130
Lys-128, Lys187, Lys-387,
Gln-306
Asp-374, Asp-40, Asp-41,
Gln-375, Thr-300
Cys-80 in the active enzyme is modified
to FGly and the FGly is further
hydrated to form an aldehyde
hydrate comprised of Oy-1 and
Oy- 2 atoms
Stabilize the hydrated FGly by
interaction with 0-7- 2. His-130 is
well positioned also for proton
abstraction from Oy-2 after the
catalytic process for elimination of
sulfate and regeneration of geminal
diol
Positioned to interact with oxygen
atoms of the 6-0-sulfate group to
enhance electron density withdrawal
from sulfate, hence contributing to
the electrophilicity increase of the
sulfur center. Also, Lys-387 is well
positioned to protonate the oxygen
atom of the leaving substrate
Asp-374, Asp-40, Asp-41, and Gln-375
are well positioned to coordinate
with a divalent metal ion such as
C2+. Asp-374 also could donate
proton and enhance nucleophilicity
of Oy-1. Thr-300 being weakly
acidic could also participate instead
of Gln-375 in metal ion coordination
Substrate positioning and specificity
Phe-189, Tyr-378 Positioned to stack with the pyranose
ring of the Glc sugar
His-507, Asp-186, Tyr-378 His-507 is positioned to interact with
equatorial 4-hydroxyl of the Glc
sugar. Asp-86 is positioned to
interact with the N-atom of the
Glc-NS or GlcNA sugars
Trp-307, Pro-188 Positioned to optimally interact with
the acetyl group of the GlcNA, sugar
for the observed kinetic preference of the monosulfated
GlcNAc,6s substrate. Furthermore, the position of the 3-OH is
such that a glucosamine sugar containing a 3-0-sulfate group
(such as GlcNS/NAc,35,6S) would have unfavorable steric hin-
drance with the Trp-307 residue.
TABLE 3
Assessment of relative activity of 6-O-sulfatase active site mutants
Mutant Classification 96 Activity-
After 0.5 h After 5 h
Wild type Control 100 100
Cys-80 -eAla Active site (FGly) 0 0
Asp-374 -* Ala Ca 2+ coordination 0 0
Asp-186 -- Ala Interaction with 2 N 53 92
GlcNs or GlCNA,
"Activitywas measured using the coupled enzyme assayunder maximum(saturat-
ing substrate) conditions as described under "Experimental Procedures."
TABLE 4
Steady state kinetic parameters for 6-0-sulfatase using 4-MU
monosaccharlde substrates
Addition k. K, km/K
min~' PM X102
None 2.5 146 1.7
0.5 mm Ca+2  3.3 217 1.5
5 mm Ca+2  6.8 327 2.1
1 mM EDTA 2.5 264 0.95
To understand the specificity of this enzyme toward a-D-glu-
cosamine sugar in HSGAGs versus 13-D-galactosamine sugar in
chondroitin and dermatan sulfate, a GalNAc.,6S sugar was
docked into the active site (Fig. 4). The ring stacking constraints
imposed by hydrophobic residues Phe-189 and Tyr-378 caused
the pyranose ring of GalNAc,6s sugar to coincide with that of
GlcNA,6s sugar. However, axial orientation of the 4-OH in
GalNAc,6s (as compared with its equatorial orientation in
GlcNAc) Causes the 6-C-sulfate group to move away from the
active site. If the 6-0-sulfate group of GalNAc,6S has to coincide
with that of GlcNAc,6s sugar, then the C6-CS bond will be cis
relative to the C4-04bond, which is not energetically favorable
given the unfavorably close proximity of 06 and 04 atoms in
this conformation. These observations provide structural
insights into the specificity of the 6-0-sulfatase enzyme toward
HSGAG oligosaccharide fragments comprising the GlcNAc/NS,6S
sugar in the reducing end.
Role of DivalentMetal Ions in Activity of6-0-Sulfatase-Our
next step was to investigate the interactions of the active site
residues with a divalent metal ion such as Ca2 + that has been
shown to play a critical role in sulfatase activity of many aryl-
sulfatases (33, 35). In each of the arylsulfatases, the metal ion
coordinates with the oxygen atoms of the sulfate group of the
respective substrate. Additionally, a cluster of four highly con-
served acidic amino acids have been observed to coordinate
with this divalent metal ion. The corresponding metal ion coor-
dinating amino acids in the 6-0-sulfatase are identified based
on the structural model as Asp-40, Asp-41, Asp-374, and Gln-
375 (Table 1). These four amino acids are well positioned to
coordinate with the Ca2 * ion (Fig. 3). The other amino acid
present near the vicinity of this tetrad is Thr-301, which is also
weakly acidic and could participate in metal ion coordination.
Based on these observations, we predict that Ca2* ions would sub-
stantially influence the activity of 6-0-sulfatase and that there
would be a reduction in the activity in the absence of Ca2 + ions.
We set out to test this hypothesis by examining the effect of
Ca 2+ and other divalent metal ions on enzyme activity. 6-0-
Sulfatase activity was indeed found to be enhanced 2-3-fold
(Table 4) by the presence of calcium in a concentration-de-
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pendent manner. Moreover, as hypothesized, the enzyme was
somewhat active even in the presence of 1 mm EDTA (Fig. 5A).
These results validate the hypothesis made from the structural
model. Interestingly, however, the divalent metal activation for
the enzyme was specific to calcium and inclusion of Mg+2 or
Mn+ 2 was determined to have only negligible effects. To exam-
ine this metal selectivity, we measured the potential for enzyme
inhibition in the presence of a calcium-specific chelator
(EGTA) but found that it had no appreciable effect on the spe-
cific activity of 6-0-sulfatase. In an attempt to determine the
FIGURE 4. Structural basis for substrate specificity of 6-0-sulfatase.
Shown In the figure is a close-up view of the active site with GlcN,,,s (colored
by atom as described in the legend to Fig. 3) superimposed on GalNA,6 5 (C-
ored by atom C, violet 0, red; N, blue; S, magenta). Only some of the key active
site amino acids are shown for clarity. Due to the axial orientation of the
C4-04 bond, the position of the 6-0-sulfate in GalNAc,6S is such that the
sulfate group is 3 A away from the optimal position of the corresponding
6-0-sulfate in the GIcNS,6S substrate. The red dotted line shows the unfa-
vorable proximity of the 04 atom of GaINA,65 and the 06 atom if the
6-0-sulfate of the GaINAcoS coincided with that of GICNS,6 .
30000
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mechanism bywhich calcium exerts its effect on the enzyme we
followed up these metal ion experiments by measuring the
effect of calcium on enzyme steady-state kinetics (Fig. 5B).
Consistent with our previous results, the initial rate of enzyme
activity was affected by calcium in a concentration-dependent
fashion and was largely manifested as a kc effect (Table 4). The
likely role of Asp-374 in coordinating calcium as predicted by
the model was confirmed by site-directed mutagenesis (Table
3). Thus, through a combination of structural analysis and bio-
chemical experiments; we were able to determine a role for
Ca2 ion coordination in the enzyme activity of 6-0-sulfatase.
Experimental Validation of Exolytic Mode of Action by
6-0-Sulfatase-The structural analysis performed on our
model indicates that the 6-0-sulfatase should be predomi-
nantly exolytic, given the highly specific orientation of the
active-site residues. To verify this hypothesis, we performed
experiments to address the possibility of this enzyme acting
exolytically/endolytically on heparin or heparan sulfate-de-
rived oligosaccharides. Of note is the fact that in the natural
degradation pathway, 6-O-sulfatase would likely act down-
stream of the heparinases and possibly the A4,5-glycuronidase
(17). Thus, these HSGAG oligosaccharide substrates could pos-
sess either an uronic acid (even number of saccharide units) or
a hexosamine (odd number oligosaccharide) at the non-reduc-
ing end. In the former case, the uronic acid would likely be
unsaturated due to the preceding action of heparin lyases,
which cleave the GAG chain through a O-eliminative catalytic
mechanism. In the latter case, loss of the unsaturated hexuronic
acid would result from the hydrolytic action. of the glycuroni-
dase. To address this important issue, the 6-0-sulfatase enzyme
was initially tested against a panel of unsaturated heparin dis-
accharides such as AU2 2SHNAC. 6 S and AU= 2SHNS,6S. For these
experiments, standard reaction conditions were chosen as
defined in the monosaccharide studies. None of the unsatur-
ated disaccharides were desulfated by 6-0-sulfatase (data not
shown). The inability of this enzyme to do so was confirmed in
a related experiment in which all possible heparin disaccharides
were first generated by pre-treating heparin with heparinase I
and III prior to adding the sulfatases to the same reaction tube.
The converse experiment was also conducted in which unfrac-
- EDTA C+2 M+2 Mn+2 0.0 0.5 1.0 1.5 2.0 2.5
Reaction Condllons [4JU-GicNAc,68L mM
FIGURE 5. Effect of divalent metals on 6-0-sulfatase activity. A, calcium specific activation of 6-0-sulfatase
activity and inhibition by EDTA (A). The divalent metal effect was not observed when calcium was replaced by
either Mg2+ or Mn* (at either 1 or 5 mm concentrations); open bars, no divalent metals added; black bars, 1 mm
EDTA added; light gray bars, 1 mm divalent metal;stippled gray bars, 5 mm divalent metal.B, effect of calcium on
steady-state kinetics for the 6-0-sulfatase as described under "Experimental Procedures' at various concentra-
tions of Ca2 or in the presence of 1 mm EDTA. Substrate saturation plots were fitted to pseudo-first order
Michaelis-Menten kinetics by non-linear regression analyses. Symbols indicate 0.5 mm Ca 2 (*), 1 mm Ca+2 (C',
5 mM Ca+ 2 (U), and 1 mm EDTA (A).
tionated heparin was preincubated
with the 6-0-sulfatase for an
extended period of time (8 h) fol-
lowed by the addition of heparinase
I and III. In this particular sequence,
sulfatase pretreatment had no effect
on the compositional profile of the
heparinase-derived cleavage prod-
ucts (data not shown). These exper-
iments categorize the 6-O-sulfatase
as an obligatorily exolytic enzyme,
confirming the hypothesis derived
from observation of the active-site
topology.
To further verify the mode of
6-0-sulfatase processing, we pro-
ceeded to examine the possibility of
6-0-sulfatase acting on the non-re-
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A. Add 2-0 sulfatase
2800 3140 3480
Mass (mlz)
B. Add A4,5 glycuronidase
100, 3213.90
t80
4 60
~40
20
0
3214.19
AUHNS,6SI2SHNS,6S
4287.73
(1073.5)
32 4160
HNS,6SI2SHNS,6S
4129.85
2800 3140 3480 3820 4160
Mass (m/z)
C. Add 6-0 sulfatase
3216.99 HuAICHL
2800 3140 3480 3820 4160
Mass (m/z)
FIGURE 6. Sequential degradation of an HSGAGtetrasaccharide using recombinantly expressed
rial enzymes. The ability of the 6-0-sulfatase to hydrolyze the non-reducing end of an oligosaccharld
strated In the context of exo-sequencing the heparin-derived tetrasaccharides AU2sHNs,6si2sHN5,6s (s
and structurally related AUHNS,65I2sHNS,6S lacking a 2-0-sulfate at the internal iduronic acid positio
shown). Sequential treatment of the HSGAG tetrasaccharlde was physically assessed after each enzym
by matrix-assisted laser desorption lonization-MS. Masses listed in each panel represent either pe
(-3216 Da) or oligosaccharide-peptide complex. The net mass of the oligosaccharide is listed in pa
addition of the 2-0-sulfatase; B, subsequent addition of the A4,5-glycuronidase; C, subsequent add
6-0-sulfatase (note loss of a sulfate represented by a shift in net molecular mass from -915 to -835 D
.Z4E+4
sponding heparin-derived tetra-
saccharide AIU2sH NS,6S 1 ±2SHNS,6S
(Fig. 6, data not shown for
AU2sHNS,6sIHNS,6S) by the tandem
use of the 2-0-sulfatase (Fig. 6A)
and the A4,5-glycuronidase (Fig.
6B) prior to the addition of 6-0-sul-
fatase. Desulfation was followed by
matrix-assisted laser desorption
ionization-MS and the 6-0-sulfat-
ase was found to singularly desulfate
both trisaccharides (Fig. 6C). The
results presented for exolytic desul-
fation of oligosaccharides at the
non-reducing end are consistent
with the substrate specificity data
pertaining to desulfation of monosac-
1.6E+4 charide substrates. Taken together,
our structural and biochemical
results indicate that 6-0-sulfatase is a
highly specific, exolytic enzyme that
acts on the non-reducing end of
GlcNS,6S or GlcNA,6s of saturated,
odd-numbered oligosaccharide sub-
strates and that its activity is
enhanced by the presence of divalent
Ca" ions.
4500 DISCUSSION
in this study, we describe the
cloning, biochemical characteriza-
tion, molecular modeling, and
4280 structure -function analysis of a sul-
4268.0 fatase gene from the F heparinum
genome. A BLASTP sequence ho-
mology search of the flavobacterial
gene against the protein data base
unambiguously identified the gene
product as a member of a large sul-
fatase family. The 6-O-sulfatase
protein sequence possesses the sig-
nature PFAM sulfatase motif
CISXPXRXXXSITG as well as the
4 0 highly conserved sequence LTG (at
o o the +9 through 11 positions rela-
tive to this motif). The two flavobac-
terial sulfatases that we have now
e Is demonm
hown here) cloned (i.e. the 2-0-sulfatase and
n (data not orflh gene product) share only a
e step (Ag) limited overall homology to one
ptiide alone
renthesei m A, another, The flavobacterial sulfat-
ition of the ase does show a strong sequence
a). homology (greater than 50%) to the
mucin-desulfating sulfatase en-
ducing end of saturated, odd-numbered oligosaccharides. We coded by the enteric bacterium Prevotella strain RS2 (MdsA
addressed this using a combination of two structurally related gene). In addition to mucin, this particular enzyme is specific
sulfated trisaccharides, HNs,6sIHNS,6S and HNS,6SI 2 SHNS,6s, for free N-acetylglucosamine-6-0-sulfate (36). Our previous
Each of these trisaccharides was generated from the corre- studies with 2-0-sulfatase and other enzymes from the same
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system have confirmed the presence of a cysteine-specific
active site (Cys-80) and it is at this conserved cysteine (and not
serine) that the critical co- or post-translational oxidation to an
L-C-a-formylglycine occurs (37, 38). This obligatory require-
ment for the covalently modified cysteine has also been dem-
onstrated by site-directed mutagenesis; mutation of Cys-80 to
Ala completely abolished 6-0-sulfatase activity (Table 4).
Beyond the predicted function as inferred from structural
homology to other known sulfatases, we set out to empirically
confirm its putative function, first, by examining the ability of
the enzyme to act as a so-called "arylsulfatase," second, to act
within the context of HSGAG degradation and finally, by per-
forming an exhaustive atomic analysis of the enzyme structural
model active-site topology. We also experimentally validated
the role of key active site residues by mutating Cys-80 -+ Ala or
Asp-374 -> Ala (as described previously in Ref. 24). These
mutants showed no activity (Table 4) in comparison to the wild
type enzyme and hence validate the critical role of these amino
acids in the catalytic activity of the enzyme.
Although the 6-0-sulfatase was found to be a poor "generic"
arylsulfatase on the basis of a rather nonspecific but commonly
used biochemical screen, our results obtained by more struc-
turally directed monosaccharide substrates have unequivocally
confirmed that we had indeed cloned the heparan N-acetylglu-
cosamine-6-0-sulfatase. These results demonstrate the exclu-
sivity of the recombinant enzyme in terms of the singular posi-
tion of the sulfate that is hydrolyzed. Moreover, this work goes
beyond this basic description and identifies putatively the
important structural determinants of enzyme specificity. In
particular, the results presented identify the critical spatial
orientation of the C4 hydroxyl as an additional structural
determinant of substrate specificity, thus making the two
flavobacterial sulfatases uniquely heparin/heparan sulfate-
degrading enzymes. The HSGAG specificity of this enzyme
points to the likely existence of a unique flavobacterial gene
(or set of genes) encoding for the 6-0-desulfation of galac-
tose/galactosamine. By analogy, distinct enzymes for desul-
fating these galacto-sugars do exist in the chondroitin sul-
fate/dermatan sulfate and keratan sulfate-specific lysosomal
degradation pathways of higher eukaryotes. At the same
time, there have been no reports that we are aware of
describing the purification of either galactose or GalNac-6-
desulfating activity directly from F heparinum.
In addition to describing the critical substrate specificity for
this sulfohydrolase, we have also defined important parameters
related to their optimal use in vitro. These include pH and the
role of divalent cations, namely calcium. In regard to pH, the
slightly acidic pH optima demonstrated for 6-0-sulfatase is
consistent with our previous observations for the pH optima of
the 2-0-sulfatase (18) and A4,5-glycuronidase (17). Collec-
tively, this profile also generally distinguishes the flavobacterial
HSGAG degrading enzymes from their lysosomal counter-
parts, which, by virtue of their subcellular localization are most
active at pH 4.5. Unlike the activity of 2-0-sulfatase that was not
enhanced by the presence of a calcium ion coordination center,
however, the intrinsic activity of 6-0-sulfatase was increased
-2-3-fold in the presence of calcium ions and in a con-
centration-dependent fashion. This calcium dependence is
clearly inferred from our structural model.
The Ca2 ion was not an absolute requirement for enzymatic
activity. Our structural model of the 6-0-sulfatase further
helped us to identify specific residues that are well positioned to
interact directly with the 6-0-sulfate group and potentially act
as a catalytic base to confer hydrolytic activity, even in the
absence of a divalent metal ion (e.g. Asp-374). This putative
structure-activity assignment to Asp-374 is supported by our
mutagenesis studies.
Pivotal in the potential use of the 6-0-sulfatase enzyme for
controlled desulfation of heparin/heparan sulfate oligosaccha-
rides is the question of its endolytic versus exolytic potential. By
definition, the former mode of action would predict their ability
to hydrolyze internally located sulfates within either a disaccha-
ride or oligosaccharide chain. Our combined structural model-
ing and biochemical characterization results argue against any
endolytic potential for this enzyme. On the other hand, an exo-
lytic mode of action would necessarily require this enzyme to
sequentially follow A4,5-glycuronidase hydrolysis of terminal
uronic acids if, in fact, it is to act on the non-reducing end of
these saccharides. The data presented here confirm this predic-
tion, i.e. by demonstrating the ability of the enzyme to hydro-
lyze the non-reducing end of heparin-derived oligosaccharides,
albeit with certain structural constraints, on the non-reducing
end of the saccharide, namely a requirement of direct access to
a sulfated hexosamine that is not sterically hindered by the
presence of an intervening uronate.
The molecular modeling of 6-0-sulfatase, together with the
biochemical characterization described herein, provide an
insightful understanding of important structure-function rela-
tionships. Taken together with our understanding of the sub-
strate specificity ofthe other flavobacterial sulfatases (including
the N-sulfamidase described in the accompanying paper (39))
this work also provides a practical frameworktoward the use of
these enzymes and discrete analytical tools for elucidating the
HSGAG fine structure and generating HSGAG-derived oligo-
saccharides of defined length and structure.
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3.4 Structure-function relationship of N-Sulfamidase from Flavobacterium Heparinum
3.4.1 Brief overview of motivation, methodology, and principalfindings
The N-sulfate group is characteristic and unique to heparin sulfate glycosaminoglycans
(HSGAGs) [313]. As mentioned previously, HSGAG degradation follows an obligatory
sequence of depolymerization steps involving multiple enzymes acting in tandem to cleave the
HSGAG chain [312]. Most of these enzymes act exolytically, but may differ in the extent of their
processivity, e.g. when comparing functionally similar enzymes between eukaryotic lysosomal
and bacterial systems. As mentioned previously, prior work in our laboratory has led to the
molecular cloning and biochemical characterization of several HSGAG-degrading enzymes
derived from the gram-negative soil bacterium Flavobacterium heparinum (also called
Pedobacter heparinus) [21, 49, 252, 254]. Although earlier work described the enzymology of
the heparin lyases (or heparinases), more recent work has focused on downstream enzymes such
as an unsaturated glucuronyl hydrolase (A4,5-glycuronidase), and the 2-0- and 6-0-sulfatases
(Figure 3.6). By their very nature, these latter enzymes provide an attractive subject of study and
application due to the following reasons: (1.) their respective unique substrate specificities, (2.)
their relevance as tools to probe multiple biological processes, and (3.) a solid biochemical
foundation of their structure-function relationships that include several protein structures and a
detailed understanding of their common catalytic mechanism. Taken together, these factors make
the enzymes a useful "tool kit" for the characterization of heparin and heparan sulfate GAGs.
6-0-sulfatase Hexos amine @ non-reducing end
..-- 
.(6-0 -sulfate & N -sulfate)
Endoglycuronidase -s
0. I
lm**-.. ,.-s. a"ms N-sulfamidase
2-0-sulfatase Sulfatases
RO60" -.- ROH
Sulfatases biocatalyze the hydrolysis HJO HoSO
of sulfate esters into alcohols
Figure 3.6 Function of HSGAG processing enzymes
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In the paper that follows this section, the cloning, recombinant expression in E. coli,
substrate specificity, metal ion requirements, mode of action, sequence of processivity, optimal
reaction conditions, kinetics, and an integrated biochemical-structural characterization of the N-
sulfamidase enzyme mechanism from F. heparinum are described. The N-sulfamidase enzyme is
unique because it hydrolyzes the sulfamate linkage (N-S) and not a sulfoester as is described for
the other HSGAG sulfohydrolases (Figure 3.6). In fact, N-sulfamidase is one of only two known
enzymes that are able to cleave the nitrogen-sulfur bond (Figure 3.7). So as to elucidate the
mechanism of N-sulfamidase action, a homology model of the N-sulfamidase enzyme was
developed as outlined in the enclosed manuscript. Based on structure-function analysis of the
derived model, with methodologies very similar to that outlined for 6-0-sulfatase in the previous
section, a possible mechanism for N-S bond cleavage by N-sulfamidase and the critical amino
acids involved in catalytic activity and substrate specificity of the enzyme were predicted.
Taken together with the reported substrate specificities for the previously characterized
F. heparinum upstream heparin lyases, and the downstream enzymes including the unsaturated
glucuronyl hydrolase, the 2-0-sulfatase, and the 6-0-sulfatase (described in the preceding
paper), we are now able to reconstruct in vitro, the complete and defined exolytic sequence for
the heparin and heparan sulfate GAG degradation pathway of F. heparinum, facilitating the
tandem application of this "enzyme tool-kit" towards sequencing of HSGAG oligosaccharides.
Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC-IUBMB)
Enzyme Nomenclature. Recommendations
EC 3.10.1
Acting on sulfur-nitrogen bonds
EC 3.10.1.1 N-sulfoglucosamine sulfohydrolase
EC 3.10.1.2 cyclamate sulfohydrolase
ROSO3~-H 20 --. ROH-HSO4-
RN(H)SO3--H 20 -+ RNH 2-HSO4~
Figure 3.7 Known Nitrogen-Sulfur bond cleaving enzymes and their chemical mechanism
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3.4.2 Published manuscript
Myette, J.R.*, Soundararajan, V.*, Behr, J., Shriver, Z., Raman, R., Sasisekharan, R. (2009)
Heparin/Heparan Sulfate N-Sulfamidase From Flavobacterium Heparinum: Structural and
Biochemical Investigation of Catalytic Nitrogen-Sulfur Bond Cleavage. Journal of Biological
Chemistry, 284(50), pp. 35189-35200. (* Joint First Authors)
Specific contributions of this Thesis research to the publication: Developed the homology-
based structural model for N-sulfamidase and predicted its structure-function relationship in
terms of substrate specificity, active site residue functions, role of divalent metal ions, mode
and mechanism of action, which were all validated subsequently by targeted experiments.
Also, proposed mechanisms of enzymatic nitrogen-sulfur bond cleavage; which at the time of
this study, had previously not been discussed in the literature for any known enzyme.
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Sulfated polysaccharides such as heparin and heparan sulfate
glycosaminoglycans (HSGAGs) are chemically and structurally
heterogeneous biopolymers that that function as key regulators of
numerous biological functions. The elucidation of HSGAG fine
structure is fundamental to understanding their functional diver-
sity, and this is facilitated by the use of select degrading enzymes of
defined substrate specificity. Our previous studies have reported
the cloning, characterization, recombinant expression, and
structure-function analysis in Escherichia coli of the Flavobac-
terium heparinum 2-0-sulfatase and 6-0-sulfatase enzymes
that cleave 0-sulfate groups from specific locations of the
HSGAG polymer. Building on these preceding studies, we
report here the molecular cloning and recombinant expression
in Escherichia coli of anN-sulfamidase, specific for HSGAGs. In
addition, we examine the basic enzymology of this enzyme
through molecular modeling studies and structure-function
analysis of substrate specificity and basic biochemistry. We use
the results from these studies to propose a novel mechanism for
nitrogen-sulfur bond cleavage by the N-sulfamidase. Taken
together, our structural and biochemical studies indicate that
N-sulfamidase is a predominantly exolytic enzyme that specifi-
cally acts on N-sulfated and 6-0-desulfated glucosamines pres-
ent as monosaccharides or at the nonreducing end of odd-num-
bered oligosaccharide substrates. In conjunction with the
previously reported specificities for the F. heparinum 2-0-sul-
fatase, 6-0-sulfatase, and unsaturated glucuronyl hydrolase, we
are able to now reconstruct in vitro the defined exolytic
sequence for the heparin and heparan sulfate degradation path-
way ofF. heparinum and apply these enzymes in tandem toward
the exo-sequencing of heparin-derived oligosaccharides.
The N-sulfate group is characteristic and unique to heparin
sulfate glycosaminoglycans (HSGAGs),4 which are commonly
* Thisworkwas supported, in whole or In part, by National Institutes of Health
Grant GM57073.
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2 Present address: Momenta Pharmaceuticals, 675 West Kendall St., Cam-
bridge, MA 02142.
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4The abbreviations used are: HSGAG, heparin/heparan sulfate glycosamin-
oglycan; AU, A4,5 unsaturated uronic acid; GlcNsE N- and 6-0-disulfated
occurring polysaccharides predominant in proteoglycans (1).
HSGAGs are linear polymers with variable repeating disaccha-
ride units and diverse chemical heterogeneity due to the vari-
able positions of O- and N-linked sulfates (2, 3). Other factors
contributing to the structural diversity of HSGAGs include the
presence of N-linked acetates and possible epimerization at the
C-5 carboxylates. The structure-function relationship of this
diversity plays out in the dynamic regulation by HSGAGs of
various signaling pathways (4), including cell death (5, 6), inter-
cellular communication, cell growth and differentiation (7),
and adhesion and tissue morphogenesis (8). Microbial patho-
genesis has also been shown to depend upon the HSGAGs that
are present as structurally defined binding epitopes on cell sur-
faces and as part of the extracellular matrix (9, 10).
GAG degradation follows an obligatory sequence of depoly-
merization steps involving multiple enzymes acting in tandem
to cleave the HSGAG chain. Most of these enzymes act exolyti-
cally (11, 12) but may differ in the extent of their processivity,
e.g. when comparing functionally similar enzymes between
eukaryotic lysosomal and bacterial systems (13). Previously
cited work in our laboratory has led to the molecular cloning
and biochemical characterization of several HSGAG-degrading
enzymes derived from the Gram-negative soil bacterium Fla-
vobacterium heparinum (Pedobacter heparinus). Although ear-
lier work described the enzymology of the heparin lyases (14-
17), more recent work has focused on downstream enzymes
such as an unsaturated glucuronyl hydrolase (A4,5-glycuroni-
dase) and the 2-0- and 6-0-sulfatases (18 -20). By their very
nature, these latter enzymes provide an attractive subject of
study and application given the following: 1) their respective
substrate specificities, 2) their relevance as tools to probe mul-
tiple biological processes, and 3) a solid biochemical foundation
of their structure-function relationships that include several
protein structures (21, 22) and a detailed understanding of their
common catalytic mechanism (23). Taken together, these fac-
tors make the enzymes a useful "tool kit" for the structural
characterization of heparin and heparan sulfate.
a-D-glucosamine; GlcNAc,6s, N-acetylated, 6-0-sulfated a-D-glucosamine;
GalNAC6S, N-acetylated, 6-0-sulfated f-D-galactosamine; 4-MU, 4-methy-
lum belliferyl; APTS, ami nopyrene-1,4,6-trisulfonate; FGIy, L-C-a-formylgly-
cine; MES,4-morpholineethanesulfonic acid; MOPS, 3-(N-morpholino)pro-
panesulfonic acid;MALDI, matrix-assisted laser desorption ionization;ORF,
open reading frame; CE, capillary electrophoresis.
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Toward this end, we describe in the preceding paper (19) the
cloning, recombinant expression, structural and biochemical
characterization of enzymatic action, and substrate specificity
of the F heparinum 6-0-sulfatase enzyme. In this paper,
we extend this work through the cloning of the N-sulfamidase
gene from F heparinum and the bacterial expression of the
gene product. A biochemical and structural characterization of
the enzyme is also described, including a determination of the
substrate specificity and metal ion requirements for optimal
enzyme activity. This sulfamidase enzyme is unique because it
hydrolyzes the sulfamate linkage (N-S) and not a sulfoester as
is described for the other HSGAG sulfohydrolases. Using
a homology-based structural model of the N-sulfamidase
enzyme, we have outlined a possible mechanism for the N-S
bond cleavage and the critical amino acids involved in both
the catalytic activity and substrate specificity of the enzyme.
Finally, taken together with the reported substrate specific-
ities for the previously characterized F heparinum 2-0-sul-
fatase, the 6-0-sulfatase (described in the preceding paper,
see Ref. 19) and the unsaturated glucuronyl hydrolase, we are
now able to reconstruct in vitro the complete and defined
exolytic sequence for the heparin and heparan sulfate degra-
dation pathway of F heparinum and apply these enzymes in
tandem toward the exo-sequencing of HSGAG-derived
oligosaccharides.
EXPERIMENTAL PROCEDURES
Reagents-Glucosamine and galactosamine monosaccha-
rides and aryl sulfate substrates 4-catechol sulfate and
4-methyllumbelliferyl sulfate were purchased from Sigma.
Exo-glucosidases were purchased from MP Biomedicals
(Irvine, CA). N-Sulfated fluorogenic glycopyranoside deriva-
tives were obtained through Toronto Research Chemicals
(Toronto, Ontario, Canada). Fluorescent glucopyranoside sub-
strates 4-methyllumbelliferyl-a/3-D-glucopyranoside (4-MU-
a-o-Glc and 4-MU-/3-D-Glc) were purchased from EMD Bio-
sciences, Inc. (San Diego). PCR enzymes, TOP10 chemically
competent cells, and oligonucleotide primers were obtained
from Invitrogen. Materials for genomic library construction
and screening and site-directed mutagenesis were obtained
from Stratagene (La Jolla, CA). Additional reagents for molec-
ular cloning were purchased from New England Biolabs (Bev-
erly, MA) or the listed manufacturers.
Molecular Cloning of Flavobacterial N-Sulfamidase-PCR
from a XZAPII flavobacterial genomic library originally
screened using DNA hybridization probes specific to the 2-0-
sulfatase (18) and subsequently used for the 6-0-sulfatase (19)
were used to clone the sulfamidase gene. Library construction,
hybridization screening, and phage excision were performed as
outlined. Two overlapping clones were expanded by chromo-
somal walking and Southern restriction mapping using the
Lambda DASH II genomic cloning kit (Stratagene). This was
used for the ligation of size-fractionated genomic DNA gener-
ated by partial digestion of Sau3AI. The DNA was purified from
a high titer lysate using standard techniques, and three succes-
sive rounds of plaque purification were performed on 2-0-sul-
fatase-positive clones from an amplified library. Recombinant
phage DNA was subcloned into pBluescript SK for sequenc-
ing the DNA. The putative N-sulfamidase gene is described
throughout this paper as orfc. The coding sequence of orfc was
identified by the canonical Protein Families Database (24) sul-
fatase family identifier (CXPXRXXX(S/T)G) and subse-
quently PCR-amplified using the primer set given by 5'-TCT
AGA CAT ATG AAA TTT AAC AAA TTG AAA TAT TTC-3'
(forward) and 5'-GGA TCC TCG AGT TAC TTC AAA TAA
TTG TAA CTG GAA T-3' (reverse). Subcloning of the ampli-
fied gene into T7-based bacterial expression vector pET28a
(Novagen) was performed as an NdeI-XhoI cassettes described
for the 6-0-sulfatase (19).
BacterialExpression and Protein Purification -Similar to the
setup in the 2-0-sulfatase (18) and 6-0-sulfatase (19) expres-
sion systems that we had designed earlier, the Escherichia coli
strain BL21(DE3) and one-step affinity purification by nickel
chelation chromatography likewise were used. von Hejne com-
putational method was used to make the prediction of the NH2-
terminal signal sequence and putative cleavage site for the pro-
tein (25). The engineering and expression of the truncated
protein lacking the signal sequence were as described for the
complete gene with the exceptions of substituting the internal
5' primer with 5'-TCT AGA CAT AT G TCC TGC ACT TCG
CCG GAA-3' (NdeI site underlined) and beginning the orfc
gene sequence at Ser-21. Site-specific protease cleavage using
the thrombin cleavage capture kit (Novagen) was performed to
remove the His 6 tag with proteolysis conditions as described for
other recombinantly expressed flavobacterial heparin-degrad-
ing enzymes. Ultrafiltration was used to concentrate the
enzymes, and cleaved proteins were dialyzed against 4 liters of
50 nm Tris, pH 7.5, and 0.1 M NaCl, 4 'C overnight using a 3-ml
Slide-a-Lyzer cassette with a 10,000 molecular weight cutoff
(Pierce). The Bradford assay (Bio-Rad) was used to determine
final protein concentrations and was confirmed by UV absorp-
tion spectroscopy with theoretical molar extinction coefficients
(E2 8 0 ) of 86,340 (53,193 Da) for the NH2-terminally truncated
orfc (N-sulfamidase). This value was calculated for the throm-
bin-cleaved protein lacking the His 6 purification tag. To retain
full enzyme activity for months, the enzyme was stored at 4 'C
and 10 mg/ml concentration.
Site-directed Mutagenesis of Putative N-Sulfamidase Active
Site Residues-Based on the homology modeling of the N-sul-
famidase (described below),three residues were initially chosen
for mutagenesis: Cys-80, Asp-40, and Lys-158. Site-directed
mutagenesis was completed by thermal cycling using the
QuickChangeT M method (Stratagene, La Jolla California) as
described in the accompanying paper (19) and using the follow-
ing oligonucleotide primer pairs: 5'-AT ATC CTG ATG ATC
ATG TCC GcT AAC CAA TCC TGG AAC CAC G-3', and
5'-CG TGG TTC CAG GAT TGG TTA gCG GAC ATG ATC
ATC AGG ATA T-3' (D40A); 5'-CT TTT TGC AGT TCA
CCT TCC gcT ACG CCC GCA AGG GCT G-3' and 5' CA
GCC CTT GCG GGC GTA gcG GAA GGT GAA CTG CAA
AAA G-3'(C80A); 5'-G TTT AAA AGT TTT GGC GCA TTT
TTA gcA GAT AAA AAA GAA GGT CCC TG-3' and 5'-CAG
GGA CCT TCT TTT TTA TCT gcT AAA AAT GCG CCA
AAA CTT TTA AAC-3' (K158A). Base pair changes are noted
in lowercase boldface type. The same pET28 (His6) vector used
for bacterial expression of the wild type N-sulfamidase-sulfat-
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ase was likewise used as the template for linear amplification.
Parental DNA was restricted using DpnI. Targeted mutations
were confirmed by direct DNA sequencing of both strands.
Arylsulfatase, N-Sulfamidase, and Coupled Enzyme Assays;
Biochemical Protocols and Kinetic Studies-The 4-catecholsul-
fate and 4-methylumbelliferyl sulfate were two chromogenic
substrates used to independently measure arylsulfatase activity.
The catechol substrate assay was conducted as described (26).
Fluorimetric arylsulfatase assay using 4-methylumbelliferyl
sulfate was also generally as described previously (27), and
detection of fluorescent methylumbelliferone was measured
using a SpectraMax microtiter plate reader (GE Healthcare) set
at excitation and emission wavelengths of 360 and 440 nm,
respectively. Fluorescence intensity was corrected against
background (minus enzyme control). In both assays, 0.5 unit
of arylsulfatase from Aerobacter aerogenes was the positive
control.
For the pilot N-sulfamidase assay, initial assessment of sub-
strate specificity and pH optima was made using a capillary
electrophoresis-based assay for detection of desulfated prod-
ucts. The fluorescently derivatized monosulfated gluco- and
galactopyranosides used as substrates to test enzyme activity
included 4-MU-GlcNAc,6s, 4-MU-GlcNS, 4-MU-GalNAc,6S,
and 4-MU-Gal6s. Standard reactions included 1 mm substrate,
1-10 skM enzyme, 50 mm sodium acetate, pH 5.5-6.5, and 5 mM
CaCl2 in a 20-41 reaction volume. Exhaustive reactions involv-
ing overnight incubations at 30 'C were used for pilot experi-
ments. N-Sulfamidase was inactivated by heat denaturation at
95 'C for 10 min, followed by a 10-fold dilution into water, and
the products were resolved by capillary electrophoresis using a
25-cm long, 75-gm inner diameter fused silica capillary (Agi-
lent Technologies). Substrate desulfation was measured as a
percentage of substrate depletion relative to a minus enzyme
control as monitored by the loss of UV absorbance at 315 nm
detected at -4 min. A standard capillary electrophoresis buffer
included 50 mM Tris and 10 jiM dextran sulfate (average molec-
ular mass of 10,000 Da) adjusted to pH 2.0 with phosphoric
acid. The effect of pH was measured by capillary electrophore-
sis using the following three sets of buffers with overlapping pH
ranging from 4.5 to 8.0:50 mm sodium citrate at 4.5, 5.0, and 5.5;
50 mM MES at 5.5,6.0,6.5, and 7.0; and 50 mm MOPS at 6.5,7.0,
7.5, and 8.0. For N-sulfamidase, the reactions included 4-MU-
GlcNS, 50 mm buffer, and 5 mm CaCl2 in a 20-sl reaction vol-
ume, and this assay was initiated by addition of 2 p1 of 1ox
enzyme stock to 18 il of preheated reaction mixture. All the
reactions were performed at 30 'C for 30 min each. The ability
of N-sulfamidase to desulfate unsaturated heparin and chon-
droitin disaccharides was assessed essentially as described for
CE-based compositional analyses of enzymatically generated
glycosaminoglycan di- and tetrasaccharides (28).
A fluorimetrically based plate assay was used for indirect
measurement of enzyme activity, in which the N-sulfamidase-
driven desulfation of the glucopyranoside 1-+4 methylbellifer-
one substrate was coupled to the glucosidase-controlled hy-
drolysis of the stereospecific 1->4 glycosidic linkage between
the pyranose ring and the adjoining fluorophore. Release of the
4-MU was monitored spectroscopically as described above for
the arylsulfatase assay. N-Sulfamidase hydrolysis of 4-MU-a-D-
GlCNs at the 2-amino position was coupled to a-glucosidase
(catalogue number 153487, MP Biomedicals), and the efficacy
of this coupled assay was contingent on the intrinsically poor
ability of the enzyme for hydrolyzing the glycosidic bond when
the adjoining glucosamine is modified by a sulfate.
The coupled N-sulfamidase assay was generally described for
the 6-0-sulfatase (19) but with the following modifications:
4-MU-GlCNS as substrate, 50 mm sodium acetate at pH 6.0
(instead of 5.5), and 1 sM enzyme. For the second enzyme step,
5 units of a-glucosidase were added. Enzyme incubation was
carried out for 22 h at 37 *C. The obvious difference in enzyme
efficacies between a-glucosidase versus -glucosidase is re-
flected in the substantially longer incubation times required for
the a-glucosidase to quantitatively hydrolyze the glycosidic
al->4 linkage between the fluorophore and the desulfated glu-
cosamine. All other reaction conditions were as described for
the coupled 6-0-sulfatase/$-glucosidase assay (19). Michaelis-
Menten kinetics were extrapolated from V, versus substrate
concentration plots fit by nonlinear regression to pseudo first-
order kinetics, and all obtained data represent mean of three
experimental trials.
The coupled enzyme assay was also used for the assessment
of enzyme activity for select site-directed mutants. Enzyme
activity was measured kinetically using a single saturating con-
centration (2 mM) of fluorescently labeled substrate. Results are
reported as % activity relative to the wild type enzyme.
Compositional Analyses ofSulfamidase-treatedHeparin-10
sm N-sulfamidase was preincubated with 20 sg of heparin for
8 h at 30 'C in a 20-p reaction, which included 25 mm sodium
acetate, pH 7.0, and 2 mm calcium acetate, pH 7.0. The enzyme
was then inactivated by heat denaturation at 95 'C for 10 min,
and the heparin was completely digested at 37 'C by the addi-
tion of 2 1A of concentrated enzyme mixture containing hepa-
rinase I and III. The CE-based compositional analyses of hepa-
rinase-derived disaccharides were performed as described (29).
Sequential Degradation of Heparin Oligosaccharide by Fla-
vobacterial Exo-enzymes-The purified penta- and hexasul-
fated tetrasaccharides AU2sHNS,6S+ 2sHNS,6S were a gift from
Dr. I. Capila (Momenta Pharmaceuticals, Inc.). The following
enzyme sequence was performed: 2-0-sulfatase, A4,5-glycu-
ronidase, 6-0-sulfatase, and N-sulfamidase. The enzyme was
heat-inactivated after each step, and 20-pd aliquots were
removed prior to the addition of the next enzyme. The initial
reaction conditions included 20 mm Tris, pH 7.2, and 60 nmol
of tetrasaccharide in a 120-p1 reaction volume, and enzyme
reactions were carried out at 30 'C. The following specific con-
ditions were also used: 1) 2-0-sulfatase, 1 fM enzyme, 6 h; 2)
A4,5-glycuronidase, 1 FM enzyme, 6 h; 3) 6-0-sulfatase, 5 sM
enzyme, 5 mM CaCl2, 12-15 h; 4) N-sulfamidase, same condi-
tions as for 6-0-sulfatase. MALDI-mass spectrometry is an
established method that was used for determination of the
molecular masses of enzyme products (30).
The APTS derivatization protocol was adapted from Chen
and Evangelista (31). Briefly, 2 pl of 100 mMAPTS in 25% acetic
acid (v/v) was mixed with 10 l of 1 M sodium cyanoborohy-
dride in tetrahydrofuran and 1 smol of saccharide. The reac-
tion mixture was incubated at 75 'C for 2 h and was diluted
1:100 prior to CE analysis. Capillary electrophoresis/laser-
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N.Sulf SEIDKTPKPSKEMQKRFKLDSSYNYLK ------
FH6S YNDKAYEPIIKDLKVQMKKLQVQYKDTNTEAL---
FH2S -
PARS OLADSQPGKLAELIEHWKRYVSETGVVEGASPFLVR
HGa16S VMNWAPPGCEKLGKCLTPPESIPKKCLWSH------
HARSA LQICCHPGCTPRPACCHCPDPHA-------------
HARSB YFPAQDPRCDPKATGVWGPWM ---------------
FIGURE 1. Structure-based multiple sequence alignment of the sulfatases using ClustaW. The flavobac-
terial N-sulfamidase enzyme is a member of a large sulfatase family. The putative active site is boxed, with the
critically modified cysteine 80 noted by an asterisk. Invariant residues are shaded in dark gray; those with partial
identity in light gray, and conservative substitutions in charcoal. Multiple sequence alignment was generated
by ClustalW using only select sequences identified from a BLASTP search of the protein data base. Enzymes
with the following GenBank" accession numbers are abbreviated as follows: F. heparinum N-sulfamidase(Nsulf); F. heparinum 6-0-sulfatase (FH6S); F. heparinum 2-O-sulfatase (FH2S); P. aeruginosa arylsulfatase (PARS,
GenBank" code CAA88421); human N-acetylgalactosamine-6-sulfate sulfatase or chondroitin-6-sulfatase
(HGaI6S, GenBank" code AAC51350); human cerebroside-3-sulfate sulfatase or arylsulfatase A (HARSA, Gen-
Banki" code AAC51350); human N-acetylgalactosamine-4 sulfate sulfatase or arylsulfatase B (HARSB, Gen-
BankTM code AAC51350).
Protein Data Bank and structure-
based multiple superposition was
obtained using CE-MC (32) and
SuperPose (33). The Homology
module of Insight II molecular sim-
ulations package (Accelrys, San
Diego) was used to obtain a struc-
tural model of N-sulfamidase with
PDB 1AUK as template. The loop
regions of the structure were mod-
eled using the homology module of
InsightII. The deletions were closed
using the Discover module of
Insight II, wherein most of the
structure was held rigid except for
the regions in the proximity of the
deletion site, followed by 200 itera-
tions of steepest descent and 300
iterations of conjugate gradient
minimization. The loop regions and
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induced fluorescence was per-
formed on a Beckman Coulter
ProteomeLab PA 800 with a 488-nm
argon laser-induced fluorescence
module. Samples were loaded onto
a N-CHO capillary (50-s.tm inner
diameter X 65-cm total length)
using 0.5 p.s.i. of pressure at the
anode for 20 s. Electrophoretic sep-
arations were performed using a
20-kV potential in a 100 mm sodium
borate, pH 10.2 buffer for 15 min at
25 "C. Fluorescence emission spec-
tra were collected using a 520-nm
narrow band filter.
Electrospray Ionization-Mass Spec-
trometry of Sulfated Glucosamine
Monosaccharides-Electrospray ion-
ization-mass spectrometry was per-
formed generally as described for
the 6-O-sulfatase (19) but with a few
modifications. Reactions were car-
ried out with 100 y.M substrate, 2
mM CaCI2, 5 yM enzyme, and 50 mM
sodium acetate buffer, pH 6.0, at
37 "C overnight.
Homology Modeling of N-Sulfa-
midase and Docking of Sub-
strates-Multiple sequence align-
ment of N-sulfamidase with human
arylsulfatase A (Protein Data Bank
code 1AUK), human arylsulfatase B
(Protein Data Bank code 1FSU), and
P. aeruginosa arylsulfatase B (Pro-
tein Data Bank code 1HDH) was
performed using ClustalW (Fig. 1).
The crystal structures of these
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FIGURE 2. Obligatory substrate-product relationship ofN-sulfamidase. Desulfation ofthe disulfated mon-
osaccharlde HNs,6s (GlCNS,6s) by the enzymes was followed by electrospray mass spectrometry. Panell, substrate
only shown here as the sodium adduct of a single Ion species (M - 1) with molecular mass of360.8 Da;panelii,
treatment of GiCNS,6S substrate with 6-0-sulfatase desulfates the 6-0 position; panel iil, Inability ofN-sulfamI-
dase to hydrolyze the original disulfated monosaccha ride (compare with panel); panel iv, co-treatment of the
disulfated substrate with both 6-O-sulfatase and N-sulfamidase enzymes showing the disappearance of all
sulfated monosaccharides and demonstrating a prerequisite 6-0-desulfation by the 6-0-sulfatase prior to
sulfate hydrolysis at the 2-amino position by the N-sulfamidase. Internal standard (458.1 Da) used to monitor
Ionization efficiency and mass callbration is noted by an asterisk.
side chains of all residues were then allowed to move freely by
performing 300 iterations of steepest descent minimization.
This was followed by further refinement of the structure by
subjecting it to 500 iterations of steepest descent minimization
without including charges and 500 iterations of conjugate gra-
dient minimization, including charges to obtain the final pre-
dicted model of N-sulfamidase.
The coordinates of a heparin-derived hexasaccharide were
obtained from co-crystal structure of FGF-1 heparin complex
(Protein Data Bank code 2AXM). The hexasaccharide coordi-
nates were imported into the Builder module of InsightIl to
generate the monosaccharide (GlcNS, GlcNSS, and GlCNS,6S)
and disaccharide (AU± 2sHNs± 6s) substrates forN-sulfamidase.
As with our previous studies on other sulfatases, the initial
docking of the substrates in the enzyme groove was facilitated
by the highly conserved position of the cleavable NHSO group
relative to the O-yl of the geminal diol. The enzyme-substrate
complexes were then subjected to optimization with 300 steps
of steepest descent followed by 400 steps of Newton-Raphson
minimization, including charges, using the Discover module of
Insight II. In this step, a force constant of 7000 kcal/mol was
utilized to constrain the ring torsion angles to maintain the ring
conformation of the substrates. The Amber force field was used
to assign potentials to enzyme and sugar substrates for the
energy minimization as described in the accompanying paper
(19).
RESULTS
Molecular Cloning and Recombinant Expression ofF hepari-
num N-Sulfamidase Gene-Screening of a genomic library with
hybridization probes directed at the flavobacterial 2-0-sulfat-
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on SDS-PAGE was consistent with the theoretical molecular
weight calculated from putative amino acid composition based
on translation of orfc.
Biochemical Characterization ofN-Sulfamidase and Optimi-
zation ofin Vitro Reaction Conditions-We first considered the
possibility of the orfc gene product functioning as a generic
arylsulfatase by testing it against 4-catechol sulfate and 4-MU
sulfate, which are two different aromatic sulfate esters com-
monly used as substrates to assess generic sulfatase activity. It
was found that the orfc gene product exhibited only negligible
activity relative to a known arylsulfatase from A. aerogenes that
served as a positive control. To further test whether more
robust activity could be determined against heparin and hepa-
ran sulfate, we used capillary electrophoresis wherein the two
commercially available "heparin" monosaccharides 4-MU-
GlcNAc,6S and 4-MU-GlCNS and the 6-0-sulfated galactose sug-
ars 4-MU-Gal6s and 4-MU-GalNAc,6s (corresponding to the
monosaccharide constituents of keratan sulfate and chon-
droitin/dermatan sulfate, respectively) were tested. This analy-
sis showed that orfc gene product could only hydrolyze the glu-
cosamine sulfated at the 2-amino position. As such, we
hereafter refer to the orfc gene product as the N-sulfamidase
(data not shown).
We further investigated the substrate specificities of N-sul-
famidase by examining the influence of various substitutions at
the 2-amino, 3-OH, and 6-OH positions of the glucosamine,
using electrospray ionization-mass spectrometry. In this anal-
ysis, we found the N-sulfamidase activity at the 2-amino posi-
tion was absolutely abolished when a 6-0-sulfate was also pres-
ent (Fig. 2). Reciprocally related to this observation, in the
accompanying paper (19) we determined that the 6-0-sulfatase
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ase (26) revealed an overlapping
phagemid clone that was then
expanded by chromosomal walking
and restriction mapping. An open
reading frame of 1524 bp (orfc) was
identified by sequence analysis of
this genomic region, and this was
found to encode a protein of 500
amino acids in length. An examina-
tion of the putative orfc gene prod-
uct revealed that it possesses an
NH2-terminal hydrophobic signal
peptide and corresponding cleavage
site sequence predicted by the von
Heijne method for Gram-negative
bacteria (25). The gene product also
possesses a canonical sulfatase do-
main as described by the Protein
Families Database identifier PF
000884 (see under "Discussion").
The orfc gene product was robustly
expressed in E coli as a soluble
enzyme by removal of the amino-
terminal signal sequence, as
detailed earlier for the 6-0-sulfatase
(19). The apparent molecular mass
of 53,193 Da for the protein based
\ 1360.3
458.1
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enzyme required a substituted amine (acetate or sulfate) at the
2-amino position. These findings imply that the 6-0-sulfatase
and N-sulfamidase process substrates in a strictly sequential
fashion with the former preceding the latter. Additionally,
N-sulfamidase was completely inhibited by the presence of a
3-0-sulfate.
The CE-based assay was also used to determine the p H opti-
mum for the enzyme. N-Sulfamidase exhibited a slightly acidic
pH optima (between 5.5 and 6.5) but was active over a broad
range, especially above pH 7.0. The enzyme showed higher
activity in acetate buffer when compared with sulfonate buffers
such as MES and MOPS when examined over this same pH
range.
Having identified a suitable chromogenic substrate for meas-
uring N-sulfamidase activity, we likewise used this substrate to
develop a fluorescence-based, coupled enzyme assay as the
means to define the optimal in vitro reaction conditions and
enzyme kinetic parameters as generally described for the 6-0-
sulfatase (19), with the exception that the secondary enzyme
that was used was an a-glucosidase. These experiments dem-
onstrated only modest hydrolysis of the 1->4-MU glycosidic
linkage of the N-sulfated glucosamine by the a-glucosidase in
the absence of an N-sulfamidase preincubation. In this assay,
the N-sulfamidase exhibited a sensitivity to increasing ionic
strength with 50% inhibition observed at -200 mm NaCl and
less than 20% activity remaining at 1 M NaCl relative to the zero
NaCl control. Addition of sulfate or phosphate anions did not
inhibit the action of N-sulfamidase.
We also investigated the action of the N-sulfamidase
toward HSGAG disaccharides that possess a uronic acid at
the nonreducing end. N-Sulfamidase was initially tested
against a panel of unsaturated heparin disaccharides repre-
sented by AU 2SHNS±6S. For these experiments, standard
reaction conditions were chosen as defined in the monosaccha-
ride studies. None of the unsaturated disaccharides were des-
ulfated by the enzyme (data not shown). The inability ofN-sul-
famidase to do so was confirmed in a related experiment in
which all possible heparin disaccharides were first generated by
pretreating heparin with heparinase I and III prior to adding
N-sulfamidase to the same reaction tube. The converse exper-
iment was also conducted in which unfractionated heparin was
preincubated with N-sulfamidase for an extended period of
time (8 h) followed by the addition of heparinase I and Ill. In
this sequence, sulfatase pretreatment had no effect on the com-
positional profile of the heparinase-derived cleavage products
(data not shown). These results confirm that the enzyme
requires an N-sulfated (and non-C-sulfated) glucosamine at the
nonreducing end of the chain. Taken together, these data also
strongly suggest that the N-sulfamidase like the 6-0-sulfatase
acts in an exclusively exolytic manner.
Structural Basis for Substrate Specificity and Enzymatic
Activity ofN-Sulfamidase-The molecular surface of the N-sul-
famidase structural model revealed a groove region that was
much wider than the 2-0-sulfatase that we have studied earlier
(20), as well as the 6-0-sulfatase described in the accompanying
paper (19). The theoretical model of the N-sulfamidase com-
plexed with GlcNS substrate was used to identify the critical
residues potentially involved in positioning of the substrate
and/or catalysis (Fig. 3). Based on this theoretical model, the
proposed roles of the putative active site residues are summa-
rized in Table 1. The residues Arg-84 and Asp-40 that stabilize
the FGly in the resting state in the active site are highly con-
served among the different sulfatases. Furthermore, there is a
pocket of oxygen atoms formed by Asp-40, Asn-41, Asp-246,
Asn-247, the geminal diol of FGly, and N-sulfate group that can
potentially coordinate a divalent metal ion such as Ca2+. The
Ca2 * coordination formed by these residues resembles a simi-
lar arrangement in the other sulfatases (such as 6-0-sulfatase in
the accompanying manuscript (19)) whose activity is critically
influenced by Ca2 + ions. Surprisingly, two critical His residues
that are highly conserved among the other sulfatases are absent
inthe putative active site of theN-sulfamidase. In the case of the
6-0-sulfatase homology model, His-130 is proposed to stabilize
the FGly, whereas His-507 is proposed to be involved in the
catalytic desulfation of the 0-sulfate group. The absence of
these critical His residues could be central to conferring the
specificity of the N-sulfamidase enzyme to solely cleave the
N-S bond (as against the O-S bond) in GlCNS containing
HSGAG substrates. Other 0-sulfated hexosamine sugars such
as GlcNAc,6S, GalNAc,6s, GalNAcAS and GalNAc,4S,6S would there-
fore not be processed by N-sulfamidase, although these sub-
strates might be accommodated in the active site. The modeled
structural complex of N-sulfamidase with a 6-0-sulfate con-
taining GlcNS,6 S substrate showed that when the N-sulfate
group is oriented toward the FGly residue, the 6-0-sulfate
would make unfavorable steric contacts with Trp-249 in
the active site (data not shown). This observation points to the
obligatory sequential activity of the 6-0-sulfatase acting first to
desulfate the 6-0-sulfate group, which is then followed by the
action of N-sulfamidase. Similarly the complex of N-sulfami-
dase with GlcNS,3S showed that the 3-0-sulfate group would
also have unfavorable steric contacts with Ile-188 and Asp-189
residues in the active site.
Using the homology model, we also investigated the struc-
tural rationale for the predominant exolytic action of N-sulfa-
midase. The unsaturated AU± 2SHNSt6S disaccharides were
docked into the active site in an attempt to optimally position
the N-sulfate group for catalysis. In so doing, the AU sugar and
its sulfate group now made unfavorable steric contacts with
several residues in the active site, including Trp-249, Leu-255,
Ile-188, Trp-131, Trp-384, and Pro-363. This structural con-
straint imposed by the model is consistent with our observation
that the N-sulfamidase will only process a GlcNS sugar at the
nonreducing end of an oligosaccharide substrate (data not
shown).
Specifcity of N-Sulfamidase toward Longer Oligosaccharide
Substrates-To experimentally validate the proposed exolytic
activity of N-sulfamidase, we studied its activity on two struc-
turally related sulfated trisaccharides (HNS,6SIHNS, 6S and
HNS,6SI 2 SHNS,6S). Each of these was generated from the corre-
spondingtetrasaccharide AU2SHNS,6S L 2SHNs,6s bythe tandem
use of the 2-0-sulfatase and the A4,5-glycuronidase prior to the
addition of 6-0-sulfatase and N-sulfamidase. Desulfation of the
resultant trisaccharide was followed by MALDI-mass spec-
trometry (Fig. 4; data not shown for AU2SHNS,6SIHNS,6S). In this
experiment, we observed that the 6-0-sulfatase was able to sin-
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FIGURE 3. Theoretical structural model of N-sulfamidase-GIcNs substrate. S
of the active site of N-sulfamidase with the docked Glc, substrate. The side
shown and colored as follows: Arg and Lys, blue-; Asp and Glu, red; Trp, Leu, an
blue; and FGly, purple. The Gic-, substrate is colored by atom as follows: C, cya
Shown at the bottom is the schematic of the active site with the key amino acids
in the schematic is the location of the divalent Ca" ion and its interactions
substrate.
gularly desulfate both trisaccharides (Fig. 4, C and E), as
detailed in the accompanying paper (19). The N-sulfamidase,
however, was not able to do so, presumably because of the pres-
ence of the interfering 6-0-sulfate. In contrast, a pretreatment
of the pentasulfated trisaccharide with the 6-0-sulfatase fol-
lowed by N-sulfamidase treatment resulted in both the loss of a
detectable pentasulfated trisaccharide mass and a dramatic
reduction of the tetrasulfated trisaccharide mass (correspond-
ing to the predicted substrate for the N-sulfamidase). Unfortu-
nately, the formation of the 2N-desulfated trisaccharide prod-
uct was not readily observable in this experiment (possibly
because of inefficient ionization or poor complexation with the
DECEMBER 11, 2009-VOLUME 284-NUMBER 50
basic RG15 peptide that normally
facilitates the flight of the intact sul-
fated saccharide).
For this reason, we used an
orthogonal CE-based method in an
attempt to confirm the ability of the
N-sulfamidase to hydrolyze odd-
numbered oligosaccharides (lacking
a 6-0-sulfate at their respective
nonreducing ends) as strongly in-
ferred in the previous experiment.
Toward this end, the trisulfated
pentasaccharide HNSIHNsIHNS was
generated by A4,5-glycuronidase
treatment of the purified hexasac-
charide AUHNsIHNsIHNs and fol-
lowed by incubation with the sulfa-
midase. All of the saccharides
(untreated,r4,5 alone, andu4,5 fol-
lowed by N-sulfamidase) were sub-
sequently fluorescently labeled at
their reducing end through reduc-
tive amination. End labeling of the
sugars permitted their detection by
laser-induced fluorescence follow-
ing resolution of the products by
capillary electrophoresis (Fig. 5). At
each step in the experiment, saccha-
ride peak assignment was inferred
by observing discrete electropho-
retic shifts in peak migration times
as a function of exo-enzyme treat-
58 ment and in accordance with their
expected elution times based on dif-
ferential charge densities. In this
experiment, a unique peak (peak Z)
eluting at 7.6 min appears following
the sequential treatment of the
starting material with the A4,5-gly-
own on top is the s o v curonidase and the N-sulfamidase.
chains of the key residues are The late elution time of this peak is
lie brown; Asn and Gin, light consistent with it possessing a lower
nI; 0, red; N, blue, and S, yellow, sulfate density than either the trisul-labeled for clarity. Also shown destthnihrtetiu-
with the active site and the fated hexasaccharide starting mate-
rial (peak X) or the pentasulfated
pentasaccharide (peak Y, interme-
diate) resultant from digestion with the unsaturated glycuroni-
dase. Such a dramatically shifted elution time is also suggestive
of the presence of a positively charged amine that would reduce
the formal negative charge of the sulfated oligosaccharide run
under the electrophoresis conditions described. From this anal-
ysis, it appears that the N-sulfamidase does desulfate oligosac-
charides devoid of the 6-0-sulfate group on the terminal hex-
osamine, and it does so in a predictably exolytic fashion.
Role of Calcium Metal Ions in Catalysis by N-Sidfamidase-
N-Sulfamidase enzyme was found to be activated by the pres-
ence of calcium in a concentration-dependent manner (Table
2). Interestingly, the enzyme was found to be almost inactive in
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TABLE 1
Functional assignment of N-sulfamidase active site residues
Amino acids listed in this table were identified by molecular interaction analysis of
the N-sulfamidase model depicted in Fig. 3 as well as the proposed enzymatic cleav-
age mechanism shown in Fig. 4.
Active site Proposed functional role
residues
Gys-Sil The active site cysteine is modified into the
Arg-84
Asp-159
Lys-160
Asp-246, Asn-247,
Asp-40, Asn-41
hydrated form of the FGly-O-yl (20) and
participates in nucleophilic attack on the
sulfate group
This primarily stabilizes the hydrated FGly by
interaction with 0-y2. This is also well
positioned for proton abstraction from O-y 2
after the catalytic process for elimination of
sulfate and regeneration of diol
The negatively charged carboxylate groups of
these residues are likely to abstract the proton
from the NH' group of Lys-160
Upon loss of the proton toAsp-159, the
nitrogen of this lysine residue is likely to be
sulfated by the NHSO3 group, thereby
breaking the existing nitrogen-sulfur bond.
This process is mediated by the calcium ion.
After this step, the sulfated lysine will be
desulfated by the FGly residue. This lysine is
also likely to increase electrophilicity of sulfur
center by coordinating with the oxygen atoms
of the sulfate group
Asp-246, Asp-247, Asp-40, and Asn-41 are well
positioned to coordinate with the divalent
Ca2 metal ion. The calcium ion is likely to
play the crucial role of coordinating with the
nitrogen of NHSO; group, hence helping Lys-
160 to break the N-S bond successfully.
Hence, this tetrad is important for optimal
N-sulfamidase function. Furthermore, Asp-40
is also understood to donate a proton and
enhance nucleophilicity of 0-yl
the absence of calcium, unlike previously analyzed sulfatases
(Fig. 6A). For example, the 6-0-sulfatase described in the
accompanying paper (19) was activated 2-3-fold by the pres-
ence of calcium but was somewhat active even in the presence
of 1 mM EDTA. Furthermore, the divalent metal activation was
found to be specific to calcium; inclusion of Mg2 + or Mn 2 + had
only negligible effects. To further examine this metal selectiv-
ity, we measured the potential for enzyme inhibition in the
presence of the calcium-specific chelator EGTA. As expected,
EGTA inhibited calcium-dependent N-sulfamidase activity (at
5 mM Ca 2 +) in a concentration-dependent manner, with 50%
inhibition occurring at -3 mm EGTA (data not shown). In an
attempt to determine the mechanism by which calcium
exerts its effect on N-sulfamidase, we followed up these
metal ion experiments by next measuring the effect of cal-
cium on enzyme steady-state kinetics (Fig. 6B). Consistent
with our previous results, the initial rate of the enzyme was
significantly affected by calcium in a concentration-depen-
dent fashion with both kinetic parameters being affected
proportionally (Table 2).
Proposed Mechanism for Nitrogen-Sulfur Bond Cleavage by
N-Sulfamidase Enzyme-The combination of our biochemical
studies and the structural model of the N-sulfamidase active
site and its interactions with the substrate led us to propose a
mechanism for the N-S bond cleavage. This mechanism is
novel giventhe uniqueness ofN-sulfamidase active site and that
it is the only enzyme from P. heparinus that cleaves N-S bond
in HSGAGs. The proposed mechanism ofN-sulfamidase action
has been depicted as a step-by-step process pictorially (Fig. 7).
In the resting state, the active site cysteine that is understood to
be modified into the hydrated form of the FGly-O--yl (20) is
likely to be stabilized by interactions with the carboxylate anion
group of Asp-40 and the amino group of Arg-84 as shown.
Furthermore, the divalent calcium ion has been proposed to
coordinate with the diol form of FGly-O--yl and also with the
negatively charged oxygen atom of the NHSO group upon
addition of a suitable substrate R-NH-SO3. Subsequently, the
carboxylate anionic group of Asp-159 is well poised to abstract
the proton from the NH3 group of Lys-160 residues. The nitro-
gen-sulfur bond cleavage is mediated by Ca 2" ion and Lys-160
resulting in the transfer of the sulfate group to the formyl gly-
cine. Alternatively, it is possible for the amine group of the
deprotonated Lys-160 to form a bond with the sulfate group
(potential transition state) that would in turn facilitate the
transfer of this group to the formyl glycine (Fig. 7, dotted
arrows). This crucial step that is unique to N-sulfamidase is
likely to be motivated by the interaction of the Ca 2* ion with
the nitrogen atom of the NHSO3 group and simultaneous pro-
tonation of this nitrogen atom by the NH; group of Lys-158 as
shown. This form of nitrogen-sulfur bond cleavage in the pres-
ence of metallic cations has been proposed for sulfonamide
reactions (34). In our proposed mechanism, the divalent cal-
cium cation and the basic Lys-160 residue provide the three
interactions of this process, whereas in the sulfonamide mech-
anism proposed, a trivalent metal cation was used. The carbox-
ylate group of Asp-40 is positioned to abstract a proton from
the geminal diol leading to acquisition of the SO3 group from
the sulfated form of Lys-160 as depicted. Following these dis-
tinguishing steps, the rest of the mechanism is likely to be sim-
ilar to the other sulfatases (35). The basic Arg-84 residue has
been indicated to interact with FGly-80 leading to the efflux of
SO' and formation of the aldehyde. This in turn is hydrolyzed
back into the diol state, and the enzyme is ready to catalyze
another desulfation process as and when a new substrate is
encountered. The functions assigned to the key amino acids
that participate in the proposed mechanism are summarized
(Table 1).
An insight into the proposed mechanism for N-sulfamidase
action based upon our structural model provides possible
rationale for the observed behavior. First, calcium ion is abso-
lutely required for coordinating the nitrogen-sulfur bond cleav-
age as outlined above. Without the presence of the divalent
cation and the coordination of nitrogen of the N-SO3 group,
the enzyme cannot act. Therefore, it is clear that the activity of
N-sulfamidase is very much dependent on calcium ion concen-
tration and that the enzyme becomes inactive in the absence of
the cation. Moreover, it is well know that magnesium ions
(Mg 2+) almost always exhibit octahedral coordination geome-
try with six being the preferred coordination number. Also,
manganese ions (Mn 2 *) prefer coordinating with four ligands
thereby exhibiting predominantly tetrahedral coordination
geometry. These are fewer ligands than calcium (Ca2 *) that is
most commonly found coordinated by seven or eight ligands.
The optimal coordination number in metal ions is a function of
the ion size typically, because close packing of maximum pos-
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FIGURE 5. Sequential degradation of an HSGAG hexasaccharlde. The
structurally defined, heparin-derived hexasaccharide AUHNsIHWIHNS was
treated with A4,5-glycuronidase alone or with A4,5-glycuronidase followed
by the N-sulfamidase. Resultant oligosaccharide products were fluorescently
labeled at the reducing end with APTS by reductive amination as described
under 'Experimental Procedures." Oligosaccharides were resolved by capil-
lary electrophoresis and detected by laser-induced fluorescence. The N-des-
ulfated pentasaccharide HNH2 HN is observed as a unique peak appear-
ing at ~7.6 min (peak Z). Oligosaccharide impurities are noted by an asterisk.
TABLE 2
Steady-state kinetic parameters using 4-MU monosaccharide
substrates
N-Sulfamidase
Addition K,,, k,1/K,,,(x102)
min-f pM
None ND ND ND
0.5 mm Ca2  5.1 45 11.3
5 mM Ca
2
" 21.9 178 12.3
1 mM EDTA ND ND ND
ND means not determined due to lack of activity.
sible ligands around the ions is generally attempted. This anal-
ysis of the enzyme-substrate interactions explains the absolute
necessity for calcium ions for N-sulfamidase action and also
helps to rationalize the inability of other divalent cations such
as manganese and magnesium to promote enzyme activity.
DISCUSSION
500 3140 3480
Mass (m/z
Add 6-0 sulfatase -- N-sulfamid
3213.86
100
3620 410 4M In this paper, we have described the cloning, characteriza-
tion, molecular modeling, and structure-function analysis of
the flavobacterial N-sulfamidase enzyme. The N-sulfamidase
(EC 3.10.1.1), commonly known as N-sulfoglucosamine sulfo-
I & hydrolase, described here is one of only two nitrogen-sulfur
HNSI2SHNS,6S cleaving enzymes currently identified by the Nomenclature
460
20 4047.97(834.11)
0 0
2800 3140 3480 4160
Mass (niz)
FIGURE 4. Sequential degradation of an HSGAG tetrasaccharlde using
recombinantly expressed flavobacterial enzymes. Sequential treatment
of the HSGAG tetrasaccharide (AU25H ,sl1sHN6 was physically assessed
after each enzyme step (A-E) by MALDI-mass spectrometry. Masses listed in
Committee of the International Union of Biochemistry and
each panel represent either peptide alone (-3216 Da) or oligosaccharide-
peptide complex. The net mass of the oligosaccharide is listed in parentheses.
A, addition of the 2-0-sulfatase; B, subsequent addition of the A4,5-glycuroni-
dase; C, subsequent addition of the 6-0-sulfatase (note loss of a sulfate rep-
resented by a shift in net molecular mass from -915 to -835 Da); D, addition
of N-sulfamidase directly after the A4,5-glycuronidase step (note the lack of
any desulfation); E, addition of the N-sulfamidase subsequent to the 6-0-
sulfatase (6-0 then NS). The results in E are equivocal inasmuch as a double
desulfated species with a net molecular mass of -755 Da was not clearly
detected in this experiment.
DECEMBER 11, 2009-VOLUML 284-NLJMBLR 50 JOURNAL OF BIOLOGICAL CHEM/SfRY 35197
168
Heparin/Heparan Sulfate Glycosaminoglycan from F. heparinum
A. B.
1000 
__0000__
15 60000
100 00
10
30000
110 15 15 jo001L 20000
10000
0.1 0 0C7
- EDTA Ca+2 Mg+2 Mn+2  0.0 0.2 0A 0.8 0.8 1.0 1.2
Reaon Conditions [4MU-GIcNSI mM
FIGURE 6. Effect of calcium metal ions on N-sulfamidase activity.A calcium-specific requirement forN-sul-
famidase activity and Inhibition by EDTA wherein the divalent metal effect was not observedwhen ca lclumwas
replaced by either Mg2+ or Mn2 (at either 1 or 5 mm concentrations). The following is the key: open bars (no
divalent metals added); black bars (1 mm EDTA added); light gray bars (1 mm divalent metal); stippled gray bars(5 mm divalent metal). B, effect of calcium on steady-state kinetics of N-sulfamldase observed while varying
concentrations of Ca2+ or in the presence of 1 mm EDTA. Substrate saturation plots were fitted to pseudo
first-order Michaells-Menten kinetics by nonlinear regression analyses. 0.5 mm Ca2+ (@), 1 mM Ca2+ (0), 5 mM
Ca2+ (). For clarlflcatlon, the EDTA result (showing a lack of activity) Is omitted.
Molecular Biology (NC-IUBMB), the other enzyme being cyc-
lamate sulfohydrolase (EC 3.10.1.2). Although significant pro-
gress has been made in understanding enzymatic 0-sulfate
cleavage mechanisms (35) involving oxygen-sulfur bond cleav-
age, surprisingly little is known about the mechanisms of enzy-
matic action by the corresponding N-sulfate cleaving hydro-
lases that specifically break the normally stable nitrogen-sulfur
bonds that are unique to HSGAGs. As such, the investigation
presented here provides valuable insight into the unique prop-
erties of this enzyme.
One of the important observations that motivated our struc-
ture-function studies ofN-sulfamidase was the notable absence
of key histidines that have been implicated as integral to the
function of 0-sulfatases (35). The absence of these key histi-
dines could potentially govern the specificity of N-sulfamidase
to cleave nitrogen-sulfur as against oxygen-sulfur bond. This
observation prompted us to further investigate the mechanism
of nitrogen-sulfur bond cleavage by this unique active site of
N-sulfamidase. Using the theoretical structural model of the
enzyme-substrate complex, we propose a new mechanism for
the N-S bond cleavage by N-sulfamidase that was different
from oxygen-sulfur cleavage of 0-sulfatases. To our knowledge,
this study is the first to propose such a mechanism of enzymatic
nitrogen-sulfur bond cleavage. We also experimentally vali-
dated the role of key active site residues by C80A or D40A as
described previously (20). These mutants showed no activity
(Table 3) in comparison with the wild type enzyme and hence
validate the critical role of these amino acids in the catalytic
activity of the enzyme.
Using this and previous studies, we have been able to recon-
struct the complete F. heparinum HSGAG degradation path-
way in vitro through a biochemical description of the respective
substrate specificities for each of the cloned enzymes. As such,
we are also able to place the activity of N-sulfamidase in a
sequential context related to the F. heparinum HSGAG degra-
dation pathway as it presumably exists in vivo, i.e. a degradation
pathway that begins with the heparin lyases (heparinases),
which leads to small oligosaccharides with AU uronic acid at
the nonreducing end. These oligosaccharides are then acted
upon by the exolytic A4,5-glycuroni-
dase and the sulfatases. Previously, we
established that 2-0-sulfatase action
must precede the A4,5-glycuronidase
cleavage because the presence of a
2-0-sulfate group inhibits the gly-
curonidase enzyme (18, 29). In the
accompanying paper (19) and this
study, we further establish that the
6-0-sulfatase enzyme should act
prior to N-sulfamidase because the
presence of the 6-0-sulfate group
inhibits the sulfamidase enzyme.
Interestingly, we still have to assign
within this sequence the functional
position ofthe 3-0-sulfatase activity
reported in the literature (36, 37).
The observations from this study
and the accompanying paper (19)
point to 3-0-sulfatase preceding the 6-0-sulfatase and N-sul-
famidase. Therefore, the complete HSGAG degradation path-
way (after action by the depolymerizing heparinases) is likely to
proceed in the following sequence of enzymatic action: 2-0-
sulfatase, A4,5-glycuronidase, 3-0-sulfatase (putative), 6-0-
sulfatase, and N-sulfamidase.
Other questions related to the concerted activity of the
N-sulfamidase enzyme in vivo also remain. Chief among them
is the question of what precise form the substrates for these
end-of-the-line sulfatases actually take. Is it reasonable to
assume, for example, the "natural" substrates for the N-sulfa-
midase are actually monosaccharides? This assumption is at
least consistent with the sequentially exolytic nature of the
flavobacterial HSGAG-degrading pathway that we have
described. It is also in line with the HSGAG structure-activity
relationships and the active site architecture implied fromthese
relationships. Ultimately, the ability of these enzymes to act on
longer oligosaccharides in a manner predicted by their sub-
strate specificities is of great practical value toward the use of
these enzymes as discrete analytical tools for elucidating
HSGAG fine structure.
N-Sulfated glucosamines are unique to heparin and heparan
sulfate, and it is not surprising that the mechanism proposed in
this paper is somewhat unique to this sulfate ester. The distinct
chemistry and atomic interactions obtained from an analysis of
our molecular model explained the empirically observed prop-
erties such as the substrate specificity, the novel mechanism of
nitrogen-sulfur cleavage, the activity of the enzyme only in the
presence of calcium ions but not other divalent metal cations,
the order of enzyme processivity, and the inhibition of the
enzyme by the presence of secondary sulfates within the gluco-
samine. As form follows function, these distinctions naturally
play out at the level of enzyme structure and, in the case of the
lysosomal N-sulfamidase, these are perceptible even at the pri-
mary sequence level where there is only about 10 -25% identity
to 0-sulfatases. We also point out that evenwhen one compares
the heparan sulfamidase between divergent organisms such as
flavobacterium and mammals, discrete structural differences
are likely given the reversed order within the degradation
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FIGURE 7. Proposed mechanism for cleavage of nitrogen-sulfur.bond by N-sulfamidase. The color coding of the amino acids is as mentioned in Fig. 3
legend. The mechanism is depicted in parts for clarity, and all Interactions are shown as broken lines. Transfer of protons and electrons are shown by arrows to
denote directionality of transfer. The alternate pathway where Lys-1 60 potentially mediates the sulfate transfer to the formylglycine is shown with dotted
arrow.
TABLE 3
Assessment of relative activity of N-sulfamidase active site mutants
% Activity'
Mutant Classification After 0.5 h After 3 h
Wild type Control 100 100
C80A Active site (FGly) 0 0
D40A Ca" coordination and catalytic role 0 0
4Activity measured using the coupled enzyne assay under maximunm (saturating
substrate) conditions as described under "Experimental Procedures."
sequence in which the sulfatase enzymes act. In the lysosomal
pathway, the N-sulfamidase is a relatively early enzyme that
precedes the 6-0-sulfatase, although our results indicate a
reverse order for the flavobacterial enzymes. As such, the lyso-
somal heparin N-sulfamidase naturally possesses broader sub-
strate specificity relative to the functional homologue from F.
DECEMBER 11, 2009-VOLUME 284- NUMBER 50 a1
heparinum. It follows that the relative active site topologies
should also differ, especially as it pertains to additional residues
for the lysosomal enzyme that must accommodate secondary
sulfate interactions.
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4. Influenza Virus Surface Proteins Interactions with
Host Sialylated Branched Glycans
Summary
This chapter focuses on decoding the structure-function relationships mediating the
interactions of Influenza virus surface proteins -- hemagglutinin (HA) and neuraminidase (NA) --
with sialylated branched glycans on the host. The findings are reported specifically from the
context of the pandemic 2009 HJN] swine-origin Influenza virus ("Swine Flu') that emerged
during the course of this Thesis research, although they are broadly applicable to influenza-host
interactions. Specifically, the structure-function relationships of the following Influenza proteins
are analyzed for the Swine Flu influenza virus:
(1.) Hemagglutinin (HA)
Since HA is key for both the sialylated glycan receptor binding and viral-host cell
membrane fusion steps, thus being a critical determinant of influenza zoonosis, human-human
transmission rates, extent of infection within human hosts, antigenic response and viral
clearance kinetics, the structure-function relationship mediating pandemic 2009 HiNJ HA
interaction with host sialylated glycans was investigated
(2.) Neuraminidase (NA)
Since NA is critical for catalyzing the hydrolysis of terminal sialic acid residues from the
newly formed Influenza virions and from the host cell receptors, in addition to being the primary
target of popular antivirals Tamiflu and Relenza for which drug resistance was an emergent
challenge, the structure-function relationship of 2009 H1N1 NA was investigated in detail.
(3.) Other key proteins: RNA polvmerase (PB2) and Matrix protein (M2)
Since PB2 and M2 proteins have emerged as critical determinants of virulence and anti-
viral therapy (with reported rampant resistance) respectively, the structure-function relationship
of these proteins on 2009 HiN] were also investigated
These studies resulted in a peer reviewed publication in Nature Biotechnology in June 2009.
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4.1 Introduction
4.1.1 Overview of Influenza A Viruses
Influenza A virus is a hypermutative negative strain RNA virus possessing eight gene
segments [317-320]. Of these segments, three of the genes - hemagglutinin (HA),
neuraminidase (NA), and the polymerase (PB2) - have emerged as critical for viral infection,
antigenic response, human-to-human transmission rates, and pandemic potential (Figure 4.1)
[321-325]. Within influenza A, five of the genome segments encoding the nucleocapsid protein
(NP), the matrix proteins (Ml and M2), the nonstructural proteins (NS1 and NS2), and
polymerase proteins (PB1, PB2 and PA) have maintained a relatively consistent evolutionary
history in humans owing to antigenic pressure [326-330]. In contrast, the two genes encoding the
major cell surface proteins (HA and NA) have been subjected to much more substantial
evolutionary pressure, including mutation (antigenic drift) and wholesale reassortment (antigenic
shift) being commonplace [321-324]. Due to such diversity, strains of influenza virus are
identified based on their serotype of HA and NA [325-327]. There are currently 16 known
serotypes of HA (H1-H16) and nine of NA (N1-N9) with various influenza strain subtypes being
referred as a combination of HA and NA serotypes (Figure 4.2) [328-331].
HA
NA
Internalization
Into Endosome
Entry Into
Nucleus
Virus Assembly
and Budding (a) mRNA Transcription
and Translation Cell Nucleus
(b) vRNA Replication
Figure 4.1 Influenza Virus Lifecycle
... . ..............  . .... -- ---- ............ .. .. .......
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The influenza viral life cycle may be briefly summarized as follows [332-337].
Hemagglutinin (HA) on the surface of the virus binds glycans terminated by sialic acid with a
specific linkage (highlighted in green and red in Figure 4.1), initiating fusion of the virus with
the host cell. This interaction is highly specific and is governed by the type of sialic acid linkage,
the underlying sugars and branching pattern of the glycan receptors. The other viral surface
proteins are the neuraminidase (NA) and the ion channel protein M2. Once the virus is
internalized in the cell, fusion between viral and nuclear membranes occurs, and complexes of
RNA and proteins termed viral ribonucleoprotein complexes (vRNPs) are transported into the
nucleus of the host cell. The transcription to mRNA takes place in the host cell nucleus followed
by export and protein synthesis. Also within the nucleus there is transcription of the RNA
genome. Assembly of progeny vRNPs then occurs, with export, assembly of the virus progeny,
and finally budding of the newly formed virus particles.
Figure 4.2 Influenza Hemagglutinin (HA) and Neuraminidase (NA) serotypes listed
according to known species they have been reported in the past (gray shading).
I ............... ... ......... ......... . . .. - , - - - - 4 --- -- - ---
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4.1.2 Influenza Hemagglutinin: Importance of Host Sialylated Glycan Topologies
As highlighted in the influenza virus lifecycle (Figure 4.1), the key first step in the
infection, transmission and virulence of influenza is viral surface HA binding to sialylated
glycans on the epithelial cell surface [338-343]. The chemical structure distribution of Human
Bronchical Epithelial (HBE) cell glycans has been studies with MALDI-MS previously and
shown to consist of a heterogenic mixture of complex, branched, predominantly sialic acid
capped glycans with a variety of linkages and monosaccharide compositions (Figure 4.3).
Recently, our group defined glycan topology as a key determinant of influenza virus
hemagglutinin (HA) binding to host sialylated glycan receptors, showing that influenza viruses
adapted for infecting and transmitting between humans have predominantly umbrella topologies
with a2,6 linkage, whereas those viruses that have adapted for predominantly avian infection
have cone topologies with a2,3 linkage (Figure 4.4) [344, 345].
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Figure 4.3 MLALDI-MS glycan profile of Human Bronchical Epithelial (HBE) cells
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Figure 4.4 Cone topology (left) and umbrella topology (right) glycans bind influenza HA
Thus, it was established that transmission from birds to humans is due to the ability of
HA to switch its preference from a2-3 sialylated glycans (cone topology) to a2-6 sialylated
glycans (umbrella topology) that are extensively expressed in the human upper respiratory
epithelial cells [344, 345].
Towards providing such molecular insight into the structure-function relationship of
influenza HA, several crystal structures of influenza proteins have been determined in recent
years (Table 4.1) [378]. These include crystal structures of HAs from H1 (human, avian, and
swine), H2 (human), H3 (avian and human), H5 (avian), H7 (avian), H9 (swine) and their
complexes with a2-3 and/or a2-6 oligosaccharides. These HA-glycan co-complex crystal
structures provide atomic resolution information into the key residues and interactions governing
the virus-host interactions for specific influenza strains. These structures have also greatly
enhanced our understanding and appreciation for both the receptor binding and membrane fusion
functions of influenza hemagglutinin (Figure 4.5).
Knowledge of the glycan-binding specificities obtained from analysis of these HA-
receptor co-complex crystal structures was extended to homology-based molecular models of
HA sequences from the 2009 H1N1 influenza virus in the enclosed manuscript, so as to
understand the structural basis for human adaptation of the ongoing flu pandemic.
"I'll, ....................... ..... :. :::: - :::::: ...... . ..................
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Table 4.1 Available Crystal Structures of Influenza Proteins Compiled from the PDB, with
the HA proteins highlighted in pink and NA proteins in blue. Influenza subtypes that have
resulted in 20th century pandemics are underlined.
HA 2WRG(3.0A)
NA 3BEQ(1.6A)
PA (partial 2ZNL:A(2.3A)
NP 2IQH:A(3.2A)
NS 3L4Q(2.3A)
M1 1EA3
artial) (2.3A)
HA 2R
NA 2.4
NS RNA- 1AILbinding (.A
Domain
NS Effector 3EE8
Domain (2.6A)
HA 1MQN(3.2A)
NA 2AEQ:A(3.0A)
PB32 Cap- 2VQZ
binding 3
Domain (2.3A)
2VYZ
(1.9A)
Influenza-A Protein PDB IDSubtype
Influenza-A Protein PDB IDSubtype
NP 2Q06:A(3.3A)
NS 3F5T(2.7A)
HA 1JSM
H5N1 (1.9A)
M1 2Z16
(partial) (2.OA)
PA 3CM8
(partial) (2.9A)
H9N2 HA 8S
H11N9 NA 1F8BA
NS 3D6R
H12N5 Effector (2.OA)
Domain
H13N9 NA 1NMB:N(2.2A)
H7N3 HA 1T18(3.OOA)
H11N6 NA 1.8A
N4 NA 2HTVH1ON4 NA(2.8A)
H1N1
H2N2
H3N2
P132 C-
terminal
Domain
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HA1
glyopn-binding
membrane fusion
HA2
Figure 4.5 The glycan-binding and membrane fusion facilitating sites on Influenza HA
4.1.3 Influenza Neuraminidase: Prominent anti-viral target and emergent drug resistance
Neuraminidase (NA) is the enzyme on the surface of influenza viruses that cleaves the
sialic acid groups on glycoproteins [378]. Specifically, influenza NA has two functions within
the host system. First, while influenza HA is required for infection (as described in the last
section), its presence on budding virions emerging from infected cells inhibits their release.
Influenza NA cleaves the terminal neuraminic acid (sialic acid) residues from glycan structures
on the surface of the infected cell, promoting release of progeny viruses and hence continued
spread of influenza to uninfected cells. Second, influenza NA also cleaves sialic acid residues
from viral proteins on other virions in the vicinity, thus preventing self-aggregation of viruses
and auto-elimination thereof. It may be noted that in some other viruses (such as the measles
virus), an integrated hemagglutinin-neuraminidase protein combines both their functions onto a
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single motif, unlike in influenza wherein HA and NA are independently expressed on the viral
surface.
Neuraminidase inhibitors (Figure 4.6) are a class of antiviral drugs targeted at influenza
NA, which work by blocking NA's function of promoting budding from infected host cells.
Oseltamivir (Tamiflu) a prodrug, Zanamivir (Relenza), and Peramivir are FDA-approved NA
inhibitors. Unlike the M2 inhibitors (e.g. the adamantane derivatives) that are only effective
against influenza A, these NA inhibitors are effective against both influenza A and influenza B.
Recent data from the Center for Disease Control (CDC) shows that there is rampant
resistance to Oseltamivir (Tamiflu) amongst the seasonal influenza strains, with over 99.6% of
all 2008 seasonal HiNi strains having acquired resistance to Tamiflu treatment, up from a mere
12% in 2007-2008 flu season. This data suggests that drug resistance to NA inhibitors is an
emerging issue of grave concern, since these drugs are the first line of defense to promote
recovery upon infection and curtail spread of virus from humans-to-humans for both seasonal
and pandemic influenza.
SIALIC ACID RANAlL3
Figure 4.6 Chemical structures of sialic acid (boxed) and popular influenza NA inhibitors
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Figure 4.7 Crystal structure rendering of the 1918 pandemic H1N1 NA with Sialic Acid
Hence, one of the objectives of NA structure-function analysis in the context of the 2009
HINI pandemic virus was to analyze the potential for NA of this virus to acquire mutations that
would enable the emergence of Tamiflu-resistant pandemic influenza. On the other hand,
Relenza-resistant NA mutations have only rarely been reported till date in the literature and this
aspect was also investigated. For this purpose, the crystal structures of influenza H1N1 NA from
the PDB complexed to sialic acid (Figure 4.7) as well as the NA inhibitor molecules were
utilized as templates to model the homology-based structure of the 2009 HINI influenza NA and
analyze its interactions with the ligand and inhibitor molecules. The results of such analysis of
2009 pandemic HiNI NA structure-function relationship as it pertains to predicting emergence
of anti-viral drug resistance are described in detail in the enclosed manuscript.
4.1.4 Other Key Influenza Proteins: Polymerase (PB2) and Matrix (M2) Proteins
Influenza polymerase is an important protein responsible for replication of the virus
within infected host cells. Mutation in the polymerase gene is believed to be responsible for
migration of the virus from avian to human hosts. Understanding the structure-function
relationship of influenza polymerase is hence key to devising new strategies in fighting seasonal
and pandemic influenza. The influenza polymerase functions as a heterotrimeric assembly of
... ......... .............. -
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PB2, PB 1 and PA proteins, with a small added open reading frame (ORF) that codes for the
PB 1 -F2 peptide which plays a role in virus-induced cell death. While it remains to be seen how
the polymerase complex must mutate to adapt to new hosts, single amino acid changes in PB2
(especially E627K) have been shown to be important determinants of human adaptation,
pathogenicity, and virulence. In the enclosed manuscript,
The matrix (M) protein of influenza is the major internal protein of the influenza virion,
constituting approximately 40% of the viral proteins. The M protein surrounds the inner core of
the virion, has a molecular weight of approximately 27,000, and occupies the inner surface of the
lipid bilayer of the envelope that contains the HA and NA subunits. The M protein is constituted
of the MI and M2 protein domains. The M2 protein is a fairly cross-type well-conserved (broad
spectrum conserved) proton-selective ion channel. The channel itself is a homotetramer (consists
of four identical M2 units) where the units are helices stabilized by two disulfide bonds and is
activated by low pH.
Influenza M2 inhibitors based on adamantane backbones were first approved by the FDA
as antivirals against influenza during the Asian Flu pandemic. Amantadine is the organic
compound that is formally referred as 1-aminoadamantane and consists of an adamantane
backbone substituted at one of the four methyne positions with an amino group (Figure 4.8).
Amantadine is FDA-approved and sold commerically under the brand name "Symmetrel" for use
as an antiviral against Influenza-A. Rimantadine is a closely related chemical derivative of
adamantane (Figure 4.8) with similar biological properties and is also FDA-approved as an anti-
influenza antiviral. Rimantadine is sold commercially under the brand name of Flumadine.
Amantadine (Symmetral) Rimantadine (Flumadine)
NH2 H
a 2I
H 3C .N,
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Figure 4.8 Chemical structures of Adamantane derivatives inhibiting influenza M2 protein
According to the CDC, 100 percent of seasonal H3N2 and seasonal HIN1 influenza
samples tested in 2008 were resistant to adamantane-derivatives, and amantadine and
rimantadine have since not been recommended for treatment of seasonal flu. With the emergence
of the 2009 HINI pandemic flu, we analyzed the structure-function relationship of the M2
protein of this virus as it pertains to amantadine and rimantadine binding and potential resistance.
A homology model of the 2009 swine flu M2 protein was derived to analyze potential resistance
to adamantanes, based on template structure with PDB ID: 3C9J as shown (Figure 4.9).
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Figure 4.9 The hydrophobic amantadine-binding pocket on Influenza M2 protein
Specifically, it was noted that the adamantane-derivative Amantadine (highlighted in
green/white in Figure 3.8) binds to a deep hydrophobic pocket in the template MP2 protein of
influenza viruses (colored gray/pink). However, from the homology model of the 2009 swine flu
M2 protein (Figure 3.9), it was seen upon superposition onto the amantadine-bound template
MP2 protein that the swine flu MP2 is polar/charged in the groove, thus presenting a very
different molecular surface internal to the transmembrane region (as compared to the more
hydrophobic patches in the wildtype MP2). Based on this analysis, we predicted almost no
binding affinity of adamantanes to the 2009 California Swine Influenza MP2. In agreement with
this prediction, recent experimental studies by the CDC have confirmed that the 2009 HiNI
virus is resistant to adamantane derivatives.
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Figure 4.10 Amantadine (green/white) docked to homology model of 2009 H1N1 virus MP2
protein (yellow/cyan/gray) developed using template with PDB ID 2RLF (82% identity)
Similarly, superposition of the template M2 protein (yellow/orange) with bound
rimantadine (cyan) and the modeled 2009 HlNl M2 protein (pink/gray) was performed (Figure
4.11). Rimantadine binds to pockets on the outer surface of the M2 domain, causing a closure of
this critical transmembrane protein in terms of pump/conformation change activities. However,
the S3 IN mutation (boxed) is seen in the 2009 California Swine Strain. This mutation is known
to confer drug resistance towards Rimantadine due to destabilization of the extreme end of the
transmembrane domain (with the Asn-31 residue making unfavorable contacts with Leu and Ala
hydrophobic residues), as seen from the figure. Such destabilization was predicted to result in
poorer binding affinity of Rimantadine towards the MP2 protein, and was later confirmed by
experimental binding assays.
....... ...............................................  .. . ........
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Figure 4.11 Rimantadine (cyan) docked to homology model of 2009 H1N1 virus MP2
protein (pink/gray) developed using template MP2 with PDB ID 2RLF (yellow/orange).
4.1.5 Pandemic potential of Influenza Viruses: Emergence of the 2009 Swine Flu Virus
Given the past history of deadly influenza pandemics, there is substantial public health
concern surrounding the prospect of influenza A pandemics and its associated potential global
implications. The past 20th century itself has seen four influenza pandemics (1918, 1957, 1968,
and 1977). The first and most deadly pandemic of the 20th century occurred in 1918 ("Spanish
Flu") and involved an H1N1 subtype of influenza virus. The Spanish flu pandemic led to the
death of over 40 million people worldwide.
Viruses containing the 16 HA and nine NA serotypes are naturally present in wild aquatic
bird populations where they exist commensally without causing disease, allowing birds and pigs
to become a reservoir for influenza strains, some with possible zoonoses potential (Figure 4.12).
This is of specific concern because of the influenza pandemics of the last century, those that
arose from H2N2 (1957) and H3N2 (1968), were avian-human reassortments that resulted in the
humanization of an avian-adapted virus and efficient human-to-human transmission. Those
genetic reassortments that led to an avian-to-human switch yield a number of important scientific
and medical questions, not the least of which is what changes lead away from infectivity and
propagation in avian species and towards human transmissibility?
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Figure 4.12 Influenza Zoonoses
In light of a particular influenza strain, H5N1 ("bird flu") with grave virulence potential
reported, addressing such questions becomes extremely critical. Transmission of avian H5Nl
influenza viruses to humans has been observed thus far only upon direct contact with infected
poultry; the virus has not yet demonstrated efficient human-to-human transmission ability. Given
that human infectivity has occurred and appreciating that this virus strain of H5N1 is extremely
lethal (estimates ~ 60% of infected individuals succumb to the viral and immune-response
onslaughts), the importance of comprehending the mechanism and specificity of viral entry and
infection as well as identifying additional therapeutic and prophylactic strategies is evident.
Given the extensive damage to life and economies caused by multiple instances of
zoonotic and pandemic influenza emergence within the 20th century, the present emergence of a
novel H1N1 virus, viz., 2009 HlN or "swine" flu is of great concern; and has rightfully being
declared the first Influenza pandemic of the 21st century by the World Health Organization
(Figure 4.13). One of the primary cause for concerns regarding the 2009 swine flu virus has
been the antigenic dissimilarity of this virus from seasonal, circulating HINis, thus implying
little pre-existing immune protection against this virus in the human population of today. The
2009 HIN1 virus has been labeled a 'triple reassortant virus' owing to its acquisition of genes
commonplace in human, swine, and avian influenza strains.
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Gene Segments, Hosts,
and Years of Introduction
-1998
P2, PA
-1968-19
~1918
-1979
P82, PA
Triple
Reassortant
IClassical
Eurasian
Swine
PB2
PA
2009 A(H1N1)
Figure 4.13 Host and lineage origins for the proteins of the 2009 H1N1 "swine flu" virus
Taken together, the recent incidence and spread in humans of the 'swine flu' influenza A
virus hence raised global concerns regarding its virulence and pandemic potential. The first cases
of human infection were reported in April 2009 in the Mexican town of La Gloria in Veracruz;
soon after, reported infections occurred in areas of southern California and Texas of the United
States of America (USA). Using the several recent studies that have focused on the necessary
determinants for human adaptation and efficient human-to-human transmission of the HINI
influenza A viruses (described in the last few sections), in the enclosed manuscript, a
representative 2009 H1NI strain was studied using homology modeling tools to predict the likely
human adaptation and transmissibility of the 2009 HiNi pandemic influenza viruses.
4.1.6 Published manuscript
Soundararajan, V.*, Tharakaraman, K.*, Raman, R., Raguram, S., Shriver, Z., Sasisekharan,
V., Sasisekharan, R. (2009) Extrapolating from sequence - the 2009 H1N1 'swine' influenza
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Specific contributions of this Thesis research to the publication: Developed the homology-
based structural models for the 2009 pandemic HJNJ 'Swine Flu' Hemagglutinin (HA),
Neuraminidase (NA), Polymerase (PB2), and Matrix (M2) proteins, in addition to proteins
corresponding to the other genes segments of the virus. Each of the developed structural
models was analyzed to predict biologically and medically salient structure-function
relationships underlying emergence and spread of the pandemic, such as, human adaptation,
human-to-human transmission, evolution of drug resistance, seasonal flu vaccine efficacy,
antigenic drift, virulence, and overall pandemic potential.
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entitytypes (e.g., diseases, pathways and organ-
isms), and eventuallyto add entity types beyond
the life sciences; we designed Reflect to be an
extendible platform, and we welcome collabora-
tion proposals for adding further entitytypes. In
addition, we welcome proposals from publishers
and data providers interested in programmatic
access to Reflect. With such access, end-users can
use'Reflected'content without needingto install
a browser plug-in.
In summary, Reflect creates a view of the web
tailored for the life scientist, that is, with system-
atic tagging of biochemical entities, and easy
access to more detailed information. Reflect is
already being used bythousands of researchers,
and we have received much positive feedback
regarding Reflect's usefulness and ease of use.
In addition, just before publication of this cor-
respondence, Reflect was awarded first prize in
the Elsevier Grand Challenge, a contest for tools
that improve the way scientific information is
communicated. Thus, we believe that Reflect
can be a valuable tool for researchers, teachers,
students and anyone who reads life science lit-
erature on the web. We further predict that in
the near future tools such as Reflect will change
dramatically how scientists use the web.
Note: Supplementary information is available on the
Nature Biotednology website.
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E Extrapolating from sequence-the
2009 H1N1 'swine' influenza virus
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To the Editor:
The recent incidence and spread in humans of
the'swine flu'influenza A virus has raised global
concerns regarding its virulence and pandemic
potential. The main cause of the so-called swine
flu has been identified as human infection by
influenza A viruses of a new HiNi (hemag-
glutinin 1, neuraminidase 1) subtype, or'2009
H iN 1 strain' The first cases of human infection
were reported in April in the Mexican town of
LaGloriainVeracruz; soon after, reportedinfec-
tions occurred in areas of southern California
and Texas. Several recent studies have focused
on the necessary determinants for human adap-
tation and efficient human-to-humantransmis-
sion of the H1N1 influenza A viruses1-9. Here,
using a representative 2009 HlNl strain as our
starting point, we offer a perspective on the
likely human adaptation and transmissibility
of 2009 H1N1 viruses.
At the time when this sequence analysis was
performed, partial or complete sequences were
available from 38 different human isolates of
the 2009 HIN1 virus. These sequences were
obtained from GISAID (Global Initiative on
Sharing Avian Influenza Data; http://platform.
gisaid.org/) and the NCBI Influenza Virus
Resource (National Center for Biotechnology
Information; http://www.ncbi.nlm.nih.gov/
genomes/FLU/FLU.itmil). Comparison of the
amino acid sequences between the 38 isolates
showed some intragenic differences: seven
amino acid positions in HA (hemagglutinin),
one in M1 (matrix 1),two in M2 (matrix 2), four
inNA (neuraminidase),three inNP (icleopro-
tein), two in PA and two in PB2 (both of which
encode subunits of viral RNA polymerase).
Given the few intragenic variations among the
38 isolates available at the time of this study, we
use /CaliforniaO4/2009 (Cal0409) as arepresen-
tative 2009 H1N1 virus strain for frther analy-
sis. The top ranking hits of the BLAST search
using the individual Cal0409 genes are shown
in Supplementary Table 1 online.
Comparison of Cal0409 HA with the HA
consensus sequences for human-adapted
HlNl, avian-adapted HlN1 and swine-
adapted H1N1 reveals important substitu-
tions in positions 100-300, where the glycan
receptor-binding sites and antigenic loops
are located (Supplementary Table 2 online).
Notably, the Cal0409 HA possesses the signa-
ture amino acids Asp 190 and Asp225 that have
been shown to play a key role in conferring
specificity to the human U2-6 sialylated glycan
receptors'. We also observe amino acid sub-
stitutions that are unique to Cal0409 HA and
have not been observed in previous human
H1NI HAs. These include substitutions at
sequence positions 74, 131, 145, 208,219,261,
263, 264, 305, 317, 368, 377 and 530. Among
these residue positions, 131 and 145 are proxi-
mal to the glycan-binding site.
To determine the possible effect of these
mutations on the glycan-binding properties
of HA, we constructed homology-based struc-
tural complexes of Cal0409 with representative
cz2-3 and W2-6 sialylated oligosaccharides, as
described earlier8 (Fig. 1). The construction
of theoretical HA-glycan structural complexes
previously8 allowed us to provide a structural
rationale for how specific amino acid muta-
tions within the 1918 HlNl HA can dramati-
cally alter its relative a2-3/c2-6 binding affinity.
Referencing these previous efforts, we deter-
mined the potential glycan binding properties
of Cal0409 HA by analyzing its contacts with
the a2-3 and a2-6 sialylated glycans.
On the basis of the observed contacts in the
HA-glycancomplexes,we summarize in Table 1
the proposed roles of the residues in Cal0409
HA that provide binding specificity to W2-3
and W2-6 oligosaccharides, respectively. The
main differences between the glycan-binding
pockets of reference HAs and Cal0409 HA lie
in the 140-loop region and the loop regionpre-
cedingthe 190-helix. Lys145, which isuniqueto
Cal0409, along with Lysl33 and Lys222, form a
positively charged'lysine fence'at the base ofthe
binding site that potentially are positioned to
anchor the N-acetylneuraminic acid (Neu5Ac)
and galactose (Gal) sugars of both 2-3 and
u2-6 glycans. In the case of the Cal0409 cx2-6
oligosaccharide structural complex, the lysine
fence also indudes Lys 156, which is positioned
to provide additional contact with the glycan.
The orientation ofAsp190 is typically stabilized
by a network of interactions involving residues
at 186, 187 and 189 that precede the 190 -helix.
In Cal0409 HA, the residues at these positions
are Ser186, Thr187 and Ala189; this set of resi-
dues is unique to the 2009 H1N1 strains. These
residues appear to retain the ability to stabilize
the orientation of Asp 190 such that it is posi-
tioned to make optimal contacts with the third
N-acetylglucosamine (GlcNAc) sugar (starting
from Neu5Ac toward the reducing end) of a2-6
glycans, defined previously8.
Our observations of the Ca10409 HA-glycan
interactions suggest that this HA has the nec-
essary residues to provide optimal contacts for
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high affinity binding to W2-6 glycans present
in the human upper airwaysO. Typically, the
Glu190Asp substitution between avian and
human-adapted Hi HA results in the loss of a
critical contact with the Neu5Aca2-3Gal motif
and a gain in contact with 2-6 glycansi'5 >8. In
the Cal0409 HA, however, this loss in contact
to W2-3 glycans appears to be compensated for
by Lys145 of the lysine fence. In summary, our
analysis suggests that Cal0409 HA possesses
residues that can be positioned to make optimal
contacts with 2-6 (a characteristic binding fea-
ture shared by human HiNi HAs' A) as well as
2-3 sialylated glycans. In future studies, it will
be important to experimentally determine the
relative a2-6 and U2-3 binding affinities of the
2009 H1N1 HAs using appropriate methods.
Comparison of the antigenic regionsi of
Cal0409 NA with the consensus sequences of
avian,human and swine-adaptedNi NAsshows
that four positions-188, 331,372 and 402-are
novel in the 2009 H1N1 NA (Supplementary
* Table 3 online). NA is presently the primary
target of therapeutic intervention for influenza
C infection, and oseltamivir (Tamiflu) and zana-
mivir (Relenza) are widely used NA-inhibiting
drug molecules. Recently, it has been reported
that there is an alarming increase in the oselta-
mivir resistance of HIN1 viruses from 12.3% in
2007-2008 to 9&5% in 2008-2009 season (prior
to the outbreak of the 2009 H1N1 infections)12
Fortunately, the 2009 HiNi strains reported
thus far are sensitive to both oseltamivir and
zanamivir.
As the His274Tyr mutation is known to be
responsible for resistance of the recent HiNi
0 human viruses to oseltamivir, we analyzed thepotential effect of this mutationshould it occur,s on the drug sensitivity of Cal0409 NA (Fig. 2).
Previous studies have provided high-resolu-
tion crystal structures of NA-drug complexes,
thereby shedding light on the structure-
function relationships mediating the emergence
of drug-resistant influenza strains13. Consistent
with these studies, our analysis suggests that the
bulkyTyr274 residue in the His274Tyr mutant
form of Cal0409 NA is likelyto displace Glu276
toward the docking site for the drug agent. The
polar glycerol C6 group in zanamivir appears
better suited than the corresponding hydropho-
bic pentyloxygroup in oseltamivir to engage the
resulting active site hydrogen bond network and
thereby provides more optimal contacts with
the His274Tyr mutant form of Cal0409 NA. The
predicted unfavorable interaction of oseltami-
virwith the His274Tyr mutant form of Cal0409
NA is consistent with observations concerning
the effect of this mutation in seasonal HiNi
strains and highlights the possibility of the
emergence of Tamiflu-resistant viruses. Given
the alarming proportion of circulatingTamiflu-
a
Aspi (Glu)
Ser1 86 (Pro)
Glu227 (Ala) Leu 94
Val155 (Thr)
Trp15SI Gn 92
Lys222
Gin226 ys 133(-)
Asp225 Lys1564
Ly s145 (Ser) Ser1 86 (Pro) 
_Asp190
Glu227 lal Va15
rp153f
Lys222
Gin226 s1 33 (Arg)
Asp225 (Gly) Thr1 36
C
15O0loop /Lys145 (Ser)
(Lys1564)
220 loop 1
(Lys22) 130 loop
(Lys1 33)
140 loop
(Lys145)
Figure 1 Glycan-binding properties of Cal0409 HA. A homology-based structural model of Cal0409 HA
was constructed using the prototypic 1918 H1N1 HA (PDB ID: 1RUZ) as a template. (a) Theoretical
structural model of Cal0409 HA (gray) bound to an c2-3 oligosaccharide (carbon; green) showing the
key amino acids on HA (carbon; purple) that are positioned to make optimal contacts with the glycan.
This complex was constructed using the PR8 (A/Puerto Rico/8/34) H1 HA-<2-3 oligosaccharide
co-crystal structure (PDB ID: 1RVX: coordinates of trisaccharide Neu5Accc2-3Gal P1-4GlcNAc are
ordered). The analogous amino acids in PR8 that are different from Cal0408 HA (labeled red with PR8
residues in parenthesis) are also shown (carbon; yellow). (b) Theoretical structural model of Cai0409
HA bound to an o2-6 ollgosaccharlde (carbon; cyan) showing the key amino acids on HA (carbon;
purple) that are positioned to make optimal contacts with the glycan. This model was constructed
using A/Swine/lowa/30 (AS130) HI HA-x2-6 co-crystal structure (PDB ID: 1RVT: coordinates of
pentasaccharide Neu5Aco2-6Galp1-4GlcNAcS1-3Gal S1-4Glc are ordered). The analogous amino
acids in ASIO HA that are different from Cal0408 HA (labeled red with AS130 residues In parenthesis)
are also shown (carbon: orange). The oxygen and nitrogen atoms are colored red and blue respectively.
(c) Molecular surface of the HA-c-2-6 oligosaccharide complex highlighting the lysine fence (circled).
resistant seasonal H1N1 viruses13 , our analysis
support for both augmentation of oseltamivir
stockpiles with additional drugs (including
zanamivir) and the prudent administration of
antivirals in general.
To probe the resistance of the 2009 H1N1
viruses to the adamantane-derivative drugs
amantadine (Symmetrel) and rimantadine
(Flumadine), we also investigated their target,
theM2 protein. The prototypic mutation associ-
ated with adamantane resistance is Ser3lAsn14)15
and the presence of this mutation in all the 2009
HiNI strains is consistent with their observed
resistance to adamantane-derivative drugs 6 .
To provide additional functional context to
the above analysis, the amino acid sequences of
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Table I Contacts observed in the structural model of Cal0409 HA-glyian complexes
Amino acid a2-3 a2-6
Aminoacids at beof HA pocket
Tyr95, Thr136, Trp153, ValI155, Highly conserved residues in all H1 HAs involved in anchoring Highly conserved residues in all H1 HAs involved in anchoring
H is183, Leul94, GIn226 Neu5Ac Neu5Ac
Lys131, Lys145, Lys222 Lysine fence that makes optimal contacts with Neu5Ac Lysine fence that makes optimal contacts with Neu5A=c2-
o2-3Gal- motif 6Gal- motif
Asp225 Minimal contact with a2-3 Optimal contact with Gal sugar of Neu5Aca2-6Gal motif
Glu227 Stabilize orientation of Lys222 side chain of the lysine fence Stabilize orientation of Lys222 side chain of the lysine fence
Amino acids contacting additionail sugars In u2-6 olfgosaccharide
Asp190 No contacts with a2-3 Optimal contact with the third GIcNAc sugar at reducing end of
Neu5Aca2-6Gal- motif
Gin192, Ser193
Lys 156
Ser186, Thr187, AlaI89
No contacts with a2-3
No contacts with a2-3
No contacts with a2-3
the HA and NA of the 2009 H1N1 strain were
compared to those of the current vaccine H1N1
strainA/Brisbane/59/07.A/Brisbane/59/07has
been associated with severe infectivity due, at
least in part, to the fact that its HA and NA
have low antigenic cross-reactivity to preex-
isting humoral immunity 7 . We then com-
pared our results to the same analysis using
A/Brisbane/59/07 and the previous H1N1 vac-
Optimal contacts with sugars beyond third GIcNAc (toward
reducing end)
Part of the lysine fence positioned to make optimal contacts
with sugars beyond the third GIcNAc (toward reducing end)
Side chains of these residues form a nemork to stabilize
orientation of Asp190
cine strain A/Solomon Islands/3/2006. This
exercise provides an important reference point
for a virus that is characterized as antigeni-
cally dissimilar to most circulating HiNis. For
the comparison between the NA of the 2009
H1N1 strain and the A/Brisbane/59/07 strain,
we find that the overall percent sequence iden-
tity is 80.6%; however, this sequence identity
drops to 38.0% within the antigenic regions
110 strand
(Supplementary Table 4 online). A similar
trend is observed in HA (Supplementary Table
5 online), where the identity is reduced from
79.2% (overall) to 56.3% (antigenic). In con-
trast, when comparing A/Brisbane/59/07 with
A/Solomon Islands/3/2006, the percent iden-
tity in NA shows only a marginal drop from
94.4% (overall) to 92.0% (antigenic). Similarly,
with regards to HA alone, the percent identity
Figure 2 Analysis of Cal0409 NA. A homology-
based structural model of Ca10409 NA was
constructed using the N1 NA crystal structure
(PDB ID; 3CKZ) as a template. (a) Active site
of the Cal0409 neuraminidase (dark gray)
docked with sialic acid (carbon: Ilight gray) is
shown highlighting key contacts Including a
dense network of hydrogen bonds (black broken
lines) in the proximity of the C6 substitution
(hydrogen atoms not displayed). Amino acid
side chains are shown with carbon atoms
colored purple. Oseltamivir and zanamivir were
docked from their native co-crystal structures
N1 NA-oseltamiv ir (PDB ID: 2 HUO/2HU4) and
N8 NA-zanamivir (PDB ID: 2HTQ) onto the
Cal0409 NA structural model. (b) Comparison
of contacts made by oseltamivir (carbon;
cyan) with the wild-type (carbon; purple) and
Hls274Tyr mutant (carbon; green) of Ca10409
NA shows the shift In Glu276 (caused by
Tyr274 in the mutant) toward oseltamivir
potentially resulting In unfavorable interactions
(red broken circle) with the hydrophobic
substitution in the C6 position. (c) Comparison
of contacts made by zanamivir (carbon: yellow)
with wild-type (carbon: purple) and His274Tyr
mutant (carbon: green) of Ca10409 NA shows
that the shift in the position of Glu276 toward
the polar C6 substitution of zanamlvir may
provide additional favorable contacts (dark
green broken circle). The oxygen and nitrogen
atoms are colored red and blue, respectively, in
all the structures.
VOLUME 27 NUMBER 6 JUNE 2009 NATURE BIOTECHNOLOGY
192
CORRESPONDENCE
drops from 98.6% (overall) to 97.2% (antigenic)
(Supplementary Tables 6 and 7 online). Taken
together, the results indicate that the substantial
variability observed in the antigenic regions of
the 2009 HlN1 viruses would mostlikelyresult
inthe presentation of new epitopes that may not
cross-react with the antibodies generated using
the current vaccine strains, thereby potentially
having important implications toward the pro-
tective effect afforded byexistingseasonal influ-
enza vaccines.
In addition to the vital role of the viral coat
proteins, most prominently HA, in governing
transmission, virulence and human adapta-
tion, recent studies have demonstrated the
critical role of the viral RNA polymerase PB2
inthe efficient respiratory droplet (or airborne)
transmissionofwild-typehumanH1N Iviruses
and avian-human reassorted influenza viruses
in the ferret model9. In this study, it was dem-
onstrated that a specific residue, Lys627, in
4) human-adapted PB2was critical for conferring
(a efficient transmissibility. Conversely, mutation
2 of this Lys627 to glutamic acid (which is typi-cm
cally found in avian and swine-adapted PB2)
;R in PB2 of the 1918 pandemic strain (SC18)
severely reduced its abilityto transmit.Analysis
of PB2 in all the 2009 HIN1 strains indicates
that it has glutamic acid atposition 627. Onthe
basis of these earlier studies, we expect that the
E 2009 H1N1 viruses may be capable of trans-
mission between humans, but the efficiency of
transmissionmightbehamperedbythe absence
of Lys627 in PB2.Although the HA of the 2009
G H1N1 viruses is human-adapted, our analysisS suggests that PB2 still requires an additional
mutation to become fully human-adapted for
efficient transmission.
A recent study' 8 evaluated the pandemic
potential of the 2009 H1N1 viruses using the
available epidemiological data. This study con-
cluded that despite the substantial uncertainty
in the data, the dinical severity of the 2009
H1N1 viruses is more comparable to the 1957
H2N2 pandemic outbreak thanthe 1918 H1N1
pandemic. Given the fact that the evolution of
this virus is uncertain at best, we must remain
vigilant for additional mutations that can ren-
der this strain more virulent.
In condusion, we set out using sequence
information to evaluate the HA, NA PB2 and
M2 genes in the new H1N1 viral strain based
Table 2 Summar
HIN1 viruses
Protein
Hemagglutinin (HA)
Neuraminidase (NA)
PB2 and M2
of predicted properties of HA, NA, PB2 and M2 for current 2009
Predicted properties
* Glycan-binding site (including Asp190
and Asp225) is similar to that of human
adapted H1N1 HAs
* Binding site contains residues that are
positioned to make optimal contacts with
both a2-6 and a2-3 glycans
* Lys145, Ser186, Thr187 and Ala189 are
novel substitutions that have not been
observed in other human H1N1 HAs
* Novel substitutions in four positions 189,
331, 369 and 398 in the putative anti-
genic site
* Active site has not yet acquired the char-
acteristic mutations such as His274Tyr
that provides resistance to oseltamivir.
+ Zanamivir can potentially make optimal
contacts with the oseltamivir-resistant NA
mutants.
* Lys627Glu mutation in PB2 reduced
transmission efficiency of a prototypic
human-adapted H1NI virus
9
* M2 protein has acquired Ser31Asn muta-
tion that provides resistance to adaman-
tane-derived drugs
on their known critical roles in the human
adaptation, human-to-human transmission
and resistance to currentlyused antiviral drugs
(Table 2).As experimental data for 2009 H1NI
viruses become available, it will be possible to
correlate those results with the analyses pre-
sented here.
Note: Supplementary infornation is available on the
Nature Biotechnology website.
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Perspectives
* HA is human adapted and is
expected to bind with high affinity
to a2-6 and better affinity to at2-3
in comparison with other human
HIN1 HAs
* Novel substitutions in the anti-
genic regions of HA might present
new epitopes
* Novel substitutions in antigenic
regions of NA might present new
epitopes
* NA can acquire mutations that
offer resistance to Tamiflu
* Zanamivir might be preferred to
oseltamivir
e Acquisition of the Glu627Lys
mutation could potentially improve
transmission efficiency of the virus
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Supplementary Information
Table S1. BLAST hits for the gene sequences of Cal0409. Results of BLAST nucleotide
analysis are arranged into four columns: (1) gene name; (2) accession # of the best BLAST hit; (3)
Name of the virus carrying the best hit from column 2; (4) percent sequence identity.
Gene Accession # of best Virus name Percent Identity
BLAST hit
Influenza A virus
HA AF455680 (A/Swine/Indiana/P12439/00 95%
(H1N2))
Influenza A virus
NA AF250366 (A/Swine/England/195852/92 94%
(H1N1))
PB2 EU301177 Influenza A virusPB2___EU301177____(A/Swine/Korea/JNS06/2004(H3N2)) 96%
PB1 AF342823 InfluenzaA virus (A/Wisconsin/10/98 96%
PB1___AF342823____(H1N1)) 96%
Influenza A virus
PA AF455722 (A/Swine/Illinois/100084/01 96%(H1N2))
NP AF251415 Influenza A virus(A/Swine/Iowa/533/99 (H3N2)) 96%
Influenza A virus
NS AF153262 (A/Swine/Minnesota/9088-2/98 96%
(H3N2))
MP AY363575 InfluenzaA virus (A/Swine/Hong 97%
Kong/5212/99(H3N2)) on
Table S2. Sequence comparison of Cal0409 HA with consensus amino acids from avian, swine and human H1N1 HA. The first
row corresponds to the sequence of Ca1O409 HA. The 2 "-4 * rows represent sequence of positions where each position contains the
consensus residue (the most predominantly occurring amino acid in all the sequences for that species in that position) in human, swine
and avian H1N1 HAs respectively. The putative antigenic sites are highlighted in blue and glycan-binding sites are highlighted in yellow.
The amino acids that are unique to Ca1O409 HA and not found in any of the human H1NI HAs are colored red.
15 40 49 69 74
Cal0409 MKAILVVLLYTFATANADTLCIGYHAN DTVLE KNVTVTHSVNLLE C LHLGKCNIAGWILGN SWSYIVE
Human MKVKLLVLLCTFTATYADTICIGYHA DTVLENVTVTHSVNLLE LQLGNCSVAGWILGN SWSYIVE
Swine MKAILLVLLCTFTAANADTLCIG DTVLEKNVTVTHSVNLLE LHLGKCNIAGWLLGN SWSYIVE
Avian MEAKLFVLFCTFTVLKADTICVG YADTVLEKNVTVTHSVNLLE DLCLQLGKCNVAGWLLGN ANSWSYIIE
85 94 122 131 145 153 170
Cal0409 GTCYPGDFIDYEELREQLSSVSSFERFEIF GVT SFYLIWLVKK SKSYI LWGI
Human TCYPGYFADYEELREQLSSVSSFERFEIF KGVSASC SYRNLLWLTG SKSWGV
Swine DNGTCYPGDFINYEELREQLSSVSSFERFEIF GS SFYRNLILVKK SKS VLWGI
Avian GTCYPGEFIDYEELREQLSSVSSFEKFEIF P GASFYRNLLWITKKc SKS VLWGV
190 208 219 225 261 270
Cal0409 HHPS4AD SLYQNADTYVFVGSSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLV ITFEATGNLVVPRYAFAMERNAGSGI CNT
Human HHPP NGDUAYHTENAYVSVVSSYSRRFTPEIAKRPKVRDQEGRINYYWTLL IIFEANGNLIAPRYAFALSRGFGSGII D ECDA
Swine HHPPTTDJSLYQNADAYVFVGSSKYNRKFKPEIAARPKVRGAGRMNYYWTLI ITFEATGNLVVPRYAFAMNRGSGSGII CNT
Avian HHPP SESLYQNTDAYVSVGSSKYNRRFTPEIAARPKVRGQAGRMNYYWTLL ITFEATGNLIAPWYAFALNKGSDSGII CDT
305 311 317 368 377
Cal0409 TCQTPKGAINTSLPFQNIHPITIGKCP LATGLRNIPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADLKSTQNAIDEI
Human KCQTPQGAINSSLPFQNVHPVTIGECP KYVM GLRNIPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADQKSTQNAINGI
Swine KCQTPKGAINTSLPFQNIHPVTIGECP GLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAIDGI
Avian RCQTPHGALNSSLPFQNVHPITIGECP GLRNVPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAIDGI
Cal0409 TNKVNSVIEKMNTQFTAVGKEFNHLEKRIENLNKKVDDGFLDIWTYNAELLVLLENERTLDYHDSNVKNLYEKVRSQLKNNAKEI GNGCFEFYHKCDN
Human TNKVNSVIEKMNTQFTAVGKEFNKLERRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVENLYEKVKSQLKNNAKEIGNGCFEFYHKCND
Swine TNKVNSVIEKMNTQFTAVGKEFNHLEKRIENLNKKVDDGFLDVWTYNAELLVLLENERTLDFHDSNVENLYEKVRSQLRNNAKEIGNGCFEFYHKCDD
Avian TNKVNSVIEKMNTQFTAVGKEFNNLERRIENLNKKVDDGFLDVWTYNAELLVLLENERTLDFHDSNVRNLYEKVRSQLRNNAKELGNGCFEFYHKCDD
530
Cal0409 TCMESVENGTYDYPKYSEEAKLNREEIDGVKLESTRIYQILAIYSTVASSLVLVVSLGAISFWMCSNGSLQCRICI
Human ECMESVENGTYDYPKYSEESKLNREKIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI
Swine TCMESVENGTYDYPKYSEESKLNREEIDGVKLESTRIYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI
Avian ECMESVENGTYDYPKYSEESKLNREEIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI
. ..... .
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Table S3. Sequence compaxison of Ca0409 NA with consensus amino acds from avian, swine and human H1NI NA. The first
row corresponds to the sequence of CaO409 NA. The 2 "-4'" rows represent sequence of positions where each position contains the
consensus residue (the most predominantly occurring amino acid in all the sequences for that species in that position) in human, swine
and avian H1N1 NAs respectively. The putative antigenic sites are highlighted in blue and the active-site residues are highlighted in
yellow. The amino acids in the antigenic region that are unique to Ca1O409 NA and not found in any of the human H1NI NAs are
colored red.
Cal0409 MNPNQKIITIGSVCMTIGMANLILQIGNIISIWISHSIQLGNQNQIETCNQSVITYENNTWVNQTYVNISNTNFAAGQSVVSVKLAGNSSLCPVSGWA
Human MNPNQKIITIGSISIAIGIISLMLQIGNIISIWASHSIQTGSQNHTGICNQRIITYENSTWVNHTYVNINNTNVVAGKDKTSVTLAGNSSLCSISGWA
Swine MNTNQRIITIGTICLIVGIISLLLQIGNIISLWISHSIQTGEKNHPETCNQSVITYENTWVNQTYVNISNTNIVAGQGVTSIILAGNSSLCPISGWA
Avian MNPNQKIITIGSICMAIGIISLVLQIGNIISIWVSHSIQTGSQNHPETCNQSVITYENNTWVNQTYINISNTNLIAEQAVAPVTLAGNSSLCPISGWA
118 134 151 156 178 187
Ca10409 IYSKDNSVRIGSKGDVFVIREPFISCSPLECRTFFLTQGALLNDKHSNGTIKDRSPYRTLMSCPIGEVPSPYNSRFESVAWSASACHD TIGIS
Human IYTKDNSIRIGSKGDVFVIREPFISCSHLECRTFFLTQGALLNDKHSNGTVKDRSPYRALMSCPLGEAPSPYNSKFESVAWSASACHD TIGIS
Swine IYSKDNSIRIGSKGDIFVIREPFISCSHLECRTFFLTQGALLNDKHSNGTVKDRSPYRTLMSCPIGEAPSPYNSRFESVAWSAACHD TIGIS
Avian IYSKDNGIRIGSKGDVFVIREPFISCSHLECRTFFLTQGALLNDKHSNGTVKDRSPYRTLMSCPVGEAPSPYNSRFESVAWSASACHD t TIGIS
221 227 246 262 274 284 292
Cal0409 GPDNGAVAVLKYNGIITDTIKS ILRTQESECACVNGSCFTVMTDG PSASYKIFRIEKG SVEMNAPNYHYEECSCYP CVCRD
Human GPDNGAVAVLKYNGIITETIKSW ILRTQESECVCVNGSCFTIMTDGP SYKIFKIEKG SIELNAPNFHYECSCYP CRD
Swine GPDNGAVAVLKYNGIITDTIKS LRTQESECVCINGSCFTIMTDG SYKIFKME E IELDAPNYHYEECSCYP CRD
Avian GPDNGAVAVLKYNGIITDTIKS ILRTQESECACINGSCFTIMTDG SSYKIFKIEKGKSVELNAPNYHYEECSCYP DC CRD
294 328 342 350 368 388
Cal0409 NWHGSNRPWVSFNQNLEYQIGYICSGIFGDNP SCGP GVKGFSEYGNGVWIGRTKSRIGFEMIWDPNGWTG
Human NWHGSNRPWVSFNQNLDYQIGYICSGVFGDNP SCNP DVK FS YGNGVWIGRTKSQ FEMIWDPNGWTD
Swine NWHASNRPWVSFDQNLDYQIGYICSGVFGDNP iCGP VNGVKGF GNGVWIGRT FEMIWDPNGWTE
Avian NWHGSNRPWVSFNQNLEYQIGYICS GVFGDNP SCGP G KGF GVWIGRTFEMIWDPNGWTED
403 406 430 434
Cal0409 SGYSGSFVQHPELTGLDCIRPCFWVELIR -TIWTSGSSISFCGVNSDTVGWSWPDGAELPFTIDK
Human SGYSGSFVQHPELTGLDCIRPCFWVELVR TIWTSGSSISFCGVNSDTANWSWPDGAELPFTIDK
Swine YSGSFVQHPELTGMDCIRPCFWVELIR TIWTSGSSISFCGVNSDTASWSWPDGADLPFTIDK
Avian GYSGSFVQHPELTGLDCMRPCFWVELIR TIWTSGSSISFCGVNSDTVGWSWPDGAELPFTIDK
Table S4. Sequence alignment between NAs of A/California/04/2009 (H1N1) (row 1) and A/
Brisbane/59/2007(H1N1) (row 2). Antigenic sites are colored red. The antigenic similarity is
measured as the percentage fraction of antigenic sites having the same amino acids (=19/50 =
38%).
Cal0409
Brisb5907
Cal0409
Brisb5907
Cal0409
BrisbS907
Cal0409
Brisb5907
Cal0409
Brisb5907
Cal0409
Brisb5907
Cal0409
Brisb5907
Cal0409
Brisb5907
MNPNQKIITIGSVCMTIGMANLILQIGNIISIWISHSIQLGNQNQIETCNQSVITYENNT
MNPNQKIITIGSISIAIGIISLMLQIGNIISIWASHSIQTGSQNNTGICNQRIITYENST
WVNQTYVNISNTNFAAGQSVVSVKLAGNSSLCPVSGWAIYSKDNSVRIGSKGDVFVIREP
WVNHTYVNINNTNVVAGEDKTSVTLAGNSSLCSISGWAIYTKDNSIRIGSKGDVFVIREP
FISCSPLECRTFFLTQGALLNDKHSNGTIKDRSPYRTLMSCPIGEVPSPYNSRFESVAWS
FISCSHLECRTFFLTQGALLNDKH.SNGTVKDRSPYRALMSCPLGEAPSPYNSKFESVAWS
ASACHDGINWLTIGISGPDNGAVAVLKYNGIITDTIKSWRNNILRTQESECACVNGSCFT
ASACHDGMGWLTIGISGPDNGAVAVLKYNGIITGTIKSWKKQILRTQESECVCMNGSCFT
VMTDGPSNGQASYKIFRIEKGKIVKSVEMNAPNYHYEECSCYPDSSEITCVCRDNWHGSN
IMTDGPSNKAASYKIFKIEKGKVTKSIELNAPNFHYEECSCYPDTGIVMCVCRDNWHGSN
RPWVSFNQNLEYQIGYICSGIFGDNPRPNDKTGSCGPVSSNGANGVKGFSFKYGNGVWIG
RPWVSFNQNLDYQIGYICSGVFGDNPRPEDGEGSCNPVTVDGANGVKGFSYKYDNGVWIG
RTKSISSRNGFEMIWDPNGWTGTDNNFSIKQDIVGINEWSGYSGSFVQHPELTGLDCIRP
RTKSNRLRKGFEMIWDPNGWTNTDSDFSVKQDVVAITDWSGYSGSFVQHPELTGLDCIRP
CFWVELIRGRPKEN-TIWTSGSSISFCGVNSDTVGWSWPDGAELPFTIDK
CFWVELVRGLPRENTTIWTSGSSISFCGVNSDTANWSWPDGAELPFT---
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Table S5. Sequence alignment between HAs of A/Califormia/04/2009 (H1N1) (row 1) and Al
Brisbane/59/2007(H1N1) (row 2). Antigenic sites are colored red. The antigenic similarity is
measured as the percentage fraction of antigenic sites having the same amino acids (=40/71=
56.33%).
Cal0409 MKAILVVLLYTFATANADTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDKHNGKLCK
Brisb5907 MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLENSHNGKLCL
Cal0409 LRGVAPLHLGKCNIAGWILGNPECESLSTASSWSYIVETPSSDNGTCYPGDFIDYEELRE
Brisb5907 LKGIAPLQLGNCSVAGWILGNPECELLISKESWSYIVEKPNPENGTCYPGHFADYEELRE
Cal0409 QLSSVSSFERFEIFPKTSSWPNHDSNKGVTAACPHAGAKSFYKNLIWLVKKGNSYPKLSK
Brisb5907 QLSSVSSFERFEIFPKESSWPNH-TVTGVSASCSHNGESSFYRNLLWLTGKNGLYPNLSK
Cal0409 SYINDKGKEVLVLWGIHHPSTSADQQSLYQNADTYVFVGSSRYSKKFKPEIAIRPKVRDQ
BrisbS907 SYANNKEKEVLVLWGVHHPPNIGDQKALYHTENAYVSVVSSHYSRKFTPEIAKRPKVRDQ
Cal0409 EGRMNYYWTLVEPGDKITFEATGNLVVPRYAFAMERNAGSGIIISDTPVHDCNTTCQTPK
Brisb5907 EGRINYYWTLLEPGDTIIFEANGNLIAPRYAFALSRGFGSGIINSNAPMDKCDAKCQTPQ
Cal0409 GAINTSLPFQNIHPITIGKCPKYVKSTKLRLATGLRNIPSIQSRGLFGAIAGFIEGGWTG
Brisb5907 GAINSSLPFQNVHPVTIGECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTG
Cal0409 MVDGWYGYHHQNEQGSGYAADLKSTQNAIDEITNKVNSVIEKMNTQFTAVGKEFNHLEKR
Brisb5907 MVDGWYGYHHQNEQGSGYAADQKSTNAINGITNKVNSVIEKMNTQFTAVGKEFNKLERR
Cal0409 IENLNKKVDDGFLDIWTYNAELLVLLENERTLDYHDSNVKNLYEKVRSQLKNNAKEIGNG
Brisb5907 MENLNKKVDDGFIDIWTYNAELLVLLENERTLDFHDSNVENLYEKVKSQLENNAKEIGNG
Cal0409 CFEFYHKCDNTCMESVKNGTYDYPKYSEEAKLNREEIDGVKLESTRIYQILAIYSTVASS
Brisb5907 CFEFYHKCNDECMESVKNGTYDYPKYSEESKLNREKIDGVKLESMGVYQILAIYSTVASS
Cal0409 LVLVVSLGAISFWMCSNGSLQCRICI
Brisb5907 LVLLVSLGAISFWMCSNGSLQCRICI
Table S6. Sequence alignment between NAs of A/Solomon Islands/3/2006 (H1N1) (row 1) and
A/ Brisbane/59/2007(H1N1) (row 2). Antigenic sites are colored red. The antigenic similarity is
measured as the percentage fraction of antigenic sites having the same amino acids (=46/50 =
92%).
SolIs3O6 MNPNQKIITIGSISIAIGIISLILQIGNIISIWASHSIQTGSQNHTGICNQRIITYENST
Brisb5907 MNPNQKIITIGSISIAIGIISLMLQIGNIISIWASHSIQTGSQNNTGICNQRIITYENST
Solls306 WVNNTYVNINNTNVVAEKDKTSVTLAGNSSLCSISGWAIYTKDNSIRIGSKGDVFVIREP
Brisb5907 WVNHTYVNINNTNVVAGEDKTSVTLAGNSSLCSISGWAIYTKDNSIRIGSKGDVFVIREP
SolIs306 FISCSHLECRTFFLTQGALLNDKHSNGTVKDRSPYRTLMSCPLGEAPSPYNSRFESVAWS
Brisb5907 FISCSHLECRTFFLTQGALLNDKHSNGTVKDRSPYRALMSCPLGEAPSPYNSKFESVAWS
SolIs306 ASACHDGMGWLTIGISGPDNGAVAVLKYNGIITETIKSWKKRILRTQESECVCMNGSCFT
Brisb5907 ASACHDGMGWLTIGISGPDNGAVAVLKYNGIITGTIKSWKKQILRTQESECVCMNGSCFT
SolIs306 IMTDGPSNGAASYKIFKIEKGKVTKTIELNAPNFHYEECSCYPDTGTVMCVCRDNWHGSN
Brisb5907 IMTDGPSNKAASYKIFKIEKGKVTKSIELNAPNFHYEECSCYPDTGIVMCVCRDNWHGSN
SolIs306 RPWVSFNQNLDYQIGYICSGVFGDNPRPKDGEGSCNPVTVDGADGVKGFSYKYGNGVWIG
Brisb5907 RPWVSFNQNLDYQIGYICSGVFGDNPRPEDGEGSCNPVTVDGANGVKGFSYKYDNGVWIG
SolIs306 RTKSNRLRKGFEMIWDPNGWTNTDSDFSVKQDVVAITDWSGYSGSFVQHPELTGLDCIRP
Brisb5907 RTKSNRLRKGFEMIWDPNGWTNTDSDFSVKQDVVAITDWSGYSGSFVQHPELTGLDCIRP
SolIs306 CFWVELVRGLPRENTTIWTSGSSISFCGVNSGTANWS----------
Brisb5907 CFWVELVRGLPRENTTIWTSGSSISFCGVNSDTANWSWPDGAELPFT
..... ... "I', "", . .......
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Table S7. Sequence alignment between HAs of A/Solomon Islands/3/2006 (H1NI) (row 1) and
A/ Brisbane/59/2007(H1N1) (row 2). Antigenic sites are colored red. The antigenic similarity is
measured as the percentage fraction of antigenic sites having the same amino acids (=69/71 =
97.2%).
SolIs3O6
Brisb5907
SolIs3O6
Brisb5907
SolIs3O6
Brisb5907
SolIs3O6
Brisb5907
SolIs3O6
Brisb5907
SolIs3O6
Brisb5907
SolIs3O6
Brisb5907
SolIs3O6
Brisb5907
SolIs3O6
Brisb5907
SolIs3O6
Brisb5907
MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCL
MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLENSHNGKLCL
LKGIAPLQLGNCSVAGWILGNPECELLISRESWSYIVEKPNPENGTCYPGHFADYEELRE
LKGIAPLQLGNCSVAGWILGNPECELLISKESWSYIVEKPNPENGTCYPGHFADYEELRE
QLSSVSSFERFEIFPKESSWPNHTTTGVSASCSHNGESSFYKNLLWLTGKNGLYPNLSKS
QLSSVSSFERFEIFPKESSWPNHTVTGVSASCSHNGESSFYRNLLWLTGKNGLYPNLSKS
YANNKEKEVLVLWGVHHPPNIGDQRALYHTENAYVSVVSSHYSRKFTPEIAKRPKVRDRE
YANNKEKEVLVLWGVHHPPNIGDQKALYHTENAYVSVVSSHYSRKFTPEIAKRPKVRDQE
GRINYYWTLLEPGDTIIFEANGNLIAPRYAFALSRGFGSGIINSNAPMDECDAKCQTPQG
GRINYYWTLLEPGDTIIFEANGNLIAPRYAFALSRGFGSGIINSNAPMDKCDAKCQTPQG
AINSSLPFQNVHPVTIGECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGM
AINSSLPFQNVHPVTIGECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGM
VDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNSVIEKMNTQFTAVGKEFNKLERRM
VDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNSVIEKMNTQFTAVGKEFNKLERRM
ENLNKKVDDGFIDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGC
ENLNKKVDDGFIDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLENNAKEIGNGC
FEFYHKCNDECMESVKNGTYDYPKYSEESKLNREKIDGVKLESMGVYQILAIYSTVASSR
FEFYHKCNDECMESVKNGTYDYPKYSEESKLNREKIDGVKLESMGVYQILAIYSTVASSL
VLLVSLGAISFWMCSNGSLQCRICI
VLLVSLGAISFWMCSNGSLQCRICI
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5. De novo Protein Structure Prediction and
Lectin Sequence-to-Function Assignment
Summary
This chapter focuses on the development of a new tool for homology-based structural
modeling based on our finding that protein core atomic interaction networks (PCAINs) in the
solvent-unexposed core ofprotein domains are 'signature' ofproteinfoldfamilies. Specifically:
(1.) Quantitative analysis of evolutionary tinkering and sequence divergence of protein folds
It is shown that evolutionary tinkering and sequence divergence are rampant across the protein
universe, with a majority ofprotein folds being rich in 'twilight' and 'midnight' homology zones.
(2.) PCAINs are universal signatures of the native folded structure of protein domains
It is deduced that PCAINs are well-conserved between domains of the same fold family, while
significantly different from PCAINs for domains of other fold families, consistently accross
families the entire universe ofproteins, emerging as "signature" ofproteins native folded state.
(3.) PCAIN is an effective tool for fold identification and structure prediction in the twilight zone
Building on the fold-specific nature of PCAINs, it is demonstrated that the use of PCAIN-based
scoring schemes permits effective classification of protein sequences into their native folds and
high-throughput, accurate homology-based (comparative) protein structure prediction. These
results are further consistent for even proteins from the twilight zone and CASP experiments.
(4.) The PCAIN methodology has tremendous applications for GBP structure prediction and
furthering the field of Glycobiologv
The developed de novo fold identification and structure prediction tools are shown to be
particularly attractive for overcoming the challenges facing GBP structure elucidation, thus
emerging as a useful tool for progressing towards de novo protein-glycan interaction analysis.
(5.) Other significant biological applications of the PCAIN methodology are explored
The highlighted applications are in Immunology, specifically, modeling the structure of YopM
effector protein from Bubonic Plague causative bacterium Yersinia Pestis and understanding its
host immune modulatory properties, as proof-of-principle of PCAIN method applications.
These studies resulted in a peer reviewed publication in PLoS ONE in February 2010.
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5.1 Pursuit of the Elusive Protein Fold Code: Implications of Ab Initio Mapping of Gene
Sequences to Folded Protein Structures
The biopolymers DNA, RNA and Proteins are linear polymers, with each monomer
connected at most to two other monomers. The sequence of their monomers effectively encodes
biological information. The genetic code is the set of rules by which information encoded in the
tri-nucleotide sequences of genetic material such as DNA or mRNA, is translated into the amino
acid sequence of proteins, by all living cells (Figure 5.1). This information flow is described by
the general transfers (normal flow) of the Central Dogma of Molecular Biology as follows: DNA
information can be copied to DNA (replication), DNA information can be copied into mRNA,
(transcription), and protein sequences can be synthesized using the information in mRNA as a
template (translation). The transfers of information described by the central dogma are faithful,
deterministic transfers, wherein one biopolymer's sequence is used as a template for the
construction of another biopolymer with a sequence that is entirely dependent on the original
biopolymer's sequence.
Genetic Code
Khorana, Holley &
N DNANirenberg (1960)
DNA aJA44AO RNA OProtein
a-lowix *Pfted hete Fibrous protile Globitopr oltie
aminoft acd
Chou-Fasman Code (1970) Uncharacterized ??
Figure 5.1 Decoding Biological Information Flow in Nature s Lego Set:
The Elusive Protein Fold Code
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The amino acid sequences of proteins that emerge from the translational machinery are
folded into their native, functional structure, by a complex and as yet uncharacterized process
termed protein folding. Protein folding is largely believed to be a templated process, going from
the sequence of amino acids to secondary structural motifs (Chou-Fasman Code), to tertiary
structural folds (Protein Fold Code), and ultimately quaternary structural assemblies (Symmetry
Code) as depicted in Figure 5.1. The discovery of a protein fold code would hence significantly
enhance universal understanding of biological information flow, providing for a direct,
templated, 1-on-1 mapping of genetic nucleotide sequences to the folded native structure of
proteins. However, the pursuit of the elusive protein fold code over the past five decades has met
with limited progress owing to several challenges as outlined in the next few sections.
5.2 Anfinsen's Dogma in the Post-Genomics Era: Significance and Implications of the
Twilight Zone of Homology
In the seminal research work published nearly four decades ago, Christian B. Anfinsen
hypothesized that "information dictating the native fold of globular protein domains is fully
encoded in their amino acid sequence" [388]. However, with the explosive amount of protein
sequence, structure, and fold data generated since the time of Anfinsen during the Omics Era of
the latter half of the 20 century, the emerging picture of the protein universe has challenged
Anfinsen's dogma, for it has become evident that numerous protein fold families have incredible
sequence diversity with a rampant "twilight zone" (less than 25% sequence identity between
proteins of the same native fold) and no consistent "fold code" (Figure 5.2) [384]. In support of
this observation, recent studies have shown that proteins with as low as 1-2% sequence identity
may still adopt the same native fold [389-392], thus defying any tangible encoding of fold-
dictating information into protein sequence. The pursuit of the elusive "fold code" has resulted in
little more than patterns of amino acid sequence conservations that are specific to certain proteins
[393-395], but no finding has been compelling enough to generalize universally or to utilize for
biological applications. So as to quantitatively estimate the extent of evolutionary sequence
divergence within the known universal set of protein fold families, we computed the Blosum62
score per amino acid pair on a fold family by fold family basis (Figure 5.2) to find that more
than 60% of protein fold families are significantly divergent in their sequences, around 30% of
protein fold families are moderately divergent in their sequences, and less than 10% of protein
fold families are well conserved in their sequences. This result shows that sequence divergence is
rampant in protein universe -- consequence of evolutionary tinkering, discussed in next section.
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Figure 5.2 Estimated Evolutionary Sequence Divergence of Protein Fold Families
5.3 Nature as a Tinkerer: How Evolutionary Tinkering Challenges Illuminating the
Twilight Zone of Homology
A snapshot of the protein folds in the universe exudes an extremely interesting and
intricate set of architectures (Figure 5.3). The domains of the protein universe are classified in
terms of secondary structural composition into architectures. The architectures are further
classified into topologies/folds by incorporating the loops/connectivity information, and each
fold is composed of several families on the basis of their evolutionary origin and function. As of
2010, there are around 1200 distinct protein folds that have been discovered, and it has been
estimated that the total number of protein folds in the entire biological universe would be around
10,000. It is indeed extraordinarily fascinating that Nature employs merely a few thousand
protein folds to generate the entire repertoire of her multimillion strong protein universe.
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Figure 5.3 The Full-Spectrum of Known Protein Architectures in the Biological Universe
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The observation that Nature has developed merely a few thousand folds to facilitate the
multi-millions of vastly diverse functions in the biological universe had led scientists to remark
that "Nature is a tinkerer rather than an innovator". Relentless evolutionary tinkering has
resulted in several biologically, phylogenetically, and functionally promiscuous protein folds.
Examples of such protein fold promiscuity has been widely appreciated in cases wherein
function has demanded massive tinkering-driven sequence divergence. For instance, molecular
recognition scaffolds are renowned to tolerate vast degrees of amino acid sequence divergence.
A classical example of such a protein fold is the immunoglobulin-like (Ig-like) J-sandwich, the
immune system's antibody and T-cell receptor (TCR) scaffold for universal molecular
recognition, that exhibits unparalleled divergence in its complementarity determining regions
(CDRs) (Figure 5.4). Another more recently characterized example is the C-type lectin fold, the
evolutionary solution for massive sequence divergence necessitated by its coding for diversity-
generating retroelements (DGRs) that permit its function as the dynamic host receptor-binding
scaffold in temperate bacteriophages. Yet another interesting example of molecular-recognition
driven diversity plays out in glycan-binding proteins (GBPs) that specifically recognize a
multitude of structurally complex and chemically heterogeneous carbohydrates to moderate key
biological processes including cell growth and development, cell-cell communication, host-
pathogen interaction, and immune function, as discussed in the next section.
The uncompromised ability of protein domains to be foldable and stable despite their vast
degrees of sequence divergence is a hallmark of Nature's intelligent design. With the exception
of rare chameleon polypeptide fragments that have shown propensity to adopt multiple
structures, a Lion's share of the known protein sequences still adhere to their one native
structural fold, implying that information in the sequence necessarily and universally codes for
its folded structure.
One of our long standing interests has been understanding principles of natural design to
engineer protein scaffolds for specific recognition of cell surface glycan and glycoprotein motifs
that regulate desired biological functions. As a first step, deducing the protein fold code and
applying this for de novo identification of fold, and prediction of protein structure directly from
gene sequence, emerged as the key goals to overcome the twilight-zone related challenges (from
the protein perspective). Taken together with the earlier chapters that focused on tools to
elucidate glycan-protein interactions (from the glycan perspective), this Thesis provides an
integrated framework to enable design-based engineering of glycoproteins with desired function.
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CDR-H2
CDR-H1
C-terminus
VARIABLE DOMAIN OF
LIGHT CHAIN (VL)
VARIABLE DOMAIN OF
HEV XXCHAIN (VII)
Serine-Glycine linker
Figure 5.4 An Example of Function-driven Evolutionary Tinkering: Complementarity
Determining Region (CDR) Loops of Antibody p-Sandwich Fold VH and VL Domains
5.4 The Twilight Zone of Glycobiology: The
GBP Structure Prediction
Need for, and Challenges Posing, Ab initio
To accommodate the structural diversity of glycans arising from their non-template
driven biosynthesis, there is substantial diversity in the sequence and three-dimensional
structural folds of various GBPs (Table 5.1) [346-349]. The three-dimensional structure of the
glycan binding domain of GBPs is therefore fundamental to understanding their specific
molecular recognition of glycan motifs which in turn is critical to decode their structure-function
relationships for a variety of biological and biotechnological applications [350-352]. Owing to
the association of the glycan-binding domains for their multivalent presentation however, there
are challenges in the recombinant expression and purification of GBPs [346-352], and therefore
in obtaining their three-dimensional crystal structures.
.. .... . . .....
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Table 5.1 Diversity of the commonly occurring fold families in Glycan-binding proteins
(GBPs) along with their occurrence frequency obtained from the cancer lectin database
and sugar-binding proteins from the PDB (negligible occurrences are denoted by dashes).
Fold family (a/3/ap) Glycan-binding Proteins (GBPs) Frequency offold occurrence in GBPsCancer lectin DB GBP folds (PDB)
Mannose-binding proteins,
C-type lectin-like (ap) Snake coagglutinins, Surfactant 25.13% 18.24%
proteins, Tetranectins, Selectins,
DC-SIGNs, CD69, CD94
Concanavalin A-like ($) Calnexins, Galectins, Lectin leg- 13.39% 20.33%
like, Legume lectins, Pentraxins
Fibroblast growth factors (FGF),
p-trefoil ($) Ricin B-like lectins, Agglutinins, 9.22% 7.89%Glycosidases, Neurotoxins,
Ribosome-inactivating proteins
Mannose-binding lectins, Delta-
p-prism (0) endotoxins, Vitelline membrane 0.97% 3.86%
outer-layer (VMO) proteins
p-sandwich ($) E set domains, Fibronectins, - 1.90%Immunoglobulins, Tenascins
Serpins (ap) Antithrombins, Heparin co- - 1.89%
factors, Protein C inhibitors
TIM beta/alpha barrel (a$) Amylases, Chitinases, - 1.87%Glycanases
RNase A-like (a$) Angiogens - 1.79%
Knottin ($) Hevein-like lectins - 1.76%
RAP domain-like (a) Receptor associated proteins - 0.98%(RAPs)
Four-helical up-and-down Apolipoproteins 
- 0.89%
bundle (a)
p-propeller (p) Tachylectins, Fucose-specific - 0.45%lectins
Protein structure prediction is an extensive area of research aimed at bridging the gap
between proteins with known primary amino acid sequences and those with available X-ray co-
crystal structures. The methods for protein structure prediction can be classified broadly into ab
initio energetics based approach to simulate folding of linear protein sequence and comparative
methods that predict the structural fold and model the structure of a target protein sequence.
Among the various methods for protein structure prediction, homology modeling is emerging as
a valuable tool to bridge the gap between sequence and structure.
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Figure 5.5 Poor intra-fold pairwise sequence identities of GBPs: Extensive presence of the
Twilight Zone (red) versus limited presence of non-twilight zone (green) wherein current
homology modeling tools are efficient.
The fundamental principle behind the homology-based modeling approaches is the
assignment of structure of a 'target' protein based on a 'template' (whose structure is known)
using the sequence identity between the template and the target. Although there are plenty of
outstanding automated/manual homology modeling servers and tools, their application to
structure prediction of GBPs is limited due to several roadblocks. One major limitation is the
generally poor pairwise sequence identity (PSI) that prevails in GBPs even within a given
structural fold, as shown herein for the trefoil (top left), prism (top right), concanavalin (bottom
left) and C-type lectin (bottom right) folds that are predominant in GBPs (Figure 5.5).
The extensive presence of the twilight zone in GBPs is believed to be a consequence of
large evolutionary sequence drift that has occurred over several millions of years of binding by
numerous chemically heterogeneous and structurally diverse glycan molecules to a handful of
folds (Figure 5.6). For instance, a very diverse set of glycans including both GAGs and branched
glycans (N-linked and 0-linked) are found co-complexed to proteins with the p-trefoil fold. This
example is an illustration of the structural and chemical diversity in glycan-binding to GBPs.
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Galactose (Gal) *
N-acetylglactosamn (GaINAc)*
Galactosamine (GaIN)
Glucose (Glc)
N-acetytglucosamlne (GIcNAc) A
Glucosamine (GIcN)
Mannose (Man)
N-aoetytmannosarmine (ManNAc) $
Mannosamine (ManN)
Xylose (Xyl)
N-Acetyneuraminic acid (NeuSAc)
N-Gycolytneuraminic acid (Neu5Gc)
2-Keto-3-deoxy-nononic acid (KDN)
Fucose (Fuc)
Glucuronic Acid (GIcA)
Idumnic Acid (IdoA)
Galacturonic Acid (GalA)
Mannuronic Acid (ManA)
Figure 5.6 Chemical and Structural Diversity of Glycans Binding to p-trefoil Proteins
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Chemical Structure of Glycan Glycan-biuding Proteins (GBPs) PDB ID
Rimnus communis aggiinn, 2AAI
Vrcum album lectin, 1PUU, 1YFS, 1TFM
4 Sambucus ebulus lectin, 1HWP
Earthwonnlectin mutant, 2D12
Tetanus toxin C-teninal domain 1DLL
Earthworn lectin mutant 2DSO
Clostrdiumbotuhimr F31
a Q3 &a4 neurotoxin-B
*4 4Tetams toxin C-temral domain 1FV3
0 Amaranthus caudatus aggutinin 1JLX
( )MaramisOreades A__ _ _i 21HO
Sambucus ebulus lectin 1HWN
Sambucus ebulus lectin 1HWO
Sambucus ebulus lectin 1HWM
Po U Vcun album ct 1M2T
Mouse mannose receptor IFWU and 1FWV
as and 3s
Asperg~Ius kawachii
a_2_ p_ _ _arabinofuranosidase 2D44
6S 6$ 6S
4.-p'gh- 4 - Fibroblast Growth Factors 2AXM, 1BFC etc.
2S NS 2S NS 2S NS
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Furthermore, not all proteins that are constituted of folds prominent in GBPs -- such as
beta-trefoil -- are necessarily glycan binding. In fact, a simple classification of proteins with the
beta-trefoil fold into glycan-binding and non-glycan binding shows that both classes of proteins
are quite prominent in this fold (Figure 5.7). Hence, in addition to the array of diverse chemical
and structural glycan molecules that may have motivated the diversification of folds constituting
GBPs, other non-glycan related factors may have also played a role in such evolutionary
tinkering and widespread twilight zone in the folds majorly constituting GBPs.
Non glycan-biding proteins with trefoil fold Glycan-bindlngProteinswithtrefollfold
Actin-binding structural protein (ldfc, lhcd, Hydrolases:Abrin (labr), Ebulin (lhwm, lhwn,
lhce) lhwo, lhwp), Xylanase (lisvjisw, lisx, lisy.
1"sz ADt, AMn, lknm, lmc9, lv~u, lv~v, iv~w,
lv6x, lxyf),GlycosylHydrolase (lups).
Glycosidase (2aai), Arabinofuranosidase (lwd3,
___________________ 
lwd4, 2643, 2d44)
Hydrolase inhibitor(lava, leyl, lfmz, 1fnO, FGF(lafclaxmibar, lbas, lbtb, lbfc, lbff,
in, eao) lbfg, bla, rbido lcvs, ldjs, ldzc ldzd, leo,
lev2, levt, lfga, lfmm, lfq9, 1g82. lhkn, llhk,
1bK, l, tt, lJqz, jt3, 1. 1jt5, 1jt7 jtc,
UjyO, lk5u, lknv, lrnk6, nnun, lnzk, op3,
lpwa, lpzz, 1q03, bq4, lqlu, lqqk, lqql,
trgq, lrL 2ry1, bafi 2axm, 2bfh, 2erm, 2fgf,
2p23,4fgf)
Senine protease inhibitor(lavu. lavw, lavx, Tetanus neurotoxin (laid, laf9, ld~h, ldfq Nofl1N-bWW"UWMt-fO
lba7, itie, lwbc, 2wbc, 4bc) ldiw, Adll, lepw, 1f31, Mf2, 1Mv, lg~b, lg9a, 1
i9C, lg9d, 4ile, lqzm, 1sb, 10, 4s1d, se, 
is~f, lsO&, lsr4, lyxw, lyyn, lz~h, 2f2f, 2nml,
1b,91b )2npO, 3bta)
Unknownfunction protein (t9f) Mannose receptor(ldq& ldgO, lfwu, lfwv)
lnterleukin-1 beta (ihib, li,, iir, lift, liob, Trichosanthes lectln-1 (lggp), Misletoe lectin
lira, irp, lltb, ijOs, 112h, id6, in41, hsOl, (ce7, 1m2t, lonk, loqi, pcs, 1pum, puu,
2szib, 2nvh, 3kbnm 4,bi, 41b, 511b, 6vb, 7,b,
Bd4b, 2db,43244
DNA-bindig protein (Ittu. 2101) Aggltinin(ljlx,ljlirzo)
StoraGge protein (wba) Transferase(lAxb)
Figure 5.7 Classification of P-trefoil fold protein domains into GBPs and non-GBPs
The extensive presence of the twilight and midnight zones in GBPs presents numerous
challenges to the currently available homology based modeling methodologies. In the twilight or
midnight zones, the homology model is very likely to have significant inaccuracies (high
RMSDs from actual crystal structures), owing to errors in the selection of an optimal template,
alignment of the target to the template amino acid sequence, and sometimes even in the very
identification of the fold of a given target sequence (Figure 5.8). However, the divide between
known protein sequences and known protein structures has been rapidly expanding (Figure 5.8).
Taken together, there is an increasing need for new homology modeling tools that are efficient in
the twilight zone, for successful application to de novo GBP structure prediction.
208
9100
w
0W o TEMPLATE - TARGET
50 * MODEL - TARGET
C0
0 20 40 60 80 100
% SEQUENCE IDENTITY
TwilightZone
2000000
1800000
e 1600000
1400000 592
1200000
0 1000000 C
0 800000
600000
400000
200000
1980 1985 1990 1995 2000 2005
Number of Sequences (2005) > 1800,000
Number of Structures (2005) > 200,000
So structure known only for 1 out of every 9 proteins
Number of Folds (2005) = 1,086
Figure 5.8. (Top) Inaccurate structure prediction by current homology modeling tools in
the twilight zone; and (Bottom) Rapidly expanding known sequence - structure divide.
5.5 Evolutionary Tinkering as Noise Masking De Novo Deduction of Fold Codes: The
Signal-to-Noise Ratio of Molecular Biology
We rationalized that, in order to perform the several orders of magnitude many functions
as the number of folds at her disposal, Nature would need to carefully encode the sequence-to-
structural fold mapping information in factors governed by just a handful of residues for each
fold. Given that conventional sequence (1-D) and structural (3-D) analysis do not generically
decode this "protein fold code", we hypothesized that such fold-dictating "signal" features are
masked by evolutionary "noise", and that in order to "denoise" the tinkered information and
improve the signal-to-noise ratio (SNR), one would need to exclusively examine the slowest
evolving regions in each protein fold (Figure 5.9).
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Figure 5.9. Depiction of Signal-to-Noise Ratio (SNR) of Molecular Biology and
its Amplification for Decoding the Protein Fold Code
5.6 The Core of it All: Shielding from Water as a Factor Mitigating Evolutionary
Tinkering in Protein Folds
We sought to decode conserved features within each fold family despite the vast degrees
of sequence divergence and rampant twilight zone (Figure 5.2), so as to better understand the
factors governing the protein fold code. Given that the residues constituting the "core" of
proteins are generally amongst the slowest evolving regions of protein structures and are known
to be central to folding and unfolding of protein chains, we focused on the core of proteins to
elucidate fold-conserved features.
Evolutionary'l- inkering a nd
l'unctional ffiversification
Inforination
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At the heart of a stable protein domain, are the solvent-unexposed residues in its core
(Figure 5.10). The identity and packing of protein core residues are known to be key factors that
mediate both the energetics of folding and the emergence of fold families. The quality of protein
core packing has also proven useful to successfully refine and validate computationally
generated structural models. Recent studies have further examined specific families of proteins
from sequence and packing/volume perspectives to delineate factors governing protein stability.
While different methods have been used to identify core residues of protein structures, in the
enclosed study we used conserved solvent inaccessibility to automate the identification of
residues constituting the core (termed scaffold) of domains from fold family alignments.
* 9
@0
Figure 5.10 Protein core/scaffold (gray circles; black sidechain lines), surface residues (red
circles; blue sidechain lines), peptide bonds (brown lines); and water molecules (blue circles)
5.7 Mining Protein Contact Maps from the Multi-dimensional Protein Universe
While information content of the protein universe has traditionally been analyzed from
the three dimensions of amino acid sequence (1-D), protein contact maps (2-D), and structural
coordinates (3-D), with the advent of databases such as pfam, SCOP, DALI, VAST, and CATH
in the Post-Genomic Era, analysis of higher dimensions of the protein universe such as protein
family (4-D), super-family (5-D), fold/topology (6-D), and architecture (7-D), are emerging as
.. .......  ...
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attractive options for mining of the truly multi-dimensional protein universe. Owing to the fact
that residue contacts are fundamental to defining protein structural folds, in this study, we
considered the information content of protein contact maps (PCMs) - a function of the distance
between atoms of all amino acids in a protein structure (Figure 5.11).
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Figure 5.11 Protein Contact Maps from architectures in the protein universe
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5.8 Introduction to the (pw) Landscape of Protein Structural Folds: A Valuable Tool for
Homology Modeling in the Twilight Zone
The enclosed manuscript describes the denoising of PCMs to compute protein core
atomic interaction networks (PCAINs) as signature of protein folds. The key steps of the
methodology are highlighted herein; for a more detailed description of the methods, refer to the
enclosed manuscript that follows this section.
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Figure 5.12 Structure-based multiple sequence alignment of p-trefoil protein fold family,
highlighting the residue columns that are identified as consistently solvent unexposed (blue).
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Figure 5.13 The PCAIN-based methodology for protein fold and structure prediction
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Input target sequence (e.g. IQXM), chosen template sequence (e.g. IISW)
and identified scaffold residue positions
Compute scaffold-anchored sequence alignment STEP 3
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Figure 5.14. Examples of structures obtained with PCAIN approach to homology modeling
(cyan) superposed onto the actual crystal structures (green), demonstrating the excellent structure
prediction capabilities of the developed tool. It may be noted that these structures are all of
GBPs, constituted of P- trefoil, p-prism, Concanavalin A-like, and C-type lectin-like folds.
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Figure 5.15. Structures predicted based on PCAIN methodology for CASP (Critical
Assessment of Structure Prediction) target sequences (top) T0203 and (bottom) T0197 are
provided (cyan) superposed on original crystal structures (pink), illustrating the universal
potential of PCAIN-based structure prediction.
. ........ ...............................  .................... .. ..... _ 
217
Published manuscript
Soundararajan, V., Raman, R., Raguram, S., Sasisekharan, V., Sasisekharan, R. (2010) Atomic
Interaction Networks in the Core of Protein Domains and Their Native Folds. PLoS ONE, 5(2):
e9391. doi:10.1371/joumal.pone.0009391
Specific contributions of this Thesis research to the publication: Conceived and developed the
PCAIN method for de novo protein fold identification and structure prediction.
* PLoS oneOPEN ACCESS Frely available online
Introcluction
Nature employs merely a few thousand protein folds to generate
the entire repertoire of the multimillion strong protein universe
[1]. Massively divergent amino acid sequences thus populate
protein families of many folds (Figure Sl), ostensibly challenging
the notion that all information dictating fold mapping of
proteins the protein fold code is programmed in the sequence
[2,3]. We sought to decode conserved features within each fold
family despite the vast degrees of sequence divergence, so as to
better understand the factors governing the protein fold code.
Given that the residues constituting the core are generally amongst
the slowest evolving regions of protein structures [4] and are
central to folding [5] and unfolding [6], we focused on the core of
proteins to elucidate fold-conserved features.
At the heart of a stable protein domain, are the solvent-
unexposed residues in its core [7,8]. The identity and packing of
protein core residues are known to be key factors that mediate
both the energetics of folding [9] and the emergence of fold
families [10]. The quality of protein core packing has also proven
useful to successfully refine and validate computationally gener-
PLoS ONE I www.plosone.org
ated structural models [11]. Recent studies have further examined
specific families of proteins from sequence and packing/volume
perspectives to delineate factors governing protein stability
[12,13]. Owing to the fact that atomic interactions are
fundamental to defining protein folds, in this study, we considered
the information content of protein contact maps (PCMs) a
function of the distance between atoms of all amino acids in a
protein [14]. Further, in order to capture the information content
in the solvent unexposed core regions of protein structures, we
defined the protein core atomic interaction netwrk or PCAIN (Figure 1).
While different methods have been used to identify core residues of
protein structures [7 14], we used conserved solvent inaccessibility
as a metric to automate the identification of residues constituting
the core of domains from protein family alignments (see Methods
section) and focused exclusively on the atomic interactions
between these residues to characterize each fold and compute a
database of PCAINs.
We find that PCAINs are well-conserved between domains of
the same fold family, while significantly different from the PCAINs
for domains of other fold families characteristics that are in sharp
contrast to the non-fold-specific nature of PCMs. The fold-specific
February 2010 | Volume 5 | Issue 2 | e9391
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Abstract
Vastly divergent sequences populate a majority of protein folds. In the quest to Identify features that are conserved within
protein domains belonging to the same fold, we set out to examine the entire protein universe on a fold-by-fold basis. We
report that the atomic interaction network in the solvent-unexposed core of protein domains are fold-conserved,
extraordinary sequence divergence notwithstanding. Further, we find that this feature, termed protein core atomic
interaction network (or PCAIN) is significantly distinguishable across different folds, thus appearing to be "signature" of a
domain's native fold. As part of this study, we computed the PCAINs for 8698 representative protein domains from families
across the 1018 known protein folds to construct our seed database and an automated framework was developed for
PCAIN-based characterization of the protein fold universe. A test set of randomly selected domains that are not in the seed
database was classified with over 97% accuracy, independent of sequence divergence. As an application of this novel fold
signature, a PCAIN-based scoring scheme was developed for comparative (homology-based) structure prediction, with 1-2
angstroms (mean 1.61A) C. RMSD generally observed between computed structures and reference crystal structures. Our
results are consistent across the full spectrum of test domains including those from recent CASP experiments and most
notably in the 'twilight' and 'midnight' zones wherein <30% and <10% target-template sequence identity prevails (mean
twilight RMSD of 1.69A). We further demonstrate the utility of the PCAIN protocol to derive biological insight into protein
structure-function relationships, by modeling the structure of the YopM effector novel E3 ligase (NEL) domain from plague-
causative bacterium Yerslnia Pestis and discussing its implications for host adaptive and innate immune modulation by the
pathogen. Considering the several high-throughput, sequence-Identity-Independent applications demonstrated in this
work, we suggest that the PCAIN is a fundamental fold feature that could be a valuable addition to the arsenal of protein
modeling and analysis tools.
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Figure 1. Computation of the protein core atomic Interaction network (PCAIN) from the 2-D protein contact map (PCM). The PCM
accounts for all atomic interactions in the 3-D protein structure while the PCAIN involves atomic interactions between just the conserved, solvent
inaccessible residues in the 'core' of protein domains.
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nature of PCAINs is further found to be consistent accross families
from the entire universe of protein folds (numbering ~1018),
highlighting the PCAIN as "signature" of the native folded state of
protein domains. Building on the fold-specific nature of PCAINs,
we demonstrate the use of PCAIN-based scoring schemes for
effective classification of protein sequences into their native folds
and for high-throughput, accurate homology-based (comparative)
protein structure prediction. We further highlight the potency of
PCAINs for extending the current capabilities of homology
modeling into the 'twilight' and 'midnight' zones [15,16] of low
target-template sequence identity (<30% and <10% respectively),
including those from recent CASP experiments [17). Having
verified the utility of PCAINs, we proceed to estimate the
sensitivity of PCAINs to threshold interaction distance (p) and
conserved solvent accessibility (w) the two fundamental physical
parameters that characterize the PCAIN thus defining a (p, to)
landscape for protein structures. From this analysis, we find that
the PCAIN is most refined around specific windows of (p, (o)
values and propose an adaptive approach for maximizing the fold
signature "signal" to evolutionary sequence divergence "noise",
thus enabling effective parameter-tuning of PCAINs for applica-
tions to derive biological insight into protein structure-function
relationships. Finally, we showcase as an application of the
developed protocols, PCAIN-based modeling of the hitherto
unknown structure of the NEL domain from the YopM effector
protein of plague-causative bacterium ersina Pestis. We conclude
with discussions on the biological implications of the modeled
bacterial protein structure, especially from the perspective of
adaptive and innate immune signaling modulation during host-
pathogen interplay.
Results and Discussion
We used the CATH database [18] as the source for our data on
protein domains and their folds. At the time when this study was
performed, the CATH database (Figure S2) had 112,450 protein
domains classified into 1,018 folds. We chose 8,698 protein
domains from accross the 1,018 folds representing all the different
homologous superfamilies in CATH to seed our database. The
structure-based multiple sequence alignments for the seeded
domains were obtained from DHS [18] and conserved, solvent-
unexposed core columns were identified for each alignment
(Figure S3) using the solvent accessibility parameters from DSSP/
CATH-wolf [19 21] for constructing the PCAIN database from
the PCM database (Figure S4) as described in the methods section.
As part of the PCAIN database, a comprehensive framework to
document key conserved interactions for each family of the protein
universe was developed (Figure 2), permitting assignment of
PCAIN scores to threaded structures.
In order to investigate the fold-specificity of PCAINs and
contrast with that of PCMs, the averaged PCM and PCAIN scores
for the seed domains from each of the 1018 folds were computed.
The averaged PCM and PCAIN scores for all fold pairs were
cross-correlated to obtain the correlation coefficients that provide
for a quantitative estimate of variations in these scores for different
folds (non-diagonal entries; Figure S5). The average degree of
correlation in PCMs and PCAINs were also computed for each
family, providing a quantitative estimate of the degree of fold-
conservation for these scores (diagonal entries from top left to
bottom right; Figure S5). From this data, it is clear that the PCM
provides for no discernable fold-specificity owing to random
correlations within (diagonal) and accross (non-diagonal) folds. On the
other hand, it is evident that the PCAIN is highly fold-specific with
low inter-family correlation coefficient values (non-diagonal) and
PLoS ONE I www.plosone.org
high intra-family correlation coefficient values (diagona). In order
to better illustrate this point, the PCM and PCAIN scores for
several randomly selected fold families from architectures
spanning a significant portion of the protein universe is also
shown (Figure 3), from which the extremely high fold-specificity of
PCAINs and low fold-specificity of PCMs is evident.
Given that the PCMs and PCAINs are functions of the
threshold interaction distance (p) and conserved solvent accessi-
bility (o) parameters, the entire analysis was repeated for various
threshold interaction distances ranging from p = 3.5 5.0 and
conserved solvent accessibility cutoffs ranging from o =0 10, to
observe consistently higher fold-specificity for PCAINs than PCMs
(data not showun). This analysis suggests that despite the large degree
of sequence divergence in a majority of fold families, atomic
interactions between amino acids in the solvent-unexposed core of
domains (PCAINs) are a highly fold-conserved feature. The poor
fold-specificity of the PCM on the other hand, is tell-tale of high
"evolutionary tinkering" noise [22] drowning out the fold-
conserved atomic interaction signals. Thus, it emerges that PCMs
have high signal-to-noise (SNR) ratio and that the solvent
accessibility parameter (o) sieves out the function-driven evolu-
tionary tinkering noise from PCMs. This implies that PCAINs are
"de-noised filtrates" of PCMs - a result that corroborates the long-
standing notion that exposure to solvent correlates with evolution-
driven amino acid substitution [23]. Furthermore, from the
perspective of 2-D and 3-D realms, this analysis suggests that
solvent exposed atomic interactions are more liable to evolutionary
tinkering than are solvent unexposed (buried) atomic interactions.
In order to examine the fold discriminating efficacy of PCAINs
and PCMs with greater detail, a general screen of 50,000
randomly selected domains was considered from the universal
set of 112,450 domains excluding the 8,698 representative
domains from which the seed databases were constructed. While
the PCAIN showed 97% accurate classification, the PCM showed
only 14% accuracy in classification of domains into their
respective folds (Figure 4A). Furthermore, the PCM's ability to
classify folds was found to be heavily dependent on the target-
template pairwise sequence identity (PSI), with an exponential
decrease in classification accuracy with decrease in PSI (Figure 4B).
It must be noted that in the higher PSI realm (>50%) wherein the
PCM shows some marginal performance, sequence-based (1-D)
methods are known to perform significantly well [24] and the
utility of the 2-D PCM based approach is defeated owing to the
higher computational cost involved. On the other hand, the
PCAIN is found to be largely uninfluenced by the drop in PSI and
consistently shows over 95% fold-classification accuracy even in
the twilight (<30% PSI) and midnight zones (<10% PSI)
(Figure 4B). This analysis showcases the 2-D PCAIN as a useful
tool to add to the existing methods for protein fold recognition
such as profile pattern recognition and protein threading [25 28].
While some existing methods are able to recognize folds
accurately [25 27], there is still an unmet need for methods that
can proceed from fold recognition towards accurate homology-based
structure prediction [28] in the 'twilight' and 'midnight' zones
wherein target-template sequence identity are <30% and <10%
respectively [15,16]. Furthermore, this breakdown of homology
modeling utility with low target-template identity challenges
elucidation of structures for newly discovered proteins, several of
which happen to fall into the twilight and midnight zones
[26,29,30]. To address this issue, we systematically evaluated the
potency of the PCAIN approach for homology-based structure
prediction, motivated by the high fold-specificity of PCAINs. For
this purpose, we developed a PCAIN-based scoring scheme
(Figure S6) outlined in the methods section for template
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Figure 2. Snapshots from the PCAIN database used for mining fold-distinguishing signatures. The solvent inaccessible core of domains
(shaded brown) from all 1018 naturally occurring folds were identified and used to compute the PCAINs (as described in the methods section) as part
of the PCAIN database. Shown herein are representative domains and PCAINs (with yellow arrow between) from the following fold families-(A.)
Orthogonal a-bundle (DNA helicase RuvA subunit); (B.) Up-down a-bundle (coiled-coil); (C.) cc-horseshoe (leucine-rich repeat variant); (D.) a-solenoid
(peridinin-chlorophyll protein); (E.) ct-barrell (glycosyltransferase); (F.) ap-roll (HIV reverse transcriptase); (G.) a$-complex (cytochrome); (H.) *p-box
(proliferating cell nuclear antigen); (L) p-ribbon (seminal fluid protein PDC-109); (J.) p-sandwich (neurophysin); (K.) s-barrel (thrombin); (L) p-propeller
(pseudo p-propeller); (M.) p-clam (outer membrane lipoprotein receptor); (N.) p-trefoil (acidic fibroblast growth factor). Fold-distinguishing PCAIN
patterns observed herein motivated systemic computation of intra-fold and inter-fold correlations on a family-by-family basis, as shown in
supplementary figure S5. Fold-conserved interactions are evolutionary markers and are demarcated (red stars) on the corresponding sample set of
the protein family alignments in supplementary figure 53.
dol0.1371fjournal.pone.0009391.g002
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Figure 3. Contrasting the fold specificity of protein contact maps (PCMs) and protein core atomic Interaction networks (PCAINs).
Averaged intra-family (diagona and inter-family (non-diagona) correlation coefficients of (A.) PCMs and (B.) PCAINs were computed at 5 angstroms
threshold distance p and normalized solvent accessibility/atom of co = 10 on a family-by-family basis for several prominent folds of the protein
universe. The complete 1018 folds by 1018 folds correlations of PCMs and PCAINs for the entire fold universe is shown in supplementary figure 55.
From these figures it is clear that PCAIN is highly fold-specific but PCM shows no discernible fold specificity.
doi:10.1371/journal.pone.0009391.g003
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Figure 4. Applications of PCAIN as a divergence4ndependent metric for protein classificaton, anchored sequence alignment, and
structure prediction. (A.) PCAiNs were computed on a general screen of unselected protein domain sequences that were not part of the database
and used to accurately classify these sequences as shown, confirming the fold-specific nature of PCAINs. PCMs of these domains are seen to be
ineffective as classifiers in the general sequence space. (B.) PCAIN is seen to be an effective classifier regardless of the sequence identity of the target
domain towards members of its native fold and is observed to be effective even in the twilight (<30% PSO and midnight (<10% PSI) zones. On the
other hand the PCM is observed to be highly dependent on this sequence identity and provides for some moderate classification accuracy only in
the high sequence identity range. (C.) The distribution of RMSD between PCAIN-based predicted structures and the reference crystal structures for
target sequences with mean RMSD of 1.61A highlights the structure prediction efficacy of the proposed method. (D.) Pie chart of RMSD distribution
for test sequences in the twilight and midnight zones is shown, indicating mean RMSD of 1.69A.
doi:10.1371(journal.pone.0009391.goo4
selection, anchored sequence alignment, and homology-based
structure prediction. This testing was performed with a general
screen of randomly selected domains from the universal set of
domains, excluding the representative domains of the seed
database, and including those from recent CASP experiments.
The reference structure-based sequence alignments were seen to
have extremely high correlations to the PCAIN-based anchored
alignments with pearson's correlation coefficient of 0.91. It is
interesting that atomic interactions are mined from 3-D structural
coordinates and 2-D PCAINs are used to identify the fold-
conserved set of atomic interactions that are finally mapped to
thread l-D amino acid sequences. This underlines the application
PLoS ONE I www.plosone.org
of fold-conserved (including in twilight and midnight zones) higher
dimensional data from structural (3D) and contact (2D) spaces for
effective protein analysis. This also establishes that PCAIN-based
anchored alignments closely mimic the actual structure-based
sequence alignments, thus confirming the utility of PCAINs vis-a-
vis sequence alignment. Furthermore, superposition of the
modeled test structures onto the reference crystal structures
demonstrated good structure prediction accuracy in the range of
1 2 angstroms, with mean RMSD of 1.61 angstroms (Figure 4C).
In order to specifically estimate the efficacy of the PCAIN
approach for structure prediction in the twilight and midnight
zones of sequence identity, the RMSD range for the predicted
February 2010 1 Volume 5 1 issue 2 | e9391
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structures corresponding to the test domains in these zones was
also computed (Figure 4D). The mean RMSD in the twilight and
midnight zone was 1.69 angstroms with the overall RMSD
distribution (Figure 4D) very similar to that obtained for the entire
set of test domains (Figure 4C), thus proving that the PCAIN
approach to structure prediction is sequence-identity-independent
and hence notably potent in twilight-midnight zones. Successful
prediction of structures for example targets from recent CASP
(critical assessment of structure prediction) proceedings that are
not part of the CATH database or the seed datasets further
illustrate the generic, database-independent efficacy of the PCAIN
approach (Figure S7). This analysis confirms the high-throughput
accuracy of PCAIN-based structure prediction and showcases it as
a valuable addition to the arsenal of structural modeling tools.
The significantly improved performance of PCAINs over PCMs
[31] is due to three distinct advantages. Primarily, owing to de-
noising of "evolutionary tinkered" contacts from the PCM, the
PCAIN enables exclusive retention of fold-specific signals. Next,
the PCAIN scores for sequences generally best match with the
representative domains from the same superfamily, rather than
domains of other superfamilies even belonging to the same fold.
Since protein folds are classified into superfamilies based on
common functions and evolutionary relationships, it is likely that
the PCAIN-based methodology enables handpicking of an optimal
functionally-related template molecule for modeling the structure
of the unknown protein, thus contributing significantly towards
improving the accuracy of structure prediction. Finally, the
PCAIN methodology provides for utilizing the fold-conserved
residues as "anchors" in the target-template sequence alignment
step, thus increasing efficacy of conventional alignment protocols.
Taken together, these three factors contribute towards the potency
of PCAINs for the discussed applications. With further improve-
ments to the accuracy of secondary structure prediction methods
and incorporation of additional fold-conserved features from
solvent-exposed regions, it is conceivable that more accurate
structures may be predicted as part of future advancements to the
PCAIN methodology.
Given that the PCAIN is a function of two fundamental
parameters, namely, threshold interaction distance (p) and
conserved solvent accessibility (to), we investigated the effect of
modulating these parameters (Figure 5). For this purpose, a
parameter scan on (p, to) was performed and the effective operable
landscape for PCAIN-based methods was mapped for the range
p = 3.5 7.0 angstroms and o = 0 40%. Given that high intra-
family PCAIN correlation scores and low inter-family PCAIN
correlation scores are necessary for defining a refined fold
signature with high SNR, the difference between these two scores
provides a reliable measure of potency. We find that the PCAIN is
sensitive to both the threshold interaction distance parameter (p)
and the conserved solvent accessibility parameter (to), with higher
sensitivity towards the former (Figure 5A). Specifically, the PCAIN
is found to be most effective as a fold signature (high intra-family
and low inter-family correlations) in the window to 2 20%
(Figure 5B) and similarly in the window p=4.0 4.5 angstroms
(Figure 5C).
The (p,co) landscape may be interpreted as follows. Protein
structures are ensembles of backbone bonded dipeptide confirma-
tions that are characterized by the (<p, *) plot [32 34) and other
side-chain interactions that are characterized by inter-residue
distance [35]. Too much threshold interaction distance (p) implies
accounting for non-influential residue pairs as interactions and
such pseudo-interactions will add to the noise thus decreasing SNR
and PCAIN potency. Too little threshold interaction distance (p),
on the other hand, is not feasible, since it will be less than inter-
atomic Van der Waals distances. The 'o' parameter accounts for
the interplay between water molecules and the residues constitut-
ing the protein structure and from this perspective the PCAIN
may be viewed as essentially the solvent unexposed network (SUN)
of interacting residues. Specifically, a higher 'o' value implies
accounting for partially solvent exposed (and hence possibly non-
conserved) atomic interaction networks, thus adding to the noise
factor and decreasing PCAIN effectiveness. A 'o' value dose to
zero, on the other hand, may be too stringent. Along the lines of
this analysis, it is conceivable that fine-tuning of the PCAIN may
be required for specific molecular biology applications. Having
mapped the effective operable landscape for PCAIN-based
methods with the goal of obtaining the maximal PCAIN
effectiveness and highest possible SNR, we propose an adaptive
framework (Figure 5D) for such fine-tuning of the (p, co)
parameters as required by the application of interest.
Protein fold recognition and structure prediction have numer-
ous biological applications [28 30]. In addition to the previously
demonstrated applications of sequence alignment, fold identifica-
tion, template selection, and homology modeling, we demonstrate
herein, application of the described PCAIN-based structure
prediction methodology to derive biological insight into potential
structure-function relationships of proteins with hitherto unre-
solved structure. As an example to highlight this application, we
consider the effector protein YopM from the plague-causative
bacterium Yersinia pestis [36]. While it is well-known that YopM is a
critical virulence determining factor, structural insight into
potential roles of YopM in . pestis pathogenesis has been elusive,
due to the unsolved structure of the YopM novel E3 ligase (NEL)
domain [37].
We modeled the YopM NEL domain structure using the
PCAIN methodology and investigated the putative ubiquitin ligase
catalytic site (Figure 6A). From the modeled structure, we note
remarkable correlation in molecular surface electrostatics includ-
ing the highly-conserved patches (Figure 6B), in NEL domain
structures from Salmonella SspH2 [38], Sabnonella SlrP [39], Shigella
IpaH [40], and Yersiniapestis YopM, in addition to high correlation
of the PCAINs for these domains (Figure 6C). Given that these
patches constitute the NEL catalytic site [40] and the recently
characterized Salmonella NEL domain interaction sites with human
leukocyte antigen-DR (HLA-DR; a major histocompatibility
complex (MHC) class II receptor) and thioredoxin (TRX)
[38,39], it is likely that the YopM NEL domain functions as an
autoregulated E3 ubiquitin ligase and degrades human intracel-
lular proteins, similar to NEL domains from Sabnone& and Shgella.
Such an ubiquitinase activity of YopM NEL has significant
implications for modulation of host adaptive and innate immune
response to plague (Figure 6D). The ubiquitination and subse-
quent degradation of HLA-DR by Salmonella effectors within
antigen presenting cells like macrophages, B-cells, and dendritic
cells, has been recently shown to diminish the surface expression of
MHC class II antigens [41]. It is conceivable that a similar
interaction of YopM NEL with HLA-DR could moderate the host
adaptive immune response (Figure 6D). Confirmation of the
proteolytic degradation of TRX by YopM will have important
implications in the regulation of mitogen-activated protein kinase
kinase kinase 5 (MAP3K5) signaling, for TRX interaction with
MAP3K5 [42] provides Ypestis a plausible direct method to
modulate innate immunity (Figure 6D). More specifically, future
studies that biochemically characterize interactions of key host
intracellular molecules to the YopM molecule modeled herein, will
further our understanding of the specific mechanisms governing
bacterial subversion of human adaptive and innate immune
signaling pathways.
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solvent accessibility ox (B.) At fixed p = 4.25 angstroms, the variation of PCAIN potency with a (C.) At fixed o= 25, the variation of PCAIN potency with
p. (D.) Implementation of adaptive tuning of p and o parameters for maximizing SNR.
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The modeling of YopM NEL domain demonstrated in this
study amply highlights application of the PCAIN methodology to
derive biological insight into protein structure-function relation-
PLoS ONE | www.plosone.org
ships. Taken together with the previously described applications of
the PCAIN methodology such as sequence alignment, fold
identification, template selection, and structural modeling, our
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Figure 6. Application of the PCAIN methodology to analyze potential structure-function relationships of the novel E3 ligase (NEL)
domain from the YopM ~ffector protein of the plague-causative bacterium Yersnifa Pest/s. (A) The YopM NEL domain structure was
modeled using the PCAIN methodology and the putative ubiquitin ligase catalytic site was characterized, based on the recent experimental
characterizations of Salmonella and Shigella NEL domains (38-41]. The likely hydrogen bonds that stabilize the active site (black lines) and the key a-
helices (H4, H7, and H9) are indicated. (B.) Vacuum electrostatics of the molecular surfaces from superposed NEL domains of YopM, SIrP, SspH2, and
ipaH were generated (see Methods) with negative, positive, and neutral patches colored red, blue, and white respectively. The finger-like extension
(pink line), globular domain (orange arc), and active site location (black arrow) are indicated. (C.) The solvent-unexposed residues that constitute the
PCAIN of the modeled YopM NEL domain structure (gray) are shown as sticks (brown). The molecular surface of the YopM NEL domain is also shown
alongside to highlight that the residues constituting the PCAIN (brown) are only very minimally solvent exposed. (D.) This is a pictorial depiction of
YopM in the intracellular context and the key structural implications for its modulation of human adaptive and innate immune signaling. Specifically,
YopM is known to interact with protein kinase C-like 2 (PRK2) and ribosomal 56 protein kinase 1 (RSK1) resulting in increased activity and mobility of
these kinases, in addition to potentiating natural killer (NK) cell depletion by suppressing expression of interleukin-15 (IL-15) [37]. YopM has also been
shown to specifically interact with al-antitrypsin (AAT) without affecting its anti-protease activity, due to which the biological significance of this
interaction remains unknown.[37] Also indicated by the question mark (?) symbols are hitherto unknown interactions for YopM, extrapolated based
on the functions of the related proteins. Specifically highlighted in this regard are the degradation of human leukocyte antigen-DR (HLA-DR) and
thioredoxin (TRX) that may cause suppression of adaptive immune response via moderation of antigen presentation and modulation of Innate
immune signaling via the MAPK cascade, respectively. It remains to be seen what precise intracellular molecules are targeted by YopM NEL for
proteolytic degradation, considering the autoregulated ubiquitin ligase activity suggested by our PCAIN-based model and analysis.
doi:10.1371/Joumal.pone.0009391.g006
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study confirms the PCAIN as a fundamental fold feature that will
be a valuable addition to the arsenal of protein modeling and
analysis tools. Additionally, the PCAINs computed as part of this
work (such as those from the database shown in Figure 2) are likely
to be useful resource for molecular engineering applications since
they provide a rigorous starting framework or scaffold upon which
rest of the protein design may be tailored based on the functions of
interest. PCAIN computation and analysis may also be valuable
for applications such as elucidating mechanisms of protein
evolution, stability, folding, unfolding, and misfolding, given the
central role of the protein core in governing these phenomena
[43 46].
It has recently been shown that two specific amino acid
sequences with overwhelming identity (-88%) adopt distinct folds,
thus postulating that for the specific protein pair considered, only
- 12% of the amino acid sequence codes for sequence-to-structure
mapping [47]. PCAIN sheds light on a 'fold code" that is
consistently encoded into residues that constitute the networks of
atomic interactions in solvent unexposed core regions of protein
native structures. This suggests that the fold code is a network
phenomenon along with sequence and structural phenomena, thus
providing rationale as to why merely sequence-based or structure-
based pattern analysis of proteins may not succeed in decoding
fold signatures. The cores of the protein domains of the same fold
as identified by our method can have low sequence identity and
poor secondary structure motif matching, but high conservation of
their PCAINs (Figure S8). Hence, defining protein cores based on
treatment of protein structures as atomic networks characterized
by the (p, o) plot and denoising of PCMs by recognition of
signature network patterns, distinguishes our PCAIN methodology
from the previously explored knowledge-based threading poten-
tials. Our finding that the atomic interactions between just 15
20% of residues in native structures of each examined fold are
conserved, further suggests that the PCAIN is a minimalistic fold
code.
Finally, this study provides compelling evidence in support of
Anfinsen's dogma [48] that information dictating the native
structural fold of protein domains is encoded in its amino acid
sequence. Herein we have shown that "a significant portion of the
fold-dictating information is encoded by the atomic interaction
network in the solvent-unexposed core of protein domains".
Materials and Methods
Automated Identification of 'Core' Residues and
Construction of a Core Composition Database
Characterizing All 1018 folds of the Protein Universe
At the time when this study was performed, the CATH database
[18] had 112,450 protein domains classified into 1,0 18 folds, from
which 8,698 protein domains representing the different homolo-
gous super families were used to seed our database. CATH defines
cores based on secondary structural element analysis, whereas in
our method the core can include non-secondary structural
elements. Taken together with several other methodology
distinctions, the cores identified by us are unique (as highlighted
for the illustrative domain in Figure S8 for which more than 75%
of CATH and PCAIN core residues are distinct). The structure-
based multiple sequence alignments were obtained from DHS [18]
(Figure S3) and the absolute solvent accessibility (ASA) factors
from DSSP/CATH-wolf [21] were obtained for the amino acids
of all 8,698 domains. The relative solvent accessibility (RSA) per
atom was computed for each residue. The mean solvent
accessibility (co) was then calculated for all columns of the seed
alignments and a threshold was used to identify the consistently
. PLoS ONE I www.plosone.org
solvent-unexposed columns as shown (Figure S3). This set of
consistently solvent inaccessible columns was mapped back onto
the conserved residue positions thus defining the core for all the
seeded protein domains from each alignment. This was compiled
into a dataset of protein core residues, one corresponding to each
protein family and each considered value of parameter w. The
frequency of each amino acid at the core positions was also
consolidated into a dataset of family-specific protein core residue
propensities. The complete protein core characterization method,
right from CATH mining until the construction of the datasets was
automated with the implementation of a script in MATLAB 7.6.0
from The MathWorks, Inc. (Nattick, MA).
Automated Construction of the PCM and PCAIN
Databases for All 1018 Folds of the Protein Universe
A MATLAB script was written to automate the computation of
protein contact maps (PCMs) for all seeded domains of the 1018
folds at various threshold interaction distance parameter (p) values.
(Figure S4). This was compiled into a database of PCMs on a fold-
by-fold basis. The previously identified core residues for each
domain of each fold at various o values was used to identify the
rows and columns of interest from PCMs at various p values and
these were concatenated into the corresponding PCAINs for each
domain of each fold at various (p, w) values, as depicted pictorially
(Figure 1). This step was automated with a MATLAB script, which
was also ultimately used to compile the generated PCAINs into an
integrated PCM-PCAIN database for various (p, w) values. A
simple python script was written and executed in PyMol for
visualization of all the protein cores and PCAINs shown in this
study (Figure 2). The pearson's correlation coefficient was
computed to quantitatively contrast PCMs and PCAINs both
within and accross all 1018 folds (Figure S5) and accross 15
unselected folds for refined visualization purposes (Figure 3).
Automated Fold Classification of Randomly Selected
Domains from the Protein Universe
(Figure _6) A general screen of 50,000 randomly selected
domains (obtained from the set of 112,450 domains excluding the
8,698 representative domains in the training set from which the
PCM and PCAIN databases were constructed) were considered
for testing the fold classification efficacy of PCAIN-based and
PCM-based scoring schemes. The effectiveness of the classification
approaches were then estimated (Figure 4A) using the actual folds
of the test sequences as reference. Variations of the classification
efficacies as a function of target-template sequence identity were
also computed (Figure 4B).
Template Selection Based on Target PCAIN Estimation
and Correlation with Protein Family PCAIN Signatures
An automated MATLAB script was written to compute the
secondary structures of the target amino acid sequences based on
secondary structure prediction consensus [49 51]. The type,
quantity and distribution of secondary structures are partially
characteristic of folds and offer a good first filter for the fold and
template selection process. Potential amino acids that correlate
with the propensity data for each core position of all the screened
folds are then identified for the target sequences, providing an
estimate of 'core fit' and serving as a second filter for fold and
template selection. The algorithm for this step is also implemented
in MATLAB 7.6.0 from The MathWorks, Inc (Natick, MA) and
accepts three inputs, namely, target amino acid sequences, the
corresponding secondary structural information, and the fold-
specific core residue propensity dataset. The target sequences for
February 2010 1 Volume 5 j Issue 2 | e9391
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which all potential core residues are identifiable are deemed 'core
fit' with respect to the screened folds and the target PCAIN scores
for these are computed using the PCAIN database. For a majority
of cases, the identical residue pairs are present in the database and
hence their corresponding pairwise score is directly utilized. In
other cases, an average of pairwise interactions between the two
considered core positions from all other members of the screened
fold family is used in this step. The target PCAIN scores are
subsequently back-correlated with the averaged PCAIN score of
each family and the resulting correlation coefficients provide an
additional estimate of the degree of 'core fit'. A simple threshold
step is used at this stage as the third and final filter to determine
the protein family, thus providing for selection of the optimal
template molecule.
Automated Anchored Sequence Alignment and
Comparative Structure Prediction for Randomly Selected
Protein Domains
The steps of this algorithm are depicted as a flowchart in Fiure
S6. Briefly, a general screen of randomly selected domains were
obtained from the set of 112,450 domains (excluding the 8,698
representative domains for which PCM and PCAIN databases
were constructed) and their PCAINs were estimated as detailed
above. The computed target PCAIN scores were then correlated
with the PCAIN scores (from the seed database) of every
representative homologous superfamily member of the identified
fold family in order to compute the optimal template, based on
similarities at the level of evolutionary origin and function. The
corresponding scaffold residues of the target and template
sequences are then 'anchored' and pairwise sequence fragments
between subsequent anchors are aligned using standard functions
from the MATLAB bioinformatics toolbox with the BLOSUM62
scoring matrix and default gap penalties. The process involving
fold identification, template selection and anchored alignment is
maximally automated with the design of a MATLAB-based
model. The structure-based sequence alignments are correlated
with the PCAIN-based anchored alignments to estimate the
efficacy of the PCAIN approach to sequence alignment
(Figure 4C). Once the optimal anchored target-template align-
ments were computed, these were input to the automated
homology modeling script of Discovery Studio from Acceirys,
Inc. (San Diego, CA) that uses standard force fields to determine
the energy minimized 3-D structural coordinates for the test
sequences, including those from recent CASP experiments (as
illustrated by examples in Figure S7). Each modeled 3D structure
was then superposed onto the actual crystal structure obtained
from the PDB using an automated MATLAB function and the
root mean square deviations upon superposition were computed
(Figure 4D).
Modeling NEL Domain Structures with the PCAIN
Methodology and Analysis of Their Putative
Structure-Function Relationships
The molecular structures of NEL domains from Tersinia pestis
YopM (NCBI Reference Sequence: ZP02316950.1) and Salmo-
nella yphimuiwn SlrP (GenBanc AAD39928. 1) were modeled
using the described PCAIN methodology with the identified
optimal template structure of Shigella type III effector IpaH (PDB
ID: 3CKD). All structure-function relationship analysis, including
vacuum electrostatics generation for the modeled Tersinia pestis
YopM NEL, modeled Salmonella pphimuiwn SlrP NEL, crystal
structures from Shigella IpaH NEL (PDB ID: 3CKD), and salmonella
SspH2 NEL (PDB ID: 3G06), were performed with PyMol.
. PLoS ONE I www.plosone.org
Supporting Information
Figure S1 Evolutionary sequence divergence of protein fami-
lies. More than 60% of protein families from the pfam database
were found to be significantly divergent in their sequences (High
range), around 30% of protein families were found to be
moderately divergenct in ther sequences (Medium range) and
less than 10% of protein families were found to be well conserved
in their sequences (Low range). This shows that evolutionary
tinkering and sequence divergence are rampant across the protein
universe.
Found at: doi: 10.137 1/journal.pone.0009391.s00l (0.14 MBJPG)
Figure S2 The diversity of protein folds. Representative protein
domains from CATH showcasing the fold diversity, classified
according to their class (mainly c/mainly P/cp) and architecture.
Found at: doi: 10.137 1/journal.pone.0009391 .s002 (0.11 MBJPG)
Figure 83 Sample sets from fold family alignments highlighting
the solvent-unexposed (core) conserved positions (blue columns).
(A) Sample proteins from a family of the architecture - Orthogonal
bundle. (B) Sample proteins from a family of the architecture - Up-
down bundle. (C) Sample proteins from a family of the
architecture - Alpha-horseshoe. (D) Sample proteins from a family
of the architecture - Alpha-alpha Barrel. (E) Sample proteins from
a family of the architecture - Beta-Ribbon. (F) Sample proteins
from a family of the architecture - Beta-Barrel. (G) Sample
proteins from a family of the architecture - Beta-Trefoil. (H)
Sample proteins from a family of the architecture - Beta-Prism. (I)
Sample proteins from a family of the architecture - Beta-
Sandwich. (J) Sample proteins from a family of architecture -
Beta-Propeller. (K) Sample proteins from a family of architecture -
mo Roll. (L) Sample proteins from a family of architecture - as
Box. (M) Sample proteins from a family of architecture -a
Complex.
Found at: doi:10.1371/journal.pone.0009391.s003 (1.50 MBJPG)
Figure S4 A sample dataset from the protein contact maps
(PCM) database. The inter-residue contact maps at 5 angstroms
threshold distance are shown for representative domains from a
diverse set of topologies/folds spanning all natural architectures in
the protein universe.
Found at: doi:10.1371/joumal.pone.0009391.s004 (0.19 MBJPG)
Figure 85 Protein contact maps (PCMs) versus protein core
atomic interaction networks (PCAINs) intra- and inter- fold family
correlations reveals striking specificity for PCAIN across the
universe of folds. Averaged intra-fold (diagonal) and inter-fold
(non-diagonal) correlation coefficients of (a.) PCMs and (b.)
PCAINs at 5 angstroms threshold, shows clears that the PCAIN
is highly fold-specific whereas the PCM shows no discernible fold
specificity.
Found at: doi: 10.137 l/journal.pone.0009391.s005 (0.43 MBJPG)
Figure 86 Flowchart governing PCAIN-based fold recognition
of target sequence, template selection, anchored target-template
alignment, and homology-based structure prediction. The detailed
procedures associated with each step are described in the methods
section. Briefly, a combination of secondary structure distribution
and PCAIN scores from the key interaction positions was used to
(i.) identify the fold of the target sequence, (ii.) compute the ideal
template structure based on the closest functional homolog
estimated from the superfamilies of the identified fold, (iii.)
converge on the set of 'anchor' positions between the target and
template sequences based on protein core amino acid frequencies
to compute the optimal anchored target-template alignments, and
(iv.) determine the target domain's 3-D structural coordinates from
February 2010 1 Volume 5 1 Issue 2 1 e9391
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the anchored alignments with an automated homology modeling
script.
Found at: doi: 10.137 1/journal.pone.0009391 .s006 (0.05 MBJPG)
Figure S7 Superposition of structures predicted based on
PCAIN methodology for CASP (Critical Assessment of Structure
Prediction) target sequences (a.) T0203 and (b.) TO 197, illustrates
PCAIN-based structure prediction. PCAIN-based structures
predicted (cyan) are superposed onto reference crystal structures
(pink) for (a.) TOP203 and (b.) TO 197 from CASP-6 with RMSDs
of 0.9 1A (at 29% target-template sequence identity) and 0.87A (at
60% target-template sequence identity) respectively. The corre-
sponding results of structure prediction accuracy from the CASP
models shown as tables shows minimum RMSDs of 1.29A and
1.37A respectively.
Found at: doi: 10.137 1/journal.pone.0009391 .s007 (0.26 MBJPG)
Figure 88 Defining protein cores and extracting their informa-
tion with the PCAIN methodology. (A.) Polar and charged
residues (yellow) are also part of the core of protein domain as
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